<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Treatment for recurrent vulvovaginal candidiasis (thrush) - Cooke, G - 2022 | Cochrane Library</title> <meta content="Treatment for recurrent vulvovaginal candidiasis (thrush) - Cooke, G - 2022 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD009151.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Treatment for recurrent vulvovaginal candidiasis (thrush) - Cooke, G - 2022 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD009151.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD009151.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Treatment for recurrent vulvovaginal candidiasis (thrush)" name="citation_title"/> <meta content="Georga Cooke" name="citation_author"/> <meta content="The University of Queensland" name="citation_author_institution"/> <meta content="Cathy Watson" name="citation_author"/> <meta content="University of Melbourne" name="citation_author_institution"/> <meta content="Laura Deckx" name="citation_author"/> <meta content="The University of Queensland" name="citation_author_institution"/> <meta content="Marie Pirotta" name="citation_author"/> <meta content="University of Melbourne" name="citation_author_institution"/> <meta content="Jane Smith" name="citation_author"/> <meta content="Centre for Research in Evidence-Based Practice (CREBP)" name="citation_author_institution"/> <meta content="Mieke L van Driel" name="citation_author"/> <meta content="The University of Queensland" name="citation_author_institution"/> <meta content="m.vandriel@uq.edu.au" name="citation_author_email"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="1" name="citation_issue"/> <meta content="10.1002/14651858.CD009151.pub2" name="citation_doi"/> <meta content="2022" name="citation_date"/> <meta content="2022/01/10" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD009151.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD009151.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD009151.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Antifungal Agents [therapeutic use]; *Candidiasis, Oral; *Candidiasis, Vulvovaginal [drug therapy]; Immunosuppressive Agents [therapeutic use]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009151.pub2&amp;doi=10.1002/14651858.CD009151.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009151.pub2&amp;doi=10.1002/14651858.CD009151.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009151.pub2&amp;doi=10.1002/14651858.CD009151.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009151.pub2&amp;doi=10.1002/14651858.CD009151.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009151.pub2&amp;doi=10.1002/14651858.CD009151.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009151.pub2&amp;doi=10.1002/14651858.CD009151.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009151.pub2&amp;doi=10.1002/14651858.CD009151.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009151.pub2&amp;doi=10.1002/14651858.CD009151.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009151.pub2&amp;doi=10.1002/14651858.CD009151.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009151.pub2&amp;doi=10.1002/14651858.CD009151.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009151.pub2&amp;doi=10.1002/14651858.CD009151.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009151.pub2&amp;doi=10.1002/14651858.CD009151.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009151.pub2&amp;doi=10.1002/14651858.CD009151.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009151.pub2&amp;doi=10.1002/14651858.CD009151.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009151.pub2&amp;doi=10.1002/14651858.CD009151.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009151.pub2&amp;doi=10.1002/14651858.CD009151.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009151.pub2&amp;doi=10.1002/14651858.CD009151.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009151.pub2&amp;doi=10.1002/14651858.CD009151.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009151.pub2&amp;doi=10.1002/14651858.CD009151.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009151.pub2&amp;doi=10.1002/14651858.CD009151.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009151.pub2&amp;doi=10.1002/14651858.CD009151.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009151.pub2&amp;doi=10.1002/14651858.CD009151.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009151.pub2&amp;doi=10.1002/14651858.CD009151.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773519000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773548000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000"}};Liferay.authToken="dLyXbLct";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD009151\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD009151\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009151\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD009151\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513680837000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","zh_HANS","zh_HANT","ru","ko","th","pt","ms","ja","fa","fr"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD009151.pub2",title:"Treatment for recurrent vulvovaginal candidiasis (thrush)",firstPublishedDate:"Jan 10, 2022 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane STI Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734739000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=dLyXbLct&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD009151.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD009151.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD009151.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD009151.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD009151.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD009151.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD009151.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD009151.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD009151.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD009151.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;초록&quot;},{&quot;language&quot;:&quot;th&quot;,&quot;title&quot;:&quot;บทคัดย่อ&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;ja&quot;,&quot;title&quot;:&quot;一般語訳&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;쉬운 말 요약&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;pt&quot;,&quot;title&quot;:&quot;Resumo para leigos&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;},{&quot;language&quot;:&quot;th&quot;,&quot;title&quot;:&quot;ข้้อสรุปภาษาธรรมดา&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;淺顯易懂的口語結論&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD009151.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD009151.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD009151.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD009151.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>26182 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD009151.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009151.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009151.pub2/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009151.pub2/full#CD009151-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009151.pub2/full#CD009151-sec-0192"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009151.pub2/full#CD009151-sec-0008"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009151.pub2/full#CD009151-sec-0009"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009151.pub2/full#CD009151-sec-0014"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009151.pub2/full#CD009151-sec-0015"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009151.pub2/full#CD009151-sec-0046"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009151.pub2/full#CD009151-sec-0186"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD009151.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009151.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009151.pub2/appendices#CD009151-sec-0197"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009151.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009151.pub2/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD009151.pub2/media/CDSR/CD009151/table_n/CD009151StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD009151.pub2/media/CDSR/CD009151/table_n/CD009151StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009151.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009151.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009151.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD009151.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD009151.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD009151.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2022 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD009151.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Treatment for recurrent vulvovaginal candidiasis (thrush)</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD009151.pub2/information#CD009151-cr-0004">Georga Cooke</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD009151.pub2/information#CD009151-cr-0005">Cathy Watson</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD009151.pub2/information#CD009151-cr-0006">Laura Deckx</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD009151.pub2/information#CD009151-cr-0007">Marie Pirotta</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD009151.pub2/information#CD009151-cr-0008">Jane Smith</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD009151.pub2/information#CD009151-cr-0009"><i class="icon corresponding-author fa fa-envelope"></i>Mieke L van Driel</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD009151.pub2/information/en#CD009151-sec-0211">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 10 January 2022 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD009151.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD009151.pub2">https://doi.org/10.1002/14651858.CD009151.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD009151-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD009151-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD009151-abs-0018">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD009151-abs-0014">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD009151-abs-0016">Français</a> </li> <li class="section-language"> <a class="" href="full/ko#CD009151-abs-0007">한국어</a> </li> <li class="section-language"> <a class="" href="full/th#CD009151-abs-0009">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD009151-abs-0003">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD009151-abs-0001" lang="en"> <section id="CD009151-sec-0001"> <h3 class="title" id="CD009151-sec-0001">Background</h3> <p>Recurrent vulvovaginal candidiasis (RVVC) affects up to 5% of women. No comprehensive systematic review of treatments for RVVC has been published. </p> </section> <section id="CD009151-sec-0002"> <h3 class="title" id="CD009151-sec-0002">Objectives</h3> <p>The primary objective was to assess the effectiveness and safety of pharmacological and non‐pharmacological treatments for RVVC. The secondary objective was to assess patient preference of treatment options. </p> </section> <section id="CD009151-sec-0003"> <h3 class="title" id="CD009151-sec-0003">Search methods</h3> <p>We conducted electronic searches of bibliographic databases, including CENTRAL, MEDLINE, Embase, and CINAHL (search date 6 October 2021). We also handsearched reference lists of identified trials and contacted authors of identified trials, experts in RVVC, and manufacturers of products for vulvovaginal candidiasis. </p> </section> <section id="CD009151-sec-0004"> <h3 class="title" id="CD009151-sec-0004">Selection criteria</h3> <p>We considered all published and unpublished randomised controlled trials evaluating RVVC treatments for at least six months, in women with four or more symptomatic episodes of vulvovaginal candidiasis in the past year. We excluded women with immunosuppressive disorders or taking immunosuppressant medication. We included women with diabetes mellitus and pregnant women. </p> <p>Diagnosis of RVVC must have been confirmed by presence of symptoms and a positive culture and/or microscopy. We included all drug and non‐drug therapies and partner treatment, assessing the following primary outcomes: </p> <p>• number of clinical recurrences per participant per year (recurrence defined as clinical signs and positive culture/microscopy);<br/>• proportion of participants with at least one clinical recurrence during the treatment and follow‐up period; and<br/>• adverse events. </p> </section> <section id="CD009151-sec-0005"> <h3 class="title" id="CD009151-sec-0005">Data collection and analysis</h3> <p>Two authors independently reviewed titles and abstracts to identify eligible trials. Duplicate data extraction was completed independently by two authors. We assessed risk of bias as described in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i>. We used the fixed‐effects model for pooling and expressed the results as risk ratio (RR) with 95% confidence intervals (CI). Where important statistical heterogeneity was present we either did not pool data (I<sup>2</sup> &gt; 70%) or used a random‐effects model (I<sup>2</sup> 40‐70%). We used the GRADE tool to assess overall certainty of the evidence for the pooled primary outcomes. </p> </section> <section id="CD009151-sec-0006"> <h3 class="title" id="CD009151-sec-0006">Main results</h3> <p><b>Studies:</b> Twenty‐three studies involving 2212 women aged 17 to 67 years met the inclusion criteria. Most studies excluded pregnant women and women with diabetes or immunosuppression. The predominant species found on culture at study entry was <i>Candida albicans</i>. Overall, the included studies were small (&lt;100 participants). Six studies compared antifungal treatment with placebo (607 participants); four studies compared oral versus topical antifungals (543 participants); one study compared different oral antifungals (45 participants); two studies compared different dosing regimens for antifungals (100 participants); one study compared two different dosing regimens of the same topical agent (23 participants); one study compared short versus longer treatment duration (26 participants); two studies assessed the effect of partner treatment (98 participants); one study compared a complementary treatment (Lactobacillus vaginal tablets and probiotic oral tablets) with placebo (34 participants); three studies compared complementary medicine with antifungals (354 participants); two studies compared 'dermasilk' briefs with cotton briefs (130 participants); one study examined Lactobacillus vaccination versus heliotherapy versus ciclopyroxolamine (90 participants); one study compared CAM treatments to an antifungal treatment combined with CAM treatments (68 participants). We did not find any studies comparing different topical antifungals. Nine studies reported industry funding, three were funded by an independent source and eleven did not report their funding source. </p> <p><b>Risk of bias:</b> Overall, the risk of bias was high or unclear due to insufficient blinding of allocation and participants and poor reporting. </p> <p><b>Primary outcomes:</b> Meta‐analyses comparing drug treatments (oral and topical) with placebo or no treatment showed there may be a clinically relevant reduction in clinical recurrence at 6 months (RR 0.36, 95% CI 0.21 to 0.63; number needed to treat for an additional beneficial outcome (NNTB) = 2; participants = 607; studies = 6; I² = 82%; low‐certainty evidence) and 12 months (RR 0.80, 95% CI 0.72 to 0.89; NNTB = 6; participants = 585; studies = 6; I² = 21%; low‐certainty evidence). No study reported on the number of clinical recurrences per participant per year. </p> <p>We are very uncertain whether oral drug treatment compared to topical treatment increases the risk of clinical recurrence at 6 months (RR 1.66, 95% CI 0.83 to 3.31; participants = 206; studies = 3; I² = 0%; very low‐certainty evidence) and reduces the risk of clinical recurrence at 12 months (RR 0.95, 95% CI 0.71 to 1.27; participants = 206; studies = 3; I² = 10%; very low‐certainty evidence). No study reported on the number of clinical recurrences per participant per year. </p> <p>Adverse events were scarce across both treatment and control groups in both comparisons. The reporting of adverse events varied amongst studies, was generally of very low quality and could not be pooled. Overall the adverse event rate was low for both placebo and treatment arms and ranged from less than 5% to no side effects or complications. </p> </section> <section id="CD009151-sec-0007"> <h3 class="title" id="CD009151-sec-0007">Authors' conclusions</h3> <p>In women with RVVC, treatment with oral or topical antifungals may reduce symptomatic clinical recurrences when compared to placebo or no treatment. We were unable to find clear differences between different treatment options (e.g. oral versus topical treatment, different doses and durations). These findings are not applicable to pregnant or immunocompromised women and women with diabetes as the studies did not include or report on them. More research is needed to determine the optimal medication, dose and frequency. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD009151-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD009151-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD009151-abs-0019">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD009151-abs-0015">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD009151-abs-0017">Français</a> </li> <li class="section-language"> <a class="" href="full/ja#CD009151-abs-0013">日本語</a> </li> <li class="section-language"> <a class="" href="full/ko#CD009151-abs-0008">한국어</a> </li> <li class="section-language"> <a class="" href="full/ms#CD009151-abs-0012">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/pt#CD009151-abs-0011">Português</a> </li> <li class="section-language"> <a class="" href="full/ru#CD009151-abs-0006">Русский</a> </li> <li class="section-language"> <a class="" href="full/th#CD009151-abs-0010">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD009151-abs-0004">简体中文</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD009151-abs-0005">繁體中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD009151-abs-0002" lang="en"> <h3>The effectiveness and safety of treatments for recurrent vulvovaginal candidiasis (thrush) </h3> <p><b>Review question</b> </p> <p>Cochrane authors set out to investigate the effectiveness and safety of drug treatments or non‐drug treatments (such as complementary and alternative medicines) for women with recurrent vulvovaginal candidiasis (thrush). </p> <p><b>Background</b> </p> <p>Thrush of the vaginal/vulvar area is caused by <i>Candida</i> , a form of yeast that is commonly found in the vagina as part of normal flora without causing symptoms. For unknown reasons, <i>Candida</i> can start growing and cause symptoms of vulvovaginal candidiasis (commonly named thrush). Symptoms of vulvovaginal thrush include itching, swelling, and irritation of the vaginal and vulval areas. It is estimated that uncomplicated vulvovaginal thrush affects up to 75% of women at some time during their reproductive years. Recurrent vulvovaginal candidiasis (RVVC) occurs when a woman has four or more fungal infections during a 12‐month period. Up to 5% of women suffer from RVVC. Some doctors advise taking antifungals as a prevention, but there are no clear evidence‐based guidelines. </p> <p><b>Study characteristics</b> </p> <p>We identified 23 studies involving 2212 participants between 17 and 67 years old with a diagnosis of RVVC confirmed by a positive test. The studies compared a range of antifungal medicines (taken by mouth or inserted into the vagina), and some complementary or alternative treatments (such as Lactobacillus vaccines or probiotics and special underwear). The studies reported the effects on recurrence of thrush after 6 and 12 months. Only one study reported the number of clinical recurrences at 12 months. Nine studies reported industry funding, three were funded by an independent source and nine studies did not report their funding source. The evidence is current to October 2021. </p> <p><b>Key results</b> </p> <p>Six studies (607 participants) compared antifungal medication with placebo or no treatment. Based on low certainty evidence antifungal treatments may give a clinically relevant reduction in clinical recurrence at 6 and 12 months. We are uncertain if oral treatments are better than topical treatments (very low certainty evidence for no difference). </p> <p>Adverse effects of taking antifungal medication to prevent recurrence of thrush were not common. Studies reported on adverse effects differently, making comparisons difficult. More research is needed to determine the optimal medication, dose and frequency. We were unable to determine the effects in women who are pregnant or have diabetes. </p> <p><b>Certainty of the evidence</b> </p> <p>Our confidence in the evidence was low to very low due to serious concerns about risk of bias, unclear reporting and the limited number of studies that could be combined. This means that new studies might change our confidence in the effects of treatments and our conclusions. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD009151-sec-0192" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD009151-sec-0192"></div> <h3 class="title" id="CD009151-sec-0193">Implications for practice</h3> <section id="CD009151-sec-0193"> <p>In non‐pregnant women with recurrent vulvovaginal candidiasis (RVVC), suppressive therapy with oral or topical antifungal agents may reduce symptomatic, clinical recurrences when compared to placebo or no treatment. The therapy used should be according to patient preference and affordability. To date, good‐quality evidence for complementary and alternative therapies and the benefit of partner treatment for RVVC is limited. </p> </section> <h3 class="title" id="CD009151-sec-0194">Implications for research</h3> <section id="CD009151-sec-0194"> <p>Further studies are required in this area. Researchers of new studies should focus on: </p> <p> <ul id="CD009151-list-0011"> <li> <p>methodological quality and the reporting of such ‐ focusing in particular on rigour of blinding (participants, personnel, and outcome assessors); </p> </li> <li> <p>collecting outcomes that are relevant to patients (e.g. mean number of recurrences in a 12‐month period, symptom‐free days, and patient preference) rather than simply the dichotomous outcome of any clinical recurrence; </p> </li> <li> <p>describing the outcomes that are collected in sufficient detail (e.g. clinical recurrence clearly including both symptoms and mycological confirmation); </p> </li> <li> <p>collecting outcome data at both defined time points as well as when symptoms develop (only nine of the 21 included studies stated that they assessed participants between planned visits if they developed symptoms in the intervening period, which is likely to result in underreporting of both primary and secondary outcomes); </p> </li> <li> <p>reporting baseline characteristics more comprehensively, especially the severity of RVVC (e.g. average number of recurrences in the preceding 12 months); </p> </li> <li> <p>using the commonly accepted case definition of RVVC (several studies were excluded from this review because they used a non‐standard definition of RVVC); </p> </li> <li> <p>complementary and alternative medicine trials should focus in particular on quality as well as appropriate, commonly used comparison treatments; </p> </li> <li> <p>only one study reported data on our first primary outcome (number of clinical recurrences per participant per year). Researchers of future studies should consider including this outcome in their study design; </p> </li> <li> <p>more studies comparing oral versus topical treatments and studies investigating the optimal dose would be of clinical interest. </p> </li> </ul> </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD009151-sec-0008" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD009151-sec-0008"></div> <div class="table" id="CD009151-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Drug treatment compared to placebo or no treatment for recurrent vulvovaginal candidiasis</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Drug treatment compared to placebo/no treatment (excluding partner treatment) for recurrent vulvovaginal candidiasis (thrush)</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> non‐pregnant women with a diagnosis of recurrent vulvovaginal candidiasis<br/><b>Setting:</b> outpatients<br/><b>Intervention:</b> antifungals (fluconazole, clotrimazole, ketoconazole, itraconazole)<br/><b>Comparison:</b> placebo or no treatment (excluding partner treatment) </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with placebo/no treatment (excluding partner treatment)</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with drug treatment</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Primary outcome 1: Number of clinical recurrences per participant per year</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(0 studies)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Primary outcome 2: Clinical recurrence at 6 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.36<br/>(0.21 to 0.63) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>607<br/>(6 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>647 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>233 per 1000<br/>(136 to 408) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Primary outcome 2: Clinical recurrence at 12 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.80<br/>(0.72 to 0.89) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>585<br/>(6 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>781 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>625 per 1000<br/>(562 to 695) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Primary outcome 3: Adverse events</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(5 RCTs)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW <sup>2 3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pooling of the incidence of adverse events was not possible as the outcome was reported differently across the included trials. Overall the adverse event rate was low for both placebo and treatment arms. <a href="./references#CD009151-bbs2-0020" title="SobelJD , WiesenfeldHC , MartensM , DannaP , HootonTM , RompaloA , et al.Maintenance fluconazole therapy for recurrent vulvovaginal candidiasis. New England Journal of Medicine2004;351:876-83. ">Sobel 2004</a> reported that 2.9% of participants dropped out due to adverse events in the fluconazole group and 1.2% in the placebo group. 2 participants dropped out in <a href="./references#CD009151-bbs2-0018" title="SobelJD .Recurrent vulvovaginal candidiasis. A prospective study of the efficacy of maintenance ketoconazole therapy. New England Journal of Medicine1986;315:1455-8. ">Sobel 1986</a>. No participants dropped out in <a href="./references#CD009151-bbs2-0001" title="BolouriF , TabriziNM , TanhaFD , NiroomandN , AzmoodehA , EmamiS , et al.Effectiveness of fluconazole for suppressive maintenance therapy in patients with RVVC: a randomized placebo-controlled study. Iranian Journal of Pharmaceutical Research2009;8:307-13. ">Bolouri 2009</a>. Less than 5% reported adverse effects in <a href="./references#CD009151-bbs2-0019" title="SobelJD , SchmittC , MeriwetherC .Clotrimazole treatment of recurrent and chronic candida vulvovaginitis. Obstetrics &amp; Gynecology1989;73:330-4. ">Sobel 1989</a>, and no side effects or complications occurred in <a href="./references#CD009151-bbs2-0016" title="RothAC , MilsomI , ForssmanL , WahlenP .Intermittent prophylactic treatment of recurrent vaginal candidiasis by postmenstrual application of a 500 mg clotrimazole vaginal tablet. Genitourinary Medicine1990;66:357-60. ">Roth 1990</a>. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> confidence interval; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Downgraded two levels due to very serious risk of bias for blinding or participants and assessors (<a href="./references#CD009151-bbs2-0022" title="SpinilloA , ColonnaL , PiazziG , BaltaroF , MonacoA , FerrariA .Managing recurrent vulvovaginal candidiasis. Intermittent prevention with itraconazole. Journal of Reproductive Medicine1997;42:83-7. ">Spinillo 1997</a>), incomplete outcome data (<a href="./references#CD009151-bbs2-0001" title="BolouriF , TabriziNM , TanhaFD , NiroomandN , AzmoodehA , EmamiS , et al.Effectiveness of fluconazole for suppressive maintenance therapy in patients with RVVC: a randomized placebo-controlled study. Iranian Journal of Pharmaceutical Research2009;8:307-13. ">Bolouri 2009</a>; <a href="./references#CD009151-bbs2-0018" title="SobelJD .Recurrent vulvovaginal candidiasis. A prospective study of the efficacy of maintenance ketoconazole therapy. New England Journal of Medicine1986;315:1455-8. ">Sobel 1986</a>; <a href="./references#CD009151-bbs2-0019" title="SobelJD , SchmittC , MeriwetherC .Clotrimazole treatment of recurrent and chronic candida vulvovaginitis. Obstetrics &amp; Gynecology1989;73:330-4. ">Sobel 1989</a>), and pharmaceutical funding (<a href="./references#CD009151-bbs2-0020" title="SobelJD , WiesenfeldHC , MartensM , DannaP , HootonTM , RompaloA , et al.Maintenance fluconazole therapy for recurrent vulvovaginal candidiasis. New England Journal of Medicine2004;351:876-83. ">Sobel 2004</a>).<br/><sup>2</sup>Downgraded two levels due to very serious risk of bias for incomplete outcome data, <a href="./references#CD009151-bbs2-0001" title="BolouriF , TabriziNM , TanhaFD , NiroomandN , AzmoodehA , EmamiS , et al.Effectiveness of fluconazole for suppressive maintenance therapy in patients with RVVC: a randomized placebo-controlled study. Iranian Journal of Pharmaceutical Research2009;8:307-13. ">Bolouri 2009</a>; <a href="./references#CD009151-bbs2-0018" title="SobelJD .Recurrent vulvovaginal candidiasis. A prospective study of the efficacy of maintenance ketoconazole therapy. New England Journal of Medicine1986;315:1455-8. ">Sobel 1986</a>; <a href="./references#CD009151-bbs2-0019" title="SobelJD , SchmittC , MeriwetherC .Clotrimazole treatment of recurrent and chronic candida vulvovaginitis. Obstetrics &amp; Gynecology1989;73:330-4. ">Sobel 1989</a>, and pharmaceutical funding, <a href="./references#CD009151-bbs2-0020" title="SobelJD , WiesenfeldHC , MartensM , DannaP , HootonTM , RompaloA , et al.Maintenance fluconazole therapy for recurrent vulvovaginal candidiasis. New England Journal of Medicine2004;351:876-83. ">Sobel 2004</a>.<br/><sup>3</sup>Downgraded one level due to imprecision (we were not able to pool the data). </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD009151-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Oral drug treatment compared to topical drug treatment for recurrent vulvovaginal candidiasis</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Oral drug treatment compared to topical drug treatment for recurrent vulvovaginal candidiasis</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> non‐pregnant women with a diagnosis of recurrent vulvovaginal candidiasis<br/><b>Setting:</b> outpatients<br/><b>Intervention:</b> oral drug treatment (fluconazole, itraconazole)<br/><b>Comparison:</b> topical drug treatment (nystatin, clotrimazole) </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with topical drug treatment</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with oral drug treatment</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Primary outcome 1: Number of clinical recurrences per participant per year</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(0 studies)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Primary outcome 2: Clinical recurrence at 6 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.66<br/>(0.83 to 3.31) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>206<br/>(3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW <sup>1 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>118 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>196 per 1000<br/>(98 to 392) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Primary outcome 2: Clinical recurrence at 12 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.95<br/>(0.71 to 1.27) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>206<br/>(3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW <sup>1 2 3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>495 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>470 per 1000<br/>(351 to 628) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Primary outcome 3: Adverse events</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(3 RCTs)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW <sup>4 5</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Due to heterogeneity in reporting we were not able to pool the data.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> confidence interval; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Downgraded two levels due to very serious risk of bias (allocation concealment (<a href="./references#CD009151-bbs2-0013" title="Lopez-OlmosJ , LermaE .Treatment of recurring vulvo-vaginal candidiasis: a comparative prospective study during six months of three anti-mycotic preparations of a single dosis. Clinica e Investigacion en Ginecologia y Obstetricia2000;27:366-75. ">Lopez‐Olmos 2000</a>), blinding of participants (<a href="./references#CD009151-bbs2-0007" title="FardyazarZ , HabibzadehS , Abdollahi-FardS , TelloM .Vaginal azoles versus oral fluconazole in treatment of recurrent vulvovaginal candidiasis. Iranian Journal of Clinical Infectious Diseases2007;2:17-22. FardyazarZ , HabibzadehS .Long term vaginal azoles versus prophylactic oral fluconazole in treatment of recurrent vulvovaginal candidiasis. Research Journal of Biological Sciences2007;2(6):663-6. ">Fardyazar 2007</a>; <a href="./references#CD009151-bbs2-0008" title="FongIW .The value of chronic suppressive therapy with itraconazole versus clotrimazole in women with recurrent vaginal candidiasis. Genitourinary Medicine1992;68:374-7. ">Fong 1992a</a>; <a href="./references#CD009151-bbs2-0013" title="Lopez-OlmosJ , LermaE .Treatment of recurring vulvo-vaginal candidiasis: a comparative prospective study during six months of three anti-mycotic preparations of a single dosis. Clinica e Investigacion en Ginecologia y Obstetricia2000;27:366-75. ">Lopez‐Olmos 2000</a>), blinding of assessment (<a href="./references#CD009151-bbs2-0008" title="FongIW .The value of chronic suppressive therapy with itraconazole versus clotrimazole in women with recurrent vaginal candidiasis. Genitourinary Medicine1992;68:374-7. ">Fong 1992a</a>), and pharmaceutical funding (<a href="./references#CD009151-bbs2-0007" title="FardyazarZ , HabibzadehS , Abdollahi-FardS , TelloM .Vaginal azoles versus oral fluconazole in treatment of recurrent vulvovaginal candidiasis. Iranian Journal of Clinical Infectious Diseases2007;2:17-22. FardyazarZ , HabibzadehS .Long term vaginal azoles versus prophylactic oral fluconazole in treatment of recurrent vulvovaginal candidiasis. Research Journal of Biological Sciences2007;2(6):663-6. ">Fardyazar 2007</a>)).<br/><sup>2</sup>Downgraded one level due to imprecision (wide confidence interval).<br/><sup>3</sup>Downgraded one level due to inconsistency (some studies showed superior effects for oral treatment, whereas others showed superior effects for topical treatment).<br/><sup>4</sup>Downgraded two levels due to very serious risk of bias (selection bias (<a href="./references#CD009151-bbs2-0006" title="FanS , LiuX , WuC , XuL , LiJ .Vaginal nystatin versus oral fluconazole for the treatment for recurrent vulvovaginal candidiasis. Mycopathologia2015;179:95-101. [DOI: https://doi.org/10.1007/s11046-014-9827-4]">Fan 2015</a>), blinding of participants (<a href="./references#CD009151-bbs2-0006" title="FanS , LiuX , WuC , XuL , LiJ .Vaginal nystatin versus oral fluconazole for the treatment for recurrent vulvovaginal candidiasis. Mycopathologia2015;179:95-101. [DOI: https://doi.org/10.1007/s11046-014-9827-4]">Fan 2015</a>; <a href="./references#CD009151-bbs2-0007" title="FardyazarZ , HabibzadehS , Abdollahi-FardS , TelloM .Vaginal azoles versus oral fluconazole in treatment of recurrent vulvovaginal candidiasis. Iranian Journal of Clinical Infectious Diseases2007;2:17-22. FardyazarZ , HabibzadehS .Long term vaginal azoles versus prophylactic oral fluconazole in treatment of recurrent vulvovaginal candidiasis. Research Journal of Biological Sciences2007;2(6):663-6. ">Fardyazar 2007</a>; <a href="./references#CD009151-bbs2-0008" title="FongIW .The value of chronic suppressive therapy with itraconazole versus clotrimazole in women with recurrent vaginal candidiasis. Genitourinary Medicine1992;68:374-7. ">Fong 1992a</a>), blinding of assessment (<a href="./references#CD009151-bbs2-0008" title="FongIW .The value of chronic suppressive therapy with itraconazole versus clotrimazole in women with recurrent vaginal candidiasis. Genitourinary Medicine1992;68:374-7. ">Fong 1992a</a>), incomplete outcome data (<a href="./references#CD009151-bbs2-0006" title="FanS , LiuX , WuC , XuL , LiJ .Vaginal nystatin versus oral fluconazole for the treatment for recurrent vulvovaginal candidiasis. Mycopathologia2015;179:95-101. [DOI: https://doi.org/10.1007/s11046-014-9827-4]">Fan 2015</a>), and pharmaceutical funding (<a href="./references#CD009151-bbs2-0007" title="FardyazarZ , HabibzadehS , Abdollahi-FardS , TelloM .Vaginal azoles versus oral fluconazole in treatment of recurrent vulvovaginal candidiasis. Iranian Journal of Clinical Infectious Diseases2007;2:17-22. FardyazarZ , HabibzadehS .Long term vaginal azoles versus prophylactic oral fluconazole in treatment of recurrent vulvovaginal candidiasis. Research Journal of Biological Sciences2007;2(6):663-6. ">Fardyazar 2007</a>)).<br/><sup>5</sup>Downgraded one level due to imprecision (we were not able to pool data). </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD009151-sec-0009" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD009151-sec-0009"></div> <section id="CD009151-sec-0010"> <h3 class="title" id="CD009151-sec-0010">Description of the condition</h3> <p><i>Candida</i> is a yeast that is commonly found in the vagina as part of normal flora without causing symptoms. For largely unknown reasons, <i>Candida</i> changes from being a commensal organism (i.e. it can live in the environment without causing problems for the host) to a pathogenic one (<a href="./references#CD009151-bbs2-0101" title="SobelJD .Vulvovaginal candidosis. Lancet2007;369(9577):1961-71.">Sobel 2007</a>), which causes symptoms of vulvovaginal candidiasis (VVC, commonly named thrush) (<a href="./references#CD009151-bbs2-0101" title="SobelJD .Vulvovaginal candidosis. Lancet2007;369(9577):1961-71.">Sobel 2007</a>). VVC can be diagnosed clinically, with signs and symptoms including vaginal itching or burning with or without redness and swelling of the vulvae, and a white discharge, and stinging or burning when passing urine. Diagnosis can be confirmed with a wet mount preparation (saline with 10% KOH) or Gram stain of the discharge, which will show budding yeasts and hyphae under the microscope, and/or a culture of <i>Candida (</i><a href="./references#CD009151-bbs2-0068" title="Vulvovaginal candidiasis. Sexually Transmitted Diseases Treatment Guidelines2015. [https://www.cdc.gov/std/tg2015/candidiasis.htm]">CDC 2015</a>). </p> <p>It is estimated that uncomplicated VVC affects up to 75% of women some time during their reproductive years (<a href="./references#CD009151-bbs2-0101" title="SobelJD .Vulvovaginal candidosis. Lancet2007;369(9577):1961-71.">Sobel 2007</a>), although these figures have been disputed (<a href="./references#CD009151-bbs2-0093" title="RathodSD , BufflerPA .Highly-cited estimates of the cumulative incidence and recurrence of vulvovaginal candidiasis are inadequately documented. BMC Women's Health2014;14:43. [DOI: 10.1186/1472-6874-14-43]">Rathod 2014</a>). Predisposing factors have been identified for uncomplicated VVC (<a href="./references#CD009151-bbs2-0088" title="PatelDA , GillespieB , SobelJD , LeamanD , NyirjesyP , WeitzMV , FoxmanB .Risk factors for recurrent vulvovaginal candidiasis in women receiving maintenance antifungal therapy: results of a prospective cohort study. American Journal of Obstetrics and Gynecology2004;190(3):644-53.">Patel 2004</a>), which include the use of antibiotics, hormone replacement therapy, pregnancy, diabetes mellitus, genetic factors, and behavioural factors (<a href="./references#CD009151-bbs2-0100" title="SobelJD .Management of recurrent vulvovaginal candidiasis: unresolved issues. Current Infectious Disease Reports2006;8(6):481-86.">Sobel 2006</a>). </p> <p>Up to 5% of women suffer from recurrent vulvovaginal candidiasis (RVVC), which is commonly defined as four or more episodes of VVC in a 12‐month period (<a href="./references#CD009151-bbs2-0101" title="SobelJD .Vulvovaginal candidosis. Lancet2007;369(9577):1961-71.">Sobel 2007</a>). On a global scale RVVC affects approximately 138 million women each year (range 103‐172 million). The global prevalence is estimated as 3871 per 100 000 women with 372 million women affected over their lifetime (<a href="./references#CD009151-bbs2-0072" title="DenningDW , KnealeM , SobelJD , Rautemaa-RichardsonR .Global burden of recurrent vulvovaginal candidiasis: a systematic review. Lancet Infect Dis2018;August 2:e339-47. [DOI: 10.1016/S1473-3099(18)30103-8]">Denning 2018</a>), specifically women between 25 and 35 years old. Denning calculated that in high‐income countries the economic burden of lost productivity could be as high as US$14.39 billion per year (<a href="./references#CD009151-bbs2-0072" title="DenningDW , KnealeM , SobelJD , Rautemaa-RichardsonR .Global burden of recurrent vulvovaginal candidiasis: a systematic review. Lancet Infect Dis2018;August 2:e339-47. [DOI: 10.1016/S1473-3099(18)30103-8]">Denning 2018</a>). The role of predisposing factors for uncomplicated vulvovaginal candidiasis is not certain in RVVC. In approximately half of women with RVVC, no risk factors can be identified (<a href="./references#CD009151-bbs2-0085" title="NyirjesyP .Vulvovaginal candidiasis and bacterial vaginosis. Infectious Disease Clinics of North America2008;22(4):637-52.">Nyirjesy 2008</a>). </p> <p>The aetiology of RVVC is unclear. Most cases (85% to 95%) of uncomplicated vulvovaginal candidiasis are caused by <i>Candida albicans.</i> However, less common candidal species such as <i>Candida glabrata</i> may be implicated in RVVC. Vaginitis caused by non‐albicans species tends to be more resistant to treatment (<a href="./references#CD009151-bbs2-0101" title="SobelJD .Vulvovaginal candidosis. Lancet2007;369(9577):1961-71.">Sobel 2007</a>). Many theories, such as maladaptive immune response and involvement of polymorphonuclear leucocytes, remain controversial (<a href="./references#CD009151-bbs2-0075" title="FidelPL , SobelJD .Protective immunity in experimental Candida vaginitis. Research in Immunology1998;149(4-5):361-73.">Fidel 1998</a>; <a href="./references#CD009151-bbs2-0089" title="PetersBM , YanoJ , NoverrMC , Fidel JrPL .Candida Vaginitis: When opportunism knocks, the host responds. PLOS Pathogens2014;10(4):e1003965. [DOI: 10.1371/journal.ppat.1003965]">Peters 2014</a>; <a href="./references#CD009151-bbs2-0101" title="SobelJD .Vulvovaginal candidosis. Lancet2007;369(9577):1961-71.">Sobel 2007</a>), and the role of individual and genetic susceptibility has not yet been defined (<a href="./references#CD009151-bbs2-0101" title="SobelJD .Vulvovaginal candidosis. Lancet2007;369(9577):1961-71.">Sobel 2007</a>). </p> <p>The effects of RVVC on the intimate relationships and daily living of women can be significant. <a href="./references#CD009151-bbs2-0073" title="EhrstromS , KornfeldD , RylanderE .Perceived stress in women with recurrent vulvovaginal candidiasis. Journal of Psychosomatic Obstetrics and Gynecology2007;28(3):169-176.">Ehrstrom 2007</a> found that women with RVVC were significantly more likely to report signs of burnout, emotional and physical stress, and poor work‐life balance than a control group of women without RVVC. The major impact of the physical symptoms, including discharge, itchiness, pain and psychological effects, often goes unrecognised (<a href="./references#CD009151-bbs2-0069" title="ChappleA , HassellK , NicholsonM , CantrillJ .&quot;You don't really feel you can function normally&quot;: women's perceptions and personal management of vaginal thrush&quot;. Journal of Reproductive and Infant Psychology2000;18(4):309-319.">Chapple 2000</a>). Additionally, in some countries long‐term treatment can be expensive (<a href="./references#CD009151-bbs2-0102" title="SobelJD .Factors involved in patient choice of oral or vaginal treatment for vulvovaginal candidiasis. Patient Preference and Adherence2013;8:31-34. [DOI: 10.2147/PPA.S8984]">Sobel 2014</a>), and approximately 50% of women experience recurrence of symptoms within months of finishing treatment (<a href="./references#CD009151-bbs2-0099" title="SobelJD , WiesenfeldHC , MartensM , DannaP , HootonTM , RompaloA , et al.Maintenance fluconazole therapy for recurrent vulvovaginal candidiasis. New England Journal of Medicine2004;351(9):876-83..">Sobel 2004b</a>). </p> </section> <section id="CD009151-sec-0011"> <h3 class="title" id="CD009151-sec-0011">Description of the intervention</h3> <p>Management of uncomplicated vulvovaginal candidiasis usually consists of topical or oral antifungal treatments with frequency ranging from a single dose to treatment for up to 14 days (<a href="./references#CD009151-bbs2-0087" title="PappasPG , KauffmanCA , AndesDR , ClancyCJ , MarrKA , Ostrosky-ZeichnerL , et al.Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America. Clinical Infectious Diseases2015;62(4):e1-e50.">Pappas 2015</a>; <a href="./references#CD009151-bbs2-0105" title="Therapeutic Guidelines.eTG: Antibiotic. updated June 2019 edition. Melbourne, Victoria: Therapeutic Guidelines Limited, 2015.">Therapeutic Guidelines 2015</a>). Antifungal drugs fall broadly into five classes: polyenes, azoles, allylamines, echinocandins, and other agents, including griseofulvin and flucytosine (<a href="./references#CD009151-bbs2-0070" title="ChenS , SorrellT .Antifungal agents. Medical Journal of Australia2007;187(7):404-409.">Chen 2007</a>). The most commonly recommended antifungals for the treatment of vulvovaginal thrush are azoles (e.g. clotrimazole, fluconazole, itraconazole, miconazole, ketoconazole) and nystatin (a polyene). These treatments have been shown to be effective as topical treatment in pregnant women (<a href="./references#CD009151-bbs2-0112" title="YoungG , JewellD .Topical treatment for vaginal candidiasis (thrush) in pregnancy. Cochrane Database of Systematic Reviews2001, Issue 4. Art. No: CD000225. [DOI: 10.1002/14651858.CD000225]">Young 2001</a>) and non‐pregnant women (<a href="./references#CD009151-bbs2-0079" title="LopezJEM .Candidiasis (vulvovaginal). BMJ Clin Evid2013;3:0815.">Lopez 2013</a>). Systematic reviews (<a href="./references#CD009151-bbs2-0079" title="LopezJEM .Candidiasis (vulvovaginal). BMJ Clin Evid2013;3:0815.">Lopez 2013</a>; <a href="./references#CD009151-bbs2-0083" title="NurbhaiM , GrimshawJ , WatsonM , BondCM , MollisonJA , LudbrookA .Oral versus intra-vaginal imidazole and triazole anti-fungal treatment of uncomplicated vulvovaginal candidiasis (thrush). Cochrane Database of Systematic Reviews2007, Issue 4. Art. No: CD002845. [DOI: 10.1002/14651858.CD002845.pub2]">Nurbhai 2007</a> and <a href="./references#CD009151-bbs2-0107" title="WatsonMC , GrimshawJM , BondCM , MollisonJ , LudbrookA .Oral versus intra-vaginal imidazole and triazole anti-fungal agents for the treatment of uncomplicated vulvovaginal candidiasis (thrush): a systematic review. British Journal of Obstetrics and Gynaecology2002;109:85-95.">Watson 2002</a>) found that oral and intravaginal (topical) treatments were equally effective in women with uncomplicated acute (i.e. less than four episodes in 12 months) vulvovaginal candidiasis, but <a href="./references#CD009151-bbs2-0083" title="NurbhaiM , GrimshawJ , WatsonM , BondCM , MollisonJA , LudbrookA .Oral versus intra-vaginal imidazole and triazole anti-fungal treatment of uncomplicated vulvovaginal candidiasis (thrush). Cochrane Database of Systematic Reviews2007, Issue 4. Art. No: CD002845. [DOI: 10.1002/14651858.CD002845.pub2]">Nurbhai 2007</a> found that women generally prefer oral treatment. </p> <p>The recommended treatment regimen for complicated vulvovaginitis such as RVVC as outlined in clinical guidelines is not effective for all women (<a href="./references#CD009151-bbs2-0087" title="PappasPG , KauffmanCA , AndesDR , ClancyCJ , MarrKA , Ostrosky-ZeichnerL , et al.Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America. Clinical Infectious Diseases2015;62(4):e1-e50.">Pappas 2015</a>; <a href="./references#CD009151-bbs2-0105" title="Therapeutic Guidelines.eTG: Antibiotic. updated June 2019 edition. Melbourne, Victoria: Therapeutic Guidelines Limited, 2015.">Therapeutic Guidelines 2015</a>), whether oral or topical (<a href="./references#CD009151-bbs2-0097" title="ShahidZ , SobelJD .Reduced fluconazole susceptibility of Candida albicans isolates in women with recurrent vulvovaginal candidiasis: effects of long-term fluconazole therapy. Diagnostic Microbiology and Infectious Disease2009;64(3):354-56.">Shahid 2009</a>). Some women experience adverse effects including headache, abdominal pain, and nausea with oral treatment and dyspareunia or irritation with vaginal treatment (<a href="./references#CD009151-bbs2-0098" title="SobelJD , BrookerD , SteinGE , ThomasonJL , WermelingDP , BradleyB , WeinsteinL .Single oral dose fluconazole compared with conventional clotrimazole topical therapy of candida-vaginitis. American Journal of Obstetrics and Gynecology1995;172(4):1263-68.">Sobel 1995</a>; <a href="./references#CD009151-bbs2-0104" title="SteinGE , MummawN .Placebo-controlled trial of itraconazole for the treatment of acute vaginal candidiasis. Antimicrobial Agents and Chemotherapy1993;37(1):89-92.">Stein 1993</a>). </p> <p>Topical antifungal agents are applied to the vaginal mucosa, and are delivered in the form of creams or pessaries. Oral antifungal treatment exists in the form of tablets or capsules. The currently recommended treatment for RVVC rarely cures this condition but rather aims to suppress symptoms (<a href="./references#CD009151-bbs2-0087" title="PappasPG , KauffmanCA , AndesDR , ClancyCJ , MarrKA , Ostrosky-ZeichnerL , et al.Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America. Clinical Infectious Diseases2015;62(4):e1-e50.">Pappas 2015</a>). Initially high doses of oral or topical antifungal agents are used for up to two weeks to induce suppression of symptoms. In severe cases, the suppression of symptoms may take up to six months (<a href="./references#CD009151-bbs2-0099" title="SobelJD , WiesenfeldHC , MartensM , DannaP , HootonTM , RompaloA , et al.Maintenance fluconazole therapy for recurrent vulvovaginal candidiasis. New England Journal of Medicine2004;351(9):876-83..">Sobel 2004b</a>). This suppression period is followed by long‐term regular (weekly or monthly) antifungal treatment to maintain clinical remission (<a href="./references#CD009151-bbs2-0087" title="PappasPG , KauffmanCA , AndesDR , ClancyCJ , MarrKA , Ostrosky-ZeichnerL , et al.Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America. Clinical Infectious Diseases2015;62(4):e1-e50.">Pappas 2015</a>; <a href="./references#CD009151-bbs2-0105" title="Therapeutic Guidelines.eTG: Antibiotic. updated June 2019 edition. Melbourne, Victoria: Therapeutic Guidelines Limited, 2015.">Therapeutic Guidelines 2015</a>). </p> <p>Hormones, such as depo‐medroxyprogesterone (<a href="./references#CD009151-bbs2-0074" title="FalagasM , BetsiGI , AthanasiouS .Probiotics for prevention of recurrent vulvovaginal candidiasis: A review. Journal of Antimicrobial Chemotherapy2006;58:266-72.">Falagas 2006</a>; <a href="./references#CD009151-bbs2-0081" title="MillerL , PattonDL , MeierA , ThwinS , HootonTM , EschenbachDA .Depomedroxyprogesterone-induced hypoestrogenism and changes in vaginal flora and epithelium. Obstetrics &amp; Gynecology2000;96(3):431-9.">Miller 2000</a>) have been suggested as treatment for VVC, but their efficacy has been questioned by some studies (<a href="./references#CD009151-bbs2-0091" title="PirottaM , GunnJ , ChondrosP , GroverS , O'MalleyP , GarlandS .The effect of lactobacillus in preventing post-antibiotic vulvovaginal candidiasis: a randomised controlled trial. British Medical Journal.2004;329:548-552.">Pirotta 2004</a>), and the lack of supporting evidence has been highlighted by others (<a href="./references#CD009151-bbs2-0106" title="Van KesselK , AssefiN , MarrazzoJ , EckertL .Common complementary and alternative therapies for yeast vaginitis and bacterial vaginosis: A systematic review. Obstetrical &amp; Gynecological Survey2003;58(5):351-58.">Van Kessel 2003</a>). </p> <p>Other treatment options include changing contraceptive, partner treatment, and use of topical gentian violet. These options have been poorly researched. </p> <p>Conventional treatment of RVVC is not always successful and often involves long‐term or multiple treatments (<a href="./references#CD009151-bbs2-0087" title="PappasPG , KauffmanCA , AndesDR , ClancyCJ , MarrKA , Ostrosky-ZeichnerL , et al.Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America. Clinical Infectious Diseases2015;62(4):e1-e50.">Pappas 2015</a>; <a href="./references#CD009151-bbs2-0105" title="Therapeutic Guidelines.eTG: Antibiotic. updated June 2019 edition. Melbourne, Victoria: Therapeutic Guidelines Limited, 2015.">Therapeutic Guidelines 2015</a>). Significant variation in approach is seen between individual practitioners (<a href="./references#CD009151-bbs2-0109" title="WatsonC , PirottaM .Recurrent vulvovaginal candidiasis - current management. Australian Family Physician March 2011;40(3):149-151.">Watson 2011</a>). Due either to the limitations of current treatments or patient preference, many women seek treatment alternatives. Complementary and alternative medicine (CAM) is highly acceptable to women and is widely used in managing this condition (<a href="./references#CD009151-bbs2-0084" title="NyirjesyP .Chronic vulvovaginal candidiasis. American Family Physician2001;63(4):697-702.">Nyirjesy 2001</a>). One study found that up to 40% of women use CAM to treat or prevent vulvovaginal candidiasis despite the wide availability of conventional antifungal agents (<a href="./references#CD009151-bbs2-0090" title="PirottaMV , GunnJM , ChondrosP .&quot;Not thrush again!&quot; Women's experience of post-antibiotic vulvovaginitis. Medical Journal of Australia2003;179(1):43-46.">Pirotta 2003</a>). Examples of CAM used are herbal preparations such as tea tree oil, garlic, probiotics such as <i>Lactobacillus</i>, and vaginal acidifying agents. Evaluation of the effectiveness and safety of CAM for vulvovaginal candidiasis in the literature has been sparse. A review of the evidence concludes the effectiveness of oral or intravaginal garlic, intravaginal teat tree oil and yoghurt (containing Lactobacillus acidophilus) either oral or intravaginal, is unknown (<a href="./references#CD009151-bbs2-0079" title="LopezJEM .Candidiasis (vulvovaginal). BMJ Clin Evid2013;3:0815.">Lopez 2013</a>). Garlic taken orally can cause gastro‐intestinal symptoms such as heartburn, nausea, diarrhoea and bloating, and prolonged intravaginal use may result in allergic reactions or chemical burns (<a href="./references#CD009151-bbs2-0079" title="LopezJEM .Candidiasis (vulvovaginal). BMJ Clin Evid2013;3:0815.">Lopez 2013</a>). Topical tea tree oil can irritate the skin and cause a severe allergic rash (<a href="./references#CD009151-bbs2-0079" title="LopezJEM .Candidiasis (vulvovaginal). BMJ Clin Evid2013;3:0815.">Lopez 2013</a>). Yoghurt can cause gastrointestinal discomfort in people with lactose intolerance (<a href="./references#CD009151-bbs2-0079" title="LopezJEM .Candidiasis (vulvovaginal). BMJ Clin Evid2013;3:0815.">Lopez 2013</a>). </p> <p>A fungal immunotherapeutic vaccine (NDV‐3A) has recently been the subject of phase 2 trials and shows potential in reducing recurrences of VVC (<a href="./references#CD009151-bbs2-0034" title="Edwards JE Jr, SchwartzMM , SchmidtCS , SobelJD , NyirjesyP , SchodelF , et al.A Fungal Immunotherapeutic Vaccine (NDV-3A) for Treatment of Recurrent Vulvovaginal Candidiasis-A Phase 2 Randomized, Double-Blind, Placebo-Controlled Trial. Clin Infect Dis2018;66(12):1928-1936. NyirjesyP , SobelJD , EdwardsJE , SchwarzMW , SchmidtCS , HennesseyJP .NDV-3A vaccine reduces the frequency of vaginitis in patients with recurrent vulvovaginal candidiasis. American Journal of Obstetrics and Gynecology2016;215(6):S822. [DOI: 10.1016/j.ajog.2016.09.019]">Edwards 2018</a>). Given that resistance to conventional antifungal treatment for RVVC has been reported and that conventional therapy does not work for all women (<a href="./references#CD009151-bbs2-0103" title="SobelJD .Recurrent vulvovaginal candidiasis. American Journal of Obstetrics &amp; Gynecology2016;214(1):15-21.">Sobel 2016</a>), it is vital to investigate novel treatments that may increase options for RVVC management. </p> </section> <section id="CD009151-sec-0012"> <h3 class="title" id="CD009151-sec-0012">How the intervention might work</h3> <p>The mode of action of antifungal agents is generally fungistatic, that is they Interfere with biosynthesis or integrity of ergosterol, the major sterol in the fungal cell membrane, and induce breakdown of the fungal cell wall (<a href="./references#CD009151-bbs2-0070" title="ChenS , SorrellT .Antifungal agents. Medical Journal of Australia2007;187(7):404-409.">Chen 2007</a>; <a href="./references#CD009151-bbs2-0110" title="WildfeuerA , LaufenH , SchmalreckAF , YeatesRA , ZimmermannT .Fluconazole: comparison of pharmacokinetics, therapy and in vitro susceptibility. Mycoses1997;40(7-8):259-65.">Wildfeuer 1997</a>). The most commonly used antifungal class is the azoles, which is made up of the imidazoles (e.g. ketoconazole, miconazole, clotrimazole and econazole) and the triazoles (e.g. fluconazole and itraconazole) (<a href="./references#CD009151-bbs2-0070" title="ChenS , SorrellT .Antifungal agents. Medical Journal of Australia2007;187(7):404-409.">Chen 2007</a>). Imidazole drugs are used in superficial fungal infections, while triazoles have a place in both superficial and invasive fungal infections (<a href="./references#CD009151-bbs2-0070" title="ChenS , SorrellT .Antifungal agents. Medical Journal of Australia2007;187(7):404-409.">Chen 2007</a>). The azoles act by inhibiting the fungal cytochrome P450–Erg11p or cytochrome P51p enzymes, inhibiting 14a‐demethylation of lanosterol in the ergosterol biosynthetic pathway (<a href="./references#CD009151-bbs2-0086" title="OddsFC , BrownAJP , GowNAR .Antifungal agents: mechanisms of action. Trends in Microbiology2003;11(6):272-9.">Odds 2003</a>). This alters the fluidity and permeability of the fungal cell wall. </p> <p>Alteration of the host environment so that it is less favourable for the proliferation of <i>Candida</i> is the underlying theory supporting the use of other therapies such as probiotics, gels used to restore vaginal acid balance, and treatments such as depo‐medroxyprogesterone (<a href="./references#CD009151-bbs2-0074" title="FalagasM , BetsiGI , AthanasiouS .Probiotics for prevention of recurrent vulvovaginal candidiasis: A review. Journal of Antimicrobial Chemotherapy2006;58:266-72.">Falagas 2006</a>; <a href="./references#CD009151-bbs2-0081" title="MillerL , PattonDL , MeierA , ThwinS , HootonTM , EschenbachDA .Depomedroxyprogesterone-induced hypoestrogenism and changes in vaginal flora and epithelium. Obstetrics &amp; Gynecology2000;96(3):431-9.">Miller 2000</a>). </p> <p>Some less commonly used treatments such as immunotherapy claim to promote the restoration of the immune system (<a href="./references#CD009151-bbs2-0082" title="MoraesPS , deLima GoiabaS , TaketomiEA .Candida albicans allergen immunotherapy in recurrent vaginal candidiasis. Journal of Investigational Allergology &amp; Clinical Immunology2000;10(5):305-9.">Moraes 2000</a>). </p> </section> <section id="CD009151-sec-0013"> <h3 class="title" id="CD009151-sec-0013">Why it is important to do this review</h3> <p>A number of systematic reviews address treatment options for uncomplicated acute VVC (<a href="./references#CD009151-bbs2-0083" title="NurbhaiM , GrimshawJ , WatsonM , BondCM , MollisonJA , LudbrookA .Oral versus intra-vaginal imidazole and triazole anti-fungal treatment of uncomplicated vulvovaginal candidiasis (thrush). Cochrane Database of Systematic Reviews2007, Issue 4. Art. No: CD002845. [DOI: 10.1002/14651858.CD002845.pub2]">Nurbhai 2007</a>; <a href="./references#CD009151-bbs2-0111" title="XieHY , FengD , WeiDM , MeiL , ChenH , WangX , FangF .Probiotics for vulvovaginal candidiasis in non-pregnant women. Cochrane Database of Systematic Reviews2017, Issue 11. Art. No: CD010496. [DOI: 10.1002/14651858.CD010496.pub2]">Xie 2017</a>; <a href="./references#CD009151-bbs2-0112" title="YoungG , JewellD .Topical treatment for vaginal candidiasis (thrush) in pregnancy. Cochrane Database of Systematic Reviews2001, Issue 4. Art. No: CD000225. [DOI: 10.1002/14651858.CD000225]">Young 2001</a>). However, RVVC poses different challenges and there is currently no comprehensive systematic review of the treatment options for RVVC. Available guidelines are based on consensus only. RVVC is a common condition that can severely impact women and their partners both physically and psychologically. Many treatments are expensive, and the evidence for the efficacy of several treatments has not been systematically collated. There are also concerns about safety, especially for the non‐conventional complementary and alternative treatment. Evaluation of the many therapies used to manage this condition is essential to provide information so that women and their healthcare practitioners can make informed decisions about the management of RVVC. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD009151-sec-0014" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD009151-sec-0014"></div> <p>The primary objective of this systematic review was to assess the effectiveness and safety of pharmacological and non‐pharmacological treatments for recurrent vulvovaginal candidiasis. The secondary objective of the review was to assess patient preference of these treatment options. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD009151-sec-0015" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD009151-sec-0015"></div> <section id="CD009151-sec-0016"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD009151-sec-0017"> <h4 class="title">Types of studies</h4> <p>We considered all published and unpublished randomised controlled trials evaluating treatments for RVVC for at least six months for inclusion. Outcome measurement at six months was considered meaningful as the focus of this review is on managing a recurring condition rather than managing a single episode. We considered all types of randomised trials (including parallel and cluster randomised trials). We did not identify any cluster‐randomised trials. </p> </section> <section id="CD009151-sec-0018"> <h4 class="title">Types of participants</h4> <p>We included all women with at least four symptomatic episodes in the past year of vulvovaginal candidiasis, confirmed by the presence of symptoms and a positive culture or symptoms and positive microscopy. We included women with diabetes and women who are pregnant. We excluded women with immunosuppressive disorders or taking immunosuppressant medication. </p> <p>We included all settings (e.g. family medicine clinic, gynaecology outpatient clinic, sexually transmitted disease or family planning clinic). </p> </section> <section id="CD009151-sec-0019"> <h4 class="title">Types of interventions</h4> <p>We considered the following interventions.</p> <p> <ul id="CD009151-list-0001"> <li> <p>Antifungal treatments, administered intravaginally or orally</p> </li> <li> <p>Other treatments for candida vulvovaginitis, such as probiotics, gentian violet, acidifying agents (including cider vinegar, boric acid, and vaginal gels), tea tree oil, douching, garlic and dietary modification </p> </li> <li> <p>Partner treatment</p> </li> </ul> </p> <p>We made the following comparisons.</p> <p> <ol id="CD009151-list-0002"> <li> <p>Drug treatment (oral and topical) versus placebo/no treatment (excluding partner treatment)</p> </li> <li> <p>Oral drug treatment versus topical drug treatment</p> </li> <li> <p>Oral drug treatment versus oral drug treatment</p> </li> <li> <p>Topical drug treatment versus topical drug treatment</p> </li> <li> <p>Comparison of different doses of the same agent</p> </li> <li> <p>Short duration of treatment versus longer duration of treatment</p> </li> <li> <p>Partner treatment versus placebo/no treatment</p> </li> <li> <p>Complementary and alternative medicine versus placebo/no treatment</p> </li> <li> <p>Complementary and alternative medicine versus drug treatments</p> </li> <li> <p>Complementary and alternative medicine versus non‐drug treatments</p> </li> <li> <p>Vaccination versus other treatment</p> </li> </ol> </p> </section> <section id="CD009151-sec-0020"> <h4 class="title">Types of outcome measures</h4> <p>We included the following primary and secondary outcome measures.</p> <section id="CD009151-sec-0021"> <h5 class="title">Primary outcomes</h5> <p> <ul id="CD009151-list-0003"> <li> <p>Number of clinical recurrences per participant per year (recurrence defined as clinical features and positive culture or microscopy) </p> </li> <li> <p>Proportion of participants with at least one clinical recurrence during the treatment and follow‐up period </p> </li> <li> <p>Adverse events</p> </li> </ul> </p> </section> <section id="CD009151-sec-0022"> <h5 class="title">Secondary outcomes</h5> <p> <ul id="CD009151-list-0004"> <li> <p>Time to first recurrence</p> </li> <li> <p>Number of symptomatic days per year</p> </li> <li> <p>Number of mycological recurrences per participant per year</p> </li> <li> <p>Proportion of participants with at least one mycological recurrence during the treatment and follow‐up period </p> </li> <li> <p>Duration of symptoms after treatment initiation</p> </li> <li> <p>Patient preference</p> </li> </ul> </p> </section> </section> </section> <section id="CD009151-sec-0023"> <h3 class="title">Search methods for identification of studies</h3> <p>We attempted to identify as many relevant randomised controlled trials (RCTs) as possible of "treatment" for "recurrent vulvovaginal candidiasis", irrespective of language of publication, publication date, and publication status (published, unpublished, in press, and in progress). We used both electronic searching in bibliographic databases and handsearching, as described in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD009151-bbs2-0071" title="DeeksJJ , HigginsJPT , AltmanDG , editor(s).Chapter 9: Analysing data and undertaking metaanalyses. In: Higgins JPT, Churchill R, Chandler J, Cumpston MS, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.2.0 (updated June 2017). Cochrane, 2017. Available from www.training.cochrane.org/handbook.">Deeks 2017</a>). </p> <section id="CD009151-sec-0024"> <h4 class="title">Electronic searches</h4> <p>We contacted the Information Specialist of the Cochrane Sexually Transmitted Infections Group and our local Information Specialist to design a comprehensive search strategy to identify as many relevant RCTs as possible in the electronic databases. We used a combination of controlled vocabulary (MeSH, Emtree, DeCS, including exploded terms) and free‐text terms (considering spelling variants, synonyms, acronyms and truncation) for "vulvovaginal candidiasis" and "recurrence", with field labels, proximity operators, and Boolean operators. There were no date or language restrictions. </p> <p>We searched the following electronic databases.</p> <p> <ul id="CD009151-list-0005"> <li> <p>Cochrane Central Register of Studies Online (CENTRAL) (inception to 6 October 2021) (<a href="./appendices#CD009151-sec-0198">Appendix 1</a>) </p> </li> <li> <p>MEDLINE, Ovid platform (1946 to 6 October 2021) (<a href="./appendices#CD009151-sec-0198">Appendix 1</a>) </p> </li> <li> <p>Embase, Embase.com platform (inception to 6 October 2021) (<a href="./appendices#CD009151-sec-0198">Appendix 1</a>) </p> </li> <li> <p>CINAHL (Cumulative Index to Nursing and Allied Health Literature) (inception to 11 September 2020) (<a href="./appendices#CD009151-sec-0199">Appendix 2</a>). Any later CINAHL output is contained in the CENTRAL 6 October 2021 search output.  </p> </li> </ul> </p> <p>The following appendices present earlier searches of CENTRAL (<a href="./appendices#CD009151-sec-0200">Appendix 3</a>; <a href="./appendices#CD009151-sec-0201">Appendix 4</a>), MEDLINE (<a href="./appendices#CD009151-sec-0200">Appendix 3</a>; <a href="./appendices#CD009151-sec-0202">Appendix 5</a>), Embase (<a href="./appendices#CD009151-sec-0200">Appendix 3</a>; <a href="./appendices#CD009151-sec-0203">Appendix 6</a>), Web of Science (<a href="./appendices#CD009151-sec-0204">Appendix 7</a>), and ProQuest (<a href="./appendices#CD009151-sec-0205">Appendix 8</a>).  </p> <p>For MEDLINE, we used the Cochrane Highly Sensitive Search Strategy for identifying RCTs: sensitivity‐ and precision‐maximising version Ovid format (<a href="./references#CD009151-bbs2-0071" title="DeeksJJ , HigginsJPT , AltmanDG , editor(s).Chapter 9: Analysing data and undertaking metaanalyses. In: Higgins JPT, Churchill R, Chandler J, Cumpston MS, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.2.0 (updated June 2017). Cochrane, 2017. Available from www.training.cochrane.org/handbook.">Deeks 2017</a>). </p> </section> <section id="CD009151-sec-0025"> <h4 class="title">Searching other resources</h4> <p>We searched the following trial registers on 27 July 2019. Ongoing trials from both trial registries were included in the 2021 CENTRAL search. </p> <p> <ul id="CD009151-list-0006"> <li> <p>US National Institutes of Health Ongoing Trials Register ClinicalTrials.gov (<a href="http://clinicaltrials.gov/" target="_blank">clinicaltrials.gov/</a>) (<a href="./appendices#CD009151-sec-0206">Appendix 9</a>) </p> </li> <li> <p>World Health Organization International Clinical Trials Registry Platform (<a href="http://apps.who.int/trialsearch/" target="_blank">apps.who.int/trialsearch/</a>) (<a href="./appendices#CD009151-sec-0207">Appendix 10</a>) </p> </li> </ul> </p> <p>We handsearched reference lists of systematic reviews, other relevant publications on the same topic, and the reference lists of all included studies to identify further potentially eligible studies. We also contacted the authors of identified trials, experts in RVVC, and manufacturers producing products for vulvovaginal candidiasis to identify unpublished studies. </p> </section> </section> <section id="CD009151-sec-0026"> <h3 class="title" id="CD009151-sec-0026">Data collection and analysis</h3> <section id="CD009151-sec-0027"> <h4 class="title">Selection of studies</h4> <p>Two review authors (GC and CW) independently reviewed the titles and abstracts identified by the search for potentially relevant studies and then assessed the full texts of those studies deemed potentially relevant for inclusion in the review. We excluded double publications and reports of the same study at different points of time of follow up. Any disagreements were resolved by discussion or by consulting with a third review author (MVD). We contacted trial authors if we needed more information before deciding on inclusion. </p> </section> <section id="CD009151-sec-0028"> <h4 class="title">Data extraction and management</h4> <p>Two review authors (GC and CW) independently extracted data using a paper data extraction form. Any discrepancies were resolved by discussion or by consulting with a third review author (MVD). The data extraction form included information on study citation; study characteristics (design, sample size, randomisation method, blinding, measurement of outcomes, method of analysis, (intention‐to‐treat, per protocol, etc.), duration of follow‐up; population (age of participants, inclusion and exclusion criteria, setting, number of excluded patients, number lost to follow up, number of analysed patients); interventions (drugs/treatments, dose, route of administration, duration of treatment, comparisons); outcomes (primary and secondary outcomes, including definition of objective and subjective outcomes, attrition); and other issues (including information on funding) (see <a href="./references#CD009151-sec-0220" title="">Characteristics of included studies</a>). We contacted authors for additional clarification or information if necessary. We performed data analysis using Review Manager 5 software (<a href="./references#CD009151-bbs2-0095" title="Nordic Cochrane Centre, The Cochrane CollaborationReview Manager 5 (RevMan 5).Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014.">Review Manager 2014</a>). </p> </section> <section id="CD009151-sec-0029"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Four review authors (JS, MP, LD, and MVD) independently evaluated risk of bias in the included trials as described in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD009151-bbs2-0078" title="HigginsJPT , Green S (editors).Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. In: The Cochrane Collaboration. The Cochrane Collaboration, 2011. [Available from www.cochrane-handbook.org.]">Higgins 2011</a>), including assessment of sequence generation, allocation concealment, blinding of participants and personnel, blinding of outcome assessment, incomplete outcome data, selective outcome reporting, and other sources of bias. Any discrepancies were resolved by discussion or by consulting with a third review author (MVD or GC). We contacted authors of trials for more information if necessary. </p> <p>We assessed the risk as 'low' if sufficient information was reported and the method described was adequate. We assessed the risk as 'high' if the described method was inadequate or if there was insufficient information to permit an assessment and it was likely that a rigorous method was not used. We assessed the risk of bias as 'unclear' if insufficient information was reported to permit assessment of the methods used. </p> <section id="CD009151-sec-0030"> <h5 class="title">Random sequence generation (selection bias)</h5> <p>We assessed the method used to generate the allocation sequence as described in the study publication (and/or protocol if available) as: </p> <p> <ul id="CD009151-list-0007"> <li> <p>'low risk' if a random process was used, e.g. random number table or computer random number generator; </p> </li> <li> <p>'high risk' if a non‐random process was used, e.g. odd or even date of birth, alternating dates, hospital record number; or </p> </li> <li> <p>'unclear risk' if the trial is described as randomised, but the method used for the allocation sequence generation is not or is insufficiently described. </p> </li> </ul> </p> </section> <section id="CD009151-sec-0031"> <h5 class="title">Allocation concealment (selection bias)</h5> <p>We assessed the method used to conceal the allocation sequence as described in the study publication (and/or protocol if available) as:<br/>• 'low risk' if an appropriately concealed method was used (e.g. central randomisation; sealed, opaque envelopes);<br/>• 'high risk' if open random allocation was used or other unblinded methods (e.g. unsealed or non‐opaque envelopes, alternate dates); or<br/>• 'unclear risk' if the trial is described as randomised but the method used to conceal sequence allocation is not or is insufficiently described. </p> </section> <section id="CD009151-sec-0032"> <h5 class="title">Blinding of participants and personnel (performance bias)</h5> <p>We assessed the method used to ensure blinding of participants and personnel as described in the study publication (and/or protocol if available) as: </p> <p>• 'low risk' if an appropriate method of blinding was used (e.g. identical appearance of treatments and identical administration routines);<br/>• 'high risk' if the method used was transparent (e.g. oral versus topical administration); or<br/>• 'unclear risk' if the trial is described as blinded but the method used to ensure blinding is not or is insufficiently described. </p> </section> <section id="CD009151-sec-0033"> <h5 class="title">Blinding of outcome assessment (detection bias)</h5> <p>We assessed the risk of bias related to blinding of outcome assessment as described in the study publication (and/or protocol if available) as: </p> <p>• 'low risk' if outcome assessors were unable to determine the treatment allocated;<br/>• 'high risk' if outcome assessors had knowledge or could have had knowledge of the allocated treatment, and this could have influenced their assessment (e.g. in the case of instruments assessed through interview); or<br/>• 'unclear risk' if information about blinding of outcome assessors was insufficient to permit a judgement of low or high risk of bias. </p> </section> <section id="CD009151-sec-0034"> <h5 class="title">Incomplete outcome data (attrition bias)</h5> <p>For each study, we reported the number of participants randomised and the number for whom outcomes were reported for the different outcomes and at different time points. We assessed the completeness of reporting and attrition as described in the study publication as:<br/>• 'low risk' if outcomes are reported for all or more than 80% of randomised participants across groups;<br/>• 'high risk' if missing data are not balanced between groups and/or outcome data are missing for &gt; 20% of randomised participants and no explanation is provided; or<br/>• 'unclear risk' if this is insufficiently described. </p> </section> <section id="CD009151-sec-0035"> <h5 class="title">Selective reporting bias</h5> <p>We assessed the risk of reporting bias by comparing the outcomes reported in the study protocol (if available) or the methods section of the published trial report with the outcomes reported in the results section of the published trial report as:<br/>• 'low risk' if it is clear that all of the study’s prespecified outcomes have been reported;<br/>• 'high risk' if not all of the study’s prespecified outcomes have been reported or one or more reported primary outcomes were not prespecified; or </p> <p>•'unclear risk' if the information provided in the study report is insufficient.</p> </section> <section id="CD009151-sec-0036"> <h5 class="title">Other bias</h5> <p>We assessed the risk of other types of bias such as conflicts of interest or funding sources that could have impacted the study results as:<br/>• 'low risk' of other bias;<br/>• 'high risk' of other bias; or<br/>• 'unclear risk' of other bias. </p> <p>We took risk of bias into account when making a judgement about the overall certainty of the pooled evidence as per the GRADE tool. </p> </section> </section> <section id="CD009151-sec-0037"> <h4 class="title">Measures of treatment effect</h4> <p>For dichotomous data, we reported the results as risk ratios with 95% confidence intervals. For continuous data, we planned to report mean difference of pre‐ and post‐measurements or weighted mean difference if different scales were used. We also reported standard deviations. </p> </section> <section id="CD009151-sec-0038"> <h4 class="title">Unit of analysis issues</h4> <p>The unit of analysis in meta‐analysis was the woman. If the woman is not the unit of randomisation, such as is the case in cluster‐randomised trials, we would make adjustments for clustering following the guidelines in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD009151-bbs2-0078" title="HigginsJPT , Green S (editors).Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. In: The Cochrane Collaboration. The Cochrane Collaboration, 2011. [Available from www.cochrane-handbook.org.]">Higgins 2011</a>). In the case of multiple study arms, we combined the active interventions if this was clinically appropriate and compared them to placebo, in order to avoid double counting. </p> </section> <section id="CD009151-sec-0039"> <h4 class="title">Dealing with missing data</h4> <p>We attempted to obtain information on missing data from study authors. If this was not successful, we performed intention‐to‐treat (ITT) analysis, which considers all missing data as treatment failures. We followed the guidance in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> to perform a sensitivity analysis that explored the impact of studies with high risk of bias due to large numbers of missing data (<a href="./references#CD009151-bbs2-0078" title="HigginsJPT , Green S (editors).Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. In: The Cochrane Collaboration. The Cochrane Collaboration, 2011. [Available from www.cochrane-handbook.org.]">Higgins 2011</a>). </p> </section> <section id="CD009151-sec-0040"> <h4 class="title">Assessment of heterogeneity</h4> <p>We assessed heterogeneity between trials that investigate effects of the same interventions in two ways. Before pooling, we first explored clinical, face value heterogeneity (study populations, interventions, etc.). If we considered the trials to be too different (e.g. clinically different populations, different interventions, clinically non‐comparable outcomes), we did not pool the studies. We then assessed statistical heterogeneity by visual exploration of the results on the forest plot and by performing a Chi<sup>2</sup> test and calculating the Higgins I<sup>2</sup> statistic according to the guidelines in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD009151-bbs2-0071" title="DeeksJJ , HigginsJPT , AltmanDG , editor(s).Chapter 9: Analysing data and undertaking metaanalyses. In: Higgins JPT, Churchill R, Chandler J, Cumpston MS, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.2.0 (updated June 2017). Cochrane, 2017. Available from www.training.cochrane.org/handbook.">Deeks 2017</a>). We interpreted the I<sup>2</sup> value as follows (<a href="./references#CD009151-bbs2-0078" title="HigginsJPT , Green S (editors).Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. In: The Cochrane Collaboration. The Cochrane Collaboration, 2011. [Available from www.cochrane-handbook.org.]">Higgins 2011</a>): </p> <p> <ul id="CD009151-list-0008"> <li> <p>0% to 40%: may not be important; a fixed effects model is recommended;</p> </li> <li> <p>40% to 70%: may represent moderate heterogeneity; a random effects model is recommended;</p> </li> <li> <p>&gt;70%: may represent substantial heterogeneity; pooling is not recommended.</p> </li> </ul> </p> </section> <section id="CD009151-sec-0041"> <h4 class="title">Assessment of reporting biases</h4> <p>If outcome data for relevant outcomes that were mentioned in the study protocol or methods of the study publication were not reported (i.e. risk of reporting bias), we contacted the authors to request information about the missing outcome data. We planned to assess publication bias by generating funnel plots if 10 or more trials were available for the comparison (<a href="./references#CD009151-bbs2-0078" title="HigginsJPT , Green S (editors).Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. In: The Cochrane Collaboration. The Cochrane Collaboration, 2011. [Available from www.cochrane-handbook.org.]">Higgins 2011</a>). </p> </section> <section id="CD009151-sec-0042"> <h4 class="title">Data synthesis</h4> <p>We used Review Manager 5 software to perform the statistical analysis (<a href="./references#CD009151-bbs2-0095" title="Nordic Cochrane Centre, The Cochrane CollaborationReview Manager 5 (RevMan 5).Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014.">Review Manager 2014</a>). Where we judged the trial populations, methods, and outcome measures to be similar (low clinical heterogeneity), and the I<sup>2</sup> was less than 40% (low statistical heterogeneity), we pooled the data using a fixed‐effect model (<a href="./references#CD009151-bbs2-0078" title="HigginsJPT , Green S (editors).Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. In: The Cochrane Collaboration. The Cochrane Collaboration, 2011. [Available from www.cochrane-handbook.org.]">Higgins 2011</a>). We did not pool data when there was obvious clinical heterogeneity and pooling studies did not make clinical sense (see <a href="#CD009151-sec-0040">Assessment of heterogeneity</a>). Where statistical heterogeneity was moderate (I<sup>2</sup> 40% to 70%) or substantial (I<sup>2</sup> &gt;70%), we pooled the data using a random‐effects model and performed a sensitivity analysis to assess the impact of heterogeneity on the robustness of the overall effect estimate (see <a href="#CD009151-sec-0044">Sensitivity analysis</a>) (<a href="./references#CD009151-bbs2-0078" title="HigginsJPT , Green S (editors).Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. In: The Cochrane Collaboration. The Cochrane Collaboration, 2011. [Available from www.cochrane-handbook.org.]">Higgins 2011</a>). </p> <p>We calculated a number needed to treat for an additional beneficial outcome (NNTB) and a number needed to treat for an additional harmful outcome (NNTH) where data were available and the results were statistically significant. We used the formulae provided in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD009151-bbs2-0078" title="HigginsJPT , Green S (editors).Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. In: The Cochrane Collaboration. The Cochrane Collaboration, 2011. [Available from www.cochrane-handbook.org.]">Higgins 2011</a>). </p> </section> <section id="CD009151-sec-0043"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We planned to carry out the following subgroup analyses based on relevant variables.</p> <p> <ul id="CD009151-list-0009"> <li> <p>Sexually active women versus non‐sexually active women</p> </li> <li> <p>Pregnant versus non‐pregnant women</p> </li> <li> <p>Women with diabetes mellitus versus non‐diabetic women</p> </li> <li> <p>RVVC caused by <i>Candida albicans</i> versus non‐albicans species </p> </li> </ul> </p> <p>Heterogeneity was assessed as per the guidance in <a href="#CD009151-sec-0040">Assessment of heterogeneity</a>. </p> </section> <section id="CD009151-sec-0044"> <h4 class="title">Sensitivity analysis</h4> <p>We performed the following sensitivity analyses:</p> <p> <ul id="CD009151-list-0010"> <li> <p>To assess the effect of risk of selection bias on the overall estimate of the meta‐analysis we first pooled all studies and then we excluded those studies with high risk of selection bias in order to evaluate the change in the pooled effect estimator. </p> </li> </ul> </p> </section> <section id="CD009151-sec-0045"> <h4 class="title">Summary of findings and assessment of the certainty of the evidence</h4> <p>We generated the Summary of findings tables using GRADEpro and Cochrane methods (<a href="./references#CD009151-bbs2-0078" title="HigginsJPT , Green S (editors).Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. In: The Cochrane Collaboration. The Cochrane Collaboration, 2011. [Available from www.cochrane-handbook.org.]">Higgins 2011</a>; <a href="./references#CD009151-bbs2-0076" title="McMaster University (developed by Evidence Prime)GRADEpro GDT.Hamilton (ON): McMaster University (developed by Evidence Prime), 2014. Available at gradepro.org.">GRADEpro GDT</a>). These tables evaluate the overall quality of the body of evidence for the main review outcomes (proportion of participants with at least one clinical recurrence during the treatment and follow‐up period, adverse events) for the main review comparisons (Drug treatment (oral and topical) versus placebo/no treatment (excluding partner treatment) and Oral drug treatment versus topical drug treatment). We assessed the certainty of the evidence using GRADE criteria (risk of bias, consistency of effect, imprecision, indirectness and publication bias). Judgements about evidence certainty (high, moderate, low or very low) were made by two review authors working independently (GC and LD), with disagreements resolved by discussion and an arbiter (MVD). We give a narrative description of the effects taking into account the level of certainty as per the handbook recommendations (<a href="./references#CD009151-bbs2-0078" title="HigginsJPT , Green S (editors).Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. In: The Cochrane Collaboration. The Cochrane Collaboration, 2011. [Available from www.cochrane-handbook.org.]">Higgins 2011</a>). </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD009151-sec-0046" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD009151-sec-0046"></div> <section id="CD009151-sec-0047"> <h3 class="title">Description of studies</h3> <p>The results of the searches and included and excluded studies are described below.</p> <section id="CD009151-sec-0048"> <h4 class="title">Results of the search</h4> <p>The searches up to 6 October 2021 identified 1782 references from electronic databases (trial registries excluded). We identified an additional four publications from contacting experts in the field (including the authors of this review) (<a href="./references#CD009151-bbs2-0006" title="FanS , LiuX , WuC , XuL , LiJ .Vaginal nystatin versus oral fluconazole for the treatment for recurrent vulvovaginal candidiasis. Mycopathologia2015;179:95-101. [DOI: https://doi.org/10.1007/s11046-014-9827-4]">Fan 2015</a>; <a href="./references#CD009151-bbs2-0007" title="FardyazarZ , HabibzadehS , Abdollahi-FardS , TelloM .Vaginal azoles versus oral fluconazole in treatment of recurrent vulvovaginal candidiasis. Iranian Journal of Clinical Infectious Diseases2007;2:17-22. FardyazarZ , HabibzadehS .Long term vaginal azoles versus prophylactic oral fluconazole in treatment of recurrent vulvovaginal candidiasis. Research Journal of Biological Sciences2007;2(6):663-6. ">Fardyazar 2007</a> (2 publications); (<a href="./references#CD009151-bbs2-0017" title="SobelJD .Management of recurrent vulvovaginal candidiasis (VVC) with ketoconazole (K) prophylaxis [abstract]. Archives of Gynecology1985;237 Suppl:281. SobelJD .Management of recurrent vulvovaginal candidiasis with intermittent ketoconazole prophylaxis. Obstetrics &amp; Gynecology1985;65:435-40. ">Sobel 1985a</a>), and one additional publication from contacting manufacturers (<a href="./references#CD009151-bbs2-0080" title="MerkusJM , Van HeusdenAM .Chronic vulvovaginal candidosis: the role of oral treatment. British Journal of Clinical Practice1990;71:s81-84.">Merkus 1990</a>). Our review of reference lists of included studies and publications selected from the electronic database searches identified one full‐text study for review (<a href="./references#CD009151-bbs2-0077" title="GuaschinoS , De SetaF , SartoreA , RicciG , De SantoD , PiccoliM , AlbericoS .Efficacy of maintenance therapy with topical boric acid in comparison with oral itraconazole in the treatment of recurrent vulvovaginal candidiasis. American Journal of Obstetrics and Gynecology2001;184(4):598-602. [ISSN 002-9378]">Guaschino 2001</a>). We identified a further study from the trial registry searches (<a href="./references#CD009151-bbs2-0059" title="IRCT2012102911302N1.Comparison of clinical response to vaginal cream zataria multiflora and boric acid in patients with recurrent vulvovaginal candidiasis. http://en.irct.ir/trial/11581 17 December 2012. [IRCT2012102911302N1]RabieeM , AkbariH , NaseriM , BekhradiR , NikzadM , TorkestaniF .Comparison of clinical response to Zatariamultiflora vaginal cream and boric acid inpatients with recurrent vulvovaginal candidiasis. Scientific-ResearchJournal of Shahed University2013;102:1-8. ">Rabiee 2013</a>). After removal of duplicates, 1181 abstracts were available for review. Of these 1070 were excluded as they did not meet our inclusion criteria. We selected a total of 111 abstracts for full‐text review (<a href="#CD009151-fig-0001">Figure 1</a>). Eighty‐two studies were excluded because participants did not have RVVC (n = 57), the study was not an RCT (n = 17), the duration of follow‐up was less than 6 months (n = 6), or the study was not a primary study (n = 2). Six full‐text publications contained inadequate information to permit a decision regarding inclusion in the review (<a href="./references#CD009151-bbs2-0030" title="CoricM , BarisicD , LovricH .Fluconazole versus 3-day clotrimazole in the treatment of sporadic and recurrent vulvovaginal candidiasis. International Journal of Gynaecology &amp; Obstetrics2006;95:171-2. ">Coric 2006</a>; <a href="./references#CD009151-bbs2-0032" title="DibaK , NamakiA , BahadoriF .Comparative study of fluconazole and clotrimazole for the treatment of vulvovaginal candidiasis. Journal of Sexual Medicine2010;7:431. ">Diba 2010</a>; <a href="./references#CD009151-bbs2-0035" title="FanSR , LiuXP , LiJW , XuAP , LiuM .Study on classification and treatment of vulvovaginal candidiasis. Chung-Hua Fu Chan Ko Tsa Chih [Chinese Journal of Obstetrics &amp; Gynecology]2005;40:532-5. ">Fan 2005</a>; <a href="./references#CD009151-bbs2-0039" title="HouangE .Fluconazole in recurrent vaginal candidiasis - preliminary-results of a double-blind, randomized clinical-trial. In: Fluconazole and its role in vaginal candidiasis. In: RichardsonRG , editors(s). International Congress and Symposium Series. Vol. 160. London: Royal Society of Medicine Services, 1989:22-31. ">Houang 1989</a>; <a href="./references#CD009151-bbs2-0040" title="MillerPI , HumphriesM , GrassickK .A single-blind comparison of oral and intravaginal treatments in acute and recurrent vaginal candidosis in general practice. Pharmatherapeutica1984;3:582-7. ">Miller 1984</a>; <a href="./references#CD009151-bbs2-0042" title="ShalevE , BattinoS , WeinerE , ColodnerR , KenessY .Ingestion of yogurt containing Lactobacillus acidophilus compared with pasteurized yogurt as prophylaxis for recurrent candidal vaginitis and bacterial vaginosis. Archives of Family Medicine1996;5:593-6. ">Shalev 1996</a>); we contacted the authors of these studies, but none of these publications were found to be suitable for inclusion. </p> <div class="figure" id="CD009151-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram." data-id="CD009151-fig-0001" src="/cdsr/doi/10.1002/14651858.CD009151.pub2/media/CDSR/CD009151/image_n/nCD009151-FIG-01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> </div> <p>Two studies were not published in English and we have placed them in Awaiting classification pending translation into English (<a href="./references#CD009151-bbs2-0059" title="IRCT2012102911302N1.Comparison of clinical response to vaginal cream zataria multiflora and boric acid in patients with recurrent vulvovaginal candidiasis. http://en.irct.ir/trial/11581 17 December 2012. [IRCT2012102911302N1]RabieeM , AkbariH , NaseriM , BekhradiR , NikzadM , TorkestaniF .Comparison of clinical response to Zatariamultiflora vaginal cream and boric acid inpatients with recurrent vulvovaginal candidiasis. Scientific-ResearchJournal of Shahed University2013;102:1-8. ">Rabiee 2013</a> ‐ published in Persian; <a href="./references#CD009151-bbs2-0062" title="ZivaljevicB , GolubovicI , SeratlicJ , NikolicP , SimicD , MagdicI , et al.Efficiency of Fenticonazole for the Treatment of Vaginal Candidiasis. Srpski Arhiv Za Celokupno Lekarstvo2012;140(7-8):469-474. ">Zivaljevic 2012</a> ‐ published in Serbian). In one study it was not clear if women met the inclusion criteria for our review (<a href="./references#CD009151-bbs2-0061" title="RussoR , SupertiF , KaradjaE , De SetaF .Randomised clinical trial in women with Recurrent Vulvovaginal Candidiasis: Efficacy of probiotics and lactoferrin as maintenance treatment. Mycoses2019;62:328–335. ">Russo 2019</a>). </p> <p>Our search in 2020 identified three registered ongoing trials: <a href="./references#CD009151-bbs2-0064" title="A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Oral Ibrexafungerp (SCY-078) Compared to Placebo in Subjects With Recurrent Vulvovaginal Candidiasis (VVC). ClinicalTrials.gov. [https://clinicaltrials.gov/ct2/show/NCT04029116]">NCT04029116</a> is recruiting, <a href="./references#CD009151-bbs2-0065" title="A Randomized Comparison of Boric Acid Versus Terconazole in Treatment of Recurrent Vulvovaginal Candidiasis. ClinicalTrials.gov. [URL: https://clinicaltrials.gov/ct2/show/NCT04208555]">NCT04208555</a> is not yet recruiting. For <a href="./references#CD009151-bbs2-0063" title="A phase IIb/III, parallel-arm, randomized, active-controlled, double-blind, double-dummy, multicenter, non-inferiority study in patients with recurrent vulvovaginal candidosis to compare the clinical efficacy, safety and tolerability of topically administered ProF-001 (Candiplus®) to oral fluconazole. ICTRP. [URL: https://trialsearch.who.int/?TrialID=EUCTR2019-000925-27-SK]A Phase IIb/III Study of Prof-001 for the Treatment of Patients With Recurrent Vulvovaginal Candidiasis (RVVC). clinicaltrials.gov. [URL: https://clinicaltrials.gov/ct2/show/NCT04734405]">EUCTR2019‐000925‐27‐SK</a> it is unclear if recruitment has started, however, this trial has also been registered in <i>clinicaltrials.gov</i> which reports the trial is still recruiting (NCT04734405). We identified 10 additional trials from the trial registry searches in 2020, however, no publication was located for these trials. We contacted the primary contact identified in the database record, but received no additional information or trial results for seven trials (<a href="./references#CD009151-bbs2-0048" title="ACTRN12614001258640.A randomized, double-blinded study investigating the safety and efficacy of daily low-dose oral fluconazole versus weekly fluconazole in patients with chronic vulvovaginal candidiasis. https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=12614001258640 2 December 2012. ">ACTRN12614001258640</a>; <a href="./references#CD009151-bbs2-0049" title='ChiCTR-IPR-15006314.Multi-center clinical study on JUC Spray Dressing under the patent technology "Physical Antimicrobial Film" in preventing the recurrence of vulvovaginal candidiasis (VVC). http://www.chictr.org.cn/showproj.aspx?proj=10772 14 April 2015. '>ChiCTR‐IPR‐15006314</a>; <a href="./references#CD009151-bbs2-0050" title="ChiCTR-TRC-10000833.The clinical research of Chinese herb XiangLian Suppository in the treatment of recurrent vulvovaginal candidiasis. http://www.chictr.org.cn/showproj.aspx?proj=8703 28 March 2010. ">ChiCTR‐TRC‐10000833</a>; <a href="./references#CD009151-bbs2-0053" title="EUCTR2013-002480-26-PL.Study of the efficacy and safety of treatment with total freeze-dried culture of Lcr Regenerans® administered intravaginally in the prevention of recurrent vulvovaginal candidiasis.International, randomized, phase III, multi-centre, 2-arm, parallel group, double-blind, placebo-controlled superiority trial.. https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-002480-26/PL 30 July 2014. [EUCTR2013-002480-26-PL]">EUCTR2013‐002480‐26‐PL</a>; <a href="./references#CD009151-bbs2-0054" title="NCT00479947.Use of Oral Probiotics as an Adjunctive Therapy to Fluconazole in the Treatment of Yeast Vaginitis. http://clinicaltrials.gov/show/NCT00479947 30 May 2007. [NCT00479947]">NCT00479947</a>; <a href="./references#CD009151-bbs2-0056" title="NCT02251093.Study of the Efficacy and Tolerance of Intra-vaginal Treatment With a Total Freeze-dried Culture of Lcr Regenerans® in the Prevention of Relapses of Recurrent Vulvovaginal Candidiasis. https://clinicaltrials.gov/ct2/show/NCT02251093 26 September 2014. ">NCT02251093</a>; <a href="./references#CD009151-bbs2-0060" title="lRBR-892mp4.Effectiveness of therapeutic exercise applied to the pelvic floor muscles to prevent recurrence of Vulvovaginitis and improve female sexuality: randomized clinical trial. http://www.ensaiosclinicos.gov.br/rg/RBR-892mp4/ 17 June 2015. [RBR-892mp4]">RBR‐892mp4</a>). The contact listed in the database record could not be contacted for three trials (<a href="./references#CD009151-bbs2-0051" title="EUCTR2010-021502-38-DE.Study for measuring vaginal interleukins in patients with cervical neoplasia (CIN 1-3) or chronic vaginal candidiasis with phenyl-4-butyrate [STUDIE ZUR MESSUNG DER VAGINALEN INTERLEUKINE BEI PATIENTINNEN MIT ZERVIKALEN NEOPLASIEN (CIN 1-3) ODER CHRONISCHER CANDIDIASIS VAGINALIS UNTER BEHANDLUNG MIT 4PHENYL-BUTYRATE]. https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-021502-38/DE 11 November 2010. [2010-021502-38]">EUCTR2010‐021502‐38‐DE</a>; <a href="./references#CD009151-bbs2-0052" title="EUCTR2011-004718-40-IT.Activities of Metronidazole + Clotrimazole in the treatment and prophylaxis of recurrent vaginal infections recurrent Candida albicans and Candida albicans spp non albicans. https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2011-004718-40 8 March 2012. [2011-004718-40]">EUCTR2011‐004718‐40‐IT</a>; <a href="./references#CD009151-bbs2-0055" title="NCT00915629.Prevention of Recurrent Vulvovaginal Candidiasis With Lactibiane Candisis 5M®. https://clinicaltrials.gov/ct2/show/NCT00915629 8 June 2009. ">NCT00915629</a>), either because there were insufficient details in the database or the details were not current. Thus this study has been assessed as awaiting classification. </p> <p>The search in October 2021 identified three additional trials in <i>clinicaltrials.gov: </i><a href="./references#CD009151-bbs2-0066" title="NCT04292704. clinicaltrials.gov. [URL: https://clinicaltrials.gov/ct2/show/record/NCT04292704]">NCT04292704</a> is still recruiting; <a href="./references#CD009151-bbs2-0057" title="">NCT04639544</a> and <a href="./references#CD009151-bbs2-0058" title="">NCT04699240</a> have been assessed as awaiting classification as it is unclear from the information in the trials database whether microbiological confirmation of VVC was an inclusion criterion. NCT04734405 was identified as a duplicate registration of <a href="./references#CD009151-bbs2-0063" title="A phase IIb/III, parallel-arm, randomized, active-controlled, double-blind, double-dummy, multicenter, non-inferiority study in patients with recurrent vulvovaginal candidosis to compare the clinical efficacy, safety and tolerability of topically administered ProF-001 (Candiplus®) to oral fluconazole. ICTRP. [URL: https://trialsearch.who.int/?TrialID=EUCTR2019-000925-27-SK]A Phase IIb/III Study of Prof-001 for the Treatment of Patients With Recurrent Vulvovaginal Candidiasis (RVVC). clinicaltrials.gov. [URL: https://clinicaltrials.gov/ct2/show/NCT04734405]">EUCTR2019‐000925‐27‐SK</a>. </p> </section> <section id="CD009151-sec-0049"> <h4 class="title">Included studies</h4> <p>We included 23 studies involving a total of 2212 participants in the review. We identified 20 studies from the electronic searches (<a href="./references#CD009151-bbs2-0001" title="BolouriF , TabriziNM , TanhaFD , NiroomandN , AzmoodehA , EmamiS , et al.Effectiveness of fluconazole for suppressive maintenance therapy in patients with RVVC: a randomized placebo-controlled study. Iranian Journal of Pharmaceutical Research2009;8:307-13. ">Bolouri 2009</a>; <a href="./references#CD009151-bbs2-0002" title="ChopraV , MarottaF , KumariA , BishierMP , HeF , ZerbinatiN , et al.Prophylactic strategies in recurrent vulvovaginal candidiasis: a 2-year study testing a phytonutrient vs itraconazole. Journal of Biological Regulators and Homeostatic Agents2013;27(3):875-82. [PMID: 24152852]">Chopra 2013</a>; <a href="./references#CD009151-bbs2-0003" title="CorthayP , PerrenoudC , GumowskiPI , GirardJP .Candida albicans specific immune responses in patients with recurrent chronic vaginitis treated with an anti-candida food regimen (ACFR) or an hyposensitization treatment (HPT). Allergy1988;43:51. ">Corthay 1988</a>; <a href="./references#CD009151-bbs2-0004" title="D'AntuonoA , BaldiE , BellavistaS , BanzolaN , ZauliS , PatriziA .Use of Dermasilk briefs in recurrent vulvovaginal candidosis: safety and effectiveness. Mycoses2012;55(3):e85-9. ">D'Antuono 2012</a>; <a href="./references#CD009151-bbs2-0005" title="D'AntuonoA , BellavistaS , GaspariV , FilippiniA , PatriziA .Dermasilk® briefs in recurrent vulvovaginal candidosis. An alternative option in long-lasting disease. Minerva Ginecologica2013;65(6):697-705. ">D'Antuono 2013</a>; <a href="./references#CD009151-bbs2-0008" title="FongIW .The value of chronic suppressive therapy with itraconazole versus clotrimazole in women with recurrent vaginal candidiasis. Genitourinary Medicine1992;68:374-7. ">Fong 1992a</a>; <a href="./references#CD009151-bbs2-0009" title="FongIW .The value of treating the sexual partners of women with recurrent vaginal candidiasis with ketoconazole. Genitourinary Medicine1992;68:174-6. ">Fong 1992b</a>; <a href="./references#CD009151-bbs2-0010" title="FongIW .The value of prophylactic (monthly) clotrimazole versus empiric self-treatment in recurrent vaginal candidiasis. Genitourinary Medicine1994;70:124-6. ">Fong 1994</a>; <a href="./references#CD009151-bbs2-0011" title="KumariA , BishierMP , NaitoY , SharmaA , SolimeneU , JainS , et al.Protective effect of an oral natural phytonutrient in recurrent vulvovaginal candidiasis: a 12-month study. Journal of Biological Regulators &amp; Homeostatic Agents2011;25(4):543-51. ">Kumari 2011</a>; <a href="./references#CD009151-bbs2-0012" title="LiW .Influence of nursing intervention on recurrent vulvovaginal candidiasis patients treated with ATP-infrared bio-effect technique. Iranian Journal of Public Health2018;47(10):1511-9. ">Li 2018</a>; <a href="./references#CD009151-bbs2-0013" title="Lopez-OlmosJ , LermaE .Treatment of recurring vulvo-vaginal candidiasis: a comparative prospective study during six months of three anti-mycotic preparations of a single dosis. Clinica e Investigacion en Ginecologia y Obstetricia2000;27:366-75. ">Lopez‐Olmos 2000</a>; <a href="./references#CD009151-bbs2-0014" title="MendlingW , BirknerV .Vaccination with inactivated lactobacilli or heliotherapy can improve the quality-of-life of women with chronic recurrent vulvovaginal candidosis a prospective randomized study [Die Vakzination mit inaktivierten Laktobazillen oder mit Heliotherapie kann die Lebensqualitat von Frauen mit rezidivierender vulvovaginaler Kandidose verbessern - Eine prospektive 3-armige randomisierte Studie]. Geburtshilfe und Frauenheilkunde2011;71(9):767-72. ">Mendling 2011</a>; <a href="./references#CD009151-bbs2-0015" title="MettsJ , FamulaTR , TrenevN , ClemensRA .Lactobacillus acidophilus, strain NAS (H2O2 positive), in reduction of recurrent candidal vulvovaginitis. Journal of Applied Research2003;3:340-8. ">Metts 2003</a>; <a href="./references#CD009151-bbs2-0016" title="RothAC , MilsomI , ForssmanL , WahlenP .Intermittent prophylactic treatment of recurrent vaginal candidiasis by postmenstrual application of a 500 mg clotrimazole vaginal tablet. Genitourinary Medicine1990;66:357-60. ">Roth 1990</a>; <a href="./references#CD009151-bbs2-0018" title="SobelJD .Recurrent vulvovaginal candidiasis. A prospective study of the efficacy of maintenance ketoconazole therapy. New England Journal of Medicine1986;315:1455-8. ">Sobel 1986</a>; <a href="./references#CD009151-bbs2-0019" title="SobelJD , SchmittC , MeriwetherC .Clotrimazole treatment of recurrent and chronic candida vulvovaginitis. Obstetrics &amp; Gynecology1989;73:330-4. ">Sobel 1989</a>; <a href="./references#CD009151-bbs2-0020" title="SobelJD , WiesenfeldHC , MartensM , DannaP , HootonTM , RompaloA , et al.Maintenance fluconazole therapy for recurrent vulvovaginal candidiasis. New England Journal of Medicine2004;351:876-83. ">Sobel 2004</a>; <a href="./references#CD009151-bbs2-0021" title="SpacekJ , BuchtaV .Itraconazole in the treatment of acute and recurrent vulvovaginal candidosis: comparison of a 1-day and a 3-day regimen. Mycoses2005;48:165-71. ">Spacek 2005</a>; <a href="./references#CD009151-bbs2-0022" title="SpinilloA , ColonnaL , PiazziG , BaltaroF , MonacoA , FerrariA .Managing recurrent vulvovaginal candidiasis. Intermittent prevention with itraconazole. Journal of Reproductive Medicine1997;42:83-7. ">Spinillo 1997</a>; <a href="./references#CD009151-bbs2-0023" title="WittA , KaufmannU , BitschnauM , TempferC , OzbalA , HaytougluE , et al.Monthly itraconazole versus classic homeopathy for the treatment of recurrent vulvovaginal candidiasis: a randomized trial. Obstetrical and Gynecological Survey2010;65(1):26-7. WittA , KaufmannU , BitschnauM , TempferC , OzbalA , HaytougluE , GregorH , KissH .Monthly itraconazole versus classic homeopathy for the treatment of recurrent vulvovaginal candidiasis: a randomised trial. British Journal of Obstetrics &amp; Gynaecology2009;116(11):1499-505. ">Witt 2009</a>). The remaining three studies were identified from the personal libraries of authors of this review (<a href="./references#CD009151-bbs2-0006" title="FanS , LiuX , WuC , XuL , LiJ .Vaginal nystatin versus oral fluconazole for the treatment for recurrent vulvovaginal candidiasis. Mycopathologia2015;179:95-101. [DOI: https://doi.org/10.1007/s11046-014-9827-4]">Fan 2015</a>; <a href="./references#CD009151-bbs2-0007" title="FardyazarZ , HabibzadehS , Abdollahi-FardS , TelloM .Vaginal azoles versus oral fluconazole in treatment of recurrent vulvovaginal candidiasis. Iranian Journal of Clinical Infectious Diseases2007;2:17-22. FardyazarZ , HabibzadehS .Long term vaginal azoles versus prophylactic oral fluconazole in treatment of recurrent vulvovaginal candidiasis. Research Journal of Biological Sciences2007;2(6):663-6. ">Fardyazar 2007</a>; <a href="./references#CD009151-bbs2-0017" title="SobelJD .Management of recurrent vulvovaginal candidiasis (VVC) with ketoconazole (K) prophylaxis [abstract]. Archives of Gynecology1985;237 Suppl:281. SobelJD .Management of recurrent vulvovaginal candidiasis with intermittent ketoconazole prophylaxis. Obstetrics &amp; Gynecology1985;65:435-40. ">Sobel 1985a</a>). However, three studies did not report data for our primary outcomes in a way that could be extracted (<a href="./references#CD009151-bbs2-0003" title="CorthayP , PerrenoudC , GumowskiPI , GirardJP .Candida albicans specific immune responses in patients with recurrent chronic vaginitis treated with an anti-candida food regimen (ACFR) or an hyposensitization treatment (HPT). Allergy1988;43:51. ">Corthay 1988</a>; <a href="./references#CD009151-bbs2-0005" title="D'AntuonoA , BellavistaS , GaspariV , FilippiniA , PatriziA .Dermasilk® briefs in recurrent vulvovaginal candidosis. An alternative option in long-lasting disease. Minerva Ginecologica2013;65(6):697-705. ">D'Antuono 2013</a>; <a href="./references#CD009151-bbs2-0012" title="LiW .Influence of nursing intervention on recurrent vulvovaginal candidiasis patients treated with ATP-infrared bio-effect technique. Iranian Journal of Public Health2018;47(10):1511-9. ">Li 2018</a>). We requested further information from <a href="./references#CD009151-bbs2-0005" title="D'AntuonoA , BellavistaS , GaspariV , FilippiniA , PatriziA .Dermasilk® briefs in recurrent vulvovaginal candidosis. An alternative option in long-lasting disease. Minerva Ginecologica2013;65(6):697-705. ">D'Antuono 2013</a>; <a href="./references#CD009151-bbs2-0012" title="LiW .Influence of nursing intervention on recurrent vulvovaginal candidiasis patients treated with ATP-infrared bio-effect technique. Iranian Journal of Public Health2018;47(10):1511-9. ">Li 2018</a>, but unfortunately the authors were not able to provide us with the required data. <a href="./references#CD009151-bbs2-0003" title="CorthayP , PerrenoudC , GumowskiPI , GirardJP .Candida albicans specific immune responses in patients with recurrent chronic vaginitis treated with an anti-candida food regimen (ACFR) or an hyposensitization treatment (HPT). Allergy1988;43:51. ">Corthay 1988</a> was a conference abstract from 1988 and the authors could not be traced. </p> <section id="CD009151-sec-0050"> <h5 class="title">Participants and setting</h5> <p>Overall, the included studies were small, with 16 of the 23 studies including fewer than 100 participants (<a href="./references#CD009151-bbs2-0001" title="BolouriF , TabriziNM , TanhaFD , NiroomandN , AzmoodehA , EmamiS , et al.Effectiveness of fluconazole for suppressive maintenance therapy in patients with RVVC: a randomized placebo-controlled study. Iranian Journal of Pharmaceutical Research2009;8:307-13. ">Bolouri 2009</a>; <a href="./references#CD009151-bbs2-0003" title="CorthayP , PerrenoudC , GumowskiPI , GirardJP .Candida albicans specific immune responses in patients with recurrent chronic vaginitis treated with an anti-candida food regimen (ACFR) or an hyposensitization treatment (HPT). Allergy1988;43:51. ">Corthay 1988</a>; <a href="./references#CD009151-bbs2-0005" title="D'AntuonoA , BellavistaS , GaspariV , FilippiniA , PatriziA .Dermasilk® briefs in recurrent vulvovaginal candidosis. An alternative option in long-lasting disease. Minerva Ginecologica2013;65(6):697-705. ">D'Antuono 2013</a>; <a href="./references#CD009151-bbs2-0008" title="FongIW .The value of chronic suppressive therapy with itraconazole versus clotrimazole in women with recurrent vaginal candidiasis. Genitourinary Medicine1992;68:374-7. ">Fong 1992a</a>; <a href="./references#CD009151-bbs2-0009" title="FongIW .The value of treating the sexual partners of women with recurrent vaginal candidiasis with ketoconazole. Genitourinary Medicine1992;68:174-6. ">Fong 1992b</a>; <a href="./references#CD009151-bbs2-0010" title="FongIW .The value of prophylactic (monthly) clotrimazole versus empiric self-treatment in recurrent vaginal candidiasis. Genitourinary Medicine1994;70:124-6. ">Fong 1994</a>; <a href="./references#CD009151-bbs2-0011" title="KumariA , BishierMP , NaitoY , SharmaA , SolimeneU , JainS , et al.Protective effect of an oral natural phytonutrient in recurrent vulvovaginal candidiasis: a 12-month study. Journal of Biological Regulators &amp; Homeostatic Agents2011;25(4):543-51. ">Kumari 2011</a>; <a href="./references#CD009151-bbs2-0012" title="LiW .Influence of nursing intervention on recurrent vulvovaginal candidiasis patients treated with ATP-infrared bio-effect technique. Iranian Journal of Public Health2018;47(10):1511-9. ">Li 2018</a>; <a href="./references#CD009151-bbs2-0013" title="Lopez-OlmosJ , LermaE .Treatment of recurring vulvo-vaginal candidiasis: a comparative prospective study during six months of three anti-mycotic preparations of a single dosis. Clinica e Investigacion en Ginecologia y Obstetricia2000;27:366-75. ">Lopez‐Olmos 2000</a>; <a href="./references#CD009151-bbs2-0014" title="MendlingW , BirknerV .Vaccination with inactivated lactobacilli or heliotherapy can improve the quality-of-life of women with chronic recurrent vulvovaginal candidosis a prospective randomized study [Die Vakzination mit inaktivierten Laktobazillen oder mit Heliotherapie kann die Lebensqualitat von Frauen mit rezidivierender vulvovaginaler Kandidose verbessern - Eine prospektive 3-armige randomisierte Studie]. Geburtshilfe und Frauenheilkunde2011;71(9):767-72. ">Mendling 2011</a>; <a href="./references#CD009151-bbs2-0015" title="MettsJ , FamulaTR , TrenevN , ClemensRA .Lactobacillus acidophilus, strain NAS (H2O2 positive), in reduction of recurrent candidal vulvovaginitis. Journal of Applied Research2003;3:340-8. ">Metts 2003</a>; <a href="./references#CD009151-bbs2-0016" title="RothAC , MilsomI , ForssmanL , WahlenP .Intermittent prophylactic treatment of recurrent vaginal candidiasis by postmenstrual application of a 500 mg clotrimazole vaginal tablet. Genitourinary Medicine1990;66:357-60. ">Roth 1990</a>; <a href="./references#CD009151-bbs2-0017" title="SobelJD .Management of recurrent vulvovaginal candidiasis (VVC) with ketoconazole (K) prophylaxis [abstract]. Archives of Gynecology1985;237 Suppl:281. SobelJD .Management of recurrent vulvovaginal candidiasis with intermittent ketoconazole prophylaxis. Obstetrics &amp; Gynecology1985;65:435-40. ">Sobel 1985a</a>; <a href="./references#CD009151-bbs2-0018" title="SobelJD .Recurrent vulvovaginal candidiasis. A prospective study of the efficacy of maintenance ketoconazole therapy. New England Journal of Medicine1986;315:1455-8. ">Sobel 1986</a>; <a href="./references#CD009151-bbs2-0019" title="SobelJD , SchmittC , MeriwetherC .Clotrimazole treatment of recurrent and chronic candida vulvovaginitis. Obstetrics &amp; Gynecology1989;73:330-4. ">Sobel 1989</a>; <a href="./references#CD009151-bbs2-0021" title="SpacekJ , BuchtaV .Itraconazole in the treatment of acute and recurrent vulvovaginal candidosis: comparison of a 1-day and a 3-day regimen. Mycoses2005;48:165-71. ">Spacek 2005</a>). The largest study included 387 participants (<a href="./references#CD009151-bbs2-0020" title="SobelJD , WiesenfeldHC , MartensM , DannaP , HootonTM , RompaloA , et al.Maintenance fluconazole therapy for recurrent vulvovaginal candidiasis. New England Journal of Medicine2004;351:876-83. ">Sobel 2004</a>). Eleven studies excluded participants with diabetes (<a href="./references#CD009151-bbs2-0001" title="BolouriF , TabriziNM , TanhaFD , NiroomandN , AzmoodehA , EmamiS , et al.Effectiveness of fluconazole for suppressive maintenance therapy in patients with RVVC: a randomized placebo-controlled study. Iranian Journal of Pharmaceutical Research2009;8:307-13. ">Bolouri 2009</a>; <a href="./references#CD009151-bbs2-0002" title="ChopraV , MarottaF , KumariA , BishierMP , HeF , ZerbinatiN , et al.Prophylactic strategies in recurrent vulvovaginal candidiasis: a 2-year study testing a phytonutrient vs itraconazole. Journal of Biological Regulators and Homeostatic Agents2013;27(3):875-82. [PMID: 24152852]">Chopra 2013</a>; <a href="./references#CD009151-bbs2-0004" title="D'AntuonoA , BaldiE , BellavistaS , BanzolaN , ZauliS , PatriziA .Use of Dermasilk briefs in recurrent vulvovaginal candidosis: safety and effectiveness. Mycoses2012;55(3):e85-9. ">D'Antuono 2012</a>; <a href="./references#CD009151-bbs2-0005" title="D'AntuonoA , BellavistaS , GaspariV , FilippiniA , PatriziA .Dermasilk® briefs in recurrent vulvovaginal candidosis. An alternative option in long-lasting disease. Minerva Ginecologica2013;65(6):697-705. ">D'Antuono 2013</a>; <a href="./references#CD009151-bbs2-0008" title="FongIW .The value of chronic suppressive therapy with itraconazole versus clotrimazole in women with recurrent vaginal candidiasis. Genitourinary Medicine1992;68:374-7. ">Fong 1992a</a>; <a href="./references#CD009151-bbs2-0009" title="FongIW .The value of treating the sexual partners of women with recurrent vaginal candidiasis with ketoconazole. Genitourinary Medicine1992;68:174-6. ">Fong 1992b</a>; <a href="./references#CD009151-bbs2-0010" title="FongIW .The value of prophylactic (monthly) clotrimazole versus empiric self-treatment in recurrent vaginal candidiasis. Genitourinary Medicine1994;70:124-6. ">Fong 1994</a>; <a href="./references#CD009151-bbs2-0011" title="KumariA , BishierMP , NaitoY , SharmaA , SolimeneU , JainS , et al.Protective effect of an oral natural phytonutrient in recurrent vulvovaginal candidiasis: a 12-month study. Journal of Biological Regulators &amp; Homeostatic Agents2011;25(4):543-51. ">Kumari 2011</a>; <a href="./references#CD009151-bbs2-0014" title="MendlingW , BirknerV .Vaccination with inactivated lactobacilli or heliotherapy can improve the quality-of-life of women with chronic recurrent vulvovaginal candidosis a prospective randomized study [Die Vakzination mit inaktivierten Laktobazillen oder mit Heliotherapie kann die Lebensqualitat von Frauen mit rezidivierender vulvovaginaler Kandidose verbessern - Eine prospektive 3-armige randomisierte Studie]. Geburtshilfe und Frauenheilkunde2011;71(9):767-72. ">Mendling 2011</a>; <a href="./references#CD009151-bbs2-0022" title="SpinilloA , ColonnaL , PiazziG , BaltaroF , MonacoA , FerrariA .Managing recurrent vulvovaginal candidiasis. Intermittent prevention with itraconazole. Journal of Reproductive Medicine1997;42:83-7. ">Spinillo 1997</a>; <a href="./references#CD009151-bbs2-0023" title="WittA , KaufmannU , BitschnauM , TempferC , OzbalA , HaytougluE , et al.Monthly itraconazole versus classic homeopathy for the treatment of recurrent vulvovaginal candidiasis: a randomized trial. Obstetrical and Gynecological Survey2010;65(1):26-7. WittA , KaufmannU , BitschnauM , TempferC , OzbalA , HaytougluE , GregorH , KissH .Monthly itraconazole versus classic homeopathy for the treatment of recurrent vulvovaginal candidiasis: a randomised trial. British Journal of Obstetrics &amp; Gynaecology2009;116(11):1499-505. ">Witt 2009</a>). One study had no participants with diabetes (<a href="./references#CD009151-bbs2-0019" title="SobelJD , SchmittC , MeriwetherC .Clotrimazole treatment of recurrent and chronic candida vulvovaginitis. Obstetrics &amp; Gynecology1989;73:330-4. ">Sobel 1989</a>). Five studies did not explicitly exclude women with diabetes but did not state if any participants had diabetes (<a href="./references#CD009151-bbs2-0003" title="CorthayP , PerrenoudC , GumowskiPI , GirardJP .Candida albicans specific immune responses in patients with recurrent chronic vaginitis treated with an anti-candida food regimen (ACFR) or an hyposensitization treatment (HPT). Allergy1988;43:51. ">Corthay 1988</a>; <a href="./references#CD009151-bbs2-0015" title="MettsJ , FamulaTR , TrenevN , ClemensRA .Lactobacillus acidophilus, strain NAS (H2O2 positive), in reduction of recurrent candidal vulvovaginitis. Journal of Applied Research2003;3:340-8. ">Metts 2003</a>; <a href="./references#CD009151-bbs2-0016" title="RothAC , MilsomI , ForssmanL , WahlenP .Intermittent prophylactic treatment of recurrent vaginal candidiasis by postmenstrual application of a 500 mg clotrimazole vaginal tablet. Genitourinary Medicine1990;66:357-60. ">Roth 1990</a>; <a href="./references#CD009151-bbs2-0021" title="SpacekJ , BuchtaV .Itraconazole in the treatment of acute and recurrent vulvovaginal candidosis: comparison of a 1-day and a 3-day regimen. Mycoses2005;48:165-71. ">Spacek 2005</a>; <a href="./references#CD009151-bbs2-0023" title="WittA , KaufmannU , BitschnauM , TempferC , OzbalA , HaytougluE , et al.Monthly itraconazole versus classic homeopathy for the treatment of recurrent vulvovaginal candidiasis: a randomized trial. Obstetrical and Gynecological Survey2010;65(1):26-7. WittA , KaufmannU , BitschnauM , TempferC , OzbalA , HaytougluE , GregorH , KissH .Monthly itraconazole versus classic homeopathy for the treatment of recurrent vulvovaginal candidiasis: a randomised trial. British Journal of Obstetrics &amp; Gynaecology2009;116(11):1499-505. ">Witt 2009</a>). Six studies included some participants with diabetes. One study included a single participant with diabetes (<a href="./references#CD009151-bbs2-0006" title="FanS , LiuX , WuC , XuL , LiJ .Vaginal nystatin versus oral fluconazole for the treatment for recurrent vulvovaginal candidiasis. Mycopathologia2015;179:95-101. [DOI: https://doi.org/10.1007/s11046-014-9827-4]">Fan 2015</a>). Almost 7% of participants had diabetes in <a href="./references#CD009151-bbs2-0013" title="Lopez-OlmosJ , LermaE .Treatment of recurring vulvo-vaginal candidiasis: a comparative prospective study during six months of three anti-mycotic preparations of a single dosis. Clinica e Investigacion en Ginecologia y Obstetricia2000;27:366-75. ">Lopez‐Olmos 2000</a>, and 11% of participants had diabetes in <a href="./references#CD009151-bbs2-0007" title="FardyazarZ , HabibzadehS , Abdollahi-FardS , TelloM .Vaginal azoles versus oral fluconazole in treatment of recurrent vulvovaginal candidiasis. Iranian Journal of Clinical Infectious Diseases2007;2:17-22. FardyazarZ , HabibzadehS .Long term vaginal azoles versus prophylactic oral fluconazole in treatment of recurrent vulvovaginal candidiasis. Research Journal of Biological Sciences2007;2(6):663-6. ">Fardyazar 2007</a>, one had 3% (<a href="./references#CD009151-bbs2-0017" title="SobelJD .Management of recurrent vulvovaginal candidiasis (VVC) with ketoconazole (K) prophylaxis [abstract]. Archives of Gynecology1985;237 Suppl:281. SobelJD .Management of recurrent vulvovaginal candidiasis with intermittent ketoconazole prophylaxis. Obstetrics &amp; Gynecology1985;65:435-40. ">Sobel 1985a</a>), one had 2% (<a href="./references#CD009151-bbs2-0018" title="SobelJD .Recurrent vulvovaginal candidiasis. A prospective study of the efficacy of maintenance ketoconazole therapy. New England Journal of Medicine1986;315:1455-8. ">Sobel 1986</a>), and one had 2% in the fluconazole group and 5% in the placebo group (<a href="./references#CD009151-bbs2-0020" title="SobelJD , WiesenfeldHC , MartensM , DannaP , HootonTM , RompaloA , et al.Maintenance fluconazole therapy for recurrent vulvovaginal candidiasis. New England Journal of Medicine2004;351:876-83. ">Sobel 2004</a>). </p> <p>We did not find any study including pregnant women. Eighteen studies excluded pregnant women (<a href="./references#CD009151-bbs2-0001" title="BolouriF , TabriziNM , TanhaFD , NiroomandN , AzmoodehA , EmamiS , et al.Effectiveness of fluconazole for suppressive maintenance therapy in patients with RVVC: a randomized placebo-controlled study. Iranian Journal of Pharmaceutical Research2009;8:307-13. ">Bolouri 2009</a>; <a href="./references#CD009151-bbs2-0002" title="ChopraV , MarottaF , KumariA , BishierMP , HeF , ZerbinatiN , et al.Prophylactic strategies in recurrent vulvovaginal candidiasis: a 2-year study testing a phytonutrient vs itraconazole. Journal of Biological Regulators and Homeostatic Agents2013;27(3):875-82. [PMID: 24152852]">Chopra 2013</a>; <a href="./references#CD009151-bbs2-0004" title="D'AntuonoA , BaldiE , BellavistaS , BanzolaN , ZauliS , PatriziA .Use of Dermasilk briefs in recurrent vulvovaginal candidosis: safety and effectiveness. Mycoses2012;55(3):e85-9. ">D'Antuono 2012</a>; <a href="./references#CD009151-bbs2-0005" title="D'AntuonoA , BellavistaS , GaspariV , FilippiniA , PatriziA .Dermasilk® briefs in recurrent vulvovaginal candidosis. An alternative option in long-lasting disease. Minerva Ginecologica2013;65(6):697-705. ">D'Antuono 2013</a>; <a href="./references#CD009151-bbs2-0006" title="FanS , LiuX , WuC , XuL , LiJ .Vaginal nystatin versus oral fluconazole for the treatment for recurrent vulvovaginal candidiasis. Mycopathologia2015;179:95-101. [DOI: https://doi.org/10.1007/s11046-014-9827-4]">Fan 2015</a>; <a href="./references#CD009151-bbs2-0008" title="FongIW .The value of chronic suppressive therapy with itraconazole versus clotrimazole in women with recurrent vaginal candidiasis. Genitourinary Medicine1992;68:374-7. ">Fong 1992a</a>; <a href="./references#CD009151-bbs2-0011" title="KumariA , BishierMP , NaitoY , SharmaA , SolimeneU , JainS , et al.Protective effect of an oral natural phytonutrient in recurrent vulvovaginal candidiasis: a 12-month study. Journal of Biological Regulators &amp; Homeostatic Agents2011;25(4):543-51. ">Kumari 2011</a>; <a href="./references#CD009151-bbs2-0012" title="LiW .Influence of nursing intervention on recurrent vulvovaginal candidiasis patients treated with ATP-infrared bio-effect technique. Iranian Journal of Public Health2018;47(10):1511-9. ">Li 2018</a>; <a href="./references#CD009151-bbs2-0014" title="MendlingW , BirknerV .Vaccination with inactivated lactobacilli or heliotherapy can improve the quality-of-life of women with chronic recurrent vulvovaginal candidosis a prospective randomized study [Die Vakzination mit inaktivierten Laktobazillen oder mit Heliotherapie kann die Lebensqualitat von Frauen mit rezidivierender vulvovaginaler Kandidose verbessern - Eine prospektive 3-armige randomisierte Studie]. Geburtshilfe und Frauenheilkunde2011;71(9):767-72. ">Mendling 2011</a>; <a href="./references#CD009151-bbs2-0015" title="MettsJ , FamulaTR , TrenevN , ClemensRA .Lactobacillus acidophilus, strain NAS (H2O2 positive), in reduction of recurrent candidal vulvovaginitis. Journal of Applied Research2003;3:340-8. ">Metts 2003</a>; <a href="./references#CD009151-bbs2-0016" title="RothAC , MilsomI , ForssmanL , WahlenP .Intermittent prophylactic treatment of recurrent vaginal candidiasis by postmenstrual application of a 500 mg clotrimazole vaginal tablet. Genitourinary Medicine1990;66:357-60. ">Roth 1990</a>; <a href="./references#CD009151-bbs2-0017" title="SobelJD .Management of recurrent vulvovaginal candidiasis (VVC) with ketoconazole (K) prophylaxis [abstract]. Archives of Gynecology1985;237 Suppl:281. SobelJD .Management of recurrent vulvovaginal candidiasis with intermittent ketoconazole prophylaxis. Obstetrics &amp; Gynecology1985;65:435-40. ">Sobel 1985a</a>; <a href="./references#CD009151-bbs2-0018" title="SobelJD .Recurrent vulvovaginal candidiasis. A prospective study of the efficacy of maintenance ketoconazole therapy. New England Journal of Medicine1986;315:1455-8. ">Sobel 1986</a>; <a href="./references#CD009151-bbs2-0019" title="SobelJD , SchmittC , MeriwetherC .Clotrimazole treatment of recurrent and chronic candida vulvovaginitis. Obstetrics &amp; Gynecology1989;73:330-4. ">Sobel 1989</a>; <a href="./references#CD009151-bbs2-0020" title="SobelJD , WiesenfeldHC , MartensM , DannaP , HootonTM , RompaloA , et al.Maintenance fluconazole therapy for recurrent vulvovaginal candidiasis. New England Journal of Medicine2004;351:876-83. ">Sobel 2004</a>; <a href="./references#CD009151-bbs2-0021" title="SpacekJ , BuchtaV .Itraconazole in the treatment of acute and recurrent vulvovaginal candidosis: comparison of a 1-day and a 3-day regimen. Mycoses2005;48:165-71. ">Spacek 2005</a>; <a href="./references#CD009151-bbs2-0022" title="SpinilloA , ColonnaL , PiazziG , BaltaroF , MonacoA , FerrariA .Managing recurrent vulvovaginal candidiasis. Intermittent prevention with itraconazole. Journal of Reproductive Medicine1997;42:83-7. ">Spinillo 1997</a>; <a href="./references#CD009151-bbs2-0023" title="WittA , KaufmannU , BitschnauM , TempferC , OzbalA , HaytougluE , et al.Monthly itraconazole versus classic homeopathy for the treatment of recurrent vulvovaginal candidiasis: a randomized trial. Obstetrical and Gynecological Survey2010;65(1):26-7. WittA , KaufmannU , BitschnauM , TempferC , OzbalA , HaytougluE , GregorH , KissH .Monthly itraconazole versus classic homeopathy for the treatment of recurrent vulvovaginal candidiasis: a randomised trial. British Journal of Obstetrics &amp; Gynaecology2009;116(11):1499-505. ">Witt 2009</a>). One study did not exclude pregnant women, but none enrolled (<a href="./references#CD009151-bbs2-0007" title="FardyazarZ , HabibzadehS , Abdollahi-FardS , TelloM .Vaginal azoles versus oral fluconazole in treatment of recurrent vulvovaginal candidiasis. Iranian Journal of Clinical Infectious Diseases2007;2:17-22. FardyazarZ , HabibzadehS .Long term vaginal azoles versus prophylactic oral fluconazole in treatment of recurrent vulvovaginal candidiasis. Research Journal of Biological Sciences2007;2(6):663-6. ">Fardyazar 2007</a>). Four further studies also did not explicitly exclude pregnant women, but did not state if any participants were pregnant (<a href="./references#CD009151-bbs2-0003" title="CorthayP , PerrenoudC , GumowskiPI , GirardJP .Candida albicans specific immune responses in patients with recurrent chronic vaginitis treated with an anti-candida food regimen (ACFR) or an hyposensitization treatment (HPT). Allergy1988;43:51. ">Corthay 1988</a>; <a href="./references#CD009151-bbs2-0009" title="FongIW .The value of treating the sexual partners of women with recurrent vaginal candidiasis with ketoconazole. Genitourinary Medicine1992;68:174-6. ">Fong 1992b</a>; <a href="./references#CD009151-bbs2-0010" title="FongIW .The value of prophylactic (monthly) clotrimazole versus empiric self-treatment in recurrent vaginal candidiasis. Genitourinary Medicine1994;70:124-6. ">Fong 1994</a>; <a href="./references#CD009151-bbs2-0013" title="Lopez-OlmosJ , LermaE .Treatment of recurring vulvo-vaginal candidiasis: a comparative prospective study during six months of three anti-mycotic preparations of a single dosis. Clinica e Investigacion en Ginecologia y Obstetricia2000;27:366-75. ">Lopez‐Olmos 2000</a>). </p> <p>Five studies required participants to have a culture <i>C albicans</i> at enrolment (<a href="./references#CD009151-bbs2-0016" title="RothAC , MilsomI , ForssmanL , WahlenP .Intermittent prophylactic treatment of recurrent vaginal candidiasis by postmenstrual application of a 500 mg clotrimazole vaginal tablet. Genitourinary Medicine1990;66:357-60. ">Roth 1990</a>; <a href="./references#CD009151-bbs2-0017" title="SobelJD .Management of recurrent vulvovaginal candidiasis (VVC) with ketoconazole (K) prophylaxis [abstract]. Archives of Gynecology1985;237 Suppl:281. SobelJD .Management of recurrent vulvovaginal candidiasis with intermittent ketoconazole prophylaxis. Obstetrics &amp; Gynecology1985;65:435-40. ">Sobel 1985a</a>; <a href="./references#CD009151-bbs2-0018" title="SobelJD .Recurrent vulvovaginal candidiasis. A prospective study of the efficacy of maintenance ketoconazole therapy. New England Journal of Medicine1986;315:1455-8. ">Sobel 1986</a>; <a href="./references#CD009151-bbs2-0022" title="SpinilloA , ColonnaL , PiazziG , BaltaroF , MonacoA , FerrariA .Managing recurrent vulvovaginal candidiasis. Intermittent prevention with itraconazole. Journal of Reproductive Medicine1997;42:83-7. ">Spinillo 1997</a>; <a href="./references#CD009151-bbs2-0023" title="WittA , KaufmannU , BitschnauM , TempferC , OzbalA , HaytougluE , et al.Monthly itraconazole versus classic homeopathy for the treatment of recurrent vulvovaginal candidiasis: a randomized trial. Obstetrical and Gynecological Survey2010;65(1):26-7. WittA , KaufmannU , BitschnauM , TempferC , OzbalA , HaytougluE , GregorH , KissH .Monthly itraconazole versus classic homeopathy for the treatment of recurrent vulvovaginal candidiasis: a randomised trial. British Journal of Obstetrics &amp; Gynaecology2009;116(11):1499-505. ">Witt 2009</a>). Nine studies did not report the prevalence of <i>C albicans</i> at enrolment (<a href="./references#CD009151-bbs2-0003" title="CorthayP , PerrenoudC , GumowskiPI , GirardJP .Candida albicans specific immune responses in patients with recurrent chronic vaginitis treated with an anti-candida food regimen (ACFR) or an hyposensitization treatment (HPT). Allergy1988;43:51. ">Corthay 1988</a>; <a href="./references#CD009151-bbs2-0002" title="ChopraV , MarottaF , KumariA , BishierMP , HeF , ZerbinatiN , et al.Prophylactic strategies in recurrent vulvovaginal candidiasis: a 2-year study testing a phytonutrient vs itraconazole. Journal of Biological Regulators and Homeostatic Agents2013;27(3):875-82. [PMID: 24152852]">Chopra 2013</a>; <a href="./references#CD009151-bbs2-0007" title="FardyazarZ , HabibzadehS , Abdollahi-FardS , TelloM .Vaginal azoles versus oral fluconazole in treatment of recurrent vulvovaginal candidiasis. Iranian Journal of Clinical Infectious Diseases2007;2:17-22. FardyazarZ , HabibzadehS .Long term vaginal azoles versus prophylactic oral fluconazole in treatment of recurrent vulvovaginal candidiasis. Research Journal of Biological Sciences2007;2(6):663-6. ">Fardyazar 2007</a>; <a href="./references#CD009151-bbs2-0008" title="FongIW .The value of chronic suppressive therapy with itraconazole versus clotrimazole in women with recurrent vaginal candidiasis. Genitourinary Medicine1992;68:374-7. ">Fong 1992a</a>; <a href="./references#CD009151-bbs2-0009" title="FongIW .The value of treating the sexual partners of women with recurrent vaginal candidiasis with ketoconazole. Genitourinary Medicine1992;68:174-6. ">Fong 1992b</a>; <a href="./references#CD009151-bbs2-0010" title="FongIW .The value of prophylactic (monthly) clotrimazole versus empiric self-treatment in recurrent vaginal candidiasis. Genitourinary Medicine1994;70:124-6. ">Fong 1994</a>; <a href="./references#CD009151-bbs2-0012" title="LiW .Influence of nursing intervention on recurrent vulvovaginal candidiasis patients treated with ATP-infrared bio-effect technique. Iranian Journal of Public Health2018;47(10):1511-9. ">Li 2018</a>; <a href="./references#CD009151-bbs2-0014" title="MendlingW , BirknerV .Vaccination with inactivated lactobacilli or heliotherapy can improve the quality-of-life of women with chronic recurrent vulvovaginal candidosis a prospective randomized study [Die Vakzination mit inaktivierten Laktobazillen oder mit Heliotherapie kann die Lebensqualitat von Frauen mit rezidivierender vulvovaginaler Kandidose verbessern - Eine prospektive 3-armige randomisierte Studie]. Geburtshilfe und Frauenheilkunde2011;71(9):767-72. ">Mendling 2011</a>; <a href="./references#CD009151-bbs2-0015" title="MettsJ , FamulaTR , TrenevN , ClemensRA .Lactobacillus acidophilus, strain NAS (H2O2 positive), in reduction of recurrent candidal vulvovaginitis. Journal of Applied Research2003;3:340-8. ">Metts 2003</a>). In the remaining studies, the predominant <i>Candida</i> species at enrolment was <i>C albicans</i>, with between 27% and 100%. <a href="./references#CD009151-bbs2-0013" title="Lopez-OlmosJ , LermaE .Treatment of recurring vulvo-vaginal candidiasis: a comparative prospective study during six months of three anti-mycotic preparations of a single dosis. Clinica e Investigacion en Ginecologia y Obstetricia2000;27:366-75. ">Lopez‐Olmos 2000</a> did not require a positive culture at enrolment; however, if the culture was positive, it was most commonly <i>C albicans</i>. </p> <p>Five studies required women to have a negative culture for <i>Candida spp</i> prior to commencing the treatment phase (<a href="./references#CD009151-bbs2-0001" title="BolouriF , TabriziNM , TanhaFD , NiroomandN , AzmoodehA , EmamiS , et al.Effectiveness of fluconazole for suppressive maintenance therapy in patients with RVVC: a randomized placebo-controlled study. Iranian Journal of Pharmaceutical Research2009;8:307-13. ">Bolouri 2009</a>; <a href="./references#CD009151-bbs2-0006" title="FanS , LiuX , WuC , XuL , LiJ .Vaginal nystatin versus oral fluconazole for the treatment for recurrent vulvovaginal candidiasis. Mycopathologia2015;179:95-101. [DOI: https://doi.org/10.1007/s11046-014-9827-4]">Fan 2015</a>; <a href="./references#CD009151-bbs2-0016" title="RothAC , MilsomI , ForssmanL , WahlenP .Intermittent prophylactic treatment of recurrent vaginal candidiasis by postmenstrual application of a 500 mg clotrimazole vaginal tablet. Genitourinary Medicine1990;66:357-60. ">Roth 1990</a>; <a href="./references#CD009151-bbs2-0019" title="SobelJD , SchmittC , MeriwetherC .Clotrimazole treatment of recurrent and chronic candida vulvovaginitis. Obstetrics &amp; Gynecology1989;73:330-4. ">Sobel 1989</a>; <a href="./references#CD009151-bbs2-0020" title="SobelJD , WiesenfeldHC , MartensM , DannaP , HootonTM , RompaloA , et al.Maintenance fluconazole therapy for recurrent vulvovaginal candidiasis. New England Journal of Medicine2004;351:876-83. ">Sobel 2004</a>). In one study participants were given additional treatment to achieve negative cultures for <i>Candida spp</i> (<a href="./references#CD009151-bbs2-0022" title="SpinilloA , ColonnaL , PiazziG , BaltaroF , MonacoA , FerrariA .Managing recurrent vulvovaginal candidiasis. Intermittent prevention with itraconazole. Journal of Reproductive Medicine1997;42:83-7. ">Spinillo 1997</a>), and in four studies participants did not need to have a negative culture for <i>Candida spp</i> (<a href="./references#CD009151-bbs2-0007" title="FardyazarZ , HabibzadehS , Abdollahi-FardS , TelloM .Vaginal azoles versus oral fluconazole in treatment of recurrent vulvovaginal candidiasis. Iranian Journal of Clinical Infectious Diseases2007;2:17-22. FardyazarZ , HabibzadehS .Long term vaginal azoles versus prophylactic oral fluconazole in treatment of recurrent vulvovaginal candidiasis. Research Journal of Biological Sciences2007;2(6):663-6. ">Fardyazar 2007</a>; <a href="./references#CD009151-bbs2-0008" title="FongIW .The value of chronic suppressive therapy with itraconazole versus clotrimazole in women with recurrent vaginal candidiasis. Genitourinary Medicine1992;68:374-7. ">Fong 1992a</a>; <a href="./references#CD009151-bbs2-0012" title="LiW .Influence of nursing intervention on recurrent vulvovaginal candidiasis patients treated with ATP-infrared bio-effect technique. Iranian Journal of Public Health2018;47(10):1511-9. ">Li 2018</a>; <a href="./references#CD009151-bbs2-0018" title="SobelJD .Recurrent vulvovaginal candidiasis. A prospective study of the efficacy of maintenance ketoconazole therapy. New England Journal of Medicine1986;315:1455-8. ">Sobel 1986</a>). </p> <p>The most common setting was an outpatient clinic (<a href="./references#CD009151-bbs2-0001" title="BolouriF , TabriziNM , TanhaFD , NiroomandN , AzmoodehA , EmamiS , et al.Effectiveness of fluconazole for suppressive maintenance therapy in patients with RVVC: a randomized placebo-controlled study. Iranian Journal of Pharmaceutical Research2009;8:307-13. ">Bolouri 2009</a>; <a href="./references#CD009151-bbs2-0002" title="ChopraV , MarottaF , KumariA , BishierMP , HeF , ZerbinatiN , et al.Prophylactic strategies in recurrent vulvovaginal candidiasis: a 2-year study testing a phytonutrient vs itraconazole. Journal of Biological Regulators and Homeostatic Agents2013;27(3):875-82. [PMID: 24152852]">Chopra 2013</a>; <a href="./references#CD009151-bbs2-0004" title="D'AntuonoA , BaldiE , BellavistaS , BanzolaN , ZauliS , PatriziA .Use of Dermasilk briefs in recurrent vulvovaginal candidosis: safety and effectiveness. Mycoses2012;55(3):e85-9. ">D'Antuono 2012</a>; <a href="./references#CD009151-bbs2-0005" title="D'AntuonoA , BellavistaS , GaspariV , FilippiniA , PatriziA .Dermasilk® briefs in recurrent vulvovaginal candidosis. An alternative option in long-lasting disease. Minerva Ginecologica2013;65(6):697-705. ">D'Antuono 2013</a>; <a href="./references#CD009151-bbs2-0006" title="FanS , LiuX , WuC , XuL , LiJ .Vaginal nystatin versus oral fluconazole for the treatment for recurrent vulvovaginal candidiasis. Mycopathologia2015;179:95-101. [DOI: https://doi.org/10.1007/s11046-014-9827-4]">Fan 2015</a>; <a href="./references#CD009151-bbs2-0007" title="FardyazarZ , HabibzadehS , Abdollahi-FardS , TelloM .Vaginal azoles versus oral fluconazole in treatment of recurrent vulvovaginal candidiasis. Iranian Journal of Clinical Infectious Diseases2007;2:17-22. FardyazarZ , HabibzadehS .Long term vaginal azoles versus prophylactic oral fluconazole in treatment of recurrent vulvovaginal candidiasis. Research Journal of Biological Sciences2007;2(6):663-6. ">Fardyazar 2007</a>; <a href="./references#CD009151-bbs2-0008" title="FongIW .The value of chronic suppressive therapy with itraconazole versus clotrimazole in women with recurrent vaginal candidiasis. Genitourinary Medicine1992;68:374-7. ">Fong 1992a</a>; <a href="./references#CD009151-bbs2-0009" title="FongIW .The value of treating the sexual partners of women with recurrent vaginal candidiasis with ketoconazole. Genitourinary Medicine1992;68:174-6. ">Fong 1992b</a>; <a href="./references#CD009151-bbs2-0011" title="KumariA , BishierMP , NaitoY , SharmaA , SolimeneU , JainS , et al.Protective effect of an oral natural phytonutrient in recurrent vulvovaginal candidiasis: a 12-month study. Journal of Biological Regulators &amp; Homeostatic Agents2011;25(4):543-51. ">Kumari 2011</a>; <a href="./references#CD009151-bbs2-0012" title="LiW .Influence of nursing intervention on recurrent vulvovaginal candidiasis patients treated with ATP-infrared bio-effect technique. Iranian Journal of Public Health2018;47(10):1511-9. ">Li 2018</a>; <a href="./references#CD009151-bbs2-0021" title="SpacekJ , BuchtaV .Itraconazole in the treatment of acute and recurrent vulvovaginal candidosis: comparison of a 1-day and a 3-day regimen. Mycoses2005;48:165-71. ">Spacek 2005</a>; <a href="./references#CD009151-bbs2-0022" title="SpinilloA , ColonnaL , PiazziG , BaltaroF , MonacoA , FerrariA .Managing recurrent vulvovaginal candidiasis. Intermittent prevention with itraconazole. Journal of Reproductive Medicine1997;42:83-7. ">Spinillo 1997</a>; <a href="./references#CD009151-bbs2-0023" title="WittA , KaufmannU , BitschnauM , TempferC , OzbalA , HaytougluE , et al.Monthly itraconazole versus classic homeopathy for the treatment of recurrent vulvovaginal candidiasis: a randomized trial. Obstetrical and Gynecological Survey2010;65(1):26-7. WittA , KaufmannU , BitschnauM , TempferC , OzbalA , HaytougluE , GregorH , KissH .Monthly itraconazole versus classic homeopathy for the treatment of recurrent vulvovaginal candidiasis: a randomised trial. British Journal of Obstetrics &amp; Gynaecology2009;116(11):1499-505. ">Witt 2009</a>). One study was conducted exclusively in a primary care setting (a university student health centre) (<a href="./references#CD009151-bbs2-0015" title="MettsJ , FamulaTR , TrenevN , ClemensRA .Lactobacillus acidophilus, strain NAS (H2O2 positive), in reduction of recurrent candidal vulvovaginitis. Journal of Applied Research2003;3:340-8. ">Metts 2003</a>). Two studies included participants from multiple sites (gynaecology/family planning clinics) (<a href="./references#CD009151-bbs2-0013" title="Lopez-OlmosJ , LermaE .Treatment of recurring vulvo-vaginal candidiasis: a comparative prospective study during six months of three anti-mycotic preparations of a single dosis. Clinica e Investigacion en Ginecologia y Obstetricia2000;27:366-75. ">Lopez‐Olmos 2000</a>; <a href="./references#CD009151-bbs2-0014" title="MendlingW , BirknerV .Vaccination with inactivated lactobacilli or heliotherapy can improve the quality-of-life of women with chronic recurrent vulvovaginal candidosis a prospective randomized study [Die Vakzination mit inaktivierten Laktobazillen oder mit Heliotherapie kann die Lebensqualitat von Frauen mit rezidivierender vulvovaginaler Kandidose verbessern - Eine prospektive 3-armige randomisierte Studie]. Geburtshilfe und Frauenheilkunde2011;71(9):767-72. ">Mendling 2011</a>). A third study was also multicentre, but the settings were not described (<a href="./references#CD009151-bbs2-0020" title="SobelJD , WiesenfeldHC , MartensM , DannaP , HootonTM , RompaloA , et al.Maintenance fluconazole therapy for recurrent vulvovaginal candidiasis. New England Journal of Medicine2004;351:876-83. ">Sobel 2004</a>). The setting was not stated in six studies (<a href="./references#CD009151-bbs2-0003" title="CorthayP , PerrenoudC , GumowskiPI , GirardJP .Candida albicans specific immune responses in patients with recurrent chronic vaginitis treated with an anti-candida food regimen (ACFR) or an hyposensitization treatment (HPT). Allergy1988;43:51. ">Corthay 1988</a>; <a href="./references#CD009151-bbs2-0010" title="FongIW .The value of prophylactic (monthly) clotrimazole versus empiric self-treatment in recurrent vaginal candidiasis. Genitourinary Medicine1994;70:124-6. ">Fong 1994</a>; <a href="./references#CD009151-bbs2-0016" title="RothAC , MilsomI , ForssmanL , WahlenP .Intermittent prophylactic treatment of recurrent vaginal candidiasis by postmenstrual application of a 500 mg clotrimazole vaginal tablet. Genitourinary Medicine1990;66:357-60. ">Roth 1990</a>; <a href="./references#CD009151-bbs2-0017" title="SobelJD .Management of recurrent vulvovaginal candidiasis (VVC) with ketoconazole (K) prophylaxis [abstract]. Archives of Gynecology1985;237 Suppl:281. SobelJD .Management of recurrent vulvovaginal candidiasis with intermittent ketoconazole prophylaxis. Obstetrics &amp; Gynecology1985;65:435-40. ">Sobel 1985a</a>; <a href="./references#CD009151-bbs2-0018" title="SobelJD .Recurrent vulvovaginal candidiasis. A prospective study of the efficacy of maintenance ketoconazole therapy. New England Journal of Medicine1986;315:1455-8. ">Sobel 1986</a>; <a href="./references#CD009151-bbs2-0019" title="SobelJD , SchmittC , MeriwetherC .Clotrimazole treatment of recurrent and chronic candida vulvovaginitis. Obstetrics &amp; Gynecology1989;73:330-4. ">Sobel 1989</a>). </p> <p>Ten studies were conducted in Europe (Austria, the Czech Republic, Germany, Italy, Spain, and Sweden) (<a href="./references#CD009151-bbs2-0002" title="ChopraV , MarottaF , KumariA , BishierMP , HeF , ZerbinatiN , et al.Prophylactic strategies in recurrent vulvovaginal candidiasis: a 2-year study testing a phytonutrient vs itraconazole. Journal of Biological Regulators and Homeostatic Agents2013;27(3):875-82. [PMID: 24152852]">Chopra 2013</a>; <a href="./references#CD009151-bbs2-0004" title="D'AntuonoA , BaldiE , BellavistaS , BanzolaN , ZauliS , PatriziA .Use of Dermasilk briefs in recurrent vulvovaginal candidosis: safety and effectiveness. Mycoses2012;55(3):e85-9. ">D'Antuono 2012</a>; <a href="./references#CD009151-bbs2-0005" title="D'AntuonoA , BellavistaS , GaspariV , FilippiniA , PatriziA .Dermasilk® briefs in recurrent vulvovaginal candidosis. An alternative option in long-lasting disease. Minerva Ginecologica2013;65(6):697-705. ">D'Antuono 2013</a>; <a href="./references#CD009151-bbs2-0011" title="KumariA , BishierMP , NaitoY , SharmaA , SolimeneU , JainS , et al.Protective effect of an oral natural phytonutrient in recurrent vulvovaginal candidiasis: a 12-month study. Journal of Biological Regulators &amp; Homeostatic Agents2011;25(4):543-51. ">Kumari 2011</a>; <a href="./references#CD009151-bbs2-0013" title="Lopez-OlmosJ , LermaE .Treatment of recurring vulvo-vaginal candidiasis: a comparative prospective study during six months of three anti-mycotic preparations of a single dosis. Clinica e Investigacion en Ginecologia y Obstetricia2000;27:366-75. ">Lopez‐Olmos 2000</a>; <a href="./references#CD009151-bbs2-0014" title="MendlingW , BirknerV .Vaccination with inactivated lactobacilli or heliotherapy can improve the quality-of-life of women with chronic recurrent vulvovaginal candidosis a prospective randomized study [Die Vakzination mit inaktivierten Laktobazillen oder mit Heliotherapie kann die Lebensqualitat von Frauen mit rezidivierender vulvovaginaler Kandidose verbessern - Eine prospektive 3-armige randomisierte Studie]. Geburtshilfe und Frauenheilkunde2011;71(9):767-72. ">Mendling 2011</a>; <a href="./references#CD009151-bbs2-0016" title="RothAC , MilsomI , ForssmanL , WahlenP .Intermittent prophylactic treatment of recurrent vaginal candidiasis by postmenstrual application of a 500 mg clotrimazole vaginal tablet. Genitourinary Medicine1990;66:357-60. ">Roth 1990</a>; <a href="./references#CD009151-bbs2-0021" title="SpacekJ , BuchtaV .Itraconazole in the treatment of acute and recurrent vulvovaginal candidosis: comparison of a 1-day and a 3-day regimen. Mycoses2005;48:165-71. ">Spacek 2005</a>; <a href="./references#CD009151-bbs2-0022" title="SpinilloA , ColonnaL , PiazziG , BaltaroF , MonacoA , FerrariA .Managing recurrent vulvovaginal candidiasis. Intermittent prevention with itraconazole. Journal of Reproductive Medicine1997;42:83-7. ">Spinillo 1997</a>; <a href="./references#CD009151-bbs2-0023" title="WittA , KaufmannU , BitschnauM , TempferC , OzbalA , HaytougluE , et al.Monthly itraconazole versus classic homeopathy for the treatment of recurrent vulvovaginal candidiasis: a randomized trial. Obstetrical and Gynecological Survey2010;65(1):26-7. WittA , KaufmannU , BitschnauM , TempferC , OzbalA , HaytougluE , GregorH , KissH .Monthly itraconazole versus classic homeopathy for the treatment of recurrent vulvovaginal candidiasis: a randomised trial. British Journal of Obstetrics &amp; Gynaecology2009;116(11):1499-505. ">Witt 2009</a>), and eight in North America (<a href="./references#CD009151-bbs2-0008" title="FongIW .The value of chronic suppressive therapy with itraconazole versus clotrimazole in women with recurrent vaginal candidiasis. Genitourinary Medicine1992;68:374-7. ">Fong 1992a</a>; <a href="./references#CD009151-bbs2-0009" title="FongIW .The value of treating the sexual partners of women with recurrent vaginal candidiasis with ketoconazole. Genitourinary Medicine1992;68:174-6. ">Fong 1992b</a>; <a href="./references#CD009151-bbs2-0010" title="FongIW .The value of prophylactic (monthly) clotrimazole versus empiric self-treatment in recurrent vaginal candidiasis. Genitourinary Medicine1994;70:124-6. ">Fong 1994</a>; <a href="./references#CD009151-bbs2-0015" title="MettsJ , FamulaTR , TrenevN , ClemensRA .Lactobacillus acidophilus, strain NAS (H2O2 positive), in reduction of recurrent candidal vulvovaginitis. Journal of Applied Research2003;3:340-8. ">Metts 2003</a>; <a href="./references#CD009151-bbs2-0017" title="SobelJD .Management of recurrent vulvovaginal candidiasis (VVC) with ketoconazole (K) prophylaxis [abstract]. Archives of Gynecology1985;237 Suppl:281. SobelJD .Management of recurrent vulvovaginal candidiasis with intermittent ketoconazole prophylaxis. Obstetrics &amp; Gynecology1985;65:435-40. ">Sobel 1985a</a>; <a href="./references#CD009151-bbs2-0018" title="SobelJD .Recurrent vulvovaginal candidiasis. A prospective study of the efficacy of maintenance ketoconazole therapy. New England Journal of Medicine1986;315:1455-8. ">Sobel 1986</a>; <a href="./references#CD009151-bbs2-0019" title="SobelJD , SchmittC , MeriwetherC .Clotrimazole treatment of recurrent and chronic candida vulvovaginitis. Obstetrics &amp; Gynecology1989;73:330-4. ">Sobel 1989</a>; <a href="./references#CD009151-bbs2-0020" title="SobelJD , WiesenfeldHC , MartensM , DannaP , HootonTM , RompaloA , et al.Maintenance fluconazole therapy for recurrent vulvovaginal candidiasis. New England Journal of Medicine2004;351:876-83. ">Sobel 2004</a>). One study did not state the location (<a href="./references#CD009151-bbs2-0003" title="CorthayP , PerrenoudC , GumowskiPI , GirardJP .Candida albicans specific immune responses in patients with recurrent chronic vaginitis treated with an anti-candida food regimen (ACFR) or an hyposensitization treatment (HPT). Allergy1988;43:51. ">Corthay 1988</a>). The remaining four studies were conducted in Asia, two in Iran ( <a href="./references#CD009151-bbs2-0001" title="BolouriF , TabriziNM , TanhaFD , NiroomandN , AzmoodehA , EmamiS , et al.Effectiveness of fluconazole for suppressive maintenance therapy in patients with RVVC: a randomized placebo-controlled study. Iranian Journal of Pharmaceutical Research2009;8:307-13. ">Bolouri 2009</a>; <a href="./references#CD009151-bbs2-0007" title="FardyazarZ , HabibzadehS , Abdollahi-FardS , TelloM .Vaginal azoles versus oral fluconazole in treatment of recurrent vulvovaginal candidiasis. Iranian Journal of Clinical Infectious Diseases2007;2:17-22. FardyazarZ , HabibzadehS .Long term vaginal azoles versus prophylactic oral fluconazole in treatment of recurrent vulvovaginal candidiasis. Research Journal of Biological Sciences2007;2(6):663-6. ">Fardyazar 2007</a>) and two in China (<a href="./references#CD009151-bbs2-0006" title="FanS , LiuX , WuC , XuL , LiJ .Vaginal nystatin versus oral fluconazole for the treatment for recurrent vulvovaginal candidiasis. Mycopathologia2015;179:95-101. [DOI: https://doi.org/10.1007/s11046-014-9827-4]">Fan 2015</a>; <a href="./references#CD009151-bbs2-0012" title="LiW .Influence of nursing intervention on recurrent vulvovaginal candidiasis patients treated with ATP-infrared bio-effect technique. Iranian Journal of Public Health2018;47(10):1511-9. ">Li 2018</a>). </p> </section> <section id="CD009151-sec-0051"> <h5 class="title">Interventions and comparators</h5> <p>The included studies involved a variety of comparisons. Six studies compared drug treatments to placebo or no treatment (<a href="./references#CD009151-bbs2-0001" title="BolouriF , TabriziNM , TanhaFD , NiroomandN , AzmoodehA , EmamiS , et al.Effectiveness of fluconazole for suppressive maintenance therapy in patients with RVVC: a randomized placebo-controlled study. Iranian Journal of Pharmaceutical Research2009;8:307-13. ">Bolouri 2009</a>; <a href="./references#CD009151-bbs2-0016" title="RothAC , MilsomI , ForssmanL , WahlenP .Intermittent prophylactic treatment of recurrent vaginal candidiasis by postmenstrual application of a 500 mg clotrimazole vaginal tablet. Genitourinary Medicine1990;66:357-60. ">Roth 1990</a>; <a href="./references#CD009151-bbs2-0018" title="SobelJD .Recurrent vulvovaginal candidiasis. A prospective study of the efficacy of maintenance ketoconazole therapy. New England Journal of Medicine1986;315:1455-8. ">Sobel 1986</a>; <a href="./references#CD009151-bbs2-0019" title="SobelJD , SchmittC , MeriwetherC .Clotrimazole treatment of recurrent and chronic candida vulvovaginitis. Obstetrics &amp; Gynecology1989;73:330-4. ">Sobel 1989</a>; <a href="./references#CD009151-bbs2-0020" title="SobelJD , WiesenfeldHC , MartensM , DannaP , HootonTM , RompaloA , et al.Maintenance fluconazole therapy for recurrent vulvovaginal candidiasis. New England Journal of Medicine2004;351:876-83. ">Sobel 2004</a>; <a href="./references#CD009151-bbs2-0022" title="SpinilloA , ColonnaL , PiazziG , BaltaroF , MonacoA , FerrariA .Managing recurrent vulvovaginal candidiasis. Intermittent prevention with itraconazole. Journal of Reproductive Medicine1997;42:83-7. ">Spinillo 1997</a>). Four studies compared oral drug treatment with topical drug treatment (<a href="./references#CD009151-bbs2-0006" title="FanS , LiuX , WuC , XuL , LiJ .Vaginal nystatin versus oral fluconazole for the treatment for recurrent vulvovaginal candidiasis. Mycopathologia2015;179:95-101. [DOI: https://doi.org/10.1007/s11046-014-9827-4]">Fan 2015</a>; <a href="./references#CD009151-bbs2-0007" title="FardyazarZ , HabibzadehS , Abdollahi-FardS , TelloM .Vaginal azoles versus oral fluconazole in treatment of recurrent vulvovaginal candidiasis. Iranian Journal of Clinical Infectious Diseases2007;2:17-22. FardyazarZ , HabibzadehS .Long term vaginal azoles versus prophylactic oral fluconazole in treatment of recurrent vulvovaginal candidiasis. Research Journal of Biological Sciences2007;2(6):663-6. ">Fardyazar 2007</a>; <a href="./references#CD009151-bbs2-0008" title="FongIW .The value of chronic suppressive therapy with itraconazole versus clotrimazole in women with recurrent vaginal candidiasis. Genitourinary Medicine1992;68:374-7. ">Fong 1992a</a>; <a href="./references#CD009151-bbs2-0013" title="Lopez-OlmosJ , LermaE .Treatment of recurring vulvo-vaginal candidiasis: a comparative prospective study during six months of three anti-mycotic preparations of a single dosis. Clinica e Investigacion en Ginecologia y Obstetricia2000;27:366-75. ">Lopez‐Olmos 2000</a>), and one compared two types of oral drugs (<a href="./references#CD009151-bbs2-0013" title="Lopez-OlmosJ , LermaE .Treatment of recurring vulvo-vaginal candidiasis: a comparative prospective study during six months of three anti-mycotic preparations of a single dosis. Clinica e Investigacion en Ginecologia y Obstetricia2000;27:366-75. ">Lopez‐Olmos 2000</a>), but none compared different topical agents. Two studies compared different oral doses of the same agent (<a href="./references#CD009151-bbs2-0018" title="SobelJD .Recurrent vulvovaginal candidiasis. A prospective study of the efficacy of maintenance ketoconazole therapy. New England Journal of Medicine1986;315:1455-8. ">Sobel 1986</a>; <a href="./references#CD009151-bbs2-0021" title="SpacekJ , BuchtaV .Itraconazole in the treatment of acute and recurrent vulvovaginal candidosis: comparison of a 1-day and a 3-day regimen. Mycoses2005;48:165-71. ">Spacek 2005</a>), and one compared different oral treatment durations (<a href="./references#CD009151-bbs2-0021" title="SpacekJ , BuchtaV .Itraconazole in the treatment of acute and recurrent vulvovaginal candidosis: comparison of a 1-day and a 3-day regimen. Mycoses2005;48:165-71. ">Spacek 2005</a>). One study compared two different dosing regimens of the same topical agent (<a href="./references#CD009151-bbs2-0010" title="FongIW .The value of prophylactic (monthly) clotrimazole versus empiric self-treatment in recurrent vaginal candidiasis. Genitourinary Medicine1994;70:124-6. ">Fong 1994</a>). Two studies compared partner treatments with placebo or no treatment (<a href="./references#CD009151-bbs2-0009" title="FongIW .The value of treating the sexual partners of women with recurrent vaginal candidiasis with ketoconazole. Genitourinary Medicine1992;68:174-6. ">Fong 1992b</a>; <a href="./references#CD009151-bbs2-0017" title="SobelJD .Management of recurrent vulvovaginal candidiasis (VVC) with ketoconazole (K) prophylaxis [abstract]. Archives of Gynecology1985;237 Suppl:281. SobelJD .Management of recurrent vulvovaginal candidiasis with intermittent ketoconazole prophylaxis. Obstetrics &amp; Gynecology1985;65:435-40. ">Sobel 1985a</a>), and two studies compared non‐drug treatments (DermaSilk briefs) with other treatments (cotton briefs) (<a href="./references#CD009151-bbs2-0004" title="D'AntuonoA , BaldiE , BellavistaS , BanzolaN , ZauliS , PatriziA .Use of Dermasilk briefs in recurrent vulvovaginal candidosis: safety and effectiveness. Mycoses2012;55(3):e85-9. ">D'Antuono 2012</a>; <a href="./references#CD009151-bbs2-0005" title="D'AntuonoA , BellavistaS , GaspariV , FilippiniA , PatriziA .Dermasilk® briefs in recurrent vulvovaginal candidosis. An alternative option in long-lasting disease. Minerva Ginecologica2013;65(6):697-705. ">D'Antuono 2013</a>). One study compared adenosine triphosphate (ATP)‐infrared bio‐effect treatment and a nursing intervention with usual care (<a href="./references#CD009151-bbs2-0012" title="LiW .Influence of nursing intervention on recurrent vulvovaginal candidiasis patients treated with ATP-infrared bio-effect technique. Iranian Journal of Public Health2018;47(10):1511-9. ">Li 2018</a>). CAM treatments were compared with placebo in one study (<a href="./references#CD009151-bbs2-0015" title="MettsJ , FamulaTR , TrenevN , ClemensRA .Lactobacillus acidophilus, strain NAS (H2O2 positive), in reduction of recurrent candidal vulvovaginitis. Journal of Applied Research2003;3:340-8. ">Metts 2003</a>), and with drug treatments in three studies (<a href="./references#CD009151-bbs2-0002" title="ChopraV , MarottaF , KumariA , BishierMP , HeF , ZerbinatiN , et al.Prophylactic strategies in recurrent vulvovaginal candidiasis: a 2-year study testing a phytonutrient vs itraconazole. Journal of Biological Regulators and Homeostatic Agents2013;27(3):875-82. [PMID: 24152852]">Chopra 2013</a>; <a href="./references#CD009151-bbs2-0011" title="KumariA , BishierMP , NaitoY , SharmaA , SolimeneU , JainS , et al.Protective effect of an oral natural phytonutrient in recurrent vulvovaginal candidiasis: a 12-month study. Journal of Biological Regulators &amp; Homeostatic Agents2011;25(4):543-51. ">Kumari 2011</a>; <a href="./references#CD009151-bbs2-0023" title="WittA , KaufmannU , BitschnauM , TempferC , OzbalA , HaytougluE , et al.Monthly itraconazole versus classic homeopathy for the treatment of recurrent vulvovaginal candidiasis: a randomized trial. Obstetrical and Gynecological Survey2010;65(1):26-7. WittA , KaufmannU , BitschnauM , TempferC , OzbalA , HaytougluE , GregorH , KissH .Monthly itraconazole versus classic homeopathy for the treatment of recurrent vulvovaginal candidiasis: a randomised trial. British Journal of Obstetrics &amp; Gynaecology2009;116(11):1499-505. ">Witt 2009</a>). Another study compared CAM treatments (HPT with an aqueous Candida albicans extract to an antifungal treatment (local + digestive), then a low‐sugar diet with vitamins, biotin and lyophilized bacillus subfilis supplements (<a href="./references#CD009151-bbs2-0003" title="CorthayP , PerrenoudC , GumowskiPI , GirardJP .Candida albicans specific immune responses in patients with recurrent chronic vaginitis treated with an anti-candida food regimen (ACFR) or an hyposensitization treatment (HPT). Allergy1988;43:51. ">Corthay 1988</a>). One study compared vaccination therapy with drug treatment and alternative medicine (<a href="./references#CD009151-bbs2-0014" title="MendlingW , BirknerV .Vaccination with inactivated lactobacilli or heliotherapy can improve the quality-of-life of women with chronic recurrent vulvovaginal candidosis a prospective randomized study [Die Vakzination mit inaktivierten Laktobazillen oder mit Heliotherapie kann die Lebensqualitat von Frauen mit rezidivierender vulvovaginaler Kandidose verbessern - Eine prospektive 3-armige randomisierte Studie]. Geburtshilfe und Frauenheilkunde2011;71(9):767-72. ">Mendling 2011</a>). </p> <p>Fifteen studies had an intervention duration of six months (<a href="./references#CD009151-bbs2-0001" title="BolouriF , TabriziNM , TanhaFD , NiroomandN , AzmoodehA , EmamiS , et al.Effectiveness of fluconazole for suppressive maintenance therapy in patients with RVVC: a randomized placebo-controlled study. Iranian Journal of Pharmaceutical Research2009;8:307-13. ">Bolouri 2009</a>; <a href="./references#CD009151-bbs2-0004" title="D'AntuonoA , BaldiE , BellavistaS , BanzolaN , ZauliS , PatriziA .Use of Dermasilk briefs in recurrent vulvovaginal candidosis: safety and effectiveness. Mycoses2012;55(3):e85-9. ">D'Antuono 2012</a>; <a href="./references#CD009151-bbs2-0005" title="D'AntuonoA , BellavistaS , GaspariV , FilippiniA , PatriziA .Dermasilk® briefs in recurrent vulvovaginal candidosis. An alternative option in long-lasting disease. Minerva Ginecologica2013;65(6):697-705. ">D'Antuono 2013</a>; <a href="./references#CD009151-bbs2-0007" title="FardyazarZ , HabibzadehS , Abdollahi-FardS , TelloM .Vaginal azoles versus oral fluconazole in treatment of recurrent vulvovaginal candidiasis. Iranian Journal of Clinical Infectious Diseases2007;2:17-22. FardyazarZ , HabibzadehS .Long term vaginal azoles versus prophylactic oral fluconazole in treatment of recurrent vulvovaginal candidiasis. Research Journal of Biological Sciences2007;2(6):663-6. ">Fardyazar 2007</a>; <a href="./references#CD009151-bbs2-0008" title="FongIW .The value of chronic suppressive therapy with itraconazole versus clotrimazole in women with recurrent vaginal candidiasis. Genitourinary Medicine1992;68:374-7. ">Fong 1992a</a>; <a href="./references#CD009151-bbs2-0010" title="FongIW .The value of prophylactic (monthly) clotrimazole versus empiric self-treatment in recurrent vaginal candidiasis. Genitourinary Medicine1994;70:124-6. ">Fong 1994</a>; <a href="./references#CD009151-bbs2-0011" title="KumariA , BishierMP , NaitoY , SharmaA , SolimeneU , JainS , et al.Protective effect of an oral natural phytonutrient in recurrent vulvovaginal candidiasis: a 12-month study. Journal of Biological Regulators &amp; Homeostatic Agents2011;25(4):543-51. ">Kumari 2011</a>; <a href="./references#CD009151-bbs2-0012" title="LiW .Influence of nursing intervention on recurrent vulvovaginal candidiasis patients treated with ATP-infrared bio-effect technique. Iranian Journal of Public Health2018;47(10):1511-9. ">Li 2018</a>; <a href="./references#CD009151-bbs2-0013" title="Lopez-OlmosJ , LermaE .Treatment of recurring vulvo-vaginal candidiasis: a comparative prospective study during six months of three anti-mycotic preparations of a single dosis. Clinica e Investigacion en Ginecologia y Obstetricia2000;27:366-75. ">Lopez‐Olmos 2000</a>; <a href="./references#CD009151-bbs2-0015" title="MettsJ , FamulaTR , TrenevN , ClemensRA .Lactobacillus acidophilus, strain NAS (H2O2 positive), in reduction of recurrent candidal vulvovaginitis. Journal of Applied Research2003;3:340-8. ">Metts 2003</a>; <a href="./references#CD009151-bbs2-0016" title="RothAC , MilsomI , ForssmanL , WahlenP .Intermittent prophylactic treatment of recurrent vaginal candidiasis by postmenstrual application of a 500 mg clotrimazole vaginal tablet. Genitourinary Medicine1990;66:357-60. ">Roth 1990</a>; <a href="./references#CD009151-bbs2-0019" title="SobelJD , SchmittC , MeriwetherC .Clotrimazole treatment of recurrent and chronic candida vulvovaginitis. Obstetrics &amp; Gynecology1989;73:330-4. ">Sobel 1989</a>; <a href="./references#CD009151-bbs2-0020" title="SobelJD , WiesenfeldHC , MartensM , DannaP , HootonTM , RompaloA , et al.Maintenance fluconazole therapy for recurrent vulvovaginal candidiasis. New England Journal of Medicine2004;351:876-83. ">Sobel 2004</a>; <a href="./references#CD009151-bbs2-0022" title="SpinilloA , ColonnaL , PiazziG , BaltaroF , MonacoA , FerrariA .Managing recurrent vulvovaginal candidiasis. Intermittent prevention with itraconazole. Journal of Reproductive Medicine1997;42:83-7. ">Spinillo 1997</a>; <a href="./references#CD009151-bbs2-0023" title="WittA , KaufmannU , BitschnauM , TempferC , OzbalA , HaytougluE , et al.Monthly itraconazole versus classic homeopathy for the treatment of recurrent vulvovaginal candidiasis: a randomized trial. Obstetrical and Gynecological Survey2010;65(1):26-7. WittA , KaufmannU , BitschnauM , TempferC , OzbalA , HaytougluE , GregorH , KissH .Monthly itraconazole versus classic homeopathy for the treatment of recurrent vulvovaginal candidiasis: a randomised trial. British Journal of Obstetrics &amp; Gynaecology2009;116(11):1499-505. ">Witt 2009</a>). One study had an intervention duration of three months (<a href="./references#CD009151-bbs2-0003" title="CorthayP , PerrenoudC , GumowskiPI , GirardJP .Candida albicans specific immune responses in patients with recurrent chronic vaginitis treated with an anti-candida food regimen (ACFR) or an hyposensitization treatment (HPT). Allergy1988;43:51. ">Corthay 1988</a>). The three arms in <a href="./references#CD009151-bbs2-0018" title="SobelJD .Recurrent vulvovaginal candidiasis. A prospective study of the efficacy of maintenance ketoconazole therapy. New England Journal of Medicine1986;315:1455-8. ">Sobel 1986</a> had variable but similar lengths (6 menstrual cycles, 5 months, 6 months). One study had a 24‐month intervention period (<a href="./references#CD009151-bbs2-0002" title="ChopraV , MarottaF , KumariA , BishierMP , HeF , ZerbinatiN , et al.Prophylactic strategies in recurrent vulvovaginal candidiasis: a 2-year study testing a phytonutrient vs itraconazole. Journal of Biological Regulators and Homeostatic Agents2013;27(3):875-82. [PMID: 24152852]">Chopra 2013</a>). The two partner treatment studies had shorter durations: <a href="./references#CD009151-bbs2-0009" title="FongIW .The value of treating the sexual partners of women with recurrent vaginal candidiasis with ketoconazole. Genitourinary Medicine1992;68:174-6. ">Fong 1992b</a> only treated participants once (for a five‐day course), and <a href="./references#CD009151-bbs2-0017" title="SobelJD .Management of recurrent vulvovaginal candidiasis (VVC) with ketoconazole (K) prophylaxis [abstract]. Archives of Gynecology1985;237 Suppl:281. SobelJD .Management of recurrent vulvovaginal candidiasis with intermittent ketoconazole prophylaxis. Obstetrics &amp; Gynecology1985;65:435-40. ">Sobel 1985a</a> treated partners for one week. The duration of the interventions varied in <a href="./references#CD009151-bbs2-0014" title="MendlingW , BirknerV .Vaccination with inactivated lactobacilli or heliotherapy can improve the quality-of-life of women with chronic recurrent vulvovaginal candidosis a prospective randomized study [Die Vakzination mit inaktivierten Laktobazillen oder mit Heliotherapie kann die Lebensqualitat von Frauen mit rezidivierender vulvovaginaler Kandidose verbessern - Eine prospektive 3-armige randomisierte Studie]. Geburtshilfe und Frauenheilkunde2011;71(9):767-72. ">Mendling 2011</a>. <a href="./references#CD009151-bbs2-0021" title="SpacekJ , BuchtaV .Itraconazole in the treatment of acute and recurrent vulvovaginal candidosis: comparison of a 1-day and a 3-day regimen. Mycoses2005;48:165-71. ">Spacek 2005</a> randomised participants to one or three days of treatment. </p> </section> <section id="CD009151-sec-0052"> <h5 class="title">Outcome measurement</h5> <p>Fifteen studies continued outcome measurement beyond the intervention period as per their study protocols (additional ~6 months ‐ <a href="./references#CD009151-bbs2-0001" title="BolouriF , TabriziNM , TanhaFD , NiroomandN , AzmoodehA , EmamiS , et al.Effectiveness of fluconazole for suppressive maintenance therapy in patients with RVVC: a randomized placebo-controlled study. Iranian Journal of Pharmaceutical Research2009;8:307-13. ">Bolouri 2009</a>; <a href="./references#CD009151-bbs2-0003" title="CorthayP , PerrenoudC , GumowskiPI , GirardJP .Candida albicans specific immune responses in patients with recurrent chronic vaginitis treated with an anti-candida food regimen (ACFR) or an hyposensitization treatment (HPT). Allergy1988;43:51. ">Corthay 1988</a>; <a href="./references#CD009151-bbs2-0002" title="ChopraV , MarottaF , KumariA , BishierMP , HeF , ZerbinatiN , et al.Prophylactic strategies in recurrent vulvovaginal candidiasis: a 2-year study testing a phytonutrient vs itraconazole. Journal of Biological Regulators and Homeostatic Agents2013;27(3):875-82. [PMID: 24152852]">Chopra 2013</a>; <a href="./references#CD009151-bbs2-0006" title="FanS , LiuX , WuC , XuL , LiJ .Vaginal nystatin versus oral fluconazole for the treatment for recurrent vulvovaginal candidiasis. Mycopathologia2015;179:95-101. [DOI: https://doi.org/10.1007/s11046-014-9827-4]">Fan 2015</a>; <a href="./references#CD009151-bbs2-0007" title="FardyazarZ , HabibzadehS , Abdollahi-FardS , TelloM .Vaginal azoles versus oral fluconazole in treatment of recurrent vulvovaginal candidiasis. Iranian Journal of Clinical Infectious Diseases2007;2:17-22. FardyazarZ , HabibzadehS .Long term vaginal azoles versus prophylactic oral fluconazole in treatment of recurrent vulvovaginal candidiasis. Research Journal of Biological Sciences2007;2(6):663-6. ">Fardyazar 2007</a>; <a href="./references#CD009151-bbs2-0008" title="FongIW .The value of chronic suppressive therapy with itraconazole versus clotrimazole in women with recurrent vaginal candidiasis. Genitourinary Medicine1992;68:374-7. ">Fong 1992a</a>; <a href="./references#CD009151-bbs2-0011" title="KumariA , BishierMP , NaitoY , SharmaA , SolimeneU , JainS , et al.Protective effect of an oral natural phytonutrient in recurrent vulvovaginal candidiasis: a 12-month study. Journal of Biological Regulators &amp; Homeostatic Agents2011;25(4):543-51. ">Kumari 2011</a>; <a href="./references#CD009151-bbs2-0013" title="Lopez-OlmosJ , LermaE .Treatment of recurring vulvo-vaginal candidiasis: a comparative prospective study during six months of three anti-mycotic preparations of a single dosis. Clinica e Investigacion en Ginecologia y Obstetricia2000;27:366-75. ">Lopez‐Olmos 2000</a>; <a href="./references#CD009151-bbs2-0016" title="RothAC , MilsomI , ForssmanL , WahlenP .Intermittent prophylactic treatment of recurrent vaginal candidiasis by postmenstrual application of a 500 mg clotrimazole vaginal tablet. Genitourinary Medicine1990;66:357-60. ">Roth 1990</a>; <a href="./references#CD009151-bbs2-0018" title="SobelJD .Recurrent vulvovaginal candidiasis. A prospective study of the efficacy of maintenance ketoconazole therapy. New England Journal of Medicine1986;315:1455-8. ">Sobel 1986</a>; <a href="./references#CD009151-bbs2-0019" title="SobelJD , SchmittC , MeriwetherC .Clotrimazole treatment of recurrent and chronic candida vulvovaginitis. Obstetrics &amp; Gynecology1989;73:330-4. ">Sobel 1989</a>; <a href="./references#CD009151-bbs2-0020" title="SobelJD , WiesenfeldHC , MartensM , DannaP , HootonTM , RompaloA , et al.Maintenance fluconazole therapy for recurrent vulvovaginal candidiasis. New England Journal of Medicine2004;351:876-83. ">Sobel 2004</a>; <a href="./references#CD009151-bbs2-0021" title="SpacekJ , BuchtaV .Itraconazole in the treatment of acute and recurrent vulvovaginal candidosis: comparison of a 1-day and a 3-day regimen. Mycoses2005;48:165-71. ">Spacek 2005</a>; <a href="./references#CD009151-bbs2-0022" title="SpinilloA , ColonnaL , PiazziG , BaltaroF , MonacoA , FerrariA .Managing recurrent vulvovaginal candidiasis. Intermittent prevention with itraconazole. Journal of Reproductive Medicine1997;42:83-7. ">Spinillo 1997</a>; <a href="./references#CD009151-bbs2-0023" title="WittA , KaufmannU , BitschnauM , TempferC , OzbalA , HaytougluE , et al.Monthly itraconazole versus classic homeopathy for the treatment of recurrent vulvovaginal candidiasis: a randomized trial. Obstetrical and Gynecological Survey2010;65(1):26-7. WittA , KaufmannU , BitschnauM , TempferC , OzbalA , HaytougluE , GregorH , KissH .Monthly itraconazole versus classic homeopathy for the treatment of recurrent vulvovaginal candidiasis: a randomised trial. British Journal of Obstetrics &amp; Gynaecology2009;116(11):1499-505. ">Witt 2009</a>; two studies additional ~12 months ‐ <a href="./references#CD009151-bbs2-0009" title="FongIW .The value of treating the sexual partners of women with recurrent vaginal candidiasis with ketoconazole. Genitourinary Medicine1992;68:174-6. ">Fong 1992b</a>; <a href="./references#CD009151-bbs2-0017" title="SobelJD .Management of recurrent vulvovaginal candidiasis (VVC) with ketoconazole (K) prophylaxis [abstract]. Archives of Gynecology1985;237 Suppl:281. SobelJD .Management of recurrent vulvovaginal candidiasis with intermittent ketoconazole prophylaxis. Obstetrics &amp; Gynecology1985;65:435-40. ">Sobel 1985a</a>; one study was variable due to the variable length of the interventions ‐ <a href="./references#CD009151-bbs2-0014" title="MendlingW , BirknerV .Vaccination with inactivated lactobacilli or heliotherapy can improve the quality-of-life of women with chronic recurrent vulvovaginal candidosis a prospective randomized study [Die Vakzination mit inaktivierten Laktobazillen oder mit Heliotherapie kann die Lebensqualitat von Frauen mit rezidivierender vulvovaginaler Kandidose verbessern - Eine prospektive 3-armige randomisierte Studie]. Geburtshilfe und Frauenheilkunde2011;71(9):767-72. ">Mendling 2011</a>). Eleven studies stated that they assessed participants between planned visits if they developed symptoms in the intervening period (<a href="./references#CD009151-bbs2-0002" title="ChopraV , MarottaF , KumariA , BishierMP , HeF , ZerbinatiN , et al.Prophylactic strategies in recurrent vulvovaginal candidiasis: a 2-year study testing a phytonutrient vs itraconazole. Journal of Biological Regulators and Homeostatic Agents2013;27(3):875-82. [PMID: 24152852]">Chopra 2013</a>; <a href="./references#CD009151-bbs2-0006" title="FanS , LiuX , WuC , XuL , LiJ .Vaginal nystatin versus oral fluconazole for the treatment for recurrent vulvovaginal candidiasis. Mycopathologia2015;179:95-101. [DOI: https://doi.org/10.1007/s11046-014-9827-4]">Fan 2015</a>; <a href="./references#CD009151-bbs2-0009" title="FongIW .The value of treating the sexual partners of women with recurrent vaginal candidiasis with ketoconazole. Genitourinary Medicine1992;68:174-6. ">Fong 1992b</a>; <a href="./references#CD009151-bbs2-0014" title="MendlingW , BirknerV .Vaccination with inactivated lactobacilli or heliotherapy can improve the quality-of-life of women with chronic recurrent vulvovaginal candidosis a prospective randomized study [Die Vakzination mit inaktivierten Laktobazillen oder mit Heliotherapie kann die Lebensqualitat von Frauen mit rezidivierender vulvovaginaler Kandidose verbessern - Eine prospektive 3-armige randomisierte Studie]. Geburtshilfe und Frauenheilkunde2011;71(9):767-72. ">Mendling 2011</a>; <a href="./references#CD009151-bbs2-0015" title="MettsJ , FamulaTR , TrenevN , ClemensRA .Lactobacillus acidophilus, strain NAS (H2O2 positive), in reduction of recurrent candidal vulvovaginitis. Journal of Applied Research2003;3:340-8. ">Metts 2003</a>; <a href="./references#CD009151-bbs2-0016" title="RothAC , MilsomI , ForssmanL , WahlenP .Intermittent prophylactic treatment of recurrent vaginal candidiasis by postmenstrual application of a 500 mg clotrimazole vaginal tablet. Genitourinary Medicine1990;66:357-60. ">Roth 1990</a>; <a href="./references#CD009151-bbs2-0017" title="SobelJD .Management of recurrent vulvovaginal candidiasis (VVC) with ketoconazole (K) prophylaxis [abstract]. Archives of Gynecology1985;237 Suppl:281. SobelJD .Management of recurrent vulvovaginal candidiasis with intermittent ketoconazole prophylaxis. Obstetrics &amp; Gynecology1985;65:435-40. ">Sobel 1985a</a>; <a href="./references#CD009151-bbs2-0018" title="SobelJD .Recurrent vulvovaginal candidiasis. A prospective study of the efficacy of maintenance ketoconazole therapy. New England Journal of Medicine1986;315:1455-8. ">Sobel 1986</a>; <a href="./references#CD009151-bbs2-0019" title="SobelJD , SchmittC , MeriwetherC .Clotrimazole treatment of recurrent and chronic candida vulvovaginitis. Obstetrics &amp; Gynecology1989;73:330-4. ">Sobel 1989</a>; <a href="./references#CD009151-bbs2-0022" title="SpinilloA , ColonnaL , PiazziG , BaltaroF , MonacoA , FerrariA .Managing recurrent vulvovaginal candidiasis. Intermittent prevention with itraconazole. Journal of Reproductive Medicine1997;42:83-7. ">Spinillo 1997</a>; <a href="./references#CD009151-bbs2-0023" title="WittA , KaufmannU , BitschnauM , TempferC , OzbalA , HaytougluE , et al.Monthly itraconazole versus classic homeopathy for the treatment of recurrent vulvovaginal candidiasis: a randomized trial. Obstetrical and Gynecological Survey2010;65(1):26-7. WittA , KaufmannU , BitschnauM , TempferC , OzbalA , HaytougluE , GregorH , KissH .Monthly itraconazole versus classic homeopathy for the treatment of recurrent vulvovaginal candidiasis: a randomised trial. British Journal of Obstetrics &amp; Gynaecology2009;116(11):1499-505. ">Witt 2009</a>). </p> </section> <section id="CD009151-sec-0053"> <h5 class="title">Reporting of primary outcomes</h5> <p>All included studies, except three studies (<a href="./references#CD009151-bbs2-0003" title="CorthayP , PerrenoudC , GumowskiPI , GirardJP .Candida albicans specific immune responses in patients with recurrent chronic vaginitis treated with an anti-candida food regimen (ACFR) or an hyposensitization treatment (HPT). Allergy1988;43:51. ">Corthay 1988</a>; <a href="./references#CD009151-bbs2-0005" title="D'AntuonoA , BellavistaS , GaspariV , FilippiniA , PatriziA .Dermasilk® briefs in recurrent vulvovaginal candidosis. An alternative option in long-lasting disease. Minerva Ginecologica2013;65(6):697-705. ">D'Antuono 2013</a>; <a href="./references#CD009151-bbs2-0012" title="LiW .Influence of nursing intervention on recurrent vulvovaginal candidiasis patients treated with ATP-infrared bio-effect technique. Iranian Journal of Public Health2018;47(10):1511-9. ">Li 2018</a>), provided information for one of our primary outcomes. Only one study presented data for number of clinical recurrences per participant per year (<a href="./references#CD009151-bbs2-0014" title="MendlingW , BirknerV .Vaccination with inactivated lactobacilli or heliotherapy can improve the quality-of-life of women with chronic recurrent vulvovaginal candidosis a prospective randomized study [Die Vakzination mit inaktivierten Laktobazillen oder mit Heliotherapie kann die Lebensqualitat von Frauen mit rezidivierender vulvovaginaler Kandidose verbessern - Eine prospektive 3-armige randomisierte Studie]. Geburtshilfe und Frauenheilkunde2011;71(9):767-72. ">Mendling 2011</a>). Eighteen studies reported the proportion of women with clinical recurrence (<a href="./references#CD009151-bbs2-0001" title="BolouriF , TabriziNM , TanhaFD , NiroomandN , AzmoodehA , EmamiS , et al.Effectiveness of fluconazole for suppressive maintenance therapy in patients with RVVC: a randomized placebo-controlled study. Iranian Journal of Pharmaceutical Research2009;8:307-13. ">Bolouri 2009</a>; <a href="./references#CD009151-bbs2-0002" title="ChopraV , MarottaF , KumariA , BishierMP , HeF , ZerbinatiN , et al.Prophylactic strategies in recurrent vulvovaginal candidiasis: a 2-year study testing a phytonutrient vs itraconazole. Journal of Biological Regulators and Homeostatic Agents2013;27(3):875-82. [PMID: 24152852]">Chopra 2013</a>; <a href="./references#CD009151-bbs2-0004" title="D'AntuonoA , BaldiE , BellavistaS , BanzolaN , ZauliS , PatriziA .Use of Dermasilk briefs in recurrent vulvovaginal candidosis: safety and effectiveness. Mycoses2012;55(3):e85-9. ">D'Antuono 2012</a>; <a href="./references#CD009151-bbs2-0005" title="D'AntuonoA , BellavistaS , GaspariV , FilippiniA , PatriziA .Dermasilk® briefs in recurrent vulvovaginal candidosis. An alternative option in long-lasting disease. Minerva Ginecologica2013;65(6):697-705. ">D'Antuono 2013</a>; <a href="./references#CD009151-bbs2-0007" title="FardyazarZ , HabibzadehS , Abdollahi-FardS , TelloM .Vaginal azoles versus oral fluconazole in treatment of recurrent vulvovaginal candidiasis. Iranian Journal of Clinical Infectious Diseases2007;2:17-22. FardyazarZ , HabibzadehS .Long term vaginal azoles versus prophylactic oral fluconazole in treatment of recurrent vulvovaginal candidiasis. Research Journal of Biological Sciences2007;2(6):663-6. ">Fardyazar 2007</a>; <a href="./references#CD009151-bbs2-0008" title="FongIW .The value of chronic suppressive therapy with itraconazole versus clotrimazole in women with recurrent vaginal candidiasis. Genitourinary Medicine1992;68:374-7. ">Fong 1992a</a>; <a href="./references#CD009151-bbs2-0009" title="FongIW .The value of treating the sexual partners of women with recurrent vaginal candidiasis with ketoconazole. Genitourinary Medicine1992;68:174-6. ">Fong 1992b</a>; <a href="./references#CD009151-bbs2-0011" title="KumariA , BishierMP , NaitoY , SharmaA , SolimeneU , JainS , et al.Protective effect of an oral natural phytonutrient in recurrent vulvovaginal candidiasis: a 12-month study. Journal of Biological Regulators &amp; Homeostatic Agents2011;25(4):543-51. ">Kumari 2011</a>; <a href="./references#CD009151-bbs2-0013" title="Lopez-OlmosJ , LermaE .Treatment of recurring vulvo-vaginal candidiasis: a comparative prospective study during six months of three anti-mycotic preparations of a single dosis. Clinica e Investigacion en Ginecologia y Obstetricia2000;27:366-75. ">Lopez‐Olmos 2000</a>; <a href="./references#CD009151-bbs2-0015" title="MettsJ , FamulaTR , TrenevN , ClemensRA .Lactobacillus acidophilus, strain NAS (H2O2 positive), in reduction of recurrent candidal vulvovaginitis. Journal of Applied Research2003;3:340-8. ">Metts 2003</a>; <a href="./references#CD009151-bbs2-0016" title="RothAC , MilsomI , ForssmanL , WahlenP .Intermittent prophylactic treatment of recurrent vaginal candidiasis by postmenstrual application of a 500 mg clotrimazole vaginal tablet. Genitourinary Medicine1990;66:357-60. ">Roth 1990</a>; <a href="./references#CD009151-bbs2-0017" title="SobelJD .Management of recurrent vulvovaginal candidiasis (VVC) with ketoconazole (K) prophylaxis [abstract]. Archives of Gynecology1985;237 Suppl:281. SobelJD .Management of recurrent vulvovaginal candidiasis with intermittent ketoconazole prophylaxis. Obstetrics &amp; Gynecology1985;65:435-40. ">Sobel 1985a</a>; <a href="./references#CD009151-bbs2-0018" title="SobelJD .Recurrent vulvovaginal candidiasis. A prospective study of the efficacy of maintenance ketoconazole therapy. New England Journal of Medicine1986;315:1455-8. ">Sobel 1986</a>; <a href="./references#CD009151-bbs2-0019" title="SobelJD , SchmittC , MeriwetherC .Clotrimazole treatment of recurrent and chronic candida vulvovaginitis. Obstetrics &amp; Gynecology1989;73:330-4. ">Sobel 1989</a>; <a href="./references#CD009151-bbs2-0020" title="SobelJD , WiesenfeldHC , MartensM , DannaP , HootonTM , RompaloA , et al.Maintenance fluconazole therapy for recurrent vulvovaginal candidiasis. New England Journal of Medicine2004;351:876-83. ">Sobel 2004</a>; <a href="./references#CD009151-bbs2-0021" title="SpacekJ , BuchtaV .Itraconazole in the treatment of acute and recurrent vulvovaginal candidosis: comparison of a 1-day and a 3-day regimen. Mycoses2005;48:165-71. ">Spacek 2005</a>; <a href="./references#CD009151-bbs2-0022" title="SpinilloA , ColonnaL , PiazziG , BaltaroF , MonacoA , FerrariA .Managing recurrent vulvovaginal candidiasis. Intermittent prevention with itraconazole. Journal of Reproductive Medicine1997;42:83-7. ">Spinillo 1997</a>; <a href="./references#CD009151-bbs2-0023" title="WittA , KaufmannU , BitschnauM , TempferC , OzbalA , HaytougluE , et al.Monthly itraconazole versus classic homeopathy for the treatment of recurrent vulvovaginal candidiasis: a randomized trial. Obstetrical and Gynecological Survey2010;65(1):26-7. WittA , KaufmannU , BitschnauM , TempferC , OzbalA , HaytougluE , GregorH , KissH .Monthly itraconazole versus classic homeopathy for the treatment of recurrent vulvovaginal candidiasis: a randomised trial. British Journal of Obstetrics &amp; Gynaecology2009;116(11):1499-505. ">Witt 2009</a>), but in three studies the data for this outcome were not presented in a way that allowed for data extraction (<a href="./references#CD009151-bbs2-0005" title="D'AntuonoA , BellavistaS , GaspariV , FilippiniA , PatriziA .Dermasilk® briefs in recurrent vulvovaginal candidosis. An alternative option in long-lasting disease. Minerva Ginecologica2013;65(6):697-705. ">D'Antuono 2013</a>; <a href="./references#CD009151-bbs2-0010" title="FongIW .The value of prophylactic (monthly) clotrimazole versus empiric self-treatment in recurrent vaginal candidiasis. Genitourinary Medicine1994;70:124-6. ">Fong 1994</a>; <a href="./references#CD009151-bbs2-0015" title="MettsJ , FamulaTR , TrenevN , ClemensRA .Lactobacillus acidophilus, strain NAS (H2O2 positive), in reduction of recurrent candidal vulvovaginitis. Journal of Applied Research2003;3:340-8. ">Metts 2003</a>; <a href="./references#CD009151-bbs2-0023" title="WittA , KaufmannU , BitschnauM , TempferC , OzbalA , HaytougluE , et al.Monthly itraconazole versus classic homeopathy for the treatment of recurrent vulvovaginal candidiasis: a randomized trial. Obstetrical and Gynecological Survey2010;65(1):26-7. WittA , KaufmannU , BitschnauM , TempferC , OzbalA , HaytougluE , GregorH , KissH .Monthly itraconazole versus classic homeopathy for the treatment of recurrent vulvovaginal candidiasis: a randomised trial. British Journal of Obstetrics &amp; Gynaecology2009;116(11):1499-505. ">Witt 2009</a>). Sixteen studies reported adverse events (<a href="./references#CD009151-bbs2-0001" title="BolouriF , TabriziNM , TanhaFD , NiroomandN , AzmoodehA , EmamiS , et al.Effectiveness of fluconazole for suppressive maintenance therapy in patients with RVVC: a randomized placebo-controlled study. Iranian Journal of Pharmaceutical Research2009;8:307-13. ">Bolouri 2009</a>; <a href="./references#CD009151-bbs2-0002" title="ChopraV , MarottaF , KumariA , BishierMP , HeF , ZerbinatiN , et al.Prophylactic strategies in recurrent vulvovaginal candidiasis: a 2-year study testing a phytonutrient vs itraconazole. Journal of Biological Regulators and Homeostatic Agents2013;27(3):875-82. [PMID: 24152852]">Chopra 2013</a>; <a href="./references#CD009151-bbs2-0004" title="D'AntuonoA , BaldiE , BellavistaS , BanzolaN , ZauliS , PatriziA .Use of Dermasilk briefs in recurrent vulvovaginal candidosis: safety and effectiveness. Mycoses2012;55(3):e85-9. ">D'Antuono 2012</a>; <a href="./references#CD009151-bbs2-0006" title="FanS , LiuX , WuC , XuL , LiJ .Vaginal nystatin versus oral fluconazole for the treatment for recurrent vulvovaginal candidiasis. Mycopathologia2015;179:95-101. [DOI: https://doi.org/10.1007/s11046-014-9827-4]">Fan 2015</a>; <a href="./references#CD009151-bbs2-0007" title="FardyazarZ , HabibzadehS , Abdollahi-FardS , TelloM .Vaginal azoles versus oral fluconazole in treatment of recurrent vulvovaginal candidiasis. Iranian Journal of Clinical Infectious Diseases2007;2:17-22. FardyazarZ , HabibzadehS .Long term vaginal azoles versus prophylactic oral fluconazole in treatment of recurrent vulvovaginal candidiasis. Research Journal of Biological Sciences2007;2(6):663-6. ">Fardyazar 2007</a>; <a href="./references#CD009151-bbs2-0008" title="FongIW .The value of chronic suppressive therapy with itraconazole versus clotrimazole in women with recurrent vaginal candidiasis. Genitourinary Medicine1992;68:374-7. ">Fong 1992a</a>; <a href="./references#CD009151-bbs2-0009" title="FongIW .The value of treating the sexual partners of women with recurrent vaginal candidiasis with ketoconazole. Genitourinary Medicine1992;68:174-6. ">Fong 1992b</a>; <a href="./references#CD009151-bbs2-0011" title="KumariA , BishierMP , NaitoY , SharmaA , SolimeneU , JainS , et al.Protective effect of an oral natural phytonutrient in recurrent vulvovaginal candidiasis: a 12-month study. Journal of Biological Regulators &amp; Homeostatic Agents2011;25(4):543-51. ">Kumari 2011</a>; <a href="./references#CD009151-bbs2-0014" title="MendlingW , BirknerV .Vaccination with inactivated lactobacilli or heliotherapy can improve the quality-of-life of women with chronic recurrent vulvovaginal candidosis a prospective randomized study [Die Vakzination mit inaktivierten Laktobazillen oder mit Heliotherapie kann die Lebensqualitat von Frauen mit rezidivierender vulvovaginaler Kandidose verbessern - Eine prospektive 3-armige randomisierte Studie]. Geburtshilfe und Frauenheilkunde2011;71(9):767-72. ">Mendling 2011</a>; <a href="./references#CD009151-bbs2-0015" title="MettsJ , FamulaTR , TrenevN , ClemensRA .Lactobacillus acidophilus, strain NAS (H2O2 positive), in reduction of recurrent candidal vulvovaginitis. Journal of Applied Research2003;3:340-8. ">Metts 2003</a>; <a href="./references#CD009151-bbs2-0016" title="RothAC , MilsomI , ForssmanL , WahlenP .Intermittent prophylactic treatment of recurrent vaginal candidiasis by postmenstrual application of a 500 mg clotrimazole vaginal tablet. Genitourinary Medicine1990;66:357-60. ">Roth 1990</a>; <a href="./references#CD009151-bbs2-0018" title="SobelJD .Recurrent vulvovaginal candidiasis. A prospective study of the efficacy of maintenance ketoconazole therapy. New England Journal of Medicine1986;315:1455-8. ">Sobel 1986</a>; <a href="./references#CD009151-bbs2-0019" title="SobelJD , SchmittC , MeriwetherC .Clotrimazole treatment of recurrent and chronic candida vulvovaginitis. Obstetrics &amp; Gynecology1989;73:330-4. ">Sobel 1989</a>; <a href="./references#CD009151-bbs2-0020" title="SobelJD , WiesenfeldHC , MartensM , DannaP , HootonTM , RompaloA , et al.Maintenance fluconazole therapy for recurrent vulvovaginal candidiasis. New England Journal of Medicine2004;351:876-83. ">Sobel 2004</a>; <a href="./references#CD009151-bbs2-0021" title="SpacekJ , BuchtaV .Itraconazole in the treatment of acute and recurrent vulvovaginal candidosis: comparison of a 1-day and a 3-day regimen. Mycoses2005;48:165-71. ">Spacek 2005</a>; <a href="./references#CD009151-bbs2-0023" title="WittA , KaufmannU , BitschnauM , TempferC , OzbalA , HaytougluE , et al.Monthly itraconazole versus classic homeopathy for the treatment of recurrent vulvovaginal candidiasis: a randomized trial. Obstetrical and Gynecological Survey2010;65(1):26-7. WittA , KaufmannU , BitschnauM , TempferC , OzbalA , HaytougluE , GregorH , KissH .Monthly itraconazole versus classic homeopathy for the treatment of recurrent vulvovaginal candidiasis: a randomised trial. British Journal of Obstetrics &amp; Gynaecology2009;116(11):1499-505. ">Witt 2009</a>). </p> </section> <section id="CD009151-sec-0054"> <h5 class="title">Reporting of secondary outcomes</h5> <p>Two studies reported data for time to first recurrence (<a href="./references#CD009151-bbs2-0018" title="SobelJD .Recurrent vulvovaginal candidiasis. A prospective study of the efficacy of maintenance ketoconazole therapy. New England Journal of Medicine1986;315:1455-8. ">Sobel 1986</a>; <a href="./references#CD009151-bbs2-0020" title="SobelJD , WiesenfeldHC , MartensM , DannaP , HootonTM , RompaloA , et al.Maintenance fluconazole therapy for recurrent vulvovaginal candidiasis. New England Journal of Medicine2004;351:876-83. ">Sobel 2004</a>). No studies reported on number of symptomatic days per year or number of mycological recurrences per participant per year. Eight studies reported data for proportion of participants with at least one mycological recurrence during the treatment and follow‐up period (<a href="./references#CD009151-bbs2-0001" title="BolouriF , TabriziNM , TanhaFD , NiroomandN , AzmoodehA , EmamiS , et al.Effectiveness of fluconazole for suppressive maintenance therapy in patients with RVVC: a randomized placebo-controlled study. Iranian Journal of Pharmaceutical Research2009;8:307-13. ">Bolouri 2009</a>; <a href="./references#CD009151-bbs2-0008" title="FongIW .The value of chronic suppressive therapy with itraconazole versus clotrimazole in women with recurrent vaginal candidiasis. Genitourinary Medicine1992;68:374-7. ">Fong 1992a</a>; <a href="./references#CD009151-bbs2-0011" title="KumariA , BishierMP , NaitoY , SharmaA , SolimeneU , JainS , et al.Protective effect of an oral natural phytonutrient in recurrent vulvovaginal candidiasis: a 12-month study. Journal of Biological Regulators &amp; Homeostatic Agents2011;25(4):543-51. ">Kumari 2011</a>; <a href="./references#CD009151-bbs2-0016" title="RothAC , MilsomI , ForssmanL , WahlenP .Intermittent prophylactic treatment of recurrent vaginal candidiasis by postmenstrual application of a 500 mg clotrimazole vaginal tablet. Genitourinary Medicine1990;66:357-60. ">Roth 1990</a>; <a href="./references#CD009151-bbs2-0017" title="SobelJD .Management of recurrent vulvovaginal candidiasis (VVC) with ketoconazole (K) prophylaxis [abstract]. Archives of Gynecology1985;237 Suppl:281. SobelJD .Management of recurrent vulvovaginal candidiasis with intermittent ketoconazole prophylaxis. Obstetrics &amp; Gynecology1985;65:435-40. ">Sobel 1985a</a>; <a href="./references#CD009151-bbs2-0018" title="SobelJD .Recurrent vulvovaginal candidiasis. A prospective study of the efficacy of maintenance ketoconazole therapy. New England Journal of Medicine1986;315:1455-8. ">Sobel 1986</a>; <a href="./references#CD009151-bbs2-0020" title="SobelJD , WiesenfeldHC , MartensM , DannaP , HootonTM , RompaloA , et al.Maintenance fluconazole therapy for recurrent vulvovaginal candidiasis. New England Journal of Medicine2004;351:876-83. ">Sobel 2004</a>; <a href="./references#CD009151-bbs2-0022" title="SpinilloA , ColonnaL , PiazziG , BaltaroF , MonacoA , FerrariA .Managing recurrent vulvovaginal candidiasis. Intermittent prevention with itraconazole. Journal of Reproductive Medicine1997;42:83-7. ">Spinillo 1997</a>). No studies reported on duration of symptoms after treatment initiation. Four studies reported data for patient preference (<a href="./references#CD009151-bbs2-0007" title="FardyazarZ , HabibzadehS , Abdollahi-FardS , TelloM .Vaginal azoles versus oral fluconazole in treatment of recurrent vulvovaginal candidiasis. Iranian Journal of Clinical Infectious Diseases2007;2:17-22. FardyazarZ , HabibzadehS .Long term vaginal azoles versus prophylactic oral fluconazole in treatment of recurrent vulvovaginal candidiasis. Research Journal of Biological Sciences2007;2(6):663-6. ">Fardyazar 2007</a>; <a href="./references#CD009151-bbs2-0010" title="FongIW .The value of prophylactic (monthly) clotrimazole versus empiric self-treatment in recurrent vaginal candidiasis. Genitourinary Medicine1994;70:124-6. ">Fong 1994</a>; <a href="./references#CD009151-bbs2-0014" title="MendlingW , BirknerV .Vaccination with inactivated lactobacilli or heliotherapy can improve the quality-of-life of women with chronic recurrent vulvovaginal candidosis a prospective randomized study [Die Vakzination mit inaktivierten Laktobazillen oder mit Heliotherapie kann die Lebensqualitat von Frauen mit rezidivierender vulvovaginaler Kandidose verbessern - Eine prospektive 3-armige randomisierte Studie]. Geburtshilfe und Frauenheilkunde2011;71(9):767-72. ">Mendling 2011</a>; <a href="./references#CD009151-bbs2-0017" title="SobelJD .Management of recurrent vulvovaginal candidiasis (VVC) with ketoconazole (K) prophylaxis [abstract]. Archives of Gynecology1985;237 Suppl:281. SobelJD .Management of recurrent vulvovaginal candidiasis with intermittent ketoconazole prophylaxis. Obstetrics &amp; Gynecology1985;65:435-40. ">Sobel 1985a</a>). </p> <p>See the <a href="./references#CD009151-sec-0220" title="">Characteristics of included studies</a> tables for more information on setting, participants, interventions, and outcomes of specific studies. </p> </section> </section> <section id="CD009151-sec-0055"> <h4 class="title">Excluded studies</h4> <p>After review of full text we excluded 23 studies that on face value appeared to have been eligible for inclusion (<a href="./references#CD009151-bbs2-0024" title="AvijganM , MirzadehF , NiaEA .The comparative study of anti-fungal effect of pharmaceutical products containing hydroalcoholic extract of Echinophora platyloba DC and fluconazole in women with chronic recurrent vaginitis caused by candida albicans. Journal of Research in Medical Sciences2012;17:S103-S107. ">Avijgan 2012</a>; <a href="./references#CD009151-bbs2-0025" title="AzimaS , HoushyarS , Motamedi FarM , KavianiM , ZareN .The Effect of Vaginal Probiotic Capsule On Vaginal Colonization and Treatment Results inPatients with Vulvar and Vaginal Candidiasis. Journal of Zanjan University of Medical Sciences and Health Services2018;26(114):40-50. ">Azima 2018</a>; <a href="./references#CD009151-bbs2-0026" title="BartzBR .Efficacy of zinc supplementation in reducing the incidence of recurrent vaginitis. ProQuest Dissertations and Theses2000:64. ">Bartz 2000</a>; <a href="./references#CD009151-bbs2-0027" title="BrandS , DegenhardtT , NyirjesyP , SobelJ , HandelsmanC , PersonK , SchotzingerR , TavakkolA .To evaluate the efficacy and safety of VT-1161, a potent, highly selective inhibitor of fungal CYP51, in treating women with a documented history of recurrent vulvovaginal candidiasis (RVVC). American Journal of Obstetrics and Gynecology2016;215(6):S821. [DOI: 10.1016/j.ajog.2016.09.016]BrandSR , DegenhardtTP , PersonK , SobelJD , NyiriesyP , SchotzingerRJ , TavakkolA .A phase 2, randomized, double-blind, placebo-controlled, dose-ranging study to evaluate the efficacy and safety of orally administered VT-1161 in the treatment of recurrent vulvovaginal candidiasis. American Journal of Obstetrics and Gynecology2018;218(6):1e.1-1e.9. SobelJD , BrandSR , DegenhardtTP , PersonK , NyirjesyP , SchotzingerRJ , TavakkolA .Results from a phase 2, randomized, double-blind, placebo-controlled, dose ranging study to evaluate the efficacy and safety of VT 1161 oral tablets in the treatment of patients with recurrent vulvovaginal candidiasis. American Journal of Obstetrics and Gynecology2017;217(6):715. ">Brand 2018</a>; <a href="./references#CD009151-bbs2-0028" title="BushellTE , EvansEG , MeadenJD , MilneJD , WarnockDW .Intermittent local prophylaxis against recurrent vaginal candidosis. Genitourinary Medicine1988;64:335-8. ">Bushell 1988a</a>; <a href="./references#CD009151-bbs2-0029" title="BushellTE , EvansEG , LlewellynPA , MeadenJD , MilneJD , WarnockDW .Prophylactic use of clotrimazole in recurrent vaginal candidosis. Annals of the New York Academy of Sciences1988;544:558-60. [ISSN 0077-8923]">Bushell 1998b</a>; <a href="./references#CD009151-bbs2-0030" title="CoricM , BarisicD , LovricH .Fluconazole versus 3-day clotrimazole in the treatment of sporadic and recurrent vulvovaginal candidiasis. International Journal of Gynaecology &amp; Obstetrics2006;95:171-2. ">Coric 2006</a>; <a href="./references#CD009151-bbs2-0031" title="DavidsonF , MouldRF .Recurrent genital candidosis in women and the effect of intermittent prophylactic treatment. British Journal of Venereal Diseases1978;54:176-83. ">Davidson 1978</a>; <a href="./references#CD009151-bbs2-0032" title="DibaK , NamakiA , BahadoriF .Comparative study of fluconazole and clotrimazole for the treatment of vulvovaginal candidiasis. Journal of Sexual Medicine2010;7:431. ">Diba 2010</a>; <a href="./references#CD009151-bbs2-0033" title="DondersG , BellenG , ByttebierG , VergutsL , HinoulP , WalckiersR , StalpaertM , VereeckenA , Van EldereJ .Individualized decreasing-dose maintenance fluconazole regimen for recurrent vulvovaginal candidiasis (ReCiDiF trial). American Journal of Obstetrics &amp; Gynecology2008;199(6):613.e1-9. [ISSN 1097-6868]">Donders 2008</a>; <a href="./references#CD009151-bbs2-0034" title="Edwards JE Jr, SchwartzMM , SchmidtCS , SobelJD , NyirjesyP , SchodelF , et al.A Fungal Immunotherapeutic Vaccine (NDV-3A) for Treatment of Recurrent Vulvovaginal Candidiasis-A Phase 2 Randomized, Double-Blind, Placebo-Controlled Trial. Clin Infect Dis2018;66(12):1928-1936. NyirjesyP , SobelJD , EdwardsJE , SchwarzMW , SchmidtCS , HennesseyJP .NDV-3A vaccine reduces the frequency of vaginitis in patients with recurrent vulvovaginal candidiasis. American Journal of Obstetrics and Gynecology2016;215(6):S822. [DOI: 10.1016/j.ajog.2016.09.019]">Edwards 2018</a>; <a href="./references#CD009151-bbs2-0035" title="FanSR , LiuXP , LiJW , XuAP , LiuM .Study on classification and treatment of vulvovaginal candidiasis. Chung-Hua Fu Chan Ko Tsa Chih [Chinese Journal of Obstetrics &amp; Gynecology]2005;40:532-5. ">Fan 2005</a>; <a href="./references#CD009151-bbs2-0037" title="GorleroF , LarosaE , CauwenberghG , WoestenborghsR , HeykantsJ , CilliP , DececcoL .Itraconazole plasma and vaginal mucosal levels in patients with chronic vaginal candidosis treated with itraconazole 200mg once-daily for 3 consecutive days. Drug Investigation1993;6(1):22-24. [ISSN 0114-2402]">Golero 1993</a>; <a href="./references#CD009151-bbs2-0038" title="HiltonE , IsenbergHD , AlpersteinP , FranceK , BorensteinMT .Ingestion of yogurt containing Lactobacillus acidophilus as prophylaxis for candidal vaginitis. Annals of Internal Medicine1992;116:353-7. ">Hilton 1992</a>; <a href="./references#CD009151-bbs2-0039" title="HouangE .Fluconazole in recurrent vaginal candidiasis - preliminary-results of a double-blind, randomized clinical-trial. In: Fluconazole and its role in vaginal candidiasis. In: RichardsonRG , editors(s). International Congress and Symposium Series. Vol. 160. London: Royal Society of Medicine Services, 1989:22-31. ">Houang 1989</a>; <a href="./references#CD009151-bbs2-0040" title="MillerPI , HumphriesM , GrassickK .A single-blind comparison of oral and intravaginal treatments in acute and recurrent vaginal candidosis in general practice. Pharmatherapeutica1984;3:582-7. ">Miller 1984</a>; <a href="./references#CD009151-bbs2-0041" title="RashidS , CollinsM , KennedyRJ .A study of candidosis: the role of fomites. Genitourinary Medicine1991;67(2):137-42. ">Rashid 1991</a>; <a href="./references#CD009151-bbs2-0042" title="ShalevE , BattinoS , WeinerE , ColodnerR , KenessY .Ingestion of yogurt containing Lactobacillus acidophilus compared with pasteurized yogurt as prophylaxis for recurrent candidal vaginitis and bacterial vaginosis. Archives of Family Medicine1996;5:593-6. ">Shalev 1996</a>; <a href="./references#CD009151-bbs2-0043" title="SilvermanM , OkunR .Oxytetracycline-nystatin in the prevention of candidal vaginitis. American Journal of Obstetrics &amp; Gynecology1971;111:398-404. ">Silverman 1971</a>; <a href="./references#CD009151-bbs2-0044" title="SobelJD , SchmittC , SteinG , MummawN , ChristensenS , MeriwetherC .Initial management of recurrent vulvovaginal candidiasis with oral ketoconazole and topical clotrimazole. Journal of Reproductive Medicine1994;39(7):517-20. [ISSN 0024-7758]">Sobel 1994</a>; <a href="./references#CD009151-bbs2-0045" title="SobelJD , KapernickPS , ZervosM , ReedBD , HootonT , SoperD , et al.Treatment of complicated Candida vaginitis: comparison of single and sequential doses of fluconazole. American Journal of Obstetrics &amp; Gynecology2001;185:363-9. ">Sobel 2001</a>; <a href="./references#CD009151-bbs2-0046" title="VladareanuR , MihuD , MitranM , MehedintuC , BoiangiuA , ManolacheM , VladareanuS .New evidence on oral L. plantarum P17630 product in women with history of recurrent vulvovaginal candidiasis (RVVC): a randomized double-blind placebo-controlled study. European Review for Medical and Pharmacological Sciences2018;22(1):262-267. [DOI: 10.26355/eurrev_201801_14128]">Vladareanu 2018</a>; <a href="./references#CD009151-bbs2-0047" title="YangF , ZhouH , MoXZ , YanDD .Itraconazole maintaining therapy in prevention recurrent vulva-vaginal candidiasis (Chinese). Chinese Journal of Leprosy and Skin Disease2000;16(4):235. ">Yang 2000</a>). The reasons excluding these studies are outlined in the <a href="./references#CD009151-sec-0221" title="">Characteristics of excluded studies</a> tables. The most common reason for exclusion was that the case definition of RVVC as reported in our protocol was not met (e.g. a case definition of only three episodes, rather than four episodes, of candidiasis in the past 12 months was used) (<a href="./references#CD009151-bbs2-0024" title="AvijganM , MirzadehF , NiaEA .The comparative study of anti-fungal effect of pharmaceutical products containing hydroalcoholic extract of Echinophora platyloba DC and fluconazole in women with chronic recurrent vaginitis caused by candida albicans. Journal of Research in Medical Sciences2012;17:S103-S107. ">Avijgan 2012</a>; <a href="./references#CD009151-bbs2-0026" title="BartzBR .Efficacy of zinc supplementation in reducing the incidence of recurrent vaginitis. ProQuest Dissertations and Theses2000:64. ">Bartz 2000</a>; <a href="./references#CD009151-bbs2-0027" title="BrandS , DegenhardtT , NyirjesyP , SobelJ , HandelsmanC , PersonK , SchotzingerR , TavakkolA .To evaluate the efficacy and safety of VT-1161, a potent, highly selective inhibitor of fungal CYP51, in treating women with a documented history of recurrent vulvovaginal candidiasis (RVVC). American Journal of Obstetrics and Gynecology2016;215(6):S821. [DOI: 10.1016/j.ajog.2016.09.016]BrandSR , DegenhardtTP , PersonK , SobelJD , NyiriesyP , SchotzingerRJ , TavakkolA .A phase 2, randomized, double-blind, placebo-controlled, dose-ranging study to evaluate the efficacy and safety of orally administered VT-1161 in the treatment of recurrent vulvovaginal candidiasis. American Journal of Obstetrics and Gynecology2018;218(6):1e.1-1e.9. SobelJD , BrandSR , DegenhardtTP , PersonK , NyirjesyP , SchotzingerRJ , TavakkolA .Results from a phase 2, randomized, double-blind, placebo-controlled, dose ranging study to evaluate the efficacy and safety of VT 1161 oral tablets in the treatment of patients with recurrent vulvovaginal candidiasis. American Journal of Obstetrics and Gynecology2017;217(6):715. ">Brand 2018</a>; <a href="./references#CD009151-bbs2-0028" title="BushellTE , EvansEG , MeadenJD , MilneJD , WarnockDW .Intermittent local prophylaxis against recurrent vaginal candidosis. Genitourinary Medicine1988;64:335-8. ">Bushell 1988a</a>; <a href="./references#CD009151-bbs2-0031" title="DavidsonF , MouldRF .Recurrent genital candidosis in women and the effect of intermittent prophylactic treatment. British Journal of Venereal Diseases1978;54:176-83. ">Davidson 1978</a>; <a href="./references#CD009151-bbs2-0034" title="Edwards JE Jr, SchwartzMM , SchmidtCS , SobelJD , NyirjesyP , SchodelF , et al.A Fungal Immunotherapeutic Vaccine (NDV-3A) for Treatment of Recurrent Vulvovaginal Candidiasis-A Phase 2 Randomized, Double-Blind, Placebo-Controlled Trial. Clin Infect Dis2018;66(12):1928-1936. NyirjesyP , SobelJD , EdwardsJE , SchwarzMW , SchmidtCS , HennesseyJP .NDV-3A vaccine reduces the frequency of vaginitis in patients with recurrent vulvovaginal candidiasis. American Journal of Obstetrics and Gynecology2016;215(6):S822. [DOI: 10.1016/j.ajog.2016.09.019]">Edwards 2018</a>; <a href="./references#CD009151-bbs2-0037" title="GorleroF , LarosaE , CauwenberghG , WoestenborghsR , HeykantsJ , CilliP , DececcoL .Itraconazole plasma and vaginal mucosal levels in patients with chronic vaginal candidosis treated with itraconazole 200mg once-daily for 3 consecutive days. Drug Investigation1993;6(1):22-24. [ISSN 0114-2402]">Golero 1993</a>; <a href="./references#CD009151-bbs2-0043" title="SilvermanM , OkunR .Oxytetracycline-nystatin in the prevention of candidal vaginitis. American Journal of Obstetrics &amp; Gynecology1971;111:398-404. ">Silverman 1971</a>; <a href="./references#CD009151-bbs2-0044" title="SobelJD , SchmittC , SteinG , MummawN , ChristensenS , MeriwetherC .Initial management of recurrent vulvovaginal candidiasis with oral ketoconazole and topical clotrimazole. Journal of Reproductive Medicine1994;39(7):517-20. [ISSN 0024-7758]">Sobel 1994</a>; <a href="./references#CD009151-bbs2-0045" title="SobelJD , KapernickPS , ZervosM , ReedBD , HootonT , SoperD , et al.Treatment of complicated Candida vaginitis: comparison of single and sequential doses of fluconazole. American Journal of Obstetrics &amp; Gynecology2001;185:363-9. ">Sobel 2001</a>; <a href="./references#CD009151-bbs2-0047" title="YangF , ZhouH , MoXZ , YanDD .Itraconazole maintaining therapy in prevention recurrent vulva-vaginal candidiasis (Chinese). Chinese Journal of Leprosy and Skin Disease2000;16(4):235. ">Yang 2000</a>). </p> </section> </section> <section id="CD009151-sec-0056"> <h3 class="title">Risk of bias in included studies</h3> <p>Summaries of the 'Risk of bias' assessments for each study are outlined in <a href="#CD009151-fig-0002">Figure 2</a> and <a href="#CD009151-fig-0003">Figure 3</a>. </p> <div class="figure" id="CD009151-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD009151-fig-0002" src="/cdsr/doi/10.1002/14651858.CD009151.pub2/media/CDSR/CD009151/image_n/nCD009151-FIG-02.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> </div> <div class="figure" id="CD009151-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD009151-fig-0003" src="/cdsr/doi/10.1002/14651858.CD009151.pub2/media/CDSR/CD009151/image_n/nCD009151-FIG-03.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <section id="CD009151-sec-0057"> <h4 class="title">Allocation</h4> <section id="CD009151-sec-0058"> <h5 class="title">Random sequence generation</h5> <p>We assessed seven studies that used computer‐generated or other adequate random number sequence processes as at low risk of bias (<a href="./references#CD009151-bbs2-0002" title="ChopraV , MarottaF , KumariA , BishierMP , HeF , ZerbinatiN , et al.Prophylactic strategies in recurrent vulvovaginal candidiasis: a 2-year study testing a phytonutrient vs itraconazole. Journal of Biological Regulators and Homeostatic Agents2013;27(3):875-82. [PMID: 24152852]">Chopra 2013</a>; <a href="./references#CD009151-bbs2-0008" title="FongIW .The value of chronic suppressive therapy with itraconazole versus clotrimazole in women with recurrent vaginal candidiasis. Genitourinary Medicine1992;68:374-7. ">Fong 1992a</a>; <a href="./references#CD009151-bbs2-0010" title="FongIW .The value of prophylactic (monthly) clotrimazole versus empiric self-treatment in recurrent vaginal candidiasis. Genitourinary Medicine1994;70:124-6. ">Fong 1994</a>; <a href="./references#CD009151-bbs2-0011" title="KumariA , BishierMP , NaitoY , SharmaA , SolimeneU , JainS , et al.Protective effect of an oral natural phytonutrient in recurrent vulvovaginal candidiasis: a 12-month study. Journal of Biological Regulators &amp; Homeostatic Agents2011;25(4):543-51. ">Kumari 2011</a>; <a href="./references#CD009151-bbs2-0015" title="MettsJ , FamulaTR , TrenevN , ClemensRA .Lactobacillus acidophilus, strain NAS (H2O2 positive), in reduction of recurrent candidal vulvovaginitis. Journal of Applied Research2003;3:340-8. ">Metts 2003</a>; <a href="./references#CD009151-bbs2-0022" title="SpinilloA , ColonnaL , PiazziG , BaltaroF , MonacoA , FerrariA .Managing recurrent vulvovaginal candidiasis. Intermittent prevention with itraconazole. Journal of Reproductive Medicine1997;42:83-7. ">Spinillo 1997</a>; <a href="./references#CD009151-bbs2-0023" title="WittA , KaufmannU , BitschnauM , TempferC , OzbalA , HaytougluE , et al.Monthly itraconazole versus classic homeopathy for the treatment of recurrent vulvovaginal candidiasis: a randomized trial. Obstetrical and Gynecological Survey2010;65(1):26-7. WittA , KaufmannU , BitschnauM , TempferC , OzbalA , HaytougluE , GregorH , KissH .Monthly itraconazole versus classic homeopathy for the treatment of recurrent vulvovaginal candidiasis: a randomised trial. British Journal of Obstetrics &amp; Gynaecology2009;116(11):1499-505. ">Witt 2009</a>). Two studies were judged to be of high risk of bias for this domain. <a href="./references#CD009151-bbs2-0012" title="LiW .Influence of nursing intervention on recurrent vulvovaginal candidiasis patients treated with ATP-infrared bio-effect technique. Iranian Journal of Public Health2018;47(10):1511-9. ">Li 2018</a> did not describe the sequence generation and method of randomisation. <a href="./references#CD009151-bbs2-0006" title="FanS , LiuX , WuC , XuL , LiJ .Vaginal nystatin versus oral fluconazole for the treatment for recurrent vulvovaginal candidiasis. Mycopathologia2015;179:95-101. [DOI: https://doi.org/10.1007/s11046-014-9827-4]">Fan 2015</a> was also classified as at high risk of bias for random sequence generation as women with RVVC known to be caused by <i>C glabrata</i> at admission (before <i>Candida</i> culture and identification) were not randomised but were enrolled in the nystatin treatment group. We assessed the remaining studies as at unclear risk of bias as the randomisation method was unclear (often claimed to be a randomised study but no description was provided to enable assessment of risk of selection bias). </p> </section> <section id="CD009151-sec-0059"> <h5 class="title">Allocation concealment</h5> <p>We assessed four studies that used sealed bags or opaque envelopes as low risk of bias for allocation concealment (<a href="./references#CD009151-bbs2-0004" title="D'AntuonoA , BaldiE , BellavistaS , BanzolaN , ZauliS , PatriziA .Use of Dermasilk briefs in recurrent vulvovaginal candidosis: safety and effectiveness. Mycoses2012;55(3):e85-9. ">D'Antuono 2012</a>; <a href="./references#CD009151-bbs2-0005" title="D'AntuonoA , BellavistaS , GaspariV , FilippiniA , PatriziA .Dermasilk® briefs in recurrent vulvovaginal candidosis. An alternative option in long-lasting disease. Minerva Ginecologica2013;65(6):697-705. ">D'Antuono 2013</a>; <a href="./references#CD009151-bbs2-0008" title="FongIW .The value of chronic suppressive therapy with itraconazole versus clotrimazole in women with recurrent vaginal candidiasis. Genitourinary Medicine1992;68:374-7. ">Fong 1992a</a>; <a href="./references#CD009151-bbs2-0015" title="MettsJ , FamulaTR , TrenevN , ClemensRA .Lactobacillus acidophilus, strain NAS (H2O2 positive), in reduction of recurrent candidal vulvovaginitis. Journal of Applied Research2003;3:340-8. ">Metts 2003</a>). We assessed six studies to be at high risk of bias for this domain (<a href="./references#CD009151-bbs2-0006" title="FanS , LiuX , WuC , XuL , LiJ .Vaginal nystatin versus oral fluconazole for the treatment for recurrent vulvovaginal candidiasis. Mycopathologia2015;179:95-101. [DOI: https://doi.org/10.1007/s11046-014-9827-4]">Fan 2015</a>; <a href="./references#CD009151-bbs2-0009" title="FongIW .The value of treating the sexual partners of women with recurrent vaginal candidiasis with ketoconazole. Genitourinary Medicine1992;68:174-6. ">Fong 1992b</a>; <a href="./references#CD009151-bbs2-0012" title="LiW .Influence of nursing intervention on recurrent vulvovaginal candidiasis patients treated with ATP-infrared bio-effect technique. Iranian Journal of Public Health2018;47(10):1511-9. ">Li 2018</a><a href="./references#CD009151-bbs2-0013" title="Lopez-OlmosJ , LermaE .Treatment of recurring vulvo-vaginal candidiasis: a comparative prospective study during six months of three anti-mycotic preparations of a single dosis. Clinica e Investigacion en Ginecologia y Obstetricia2000;27:366-75. ">Lopez‐Olmos 2000</a>; <a href="./references#CD009151-bbs2-0014" title="MendlingW , BirknerV .Vaccination with inactivated lactobacilli or heliotherapy can improve the quality-of-life of women with chronic recurrent vulvovaginal candidosis a prospective randomized study [Die Vakzination mit inaktivierten Laktobazillen oder mit Heliotherapie kann die Lebensqualitat von Frauen mit rezidivierender vulvovaginaler Kandidose verbessern - Eine prospektive 3-armige randomisierte Studie]. Geburtshilfe und Frauenheilkunde2011;71(9):767-72. ">Mendling 2011</a>; <a href="./references#CD009151-bbs2-0017" title="SobelJD .Management of recurrent vulvovaginal candidiasis (VVC) with ketoconazole (K) prophylaxis [abstract]. Archives of Gynecology1985;237 Suppl:281. SobelJD .Management of recurrent vulvovaginal candidiasis with intermittent ketoconazole prophylaxis. Obstetrics &amp; Gynecology1985;65:435-40. ">Sobel 1985a</a>). <a href="./references#CD009151-bbs2-0013" title="Lopez-OlmosJ , LermaE .Treatment of recurring vulvo-vaginal candidiasis: a comparative prospective study during six months of three anti-mycotic preparations of a single dosis. Clinica e Investigacion en Ginecologia y Obstetricia2000;27:366-75. ">Lopez‐Olmos 2000</a> allocated treatment by day of the week, which implies lack of proper concealment and therefore a high risk of bias for this domain. There was no clear description of concealment in the remaining studies, which were therefore assessed as at unclear risk of selection bias (<a href="./references#CD009151-bbs2-0001" title="BolouriF , TabriziNM , TanhaFD , NiroomandN , AzmoodehA , EmamiS , et al.Effectiveness of fluconazole for suppressive maintenance therapy in patients with RVVC: a randomized placebo-controlled study. Iranian Journal of Pharmaceutical Research2009;8:307-13. ">Bolouri 2009</a>; <a href="./references#CD009151-bbs2-0002" title="ChopraV , MarottaF , KumariA , BishierMP , HeF , ZerbinatiN , et al.Prophylactic strategies in recurrent vulvovaginal candidiasis: a 2-year study testing a phytonutrient vs itraconazole. Journal of Biological Regulators and Homeostatic Agents2013;27(3):875-82. [PMID: 24152852]">Chopra 2013</a>; <a href="./references#CD009151-bbs2-0003" title="CorthayP , PerrenoudC , GumowskiPI , GirardJP .Candida albicans specific immune responses in patients with recurrent chronic vaginitis treated with an anti-candida food regimen (ACFR) or an hyposensitization treatment (HPT). Allergy1988;43:51. ">Corthay 1988</a>; <a href="./references#CD009151-bbs2-0007" title="FardyazarZ , HabibzadehS , Abdollahi-FardS , TelloM .Vaginal azoles versus oral fluconazole in treatment of recurrent vulvovaginal candidiasis. Iranian Journal of Clinical Infectious Diseases2007;2:17-22. FardyazarZ , HabibzadehS .Long term vaginal azoles versus prophylactic oral fluconazole in treatment of recurrent vulvovaginal candidiasis. Research Journal of Biological Sciences2007;2(6):663-6. ">Fardyazar 2007</a>; <a href="./references#CD009151-bbs2-0010" title="FongIW .The value of prophylactic (monthly) clotrimazole versus empiric self-treatment in recurrent vaginal candidiasis. Genitourinary Medicine1994;70:124-6. ">Fong 1994</a>; <a href="./references#CD009151-bbs2-0011" title="KumariA , BishierMP , NaitoY , SharmaA , SolimeneU , JainS , et al.Protective effect of an oral natural phytonutrient in recurrent vulvovaginal candidiasis: a 12-month study. Journal of Biological Regulators &amp; Homeostatic Agents2011;25(4):543-51. ">Kumari 2011</a>; <a href="./references#CD009151-bbs2-0016" title="RothAC , MilsomI , ForssmanL , WahlenP .Intermittent prophylactic treatment of recurrent vaginal candidiasis by postmenstrual application of a 500 mg clotrimazole vaginal tablet. Genitourinary Medicine1990;66:357-60. ">Roth 1990</a>; <a href="./references#CD009151-bbs2-0018" title="SobelJD .Recurrent vulvovaginal candidiasis. A prospective study of the efficacy of maintenance ketoconazole therapy. New England Journal of Medicine1986;315:1455-8. ">Sobel 1986</a>; <a href="./references#CD009151-bbs2-0019" title="SobelJD , SchmittC , MeriwetherC .Clotrimazole treatment of recurrent and chronic candida vulvovaginitis. Obstetrics &amp; Gynecology1989;73:330-4. ">Sobel 1989</a>; <a href="./references#CD009151-bbs2-0020" title="SobelJD , WiesenfeldHC , MartensM , DannaP , HootonTM , RompaloA , et al.Maintenance fluconazole therapy for recurrent vulvovaginal candidiasis. New England Journal of Medicine2004;351:876-83. ">Sobel 2004</a>; <a href="./references#CD009151-bbs2-0021" title="SpacekJ , BuchtaV .Itraconazole in the treatment of acute and recurrent vulvovaginal candidosis: comparison of a 1-day and a 3-day regimen. Mycoses2005;48:165-71. ">Spacek 2005</a>; <a href="./references#CD009151-bbs2-0022" title="SpinilloA , ColonnaL , PiazziG , BaltaroF , MonacoA , FerrariA .Managing recurrent vulvovaginal candidiasis. Intermittent prevention with itraconazole. Journal of Reproductive Medicine1997;42:83-7. ">Spinillo 1997</a>; <a href="./references#CD009151-bbs2-0023" title="WittA , KaufmannU , BitschnauM , TempferC , OzbalA , HaytougluE , et al.Monthly itraconazole versus classic homeopathy for the treatment of recurrent vulvovaginal candidiasis: a randomized trial. Obstetrical and Gynecological Survey2010;65(1):26-7. WittA , KaufmannU , BitschnauM , TempferC , OzbalA , HaytougluE , GregorH , KissH .Monthly itraconazole versus classic homeopathy for the treatment of recurrent vulvovaginal candidiasis: a randomised trial. British Journal of Obstetrics &amp; Gynaecology2009;116(11):1499-505. ">Witt 2009</a>). </p> </section> </section> <section id="CD009151-sec-0060"> <h4 class="title">Blinding</h4> <section id="CD009151-sec-0061"> <h5 class="title">Performance bias</h5> <p>We assessed blinding against the primary outcomes, which all involved a component of patient reporting/symptoms. We initially considered only two studies as low risk of performance bias for the primary outcomes (<a href="./references#CD009151-bbs2-0015" title="MettsJ , FamulaTR , TrenevN , ClemensRA .Lactobacillus acidophilus, strain NAS (H2O2 positive), in reduction of recurrent candidal vulvovaginitis. Journal of Applied Research2003;3:340-8. ">Metts 2003</a>; <a href="./references#CD009151-bbs2-0016" title="RothAC , MilsomI , ForssmanL , WahlenP .Intermittent prophylactic treatment of recurrent vaginal candidiasis by postmenstrual application of a 500 mg clotrimazole vaginal tablet. Genitourinary Medicine1990;66:357-60. ">Roth 1990</a>), as both were blinded to both participants and investigators. It was initially unclear if the studies by D'Antuono were adequately blinded (<a href="./references#CD009151-bbs2-0004" title="D'AntuonoA , BaldiE , BellavistaS , BanzolaN , ZauliS , PatriziA .Use of Dermasilk briefs in recurrent vulvovaginal candidosis: safety and effectiveness. Mycoses2012;55(3):e85-9. ">D'Antuono 2012</a>; <a href="./references#CD009151-bbs2-0005" title="D'AntuonoA , BellavistaS , GaspariV , FilippiniA , PatriziA .Dermasilk® briefs in recurrent vulvovaginal candidosis. An alternative option in long-lasting disease. Minerva Ginecologica2013;65(6):697-705. ">D'Antuono 2013</a>), but author correspondence reassured us about the difficulty distinguishing between the different underwear fabrics, therefore we rated these studies as at low risk of bias for this domain. Five studies were assessed as having unclear risk of bias; two studies lacked clarity about whether the placebo was identical to the intervention (<a href="./references#CD009151-bbs2-0001" title="BolouriF , TabriziNM , TanhaFD , NiroomandN , AzmoodehA , EmamiS , et al.Effectiveness of fluconazole for suppressive maintenance therapy in patients with RVVC: a randomized placebo-controlled study. Iranian Journal of Pharmaceutical Research2009;8:307-13. ">Bolouri 2009</a>; <a href="./references#CD009151-bbs2-0018" title="SobelJD .Recurrent vulvovaginal candidiasis. A prospective study of the efficacy of maintenance ketoconazole therapy. New England Journal of Medicine1986;315:1455-8. ">Sobel 1986</a>), one study did not refer to blinding (<a href="./references#CD009151-bbs2-0003" title="CorthayP , PerrenoudC , GumowskiPI , GirardJP .Candida albicans specific immune responses in patients with recurrent chronic vaginitis treated with an anti-candida food regimen (ACFR) or an hyposensitization treatment (HPT). Allergy1988;43:51. ">Corthay 1988</a>) and the remaining two studies reported blinding but lacked clarity about whether it was participants, clinicians, or laboratory staff being blinded (<a href="./references#CD009151-bbs2-0019" title="SobelJD , SchmittC , MeriwetherC .Clotrimazole treatment of recurrent and chronic candida vulvovaginitis. Obstetrics &amp; Gynecology1989;73:330-4. ">Sobel 1989</a>; <a href="./references#CD009151-bbs2-0020" title="SobelJD , WiesenfeldHC , MartensM , DannaP , HootonTM , RompaloA , et al.Maintenance fluconazole therapy for recurrent vulvovaginal candidiasis. New England Journal of Medicine2004;351:876-83. ">Sobel 2004</a>). </p> <p>We assessed 14 studies as at high risk of bias for this domain (<a href="./references#CD009151-bbs2-0002" title="ChopraV , MarottaF , KumariA , BishierMP , HeF , ZerbinatiN , et al.Prophylactic strategies in recurrent vulvovaginal candidiasis: a 2-year study testing a phytonutrient vs itraconazole. Journal of Biological Regulators and Homeostatic Agents2013;27(3):875-82. [PMID: 24152852]">Chopra 2013</a>; <a href="./references#CD009151-bbs2-0006" title="FanS , LiuX , WuC , XuL , LiJ .Vaginal nystatin versus oral fluconazole for the treatment for recurrent vulvovaginal candidiasis. Mycopathologia2015;179:95-101. [DOI: https://doi.org/10.1007/s11046-014-9827-4]">Fan 2015</a>; <a href="./references#CD009151-bbs2-0007" title="FardyazarZ , HabibzadehS , Abdollahi-FardS , TelloM .Vaginal azoles versus oral fluconazole in treatment of recurrent vulvovaginal candidiasis. Iranian Journal of Clinical Infectious Diseases2007;2:17-22. FardyazarZ , HabibzadehS .Long term vaginal azoles versus prophylactic oral fluconazole in treatment of recurrent vulvovaginal candidiasis. Research Journal of Biological Sciences2007;2(6):663-6. ">Fardyazar 2007</a>; <a href="./references#CD009151-bbs2-0008" title="FongIW .The value of chronic suppressive therapy with itraconazole versus clotrimazole in women with recurrent vaginal candidiasis. Genitourinary Medicine1992;68:374-7. ">Fong 1992a</a>; <a href="./references#CD009151-bbs2-0009" title="FongIW .The value of treating the sexual partners of women with recurrent vaginal candidiasis with ketoconazole. Genitourinary Medicine1992;68:174-6. ">Fong 1992b</a>; <a href="./references#CD009151-bbs2-0010" title="FongIW .The value of prophylactic (monthly) clotrimazole versus empiric self-treatment in recurrent vaginal candidiasis. Genitourinary Medicine1994;70:124-6. ">Fong 1994</a>; <a href="./references#CD009151-bbs2-0011" title="KumariA , BishierMP , NaitoY , SharmaA , SolimeneU , JainS , et al.Protective effect of an oral natural phytonutrient in recurrent vulvovaginal candidiasis: a 12-month study. Journal of Biological Regulators &amp; Homeostatic Agents2011;25(4):543-51. ">Kumari 2011</a>; <a href="./references#CD009151-bbs2-0012" title="LiW .Influence of nursing intervention on recurrent vulvovaginal candidiasis patients treated with ATP-infrared bio-effect technique. Iranian Journal of Public Health2018;47(10):1511-9. ">Li 2018</a>; <a href="./references#CD009151-bbs2-0013" title="Lopez-OlmosJ , LermaE .Treatment of recurring vulvo-vaginal candidiasis: a comparative prospective study during six months of three anti-mycotic preparations of a single dosis. Clinica e Investigacion en Ginecologia y Obstetricia2000;27:366-75. ">Lopez‐Olmos 2000</a>; <a href="./references#CD009151-bbs2-0014" title="MendlingW , BirknerV .Vaccination with inactivated lactobacilli or heliotherapy can improve the quality-of-life of women with chronic recurrent vulvovaginal candidosis a prospective randomized study [Die Vakzination mit inaktivierten Laktobazillen oder mit Heliotherapie kann die Lebensqualitat von Frauen mit rezidivierender vulvovaginaler Kandidose verbessern - Eine prospektive 3-armige randomisierte Studie]. Geburtshilfe und Frauenheilkunde2011;71(9):767-72. ">Mendling 2011</a>; <a href="./references#CD009151-bbs2-0017" title="SobelJD .Management of recurrent vulvovaginal candidiasis (VVC) with ketoconazole (K) prophylaxis [abstract]. Archives of Gynecology1985;237 Suppl:281. SobelJD .Management of recurrent vulvovaginal candidiasis with intermittent ketoconazole prophylaxis. Obstetrics &amp; Gynecology1985;65:435-40. ">Sobel 1985a</a>; <a href="./references#CD009151-bbs2-0021" title="SpacekJ , BuchtaV .Itraconazole in the treatment of acute and recurrent vulvovaginal candidosis: comparison of a 1-day and a 3-day regimen. Mycoses2005;48:165-71. ">Spacek 2005</a>; <a href="./references#CD009151-bbs2-0022" title="SpinilloA , ColonnaL , PiazziG , BaltaroF , MonacoA , FerrariA .Managing recurrent vulvovaginal candidiasis. Intermittent prevention with itraconazole. Journal of Reproductive Medicine1997;42:83-7. ">Spinillo 1997</a>; <a href="./references#CD009151-bbs2-0023" title="WittA , KaufmannU , BitschnauM , TempferC , OzbalA , HaytougluE , et al.Monthly itraconazole versus classic homeopathy for the treatment of recurrent vulvovaginal candidiasis: a randomized trial. Obstetrical and Gynecological Survey2010;65(1):26-7. WittA , KaufmannU , BitschnauM , TempferC , OzbalA , HaytougluE , GregorH , KissH .Monthly itraconazole versus classic homeopathy for the treatment of recurrent vulvovaginal candidiasis: a randomised trial. British Journal of Obstetrics &amp; Gynaecology2009;116(11):1499-505. ">Witt 2009</a>), due predominantly to lack of masking between the intervention and control groups. The three comparators used by <a href="./references#CD009151-bbs2-0014" title="MendlingW , BirknerV .Vaccination with inactivated lactobacilli or heliotherapy can improve the quality-of-life of women with chronic recurrent vulvovaginal candidosis a prospective randomized study [Die Vakzination mit inaktivierten Laktobazillen oder mit Heliotherapie kann die Lebensqualitat von Frauen mit rezidivierender vulvovaginaler Kandidose verbessern - Eine prospektive 3-armige randomisierte Studie]. Geburtshilfe und Frauenheilkunde2011;71(9):767-72. ">Mendling 2011</a> were quite different, being ultraviolet A and B rays, vaginal pessaries, and intramuscular injections, and were therefore easy to distinguish. </p> </section> <section id="CD009151-sec-0062"> <h5 class="title">Detection bias</h5> <p>We considered the risk of detection bias to be low in only one study (<a href="./references#CD009151-bbs2-0016" title="RothAC , MilsomI , ForssmanL , WahlenP .Intermittent prophylactic treatment of recurrent vaginal candidiasis by postmenstrual application of a 500 mg clotrimazole vaginal tablet. Genitourinary Medicine1990;66:357-60. ">Roth 1990</a>). Blinding of outcome assessment was unclear for sixteen of the studies (<a href="./references#CD009151-bbs2-0001" title="BolouriF , TabriziNM , TanhaFD , NiroomandN , AzmoodehA , EmamiS , et al.Effectiveness of fluconazole for suppressive maintenance therapy in patients with RVVC: a randomized placebo-controlled study. Iranian Journal of Pharmaceutical Research2009;8:307-13. ">Bolouri 2009</a>; <a href="./references#CD009151-bbs2-0002" title="ChopraV , MarottaF , KumariA , BishierMP , HeF , ZerbinatiN , et al.Prophylactic strategies in recurrent vulvovaginal candidiasis: a 2-year study testing a phytonutrient vs itraconazole. Journal of Biological Regulators and Homeostatic Agents2013;27(3):875-82. [PMID: 24152852]">Chopra 2013</a>; <a href="./references#CD009151-bbs2-0003" title="CorthayP , PerrenoudC , GumowskiPI , GirardJP .Candida albicans specific immune responses in patients with recurrent chronic vaginitis treated with an anti-candida food regimen (ACFR) or an hyposensitization treatment (HPT). Allergy1988;43:51. ">Corthay 1988</a>; <a href="./references#CD009151-bbs2-0004" title="D'AntuonoA , BaldiE , BellavistaS , BanzolaN , ZauliS , PatriziA .Use of Dermasilk briefs in recurrent vulvovaginal candidosis: safety and effectiveness. Mycoses2012;55(3):e85-9. ">D'Antuono 2012</a>; <a href="./references#CD009151-bbs2-0005" title="D'AntuonoA , BellavistaS , GaspariV , FilippiniA , PatriziA .Dermasilk® briefs in recurrent vulvovaginal candidosis. An alternative option in long-lasting disease. Minerva Ginecologica2013;65(6):697-705. ">D'Antuono 2013</a>; <a href="./references#CD009151-bbs2-0006" title="FanS , LiuX , WuC , XuL , LiJ .Vaginal nystatin versus oral fluconazole for the treatment for recurrent vulvovaginal candidiasis. Mycopathologia2015;179:95-101. [DOI: https://doi.org/10.1007/s11046-014-9827-4]">Fan 2015</a>; <a href="./references#CD009151-bbs2-0007" title="FardyazarZ , HabibzadehS , Abdollahi-FardS , TelloM .Vaginal azoles versus oral fluconazole in treatment of recurrent vulvovaginal candidiasis. Iranian Journal of Clinical Infectious Diseases2007;2:17-22. FardyazarZ , HabibzadehS .Long term vaginal azoles versus prophylactic oral fluconazole in treatment of recurrent vulvovaginal candidiasis. Research Journal of Biological Sciences2007;2(6):663-6. ">Fardyazar 2007</a>; <a href="./references#CD009151-bbs2-0009" title="FongIW .The value of treating the sexual partners of women with recurrent vaginal candidiasis with ketoconazole. Genitourinary Medicine1992;68:174-6. ">Fong 1992b</a>; <a href="./references#CD009151-bbs2-0010" title="FongIW .The value of prophylactic (monthly) clotrimazole versus empiric self-treatment in recurrent vaginal candidiasis. Genitourinary Medicine1994;70:124-6. ">Fong 1994</a>; <a href="./references#CD009151-bbs2-0011" title="KumariA , BishierMP , NaitoY , SharmaA , SolimeneU , JainS , et al.Protective effect of an oral natural phytonutrient in recurrent vulvovaginal candidiasis: a 12-month study. Journal of Biological Regulators &amp; Homeostatic Agents2011;25(4):543-51. ">Kumari 2011</a>; <a href="./references#CD009151-bbs2-0012" title="LiW .Influence of nursing intervention on recurrent vulvovaginal candidiasis patients treated with ATP-infrared bio-effect technique. Iranian Journal of Public Health2018;47(10):1511-9. ">Li 2018</a>; <a href="./references#CD009151-bbs2-0013" title="Lopez-OlmosJ , LermaE .Treatment of recurring vulvo-vaginal candidiasis: a comparative prospective study during six months of three anti-mycotic preparations of a single dosis. Clinica e Investigacion en Ginecologia y Obstetricia2000;27:366-75. ">Lopez‐Olmos 2000</a>; <a href="./references#CD009151-bbs2-0015" title="MettsJ , FamulaTR , TrenevN , ClemensRA .Lactobacillus acidophilus, strain NAS (H2O2 positive), in reduction of recurrent candidal vulvovaginitis. Journal of Applied Research2003;3:340-8. ">Metts 2003</a>; <a href="./references#CD009151-bbs2-0018" title="SobelJD .Recurrent vulvovaginal candidiasis. A prospective study of the efficacy of maintenance ketoconazole therapy. New England Journal of Medicine1986;315:1455-8. ">Sobel 1986</a>; <a href="./references#CD009151-bbs2-0019" title="SobelJD , SchmittC , MeriwetherC .Clotrimazole treatment of recurrent and chronic candida vulvovaginitis. Obstetrics &amp; Gynecology1989;73:330-4. ">Sobel 1989</a>; <a href="./references#CD009151-bbs2-0020" title="SobelJD , WiesenfeldHC , MartensM , DannaP , HootonTM , RompaloA , et al.Maintenance fluconazole therapy for recurrent vulvovaginal candidiasis. New England Journal of Medicine2004;351:876-83. ">Sobel 2004</a>; <a href="./references#CD009151-bbs2-0021" title="SpacekJ , BuchtaV .Itraconazole in the treatment of acute and recurrent vulvovaginal candidosis: comparison of a 1-day and a 3-day regimen. Mycoses2005;48:165-71. ">Spacek 2005</a>). We assessed the risk of detection bias to be high for five studies, usually because outcomes were assessed by participants who were not blinded and the outcome was "soft" (<a href="./references#CD009151-bbs2-0009" title="FongIW .The value of treating the sexual partners of women with recurrent vaginal candidiasis with ketoconazole. Genitourinary Medicine1992;68:174-6. ">Fong 1992b</a>; <a href="./references#CD009151-bbs2-0014" title="MendlingW , BirknerV .Vaccination with inactivated lactobacilli or heliotherapy can improve the quality-of-life of women with chronic recurrent vulvovaginal candidosis a prospective randomized study [Die Vakzination mit inaktivierten Laktobazillen oder mit Heliotherapie kann die Lebensqualitat von Frauen mit rezidivierender vulvovaginaler Kandidose verbessern - Eine prospektive 3-armige randomisierte Studie]. Geburtshilfe und Frauenheilkunde2011;71(9):767-72. ">Mendling 2011</a>; <a href="./references#CD009151-bbs2-0017" title="SobelJD .Management of recurrent vulvovaginal candidiasis (VVC) with ketoconazole (K) prophylaxis [abstract]. Archives of Gynecology1985;237 Suppl:281. SobelJD .Management of recurrent vulvovaginal candidiasis with intermittent ketoconazole prophylaxis. Obstetrics &amp; Gynecology1985;65:435-40. ">Sobel 1985a</a>; <a href="./references#CD009151-bbs2-0022" title="SpinilloA , ColonnaL , PiazziG , BaltaroF , MonacoA , FerrariA .Managing recurrent vulvovaginal candidiasis. Intermittent prevention with itraconazole. Journal of Reproductive Medicine1997;42:83-7. ">Spinillo 1997</a>; <a href="./references#CD009151-bbs2-0023" title="WittA , KaufmannU , BitschnauM , TempferC , OzbalA , HaytougluE , et al.Monthly itraconazole versus classic homeopathy for the treatment of recurrent vulvovaginal candidiasis: a randomized trial. Obstetrical and Gynecological Survey2010;65(1):26-7. WittA , KaufmannU , BitschnauM , TempferC , OzbalA , HaytougluE , GregorH , KissH .Monthly itraconazole versus classic homeopathy for the treatment of recurrent vulvovaginal candidiasis: a randomised trial. British Journal of Obstetrics &amp; Gynaecology2009;116(11):1499-505. ">Witt 2009</a>). </p> </section> </section> <section id="CD009151-sec-0063"> <h4 class="title">Incomplete outcome data</h4> <p>We assessed eight studies with low attrition rates (15% or less) as well as good explanations for any loss to follow‐up as at low risk of attrition bias (<a href="./references#CD009151-bbs2-0002" title="ChopraV , MarottaF , KumariA , BishierMP , HeF , ZerbinatiN , et al.Prophylactic strategies in recurrent vulvovaginal candidiasis: a 2-year study testing a phytonutrient vs itraconazole. Journal of Biological Regulators and Homeostatic Agents2013;27(3):875-82. [PMID: 24152852]">Chopra 2013</a>; <a href="https://mail.google.com/mail/ca/u/0/D'Antuono%202012" target="_blank">D'Antuono 2012</a>; <a href="./references#CD009151-bbs2-0005" title="D'AntuonoA , BellavistaS , GaspariV , FilippiniA , PatriziA .Dermasilk® briefs in recurrent vulvovaginal candidosis. An alternative option in long-lasting disease. Minerva Ginecologica2013;65(6):697-705. ">D'Antuono 2013</a>; <a href="https://mail.google.com/mail/ca/u/0/Fardyazar%202007" target="_blank">Fardyazar 2007</a>; <a href="https://mail.google.com/mail/ca/u/0/Fong%201992a" target="_blank">Fong 1992a</a>; <a href="https://mail.google.com/mail/ca/u/0/Fong%201992b" target="_blank">Fong 1992b</a>; <a href="./references#CD009151-bbs2-0010" title="FongIW .The value of prophylactic (monthly) clotrimazole versus empiric self-treatment in recurrent vaginal candidiasis. Genitourinary Medicine1994;70:124-6. ">Fong 1994</a><a href="https://mail.google.com/mail/ca/u/0/Roth%201990" target="_blank">; Roth 1990</a>). <a href="./references#CD009151-bbs2-0020" title="SobelJD , WiesenfeldHC , MartensM , DannaP , HootonTM , RompaloA , et al.Maintenance fluconazole therapy for recurrent vulvovaginal candidiasis. New England Journal of Medicine2004;351:876-83. ">Sobel 2004</a> reported only the per‐protocol analysis but claimed that the results were similar in a modified intention‐to‐treat‐analysis for which the data were not shown, therefore we assessed the risk of attrition bias for this study to be unclear. Other studies that were deemed to have unclear risk of bias for this domain were two studies that described per‐protocol analysis rather than intention‐to‐treat (<a href="./references#CD009151-bbs2-0013" title="Lopez-OlmosJ , LermaE .Treatment of recurring vulvo-vaginal candidiasis: a comparative prospective study during six months of three anti-mycotic preparations of a single dosis. Clinica e Investigacion en Ginecologia y Obstetricia2000;27:366-75. ">Lopez‐Olmos 2000</a>; <a href="./references#CD009151-bbs2-0022" title="SpinilloA , ColonnaL , PiazziG , BaltaroF , MonacoA , FerrariA .Managing recurrent vulvovaginal candidiasis. Intermittent prevention with itraconazole. Journal of Reproductive Medicine1997;42:83-7. ">Spinillo 1997</a>), and two studies where withdrawal and loss to follow‐up were not clearly described (<a href="./references#CD009151-bbs2-0021" title="SpacekJ , BuchtaV .Itraconazole in the treatment of acute and recurrent vulvovaginal candidosis: comparison of a 1-day and a 3-day regimen. Mycoses2005;48:165-71. ">Spacek 2005</a>; <a href="./references#CD009151-bbs2-0017" title="SobelJD .Management of recurrent vulvovaginal candidiasis (VVC) with ketoconazole (K) prophylaxis [abstract]. Archives of Gynecology1985;237 Suppl:281. SobelJD .Management of recurrent vulvovaginal candidiasis with intermittent ketoconazole prophylaxis. Obstetrics &amp; Gynecology1985;65:435-40. ">Sobel 1985a</a>). We considered 10 studies as at high risk of attrition bias due to high attrition rates or incomplete explanations for this, or both (<a href="https://mail.google.com/mail/ca/u/0/Bolouri%202009" target="_blank">Bolouri 2009</a>; <a href="./references#CD009151-bbs2-0003" title="CorthayP , PerrenoudC , GumowskiPI , GirardJP .Candida albicans specific immune responses in patients with recurrent chronic vaginitis treated with an anti-candida food regimen (ACFR) or an hyposensitization treatment (HPT). Allergy1988;43:51. ">Corthay 1988</a>; <a href="./references#CD009151-bbs2-0006" title="FanS , LiuX , WuC , XuL , LiJ .Vaginal nystatin versus oral fluconazole for the treatment for recurrent vulvovaginal candidiasis. Mycopathologia2015;179:95-101. [DOI: https://doi.org/10.1007/s11046-014-9827-4]">Fan 2015</a>; <a href="https://mail.google.com/mail/ca/u/0/Kumari%202011" target="_blank">Kumari 2011</a>; <a href="./references#CD009151-bbs2-0012" title="LiW .Influence of nursing intervention on recurrent vulvovaginal candidiasis patients treated with ATP-infrared bio-effect technique. Iranian Journal of Public Health2018;47(10):1511-9. ">Li 2018</a>; <a href="https://mail.google.com/mail/ca/u/0/Mendling%202011" target="_blank">Mendling 2011</a>; <a href="https://mail.google.com/mail/ca/u/0/Metts%202003" target="_blank">Metts 2003</a>; <a href="https://mail.google.com/mail/ca/u/0/Sobel%201986" target="_blank">Sobel 1986</a>; <a href="https://mail.google.com/mail/ca/u/0/Sobel%201989" target="_blank">Sobel 1989</a>; <a href="https://mail.google.com/mail/ca/u/0/Witt%202009" target="_blank">Witt 2009</a>). </p> </section> <section id="CD009151-sec-0064"> <h4 class="title">Selective reporting</h4> <p>No published protocol was available for any of the studies. We considered all but two studies as at unclear risk of reporting bias as there was insufficient information in the available publications to assess whether all intended outcomes had been reported. We assessed <a href="./references#CD009151-bbs2-0011" title="KumariA , BishierMP , NaitoY , SharmaA , SolimeneU , JainS , et al.Protective effect of an oral natural phytonutrient in recurrent vulvovaginal candidiasis: a 12-month study. Journal of Biological Regulators &amp; Homeostatic Agents2011;25(4):543-51. ">Kumari 2011</a> as at high risk for selective reporting because outcome measures were not described in sufficient detail. <a href="./references#CD009151-bbs2-0020" title="SobelJD , WiesenfeldHC , MartensM , DannaP , HootonTM , RompaloA , et al.Maintenance fluconazole therapy for recurrent vulvovaginal candidiasis. New England Journal of Medicine2004;351:876-83. ">Sobel 2004</a> was also considered high risk of bias for this domain, as one of the primary outcome (number of clinical recurrences per participant per year) was not reported. </p> </section> <section id="CD009151-sec-0065"> <h4 class="title">Other potential sources of bias</h4> <p>We considered four studies to a lowrisk of other bias, as the studies and their authors appeared to be independent of pharmaceutical financial support (<a href="./references#CD009151-bbs2-0001" title="BolouriF , TabriziNM , TanhaFD , NiroomandN , AzmoodehA , EmamiS , et al.Effectiveness of fluconazole for suppressive maintenance therapy in patients with RVVC: a randomized placebo-controlled study. Iranian Journal of Pharmaceutical Research2009;8:307-13. ">Bolouri 2009</a>; <a href="./references#CD009151-bbs2-0006" title="FanS , LiuX , WuC , XuL , LiJ .Vaginal nystatin versus oral fluconazole for the treatment for recurrent vulvovaginal candidiasis. Mycopathologia2015;179:95-101. [DOI: https://doi.org/10.1007/s11046-014-9827-4]">Fan 2015</a>; <a href="./references#CD009151-bbs2-0015" title="MettsJ , FamulaTR , TrenevN , ClemensRA .Lactobacillus acidophilus, strain NAS (H2O2 positive), in reduction of recurrent candidal vulvovaginitis. Journal of Applied Research2003;3:340-8. ">Metts 2003</a>; <a href="./references#CD009151-bbs2-0021" title="SpacekJ , BuchtaV .Itraconazole in the treatment of acute and recurrent vulvovaginal candidosis: comparison of a 1-day and a 3-day regimen. Mycoses2005;48:165-71. ">Spacek 2005</a>). Three studies were funded by companies with vested interests such as pharmaceutical manufacturers and were therefore assessed as at high risk of bias (<a href="./references#CD009151-bbs2-0007" title="FardyazarZ , HabibzadehS , Abdollahi-FardS , TelloM .Vaginal azoles versus oral fluconazole in treatment of recurrent vulvovaginal candidiasis. Iranian Journal of Clinical Infectious Diseases2007;2:17-22. FardyazarZ , HabibzadehS .Long term vaginal azoles versus prophylactic oral fluconazole in treatment of recurrent vulvovaginal candidiasis. Research Journal of Biological Sciences2007;2(6):663-6. ">Fardyazar 2007</a>; <a href="./references#CD009151-bbs2-0020" title="SobelJD , WiesenfeldHC , MartensM , DannaP , HootonTM , RompaloA , et al.Maintenance fluconazole therapy for recurrent vulvovaginal candidiasis. New England Journal of Medicine2004;351:876-83. ">Sobel 2004</a>; <a href="./references#CD009151-bbs2-0023" title="WittA , KaufmannU , BitschnauM , TempferC , OzbalA , HaytougluE , et al.Monthly itraconazole versus classic homeopathy for the treatment of recurrent vulvovaginal candidiasis: a randomized trial. Obstetrical and Gynecological Survey2010;65(1):26-7. WittA , KaufmannU , BitschnauM , TempferC , OzbalA , HaytougluE , GregorH , KissH .Monthly itraconazole versus classic homeopathy for the treatment of recurrent vulvovaginal candidiasis: a randomised trial. British Journal of Obstetrics &amp; Gynaecology2009;116(11):1499-505. ">Witt 2009</a>). Furthermore, in <a href="./references#CD009151-bbs2-0007" title="FardyazarZ , HabibzadehS , Abdollahi-FardS , TelloM .Vaginal azoles versus oral fluconazole in treatment of recurrent vulvovaginal candidiasis. Iranian Journal of Clinical Infectious Diseases2007;2:17-22. FardyazarZ , HabibzadehS .Long term vaginal azoles versus prophylactic oral fluconazole in treatment of recurrent vulvovaginal candidiasis. Research Journal of Biological Sciences2007;2(6):663-6. ">Fardyazar 2007</a> non‐compliant participants were excluded from the analysis. In <a href="./references#CD009151-bbs2-0020" title="SobelJD , WiesenfeldHC , MartensM , DannaP , HootonTM , RompaloA , et al.Maintenance fluconazole therapy for recurrent vulvovaginal candidiasis. New England Journal of Medicine2004;351:876-83. ">Sobel 2004</a>, the authors report that "about halfway through the enrolment period (before the data were analysed), the sponsor decided to combine the parallel trials into a single trial". The third study judged to be at high risk of bias did not provide details about similarity between treatment groups at baseline (<a href="./references#CD009151-bbs2-0023" title="WittA , KaufmannU , BitschnauM , TempferC , OzbalA , HaytougluE , et al.Monthly itraconazole versus classic homeopathy for the treatment of recurrent vulvovaginal candidiasis: a randomized trial. Obstetrical and Gynecological Survey2010;65(1):26-7. WittA , KaufmannU , BitschnauM , TempferC , OzbalA , HaytougluE , GregorH , KissH .Monthly itraconazole versus classic homeopathy for the treatment of recurrent vulvovaginal candidiasis: a randomised trial. British Journal of Obstetrics &amp; Gynaecology2009;116(11):1499-505. ">Witt 2009</a>). One study was considered at high risk of bias as a conference paper abstract only was located, with no full publication identified <a href="./references#CD009151-bbs2-0003" title="CorthayP , PerrenoudC , GumowskiPI , GirardJP .Candida albicans specific immune responses in patients with recurrent chronic vaginitis treated with an anti-candida food regimen (ACFR) or an hyposensitization treatment (HPT). Allergy1988;43:51. ">Corthay 1988</a>. We considered the remaining 14 studies as at unclear risk of bias as the role of the founder was not clear or the funding source was not reported (<a href="./references#CD009151-bbs2-0002" title="ChopraV , MarottaF , KumariA , BishierMP , HeF , ZerbinatiN , et al.Prophylactic strategies in recurrent vulvovaginal candidiasis: a 2-year study testing a phytonutrient vs itraconazole. Journal of Biological Regulators and Homeostatic Agents2013;27(3):875-82. [PMID: 24152852]">Chopra 2013</a>; <a href="./references#CD009151-bbs2-0004" title="D'AntuonoA , BaldiE , BellavistaS , BanzolaN , ZauliS , PatriziA .Use of Dermasilk briefs in recurrent vulvovaginal candidosis: safety and effectiveness. Mycoses2012;55(3):e85-9. ">D'Antuono 2012</a>; <a href="./references#CD009151-bbs2-0005" title="D'AntuonoA , BellavistaS , GaspariV , FilippiniA , PatriziA .Dermasilk® briefs in recurrent vulvovaginal candidosis. An alternative option in long-lasting disease. Minerva Ginecologica2013;65(6):697-705. ">D'Antuono 2013</a>; <a href="./references#CD009151-bbs2-0008" title="FongIW .The value of chronic suppressive therapy with itraconazole versus clotrimazole in women with recurrent vaginal candidiasis. Genitourinary Medicine1992;68:374-7. ">Fong 1992a</a>; <a href="./references#CD009151-bbs2-0009" title="FongIW .The value of treating the sexual partners of women with recurrent vaginal candidiasis with ketoconazole. Genitourinary Medicine1992;68:174-6. ">Fong 1992b</a>; <a href="./references#CD009151-bbs2-0010" title="FongIW .The value of prophylactic (monthly) clotrimazole versus empiric self-treatment in recurrent vaginal candidiasis. Genitourinary Medicine1994;70:124-6. ">Fong 1994</a>; <a href="./references#CD009151-bbs2-0011" title="KumariA , BishierMP , NaitoY , SharmaA , SolimeneU , JainS , et al.Protective effect of an oral natural phytonutrient in recurrent vulvovaginal candidiasis: a 12-month study. Journal of Biological Regulators &amp; Homeostatic Agents2011;25(4):543-51. ">Kumari 2011</a>; <a href="./references#CD009151-bbs2-0013" title="Lopez-OlmosJ , LermaE .Treatment of recurring vulvo-vaginal candidiasis: a comparative prospective study during six months of three anti-mycotic preparations of a single dosis. Clinica e Investigacion en Ginecologia y Obstetricia2000;27:366-75. ">Lopez‐Olmos 2000</a>; <a href="./references#CD009151-bbs2-0014" title="MendlingW , BirknerV .Vaccination with inactivated lactobacilli or heliotherapy can improve the quality-of-life of women with chronic recurrent vulvovaginal candidosis a prospective randomized study [Die Vakzination mit inaktivierten Laktobazillen oder mit Heliotherapie kann die Lebensqualitat von Frauen mit rezidivierender vulvovaginaler Kandidose verbessern - Eine prospektive 3-armige randomisierte Studie]. Geburtshilfe und Frauenheilkunde2011;71(9):767-72. ">Mendling 2011</a>; <a href="./references#CD009151-bbs2-0016" title="RothAC , MilsomI , ForssmanL , WahlenP .Intermittent prophylactic treatment of recurrent vaginal candidiasis by postmenstrual application of a 500 mg clotrimazole vaginal tablet. Genitourinary Medicine1990;66:357-60. ">Roth 1990</a>; <a href="./references#CD009151-bbs2-0017" title="SobelJD .Management of recurrent vulvovaginal candidiasis (VVC) with ketoconazole (K) prophylaxis [abstract]. Archives of Gynecology1985;237 Suppl:281. SobelJD .Management of recurrent vulvovaginal candidiasis with intermittent ketoconazole prophylaxis. Obstetrics &amp; Gynecology1985;65:435-40. ">Sobel 1985a</a>; <a href="./references#CD009151-bbs2-0018" title="SobelJD .Recurrent vulvovaginal candidiasis. A prospective study of the efficacy of maintenance ketoconazole therapy. New England Journal of Medicine1986;315:1455-8. ">Sobel 1986</a>; <a href="./references#CD009151-bbs2-0019" title="SobelJD , SchmittC , MeriwetherC .Clotrimazole treatment of recurrent and chronic candida vulvovaginitis. Obstetrics &amp; Gynecology1989;73:330-4. ">Sobel 1989</a>; <a href="./references#CD009151-bbs2-0022" title="SpinilloA , ColonnaL , PiazziG , BaltaroF , MonacoA , FerrariA .Managing recurrent vulvovaginal candidiasis. Intermittent prevention with itraconazole. Journal of Reproductive Medicine1997;42:83-7. ">Spinillo 1997</a>). </p> </section> </section> <section id="CD009151-sec-0066"> <h3 class="title" id="CD009151-sec-0066">Effects of interventions</h3> <p>See: <a href="./full#CD009151-tbl-0001"><b>Summary of findings 1</b> Drug treatment compared to placebo or no treatment for recurrent vulvovaginal candidiasis</a>; <a href="./full#CD009151-tbl-0002"><b>Summary of findings 2</b> Oral drug treatment compared to topical drug treatment for recurrent vulvovaginal candidiasis</a> </p> <p>This section presents the available data from the included studies only. Two 'Summary of findings' tables collate the main results of this review (<a href="./full#CD009151-tbl-0001">summary of findings Table 1</a>; <a href="./full#CD009151-tbl-0002">summary of findings Table 2</a>). </p> <section id="CD009151-sec-0067"> <h4 class="title">Comparison 1: Drug treatment versus placebo/no treatment (excluding partner treatment)</h4> <p>See <a href="./full#CD009151-tbl-0001">summary of findings Table 1</a>. </p> <p>Six studies examined drug treatment versus placebo/no treatment (excluding partner treatment) (<a href="./references#CD009151-bbs2-0001" title="BolouriF , TabriziNM , TanhaFD , NiroomandN , AzmoodehA , EmamiS , et al.Effectiveness of fluconazole for suppressive maintenance therapy in patients with RVVC: a randomized placebo-controlled study. Iranian Journal of Pharmaceutical Research2009;8:307-13. ">Bolouri 2009</a>; <a href="./references#CD009151-bbs2-0016" title="RothAC , MilsomI , ForssmanL , WahlenP .Intermittent prophylactic treatment of recurrent vaginal candidiasis by postmenstrual application of a 500 mg clotrimazole vaginal tablet. Genitourinary Medicine1990;66:357-60. ">Roth 1990</a>; <a href="./references#CD009151-bbs2-0018" title="SobelJD .Recurrent vulvovaginal candidiasis. A prospective study of the efficacy of maintenance ketoconazole therapy. New England Journal of Medicine1986;315:1455-8. ">Sobel 1986</a>; <a href="./references#CD009151-bbs2-0019" title="SobelJD , SchmittC , MeriwetherC .Clotrimazole treatment of recurrent and chronic candida vulvovaginitis. Obstetrics &amp; Gynecology1989;73:330-4. ">Sobel 1989</a>; <a href="./references#CD009151-bbs2-0020" title="SobelJD , WiesenfeldHC , MartensM , DannaP , HootonTM , RompaloA , et al.Maintenance fluconazole therapy for recurrent vulvovaginal candidiasis. New England Journal of Medicine2004;351:876-83. ">Sobel 2004</a>; <a href="./references#CD009151-bbs2-0022" title="SpinilloA , ColonnaL , PiazziG , BaltaroF , MonacoA , FerrariA .Managing recurrent vulvovaginal candidiasis. Intermittent prevention with itraconazole. Journal of Reproductive Medicine1997;42:83-7. ">Spinillo 1997</a>). <a href="./references#CD009151-bbs2-0022" title="SpinilloA , ColonnaL , PiazziG , BaltaroF , MonacoA , FerrariA .Managing recurrent vulvovaginal candidiasis. Intermittent prevention with itraconazole. Journal of Reproductive Medicine1997;42:83-7. ">Spinillo 1997</a> used a no‐treatment comparator, whilst the remaining five studies used a placebo comparator. All studies presenting data for this comparison involved treatment with azoles, therefore a single analysis, grouped into two categories (oral and topical treatments), was performed for each relevant outcome. The characteristics of studies against this comparison are summarised in a supplementary table (<a href="#CD009151-tbl-0003">Table 1</a>). </p> <div class="table" id="CD009151-tbl-0003"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Summary of characteristics of studies included in Comparison 1: Drug treatment versus placebo/no treatment (excluding partner treatment)</span></div> <tbody> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study ID</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><a href="./references#CD009151-bbs2-0001" title="BolouriF , TabriziNM , TanhaFD , NiroomandN , AzmoodehA , EmamiS , et al.Effectiveness of fluconazole for suppressive maintenance therapy in patients with RVVC: a randomized placebo-controlled study. Iranian Journal of Pharmaceutical Research2009;8:307-13. "><b>Bolouri 2009</b> </a> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><a href="./references#CD009151-bbs2-0016" title="RothAC , MilsomI , ForssmanL , WahlenP .Intermittent prophylactic treatment of recurrent vaginal candidiasis by postmenstrual application of a 500 mg clotrimazole vaginal tablet. Genitourinary Medicine1990;66:357-60. "><b>Roth 1990</b> </a> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><a href="./references#CD009151-bbs2-0018" title="SobelJD .Recurrent vulvovaginal candidiasis. A prospective study of the efficacy of maintenance ketoconazole therapy. New England Journal of Medicine1986;315:1455-8. "><b>Sobel 1986</b> </a> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><a href="./references#CD009151-bbs2-0019" title="SobelJD , SchmittC , MeriwetherC .Clotrimazole treatment of recurrent and chronic candida vulvovaginitis. Obstetrics &amp; Gynecology1989;73:330-4. "><b>Sobel 1989</b> </a> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><a href="./references#CD009151-bbs2-0020" title="SobelJD , WiesenfeldHC , MartensM , DannaP , HootonTM , RompaloA , et al.Maintenance fluconazole therapy for recurrent vulvovaginal candidiasis. New England Journal of Medicine2004;351:876-83. "><b>Sobel 2004</b> </a> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><a href="./references#CD009151-bbs2-0022" title="SpinilloA , ColonnaL , PiazziG , BaltaroF , MonacoA , FerrariA .Managing recurrent vulvovaginal candidiasis. Intermittent prevention with itraconazole. Journal of Reproductive Medicine1997;42:83-7. "><b>Spinillo 1997</b> </a> </p> </th> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Participants (n)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>97</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>64</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>74</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>42</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>387</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>114</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i><b>Candida albicans</b> </i><b>at enrolment (%)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>78</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>87</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>86</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>94</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100<sup>a</sup> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mean episodes in previous 12 months</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NS<sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6.2 (clotrimazole), 6.5 (placebo)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NS<sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9.2 (clotrimazole), 8.3 (placebo)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NS<sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NS<sup>b</sup> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Withdrawals/loss to follow‐up (%)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Setting</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hospital outpatient clinic</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NS<sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NS<sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NS<sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Multicentre</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Outpatient clinic</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Country</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Iran</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sweden</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>USA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>USA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>USA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Italy</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Intervention 1</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fluconazole (weekly)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clotrimazole (postmenstrual)*</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ketoconazole (with menses)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clotrimazole (postmenstrual)*</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fluconazole (weekly)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Itraconazole (with menses)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Intervention 2</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo (weekly)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo (postmenstrual)*</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ketoconazole (daily)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo (postmenstrual)*</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo (weekly)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No treatment (with menses)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Intervention 3</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo (daily)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Duration of intervention</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 months</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Duration of observation after intervention</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 months</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Planned assessments</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Monthly for 6 months, then 9 months, 12 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Monthly for 6 months, then 9 months, 12 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Monthly for 12 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Monthly for 6 months, then 9 months, 12 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Monthly for 6 months, then 9 months, 12 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3, 6, and 12 months</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Assessment between planned visits if symptoms developed</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><sup>a</sup><i>C albicans</i> was a selection criterion.<br/><sup>b</sup>Not reported or unclear. </p> <p>*Topical treatment</p> </div> </div> <section id="CD009151-sec-0068"> <h5 class="title">Primary outcomes</h5> <section id="CD009151-sec-0069"> <h6 class="title">1. Number of clinical recurrences per participant per year</h6> <p>None of the six studies in this comparison reported this outcome (<a href="./references#CD009151-bbs2-0001" title="BolouriF , TabriziNM , TanhaFD , NiroomandN , AzmoodehA , EmamiS , et al.Effectiveness of fluconazole for suppressive maintenance therapy in patients with RVVC: a randomized placebo-controlled study. Iranian Journal of Pharmaceutical Research2009;8:307-13. ">Bolouri 2009</a>; <a href="./references#CD009151-bbs2-0016" title="RothAC , MilsomI , ForssmanL , WahlenP .Intermittent prophylactic treatment of recurrent vaginal candidiasis by postmenstrual application of a 500 mg clotrimazole vaginal tablet. Genitourinary Medicine1990;66:357-60. ">Roth 1990</a>; <a href="./references#CD009151-bbs2-0018" title="SobelJD .Recurrent vulvovaginal candidiasis. A prospective study of the efficacy of maintenance ketoconazole therapy. New England Journal of Medicine1986;315:1455-8. ">Sobel 1986</a>; <a href="./references#CD009151-bbs2-0019" title="SobelJD , SchmittC , MeriwetherC .Clotrimazole treatment of recurrent and chronic candida vulvovaginitis. Obstetrics &amp; Gynecology1989;73:330-4. ">Sobel 1989</a>; <a href="./references#CD009151-bbs2-0020" title="SobelJD , WiesenfeldHC , MartensM , DannaP , HootonTM , RompaloA , et al.Maintenance fluconazole therapy for recurrent vulvovaginal candidiasis. New England Journal of Medicine2004;351:876-83. ">Sobel 2004</a>; <a href="./references#CD009151-bbs2-0022" title="SpinilloA , ColonnaL , PiazziG , BaltaroF , MonacoA , FerrariA .Managing recurrent vulvovaginal candidiasis. Intermittent prevention with itraconazole. Journal of Reproductive Medicine1997;42:83-7. ">Spinillo 1997</a>). </p> </section> <section id="CD009151-sec-0070"> <h6 class="title">2. Proportion of participants with at least one clinical recurrence during the treatment and follow‐up period </h6> <p>Data were available for this outcome from all six studies at both six and 12 months for 607 and 585 participants, respectively. Each study had an active treatment phase of six months and a further period of six months of surveillance after the active treatment had been completed, therefore clinical recurrence at six months represented recurrence whilst on treatment and at 12 months included a six‐month period where participants were not on active treatment. </p> </section> <section id="CD009151-sec-0071"> <h6 class="title">Clinical recurrence at 6 months</h6> <section id="CD009151-sec-0072"> <p><b>Oral treatments</b></p> <p>When results were pooled for oral treatments (fluconazole, itraconazole, ketoconazole ‐ <a href="./references#CD009151-bbs2-0001" title="BolouriF , TabriziNM , TanhaFD , NiroomandN , AzmoodehA , EmamiS , et al.Effectiveness of fluconazole for suppressive maintenance therapy in patients with RVVC: a randomized placebo-controlled study. Iranian Journal of Pharmaceutical Research2009;8:307-13. ">Bolouri 2009</a>; <a href="./references#CD009151-bbs2-0018" title="SobelJD .Recurrent vulvovaginal candidiasis. A prospective study of the efficacy of maintenance ketoconazole therapy. New England Journal of Medicine1986;315:1455-8. ">Sobel 1986</a>; <a href="./references#CD009151-bbs2-0020" title="SobelJD , WiesenfeldHC , MartensM , DannaP , HootonTM , RompaloA , et al.Maintenance fluconazole therapy for recurrent vulvovaginal candidiasis. New England Journal of Medicine2004;351:876-83. ">Sobel 2004</a>; <a href="./references#CD009151-bbs2-0022" title="SpinilloA , ColonnaL , PiazziG , BaltaroF , MonacoA , FerrariA .Managing recurrent vulvovaginal candidiasis. Intermittent prevention with itraconazole. Journal of Reproductive Medicine1997;42:83-7. ">Spinillo 1997</a>), oral treatments may reduce clinical recurrence at six months (risk ratio (RR) 0.29, 95% confidence interval (CI) 0.14 to 0.62; participants = 518; studies = 4; I<sup>2</sup>= 84%; low certainty evidence; <a href="./references#CD009151-fig-0008" title="">Analysis 1.1</a>, <a href="#CD009151-fig-0004">Figure 4</a>). The incidence of recurrence in the treatment group was 17% (46/270) compared to 63% (156/248) in the placebo/no treatment group. The number needed to treat to prevent one participant having one or more clinical recurrence at six months was two (number needed to treat for an additional beneficial outcome (NNTB) = 2). Given the I<sup>2</sup> of 84%, we applied a random‐effects model. However, our confidence in these findings is low. </p> <div class="figure" id="CD009151-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 Drug treatment versus placebo/no treatment (excluding partner treatment) (Comparison 1), outcome: 1.1 Clinical recurrence at 6 months." data-id="CD009151-fig-0004" src="/cdsr/doi/10.1002/14651858.CD009151.pub2/media/CDSR/CD009151/image_n/nCD009151-FIG-04.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 Drug treatment versus placebo/no treatment (excluding partner treatment) (Comparison 1), outcome: 1.1 Clinical recurrence at 6 months. </p> </div> </div> </div> <p>We downgraded the certainty of the evidence by two levels to low due to very serious risk of bias in several studies (high risk of bias for blinding of participants and assessors (<a href="./references#CD009151-bbs2-0022" title="SpinilloA , ColonnaL , PiazziG , BaltaroF , MonacoA , FerrariA .Managing recurrent vulvovaginal candidiasis. Intermittent prevention with itraconazole. Journal of Reproductive Medicine1997;42:83-7. ">Spinillo 1997</a>), incomplete outcome data (<a href="./references#CD009151-bbs2-0001" title="BolouriF , TabriziNM , TanhaFD , NiroomandN , AzmoodehA , EmamiS , et al.Effectiveness of fluconazole for suppressive maintenance therapy in patients with RVVC: a randomized placebo-controlled study. Iranian Journal of Pharmaceutical Research2009;8:307-13. ">Bolouri 2009</a>; <a href="./references#CD009151-bbs2-0018" title="SobelJD .Recurrent vulvovaginal candidiasis. A prospective study of the efficacy of maintenance ketoconazole therapy. New England Journal of Medicine1986;315:1455-8. ">Sobel 1986</a>), and pharmaceutical funding (<a href="./references#CD009151-bbs2-0020" title="SobelJD , WiesenfeldHC , MartensM , DannaP , HootonTM , RompaloA , et al.Maintenance fluconazole therapy for recurrent vulvovaginal candidiasis. New England Journal of Medicine2004;351:876-83. ">Sobel 2004</a>)). </p> <p>Regarding the sensitivity of this finding to heterogeneity, removing <a href="./references#CD009151-bbs2-0022" title="SpinilloA , ColonnaL , PiazziG , BaltaroF , MonacoA , FerrariA .Managing recurrent vulvovaginal candidiasis. Intermittent prevention with itraconazole. Journal of Reproductive Medicine1997;42:83-7. ">Spinillo 1997</a> (the only study without a placebo) from the analysis reduced the I<sup>2</sup> to 51%, with no impact on direction of effect and no meaningful change to the magnitude of effect (RR 0.22, 95% CI 0.12 to 0.39). When we regarded missing data as treatment failures, the findings remained similar but the magnitude of the potential reduction was reduced (RR 0.52, 95% CI 0.41 to 0.66; random‐effects; I<sup>2</sup>= 47%; NNTB = 3). When pooling the two studies involving fluconazole (<a href="./references#CD009151-bbs2-0001" title="BolouriF , TabriziNM , TanhaFD , NiroomandN , AzmoodehA , EmamiS , et al.Effectiveness of fluconazole for suppressive maintenance therapy in patients with RVVC: a randomized placebo-controlled study. Iranian Journal of Pharmaceutical Research2009;8:307-13. ">Bolouri 2009</a>; <a href="./references#CD009151-bbs2-0020" title="SobelJD , WiesenfeldHC , MartensM , DannaP , HootonTM , RompaloA , et al.Maintenance fluconazole therapy for recurrent vulvovaginal candidiasis. New England Journal of Medicine2004;351:876-83. ">Sobel 2004</a>), the incidence of clinical recurrence in the treatment groups was 11% (19/173) compared to 61% (107/174) for placebo (RR 0.22, 95% CI 0.09 to 0.57; participants = 347; random‐effects; I<sup>2</sup> = 75%; <a href="./references#CD009151-fig-0008" title="">Analysis 1.1</a>). The number needed to treat to prevent one participant having one or more clinical recurrence at six months was two (NNTB = 2). When we regarded missing data as treatment failures, the findings were similar but the magnitude of the potential reduction was reduced (RR 0.54, 95% CI 0.37 to 0.80; random‐effects; I<sup>2</sup> = 71%; NNTB = 3). </p> <p>We downgraded the certainty of the evidence by two levels to low due to very serious risk of bias (incomplete outcome data in <a href="./references#CD009151-bbs2-0001" title="BolouriF , TabriziNM , TanhaFD , NiroomandN , AzmoodehA , EmamiS , et al.Effectiveness of fluconazole for suppressive maintenance therapy in patients with RVVC: a randomized placebo-controlled study. Iranian Journal of Pharmaceutical Research2009;8:307-13. ">Bolouri 2009</a> and pharmaceutical funding in <a href="./references#CD009151-bbs2-0020" title="SobelJD , WiesenfeldHC , MartensM , DannaP , HootonTM , RompaloA , et al.Maintenance fluconazole therapy for recurrent vulvovaginal candidiasis. New England Journal of Medicine2004;351:876-83. ">Sobel 2004</a>). </p> </section> <section id="CD009151-sec-0073"> <p><b>Topical treatments</b></p> <p>Of the two trials using a topical agent (clotrimazole), one reported a reduction in clinical recurrence at six months (<a href="./references#CD009151-bbs2-0016" title="RothAC , MilsomI , ForssmanL , WahlenP .Intermittent prophylactic treatment of recurrent vaginal candidiasis by postmenstrual application of a 500 mg clotrimazole vaginal tablet. Genitourinary Medicine1990;66:357-60. ">Roth 1990</a>), but the other did not (<a href="./references#CD009151-bbs2-0019" title="SobelJD , SchmittC , MeriwetherC .Clotrimazole treatment of recurrent and chronic candida vulvovaginitis. Obstetrics &amp; Gynecology1989;73:330-4. ">Sobel 1989</a>). When pooling these two studies topical treatment with clotrimazole may have little to no effect on clinical recurrence at six months, but the evidence is very uncertain (RR 0.55, 95% CI 0.26 to 1.14; participants = 89; studies = 2; I<sup>2</sup> = 68%; random‐effects; very low certainty evidence; <a href="./references#CD009151-fig-0008" title="">Analysis 1.1</a>). The clotrimazole group had a recurrence rate of 38% (18/48) compared to 76% (31/41) in the placebo group. However, our confidence in these findings is very low. </p> <p>We downgraded the certainty of the evidence by three levels to very low due to very serious risk of bias (incomplete outcome data in <a href="./references#CD009151-bbs2-0019" title="SobelJD , SchmittC , MeriwetherC .Clotrimazole treatment of recurrent and chronic candida vulvovaginitis. Obstetrics &amp; Gynecology1989;73:330-4. ">Sobel 1989</a>) and imprecision (data came from only two studies). </p> </section> <section id="CD009151-sec-0074"> <p><b>Oral and topical treatments combined</b></p> <p>When all drug treatments versus placebo/no treatment were considered, the pooled analysis showed that clinical recurrence at six months may be reduced with oral/topical treatments compared with placebo (RR 0.36, 95% CI 0.21 to 0.63; participants = 607; studies = 6; I<sup>2</sup> = 82%; random‐effects; NNTB = 2; low certainty evidence; <a href="./references#CD009151-fig-0008" title="">Analysis 1.1</a>). The incidence in the treatment group was 20% (64/318) compared to 65% (187/289) in the placebo group. However, our confidence in these findings is low. </p> <p>We performed a sensitivity analysis to assess the impact of heterogeneity on the pooled result by removing <a href="./references#CD009151-bbs2-0020" title="SobelJD , WiesenfeldHC , MartensM , DannaP , HootonTM , RompaloA , et al.Maintenance fluconazole therapy for recurrent vulvovaginal candidiasis. New England Journal of Medicine2004;351:876-83. ">Sobel 2004</a> from the pooled analysis. This reduced the I<sup>2</sup> to 51% with no impact on the direction of effect and no meaningful change to the magnitude of effect (RR 0.45, 95% CI 0.31 to 0.66). The number needed to treat to prevent one participant having one or more clinical recurrence at six months was two participants. When regarding the missing data as treatment failures, the findings remained similar (RR 0.54, 95% CI 0.43 to 0.69; I<sup>2</sup> = 61%; random‐effects; NNTB = 3). </p> <p>We downgraded the certainty of the evidence by two levels to low due to very serious risk of bias in several studies (blinding of participants and assessors (<a href="./references#CD009151-bbs2-0022" title="SpinilloA , ColonnaL , PiazziG , BaltaroF , MonacoA , FerrariA .Managing recurrent vulvovaginal candidiasis. Intermittent prevention with itraconazole. Journal of Reproductive Medicine1997;42:83-7. ">Spinillo 1997</a>), incomplete outcome data (<a href="./references#CD009151-bbs2-0001" title="BolouriF , TabriziNM , TanhaFD , NiroomandN , AzmoodehA , EmamiS , et al.Effectiveness of fluconazole for suppressive maintenance therapy in patients with RVVC: a randomized placebo-controlled study. Iranian Journal of Pharmaceutical Research2009;8:307-13. ">Bolouri 2009</a>; <a href="./references#CD009151-bbs2-0018" title="SobelJD .Recurrent vulvovaginal candidiasis. A prospective study of the efficacy of maintenance ketoconazole therapy. New England Journal of Medicine1986;315:1455-8. ">Sobel 1986</a>; <a href="./references#CD009151-bbs2-0019" title="SobelJD , SchmittC , MeriwetherC .Clotrimazole treatment of recurrent and chronic candida vulvovaginitis. Obstetrics &amp; Gynecology1989;73:330-4. ">Sobel 1989</a>), and pharmaceutical funding (<a href="./references#CD009151-bbs2-0020" title="SobelJD , WiesenfeldHC , MartensM , DannaP , HootonTM , RompaloA , et al.Maintenance fluconazole therapy for recurrent vulvovaginal candidiasis. New England Journal of Medicine2004;351:876-83. ">Sobel 2004</a>)) and heterogeneity. </p> </section> </section> <section id="CD009151-sec-0075"> <h6 class="title">Clinical recurrence at 12 months</h6> <section id="CD009151-sec-0076"> <p><b>Oral treatments</b></p> <p>Four trials assessed the recurrence at 12 months with oral active drugs (<a href="./references#CD009151-bbs2-0001" title="BolouriF , TabriziNM , TanhaFD , NiroomandN , AzmoodehA , EmamiS , et al.Effectiveness of fluconazole for suppressive maintenance therapy in patients with RVVC: a randomized placebo-controlled study. Iranian Journal of Pharmaceutical Research2009;8:307-13. ">Bolouri 2009</a>; <a href="./references#CD009151-bbs2-0018" title="SobelJD .Recurrent vulvovaginal candidiasis. A prospective study of the efficacy of maintenance ketoconazole therapy. New England Journal of Medicine1986;315:1455-8. ">Sobel 1986</a>; <a href="./references#CD009151-bbs2-0020" title="SobelJD , WiesenfeldHC , MartensM , DannaP , HootonTM , RompaloA , et al.Maintenance fluconazole therapy for recurrent vulvovaginal candidiasis. New England Journal of Medicine2004;351:876-83. ">Sobel 2004</a>; <a href="./references#CD009151-bbs2-0022" title="SpinilloA , ColonnaL , PiazziG , BaltaroF , MonacoA , FerrariA .Managing recurrent vulvovaginal candidiasis. Intermittent prevention with itraconazole. Journal of Reproductive Medicine1997;42:83-7. ">Spinillo 1997</a>). When results were pooled, the analysis showed that oral treatments may reduce clinical recurrence at 12 months (RR 0.77, 95% CI 0.68 to 0.88; participants = 496; studies = 4; I<sup>2</sup> = 0%, fixed‐effect; low certainty evidence; <a href="./references#CD009151-fig-0009" title="">Analysis 1.2</a>, <a href="#CD009151-fig-0005">Figure 5</a>). This suggests that there may be a persistence of an effect of the drug beyond the six‐month treatment period. The number needed to treat to prevent one participant having one or more clinical recurrence at 12 months was 5.6 (NNTB = 6). When regarding the missing data as treatment failures, the findings remained similar (RR 0.86, 95% CI 0.79 to 0.93; fixed‐effect; I<sup>2</sup> = 0%; NNTB = 8). However, our confidence in these findings is low. </p> <div class="figure" id="CD009151-fig-0005"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 5</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 Drug treatment versus placebo/no treatment (excluding partner treatment) (Comparison 1), outcome: 1.2 Clinical recurrence at 12 months (6 months active, 6 months observation)." data-id="CD009151-fig-0005" src="/cdsr/doi/10.1002/14651858.CD009151.pub2/media/CDSR/CD009151/image_n/nCD009151-FIG-05.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 Drug treatment versus placebo/no treatment (excluding partner treatment) (Comparison 1), outcome: 1.2 Clinical recurrence at 12 months (6 months active, 6 months observation). </p> </div> </div> </div> <p>We downgraded the certainty of the evidence by two levels to low due to very serious risk of bias (blinding of participants and assessors (<a href="./references#CD009151-bbs2-0022" title="SpinilloA , ColonnaL , PiazziG , BaltaroF , MonacoA , FerrariA .Managing recurrent vulvovaginal candidiasis. Intermittent prevention with itraconazole. Journal of Reproductive Medicine1997;42:83-7. ">Spinillo 1997</a>), incomplete outcome data (<a href="./references#CD009151-bbs2-0001" title="BolouriF , TabriziNM , TanhaFD , NiroomandN , AzmoodehA , EmamiS , et al.Effectiveness of fluconazole for suppressive maintenance therapy in patients with RVVC: a randomized placebo-controlled study. Iranian Journal of Pharmaceutical Research2009;8:307-13. ">Bolouri 2009</a>; <a href="./references#CD009151-bbs2-0018" title="SobelJD .Recurrent vulvovaginal candidiasis. A prospective study of the efficacy of maintenance ketoconazole therapy. New England Journal of Medicine1986;315:1455-8. ">Sobel 1986</a>), and pharmaceutical funding (<a href="./references#CD009151-bbs2-0020" title="SobelJD , WiesenfeldHC , MartensM , DannaP , HootonTM , RompaloA , et al.Maintenance fluconazole therapy for recurrent vulvovaginal candidiasis. New England Journal of Medicine2004;351:876-83. ">Sobel 2004</a>)). </p> <p>For studies examining fluconazole (<a href="./references#CD009151-bbs2-0001" title="BolouriF , TabriziNM , TanhaFD , NiroomandN , AzmoodehA , EmamiS , et al.Effectiveness of fluconazole for suppressive maintenance therapy in patients with RVVC: a randomized placebo-controlled study. Iranian Journal of Pharmaceutical Research2009;8:307-13. ">Bolouri 2009</a>; <a href="./references#CD009151-bbs2-0020" title="SobelJD , WiesenfeldHC , MartensM , DannaP , HootonTM , RompaloA , et al.Maintenance fluconazole therapy for recurrent vulvovaginal candidiasis. New England Journal of Medicine2004;351:876-83. ">Sobel 2004</a>), when pooled, results show that fluconazole may reduce clinical recurrence at 12 months (RR 0.76, 95% CI 0.66 to 0.89; participants = 327; studies = 2; I<sup>2</sup> = 26%; fixed‐effect; low certainty evidence). The number needed to treat to prevent one participant having one or more clinical recurrence at 12 months was 6. When regarding the missing data as treatment failures, the findings remained in the same (RR 0.87, 95% CI 0.79 to 0.95; fixed‐effect; I<sup>2</sup> = 0%; NNTB = 9). However, our confidence in these findings is low. </p> <p>We downgraded the certainty of the evidence by two levels to low due to very serious risk of bias (incomplete outcome data in <a href="./references#CD009151-bbs2-0001" title="BolouriF , TabriziNM , TanhaFD , NiroomandN , AzmoodehA , EmamiS , et al.Effectiveness of fluconazole for suppressive maintenance therapy in patients with RVVC: a randomized placebo-controlled study. Iranian Journal of Pharmaceutical Research2009;8:307-13. ">Bolouri 2009</a> and pharmaceutical funding in <a href="./references#CD009151-bbs2-0020" title="SobelJD , WiesenfeldHC , MartensM , DannaP , HootonTM , RompaloA , et al.Maintenance fluconazole therapy for recurrent vulvovaginal candidiasis. New England Journal of Medicine2004;351:876-83. ">Sobel 2004</a>). </p> </section> <section id="CD009151-sec-0077"> <p><b>Topical treatments</b></p> <p>Two studies assessed topical treatment (<a href="./references#CD009151-bbs2-0019" title="SobelJD , SchmittC , MeriwetherC .Clotrimazole treatment of recurrent and chronic candida vulvovaginitis. Obstetrics &amp; Gynecology1989;73:330-4. ">Sobel 1989</a> ; <a href="./references#CD009151-bbs2-0016" title="RothAC , MilsomI , ForssmanL , WahlenP .Intermittent prophylactic treatment of recurrent vaginal candidiasis by postmenstrual application of a 500 mg clotrimazole vaginal tablet. Genitourinary Medicine1990;66:357-60. ">Roth 1990</a>). When they were pooled the results show that topical treatment with clotrimazole may have effect to no effect on clinical recurrence at 12 months (RR 0.93, 95% CI 0.77 to 1.13; participants = 89; studies = 2; I<sup>2</sup> = 0%; fixed‐effect; very low certainty evidence; <a href="./references#CD009151-fig-0009" title="">Analysis 1.2</a>). However, our confidence in these findings is very low. </p> <p>We downgraded the certainty of the evidence by three levels to very low due to very serious risk of bias (incomplete outcome data in <a href="./references#CD009151-bbs2-0019" title="SobelJD , SchmittC , MeriwetherC .Clotrimazole treatment of recurrent and chronic candida vulvovaginitis. Obstetrics &amp; Gynecology1989;73:330-4. ">Sobel 1989</a>) and imprecision (data came from only two studies). </p> </section> <section id="CD009151-sec-0078"> <p><b>Oral and topical treatments combined</b></p> <p>When topical and oral treatment studies are considered together results show oral/topical treatments may reduce clinical recurrence at 12 months (RR 0.80, 95% CI 0.72 to 0.89; participants = 585; studies = 6; I<sup>2</sup> = 21%, fixed‐effect; NNTB = 6; low certainty evidence; <a href="./references#CD009151-fig-0009" title="">Analysis 1.2</a>). The incidence was 62% (188/302) in the treatment group compared to 78% (221/283) in the placebo/no treatment group. The number needed to treat to prevent one participant having one or more clinical recurrence at 12 months was 6 (NNTB = 6). When regarding the missing data as treatment failures the findings remained similar (RR 0.87, 95% CI 0.80 to 0.93; fixed‐effect; I<sup>2</sup> = 0%; NNTB = 8.5). However, our confidence in these findings is low. </p> <p>We downgraded the certainty of the evidence by two levels to low due to very serious risk of bias in several studies (blinding of participants and assessors (<a href="./references#CD009151-bbs2-0022" title="SpinilloA , ColonnaL , PiazziG , BaltaroF , MonacoA , FerrariA .Managing recurrent vulvovaginal candidiasis. Intermittent prevention with itraconazole. Journal of Reproductive Medicine1997;42:83-7. ">Spinillo 1997</a>), incomplete outcome data (<a href="./references#CD009151-bbs2-0001" title="BolouriF , TabriziNM , TanhaFD , NiroomandN , AzmoodehA , EmamiS , et al.Effectiveness of fluconazole for suppressive maintenance therapy in patients with RVVC: a randomized placebo-controlled study. Iranian Journal of Pharmaceutical Research2009;8:307-13. ">Bolouri 2009</a>; <a href="./references#CD009151-bbs2-0018" title="SobelJD .Recurrent vulvovaginal candidiasis. A prospective study of the efficacy of maintenance ketoconazole therapy. New England Journal of Medicine1986;315:1455-8. ">Sobel 1986</a>; <a href="./references#CD009151-bbs2-0019" title="SobelJD , SchmittC , MeriwetherC .Clotrimazole treatment of recurrent and chronic candida vulvovaginitis. Obstetrics &amp; Gynecology1989;73:330-4. ">Sobel 1989</a>), and pharmaceutical funding (<a href="./references#CD009151-bbs2-0020" title="SobelJD , WiesenfeldHC , MartensM , DannaP , HootonTM , RompaloA , et al.Maintenance fluconazole therapy for recurrent vulvovaginal candidiasis. New England Journal of Medicine2004;351:876-83. ">Sobel 2004</a>)). </p> </section> </section> <section id="CD009151-sec-0079"> <h6 class="title">3. Adverse events</h6> <p>Of the six studies reporting this comparison (<a href="./references#CD009151-bbs2-0001" title="BolouriF , TabriziNM , TanhaFD , NiroomandN , AzmoodehA , EmamiS , et al.Effectiveness of fluconazole for suppressive maintenance therapy in patients with RVVC: a randomized placebo-controlled study. Iranian Journal of Pharmaceutical Research2009;8:307-13. ">Bolouri 2009</a>; <a href="./references#CD009151-bbs2-0016" title="RothAC , MilsomI , ForssmanL , WahlenP .Intermittent prophylactic treatment of recurrent vaginal candidiasis by postmenstrual application of a 500 mg clotrimazole vaginal tablet. Genitourinary Medicine1990;66:357-60. ">Roth 1990</a>; <a href="./references#CD009151-bbs2-0018" title="SobelJD .Recurrent vulvovaginal candidiasis. A prospective study of the efficacy of maintenance ketoconazole therapy. New England Journal of Medicine1986;315:1455-8. ">Sobel 1986</a>; <a href="./references#CD009151-bbs2-0019" title="SobelJD , SchmittC , MeriwetherC .Clotrimazole treatment of recurrent and chronic candida vulvovaginitis. Obstetrics &amp; Gynecology1989;73:330-4. ">Sobel 1989</a>; <a href="./references#CD009151-bbs2-0020" title="SobelJD , WiesenfeldHC , MartensM , DannaP , HootonTM , RompaloA , et al.Maintenance fluconazole therapy for recurrent vulvovaginal candidiasis. New England Journal of Medicine2004;351:876-83. ">Sobel 2004</a>; <a href="./references#CD009151-bbs2-0022" title="SpinilloA , ColonnaL , PiazziG , BaltaroF , MonacoA , FerrariA .Managing recurrent vulvovaginal candidiasis. Intermittent prevention with itraconazole. Journal of Reproductive Medicine1997;42:83-7. ">Spinillo 1997</a>), only <a href="./references#CD009151-bbs2-0022" title="SpinilloA , ColonnaL , PiazziG , BaltaroF , MonacoA , FerrariA .Managing recurrent vulvovaginal candidiasis. Intermittent prevention with itraconazole. Journal of Reproductive Medicine1997;42:83-7. ">Spinillo 1997</a> did not present any information regarding adverse events. Overall, the adverse event rate was low for both placebo and treatment arms in these trials. It was not possible to pool data for this outcome due to the variability in the way the outcome was reported. We downgraded the certainty of the evidence for this outcome (adverse events) by three levels to very low due to very serious risk of bias in multiple domains for the included studies, in particular relating to selective reporting and incomplete outcome data, and imprecision (we were not able to pool results). </p> <p>Regarding clotrimazole, no cessation of therapy occurred due to adverse effects (<a href="./references#CD009151-bbs2-0016" title="RothAC , MilsomI , ForssmanL , WahlenP .Intermittent prophylactic treatment of recurrent vaginal candidiasis by postmenstrual application of a 500 mg clotrimazole vaginal tablet. Genitourinary Medicine1990;66:357-60. ">Roth 1990</a>; <a href="./references#CD009151-bbs2-0019" title="SobelJD , SchmittC , MeriwetherC .Clotrimazole treatment of recurrent and chronic candida vulvovaginitis. Obstetrics &amp; Gynecology1989;73:330-4. ">Sobel 1989</a>). More specifically, in <a href="./references#CD009151-bbs2-0016" title="RothAC , MilsomI , ForssmanL , WahlenP .Intermittent prophylactic treatment of recurrent vaginal candidiasis by postmenstrual application of a 500 mg clotrimazole vaginal tablet. Genitourinary Medicine1990;66:357-60. ">Roth 1990</a> no side effects or complications resulted from prophylactic treatment with either clotrimazole vaginal tablets or placebo vaginal tablets were reported. Regarding fluconazole, <a href="./references#CD009151-bbs2-0020" title="SobelJD , WiesenfeldHC , MartensM , DannaP , HootonTM , RompaloA , et al.Maintenance fluconazole therapy for recurrent vulvovaginal candidiasis. New England Journal of Medicine2004;351:876-83. ">Sobel 2004</a> reported adverse reactions resulting in discontinuation as 2.9% in the fluconazole group and 1.2% in the placebo group, whilst no cessation of therapy occurred due to side effects in the other study of this drug (<a href="./references#CD009151-bbs2-0001" title="BolouriF , TabriziNM , TanhaFD , NiroomandN , AzmoodehA , EmamiS , et al.Effectiveness of fluconazole for suppressive maintenance therapy in patients with RVVC: a randomized placebo-controlled study. Iranian Journal of Pharmaceutical Research2009;8:307-13. ">Bolouri 2009</a>). In <a href="./references#CD009151-bbs2-0020" title="SobelJD , WiesenfeldHC , MartensM , DannaP , HootonTM , RompaloA , et al.Maintenance fluconazole therapy for recurrent vulvovaginal candidiasis. New England Journal of Medicine2004;351:876-83. ">Sobel 2004</a> the main reported adverse events were: abdominal pain (22), nausea/vomiting (17), diarrhoea (15), flatulence (4), headache/migraine (56), central nervous system disorder (27), musculoskeletal disorder (29), rash (12), allergic reaction (9), menstrual disorder (3), alopecia (1). In the study of itraconazole (<a href="./references#CD009151-bbs2-0018" title="SobelJD .Recurrent vulvovaginal candidiasis. A prospective study of the efficacy of maintenance ketoconazole therapy. New England Journal of Medicine1986;315:1455-8. ">Sobel 1986</a>), two women dropped out due to adverse events (1 due to a rash and 1 due to nausea); however, it was not stated if these dropouts occurred in the treatment or placebo group. <a href="./references#CD009151-bbs2-0018" title="SobelJD .Recurrent vulvovaginal candidiasis. A prospective study of the efficacy of maintenance ketoconazole therapy. New England Journal of Medicine1986;315:1455-8. ">Sobel 1986</a> reports the following adverse effects: mild to moderate nausea (7/63), headache (2/63), mild transient rise in serum aspartate aminotransferase level (3/63). </p> </section> </section> <section id="CD009151-sec-0080"> <h5 class="title">Secondary outcomes</h5> <section id="CD009151-sec-0081"> <h6 class="title">1. Time to first recurrence</h6> <p>Two studies reported time to first recurrence for this comparison (<a href="./references#CD009151-bbs2-0018" title="SobelJD .Recurrent vulvovaginal candidiasis. A prospective study of the efficacy of maintenance ketoconazole therapy. New England Journal of Medicine1986;315:1455-8. ">Sobel 1986</a>; <a href="./references#CD009151-bbs2-0020" title="SobelJD , WiesenfeldHC , MartensM , DannaP , HootonTM , RompaloA , et al.Maintenance fluconazole therapy for recurrent vulvovaginal candidiasis. New England Journal of Medicine2004;351:876-83. ">Sobel 2004</a>). In the <a href="./references#CD009151-bbs2-0018" title="SobelJD .Recurrent vulvovaginal candidiasis. A prospective study of the efficacy of maintenance ketoconazole therapy. New England Journal of Medicine1986;315:1455-8. ">Sobel 1986</a> study, which examined the effect of ketoconazole versus placebo, the mean time to first recurrence in the perimenstrual treatment group was 3.6 months compared to 1.8 months for the placebo group. No data were presented for the mean time to recurrence in the continuous treatment group. In <a href="./references#CD009151-bbs2-0020" title="SobelJD , WiesenfeldHC , MartensM , DannaP , HootonTM , RompaloA , et al.Maintenance fluconazole therapy for recurrent vulvovaginal candidiasis. New England Journal of Medicine2004;351:876-83. ">Sobel 2004</a>, fluconazole also increased the time to first recurrence (P &lt; 0.001): the median time to first recurrence was 4.0 months in the placebo group compared to 10.2 months in the fluconazole group. Data for this outcome were limited and could not be pooled in a meta‐analysis. We downgraded the certainty of the evidence for this outcome by two levels to very low due to very serious risk of bias (incomplete outcome data in <a href="./references#CD009151-bbs2-0018" title="SobelJD .Recurrent vulvovaginal candidiasis. A prospective study of the efficacy of maintenance ketoconazole therapy. New England Journal of Medicine1986;315:1455-8. ">Sobel 1986</a> and pharmaceutical funding in <a href="./references#CD009151-bbs2-0020" title="SobelJD , WiesenfeldHC , MartensM , DannaP , HootonTM , RompaloA , et al.Maintenance fluconazole therapy for recurrent vulvovaginal candidiasis. New England Journal of Medicine2004;351:876-83. ">Sobel 2004</a>) and imprecision. </p> </section> <section id="CD009151-sec-0082"> <h6 class="title">2. Number of symptomatic days per year</h6> <p>None of the six studies in this comparison reported this outcome (<a href="./references#CD009151-bbs2-0001" title="BolouriF , TabriziNM , TanhaFD , NiroomandN , AzmoodehA , EmamiS , et al.Effectiveness of fluconazole for suppressive maintenance therapy in patients with RVVC: a randomized placebo-controlled study. Iranian Journal of Pharmaceutical Research2009;8:307-13. ">Bolouri 2009</a>; <a href="./references#CD009151-bbs2-0016" title="RothAC , MilsomI , ForssmanL , WahlenP .Intermittent prophylactic treatment of recurrent vaginal candidiasis by postmenstrual application of a 500 mg clotrimazole vaginal tablet. Genitourinary Medicine1990;66:357-60. ">Roth 1990</a>; <a href="./references#CD009151-bbs2-0018" title="SobelJD .Recurrent vulvovaginal candidiasis. A prospective study of the efficacy of maintenance ketoconazole therapy. New England Journal of Medicine1986;315:1455-8. ">Sobel 1986</a>; <a href="./references#CD009151-bbs2-0019" title="SobelJD , SchmittC , MeriwetherC .Clotrimazole treatment of recurrent and chronic candida vulvovaginitis. Obstetrics &amp; Gynecology1989;73:330-4. ">Sobel 1989</a>; <a href="./references#CD009151-bbs2-0020" title="SobelJD , WiesenfeldHC , MartensM , DannaP , HootonTM , RompaloA , et al.Maintenance fluconazole therapy for recurrent vulvovaginal candidiasis. New England Journal of Medicine2004;351:876-83. ">Sobel 2004</a>; <a href="./references#CD009151-bbs2-0022" title="SpinilloA , ColonnaL , PiazziG , BaltaroF , MonacoA , FerrariA .Managing recurrent vulvovaginal candidiasis. Intermittent prevention with itraconazole. Journal of Reproductive Medicine1997;42:83-7. ">Spinillo 1997</a>). </p> </section> <section id="CD009151-sec-0083"> <h6 class="title">3. Number of mycological recurrences per participant per year</h6> <p>None of the six studies in this comparison reported this outcome (<a href="./references#CD009151-bbs2-0001" title="BolouriF , TabriziNM , TanhaFD , NiroomandN , AzmoodehA , EmamiS , et al.Effectiveness of fluconazole for suppressive maintenance therapy in patients with RVVC: a randomized placebo-controlled study. Iranian Journal of Pharmaceutical Research2009;8:307-13. ">Bolouri 2009</a>; <a href="./references#CD009151-bbs2-0016" title="RothAC , MilsomI , ForssmanL , WahlenP .Intermittent prophylactic treatment of recurrent vaginal candidiasis by postmenstrual application of a 500 mg clotrimazole vaginal tablet. Genitourinary Medicine1990;66:357-60. ">Roth 1990</a>; <a href="./references#CD009151-bbs2-0018" title="SobelJD .Recurrent vulvovaginal candidiasis. A prospective study of the efficacy of maintenance ketoconazole therapy. New England Journal of Medicine1986;315:1455-8. ">Sobel 1986</a>; <a href="./references#CD009151-bbs2-0019" title="SobelJD , SchmittC , MeriwetherC .Clotrimazole treatment of recurrent and chronic candida vulvovaginitis. Obstetrics &amp; Gynecology1989;73:330-4. ">Sobel 1989</a>; <a href="./references#CD009151-bbs2-0020" title="SobelJD , WiesenfeldHC , MartensM , DannaP , HootonTM , RompaloA , et al.Maintenance fluconazole therapy for recurrent vulvovaginal candidiasis. New England Journal of Medicine2004;351:876-83. ">Sobel 2004</a>; <a href="./references#CD009151-bbs2-0022" title="SpinilloA , ColonnaL , PiazziG , BaltaroF , MonacoA , FerrariA .Managing recurrent vulvovaginal candidiasis. Intermittent prevention with itraconazole. Journal of Reproductive Medicine1997;42:83-7. ">Spinillo 1997</a>). </p> </section> <section id="CD009151-sec-0084"> <h6 class="title">4. Proportion of participants with at least one mycological recurrence during the treatment and follow‐up period </h6> <p>Mycological recurrence at 6 months</p> <section id="CD009151-sec-0085"> <p><b>Oral treatments</b></p> <p>At six months, all four trials comparing oral treatments to placebo/no treatment drugs demonstrated a reduction in mycological recurrence (<a href="./references#CD009151-bbs2-0001" title="BolouriF , TabriziNM , TanhaFD , NiroomandN , AzmoodehA , EmamiS , et al.Effectiveness of fluconazole for suppressive maintenance therapy in patients with RVVC: a randomized placebo-controlled study. Iranian Journal of Pharmaceutical Research2009;8:307-13. ">Bolouri 2009</a>; <a href="./references#CD009151-bbs2-0018" title="SobelJD .Recurrent vulvovaginal candidiasis. A prospective study of the efficacy of maintenance ketoconazole therapy. New England Journal of Medicine1986;315:1455-8. ">Sobel 1986</a>; <a href="./references#CD009151-bbs2-0020" title="SobelJD , WiesenfeldHC , MartensM , DannaP , HootonTM , RompaloA , et al.Maintenance fluconazole therapy for recurrent vulvovaginal candidiasis. New England Journal of Medicine2004;351:876-83. ">Sobel 2004</a>; <a href="./references#CD009151-bbs2-0022" title="SpinilloA , ColonnaL , PiazziG , BaltaroF , MonacoA , FerrariA .Managing recurrent vulvovaginal candidiasis. Intermittent prevention with itraconazole. Journal of Reproductive Medicine1997;42:83-7. ">Spinillo 1997</a>). When pooled, the two studies of fluconazole showed fluconazole may reduce mycological recurrence at 6 months (<a href="./references#CD009151-bbs2-0001" title="BolouriF , TabriziNM , TanhaFD , NiroomandN , AzmoodehA , EmamiS , et al.Effectiveness of fluconazole for suppressive maintenance therapy in patients with RVVC: a randomized placebo-controlled study. Iranian Journal of Pharmaceutical Research2009;8:307-13. ">Bolouri 2009</a>; <a href="./references#CD009151-bbs2-0020" title="SobelJD , WiesenfeldHC , MartensM , DannaP , HootonTM , RompaloA , et al.Maintenance fluconazole therapy for recurrent vulvovaginal candidiasis. New England Journal of Medicine2004;351:876-83. ">Sobel 2004</a>) (RR 0.27, 95% CI 0.20 to 0.38; two studies, participants = 335; I<sup>2</sup> = 35%; fixed‐effect; NNTB = 2; low certainty evidence). The incidence was 19% (33/172) in the treatment group compared to 70% (114/163) in the placebo group. However, our confidence in these findings is low. </p> <p>When results were pooled for all oral treatments (fluconazole, itraconazole, ketoconazole), results show that oral treatments may reduce microbiological recurrence at 6 months (RR 0.37, 95% CI 0.22 to 0.63; participants = 506; studies = 4; I<sup>2</sup> = 78%; random‐effects; low certainty evidence; <a href="./references#CD009151-fig-0010" title="">Analysis 1.3</a> ). However, our confidence in these findings is low. There was an incidence of 38% (65/269) in the treatment group compared to 69% (164/237) in the placebo/no treatment group. We performed a sensitivity analysis to assess the impact of heterogeneity on the pooled result by removing <a href="./references#CD009151-bbs2-0022" title="SpinilloA , ColonnaL , PiazziG , BaltaroF , MonacoA , FerrariA .Managing recurrent vulvovaginal candidiasis. Intermittent prevention with itraconazole. Journal of Reproductive Medicine1997;42:83-7. ">Spinillo 1997</a>, the only study with a no treatment control rather than a placebo. This reduced the I<sup>2</sup> to 0% with no impact on the direction of effect and no meaningful change to the magnitude of effect (RR 0.40, 95% CI 0.18 to 0.88; heterogeneity: Tau<sup>2</sup> = 0.00; Chi<sup>2</sup> = 1.57, df = 2 (P = 0.46); I<sup>2</sup> = 0%). </p> <p>We downgraded the certainty of the evidence by two levels to low due to very serious risk of bias (blinding of participants and assessors (<a href="./references#CD009151-bbs2-0022" title="SpinilloA , ColonnaL , PiazziG , BaltaroF , MonacoA , FerrariA .Managing recurrent vulvovaginal candidiasis. Intermittent prevention with itraconazole. Journal of Reproductive Medicine1997;42:83-7. ">Spinillo 1997</a>), incomplete outcome data (<a href="./references#CD009151-bbs2-0001" title="BolouriF , TabriziNM , TanhaFD , NiroomandN , AzmoodehA , EmamiS , et al.Effectiveness of fluconazole for suppressive maintenance therapy in patients with RVVC: a randomized placebo-controlled study. Iranian Journal of Pharmaceutical Research2009;8:307-13. ">Bolouri 2009</a>; <a href="./references#CD009151-bbs2-0018" title="SobelJD .Recurrent vulvovaginal candidiasis. A prospective study of the efficacy of maintenance ketoconazole therapy. New England Journal of Medicine1986;315:1455-8. ">Sobel 1986</a>), and pharmaceutical funding (<a href="./references#CD009151-bbs2-0020" title="SobelJD , WiesenfeldHC , MartensM , DannaP , HootonTM , RompaloA , et al.Maintenance fluconazole therapy for recurrent vulvovaginal candidiasis. New England Journal of Medicine2004;351:876-83. ">Sobel 2004</a>)). </p> </section> <section id="CD009151-sec-0086"> <p><b>Topical treatments</b></p> <p>Of the two studies examining clotrimazole versus placebo, only <a href="./references#CD009151-bbs2-0016" title="RothAC , MilsomI , ForssmanL , WahlenP .Intermittent prophylactic treatment of recurrent vaginal candidiasis by postmenstrual application of a 500 mg clotrimazole vaginal tablet. Genitourinary Medicine1990;66:357-60. ">Roth 1990</a> presented information for this outcome. In this publication, the difference between the treatment and placebo arms for mycological recurrence was not significant at six months. We downgraded the certainty of the evidence by two levels to low due to serious risk of bias (unclear reporting of randomisation and allocation concealment) and imprecision (data came from only one study). </p> </section> <section id="CD009151-sec-0087"> <p><b>Oral and topical treatments combined</b></p> <p>Five studies presented findings for this outcome at six months (<a href="./references#CD009151-bbs2-0001" title="BolouriF , TabriziNM , TanhaFD , NiroomandN , AzmoodehA , EmamiS , et al.Effectiveness of fluconazole for suppressive maintenance therapy in patients with RVVC: a randomized placebo-controlled study. Iranian Journal of Pharmaceutical Research2009;8:307-13. ">Bolouri 2009</a>; <a href="./references#CD009151-bbs2-0016" title="RothAC , MilsomI , ForssmanL , WahlenP .Intermittent prophylactic treatment of recurrent vaginal candidiasis by postmenstrual application of a 500 mg clotrimazole vaginal tablet. Genitourinary Medicine1990;66:357-60. ">Roth 1990</a>; <a href="./references#CD009151-bbs2-0018" title="SobelJD .Recurrent vulvovaginal candidiasis. A prospective study of the efficacy of maintenance ketoconazole therapy. New England Journal of Medicine1986;315:1455-8. ">Sobel 1986</a>; <a href="./references#CD009151-bbs2-0020" title="SobelJD , WiesenfeldHC , MartensM , DannaP , HootonTM , RompaloA , et al.Maintenance fluconazole therapy for recurrent vulvovaginal candidiasis. New England Journal of Medicine2004;351:876-83. ">Sobel 2004</a>; <a href="./references#CD009151-bbs2-0022" title="SpinilloA , ColonnaL , PiazziG , BaltaroF , MonacoA , FerrariA .Managing recurrent vulvovaginal candidiasis. Intermittent prevention with itraconazole. Journal of Reproductive Medicine1997;42:83-7. ">Spinillo 1997</a>). When all drug treatments versus placebo/no treatment were considered, the pooled analysis demonstrated that oral/topical treatments may reduce mycological recurrence at 6 months. There was an incidence of 29% (88/302) in the treatment group compared to 71% (189/266) in the placebo/no treatment group (RR 0.44, 95% CI 0.25 to 0.78; participants = 568; studies = 5; I<sup>2</sup> = 89%; random‐effects; NNTB = 3; low certainty evidence; <a href="./references#CD009151-fig-0010" title="">Analysis 1.3</a>). However, our confidence in these findings is low. </p> <p>We downgraded the certainty of the evidence by two levels to low due to very serious risk of bias (blinding of participants and assessors (<a href="./references#CD009151-bbs2-0022" title="SpinilloA , ColonnaL , PiazziG , BaltaroF , MonacoA , FerrariA .Managing recurrent vulvovaginal candidiasis. Intermittent prevention with itraconazole. Journal of Reproductive Medicine1997;42:83-7. ">Spinillo 1997</a>), incomplete outcome data (<a href="./references#CD009151-bbs2-0001" title="BolouriF , TabriziNM , TanhaFD , NiroomandN , AzmoodehA , EmamiS , et al.Effectiveness of fluconazole for suppressive maintenance therapy in patients with RVVC: a randomized placebo-controlled study. Iranian Journal of Pharmaceutical Research2009;8:307-13. ">Bolouri 2009</a>; <a href="./references#CD009151-bbs2-0018" title="SobelJD .Recurrent vulvovaginal candidiasis. A prospective study of the efficacy of maintenance ketoconazole therapy. New England Journal of Medicine1986;315:1455-8. ">Sobel 1986</a>), and pharmaceutical funding (<a href="./references#CD009151-bbs2-0020" title="SobelJD , WiesenfeldHC , MartensM , DannaP , HootonTM , RompaloA , et al.Maintenance fluconazole therapy for recurrent vulvovaginal candidiasis. New England Journal of Medicine2004;351:876-83. ">Sobel 2004</a>)). </p> </section> </section> <section id="CD009151-sec-0088"> <h6 class="title">Mycological recurrence at 12 months</h6> <section id="CD009151-sec-0089"> <p><b>Oral treatments</b></p> <p>Two trials with oral active drugs presented findings for this outcome at 12 months (6 months active treatment, 6‐month surveillance period) (<a href="./references#CD009151-bbs2-0001" title="BolouriF , TabriziNM , TanhaFD , NiroomandN , AzmoodehA , EmamiS , et al.Effectiveness of fluconazole for suppressive maintenance therapy in patients with RVVC: a randomized placebo-controlled study. Iranian Journal of Pharmaceutical Research2009;8:307-13. ">Bolouri 2009</a>; <a href="./references#CD009151-bbs2-0018" title="SobelJD .Recurrent vulvovaginal candidiasis. A prospective study of the efficacy of maintenance ketoconazole therapy. New England Journal of Medicine1986;315:1455-8. ">Sobel 1986</a>). When the results were pooled oral treatments may have no effect on mycological recurrence at 12 months (RR 0.86, 95% CI 0.71 to 1.04; participants = 127; studies = 2; I<sup>2</sup> = 0%; fixed‐effect; very low certainty evidence; <a href="./references#CD009151-fig-0011" title="">Analysis 1.4</a>). The incidence of mycological recurrence was 69% (51/74) in the treatment group compared to 83% (44/53) in the placebo group. However, our confidence in these findings is very low. </p> <p>We downgraded the certainty of the evidence by three levels to very low due to very serious risk of bias (incomplete outcome data (<a href="./references#CD009151-bbs2-0001" title="BolouriF , TabriziNM , TanhaFD , NiroomandN , AzmoodehA , EmamiS , et al.Effectiveness of fluconazole for suppressive maintenance therapy in patients with RVVC: a randomized placebo-controlled study. Iranian Journal of Pharmaceutical Research2009;8:307-13. ">Bolouri 2009</a>; <a href="./references#CD009151-bbs2-0018" title="SobelJD .Recurrent vulvovaginal candidiasis. A prospective study of the efficacy of maintenance ketoconazole therapy. New England Journal of Medicine1986;315:1455-8. ">Sobel 1986</a>)) and imprecision (based on only two studies). </p> </section> <section id="CD009151-sec-0090"> <p><b>Topical treatments</b></p> <p>Of the two studies examining clotrimazole versus placebo, only <a href="./references#CD009151-bbs2-0016" title="RothAC , MilsomI , ForssmanL , WahlenP .Intermittent prophylactic treatment of recurrent vaginal candidiasis by postmenstrual application of a 500 mg clotrimazole vaginal tablet. Genitourinary Medicine1990;66:357-60. ">Roth 1990</a> presented information for this outcome. In this publication, the difference between the treatment and placebo arms for mycological recurrence was not significant at 12 months. We downgraded the certainty of the evidence by two levels to low due to serious risk of bias (unclear reporting of randomisation and allocation concealment) and imprecision (data came from only one study). </p> </section> <section id="CD009151-sec-0091"> <p><b>Oral and topical treatments combined</b></p> <p>Only three studies presented data for this outcome at 12 months (<a href="./references#CD009151-bbs2-0001" title="BolouriF , TabriziNM , TanhaFD , NiroomandN , AzmoodehA , EmamiS , et al.Effectiveness of fluconazole for suppressive maintenance therapy in patients with RVVC: a randomized placebo-controlled study. Iranian Journal of Pharmaceutical Research2009;8:307-13. ">Bolouri 2009</a>; <a href="./references#CD009151-bbs2-0016" title="RothAC , MilsomI , ForssmanL , WahlenP .Intermittent prophylactic treatment of recurrent vaginal candidiasis by postmenstrual application of a 500 mg clotrimazole vaginal tablet. Genitourinary Medicine1990;66:357-60. ">Roth 1990</a>; <a href="./references#CD009151-bbs2-0018" title="SobelJD .Recurrent vulvovaginal candidiasis. A prospective study of the efficacy of maintenance ketoconazole therapy. New England Journal of Medicine1986;315:1455-8. ">Sobel 1986</a>). When pooled oral/topical treatments may not have an effect on mycological recurrence at 12 months (RR 0.90, 95% CI 0.79 to 1.03; participants = 189; studies = 3; I<sup>2</sup> = 0%; fixed‐effect; low certainty evidence; <a href="./references#CD009151-fig-0011" title="">Analysis 1.4</a>). However, our confidence in these findings is low. </p> <p>We downgraded the certainty of the evidence by two levels to low due to very serious risk of bias (incomplete outcome data (<a href="./references#CD009151-bbs2-0001" title="BolouriF , TabriziNM , TanhaFD , NiroomandN , AzmoodehA , EmamiS , et al.Effectiveness of fluconazole for suppressive maintenance therapy in patients with RVVC: a randomized placebo-controlled study. Iranian Journal of Pharmaceutical Research2009;8:307-13. ">Bolouri 2009</a>; <a href="./references#CD009151-bbs2-0018" title="SobelJD .Recurrent vulvovaginal candidiasis. A prospective study of the efficacy of maintenance ketoconazole therapy. New England Journal of Medicine1986;315:1455-8. ">Sobel 1986</a>)). </p> </section> </section> <section id="CD009151-sec-0092"> <h6 class="title">5. Duration of symptoms after treatment initiation</h6> <p>None of the six studies in this comparison reported this outcome (<a href="./references#CD009151-bbs2-0001" title="BolouriF , TabriziNM , TanhaFD , NiroomandN , AzmoodehA , EmamiS , et al.Effectiveness of fluconazole for suppressive maintenance therapy in patients with RVVC: a randomized placebo-controlled study. Iranian Journal of Pharmaceutical Research2009;8:307-13. ">Bolouri 2009</a>; <a href="./references#CD009151-bbs2-0016" title="RothAC , MilsomI , ForssmanL , WahlenP .Intermittent prophylactic treatment of recurrent vaginal candidiasis by postmenstrual application of a 500 mg clotrimazole vaginal tablet. Genitourinary Medicine1990;66:357-60. ">Roth 1990</a>; <a href="./references#CD009151-bbs2-0018" title="SobelJD .Recurrent vulvovaginal candidiasis. A prospective study of the efficacy of maintenance ketoconazole therapy. New England Journal of Medicine1986;315:1455-8. ">Sobel 1986</a>; <a href="./references#CD009151-bbs2-0019" title="SobelJD , SchmittC , MeriwetherC .Clotrimazole treatment of recurrent and chronic candida vulvovaginitis. Obstetrics &amp; Gynecology1989;73:330-4. ">Sobel 1989</a>; <a href="./references#CD009151-bbs2-0020" title="SobelJD , WiesenfeldHC , MartensM , DannaP , HootonTM , RompaloA , et al.Maintenance fluconazole therapy for recurrent vulvovaginal candidiasis. New England Journal of Medicine2004;351:876-83. ">Sobel 2004</a>; <a href="./references#CD009151-bbs2-0022" title="SpinilloA , ColonnaL , PiazziG , BaltaroF , MonacoA , FerrariA .Managing recurrent vulvovaginal candidiasis. Intermittent prevention with itraconazole. Journal of Reproductive Medicine1997;42:83-7. ">Spinillo 1997</a>). </p> </section> <section id="CD009151-sec-0093"> <h6 class="title">6. Patient preference</h6> <p>None of the six studies in this comparison reported this outcome (<a href="./references#CD009151-bbs2-0001" title="BolouriF , TabriziNM , TanhaFD , NiroomandN , AzmoodehA , EmamiS , et al.Effectiveness of fluconazole for suppressive maintenance therapy in patients with RVVC: a randomized placebo-controlled study. Iranian Journal of Pharmaceutical Research2009;8:307-13. ">Bolouri 2009</a>; <a href="./references#CD009151-bbs2-0016" title="RothAC , MilsomI , ForssmanL , WahlenP .Intermittent prophylactic treatment of recurrent vaginal candidiasis by postmenstrual application of a 500 mg clotrimazole vaginal tablet. Genitourinary Medicine1990;66:357-60. ">Roth 1990</a>; <a href="./references#CD009151-bbs2-0018" title="SobelJD .Recurrent vulvovaginal candidiasis. A prospective study of the efficacy of maintenance ketoconazole therapy. New England Journal of Medicine1986;315:1455-8. ">Sobel 1986</a>; <a href="./references#CD009151-bbs2-0019" title="SobelJD , SchmittC , MeriwetherC .Clotrimazole treatment of recurrent and chronic candida vulvovaginitis. Obstetrics &amp; Gynecology1989;73:330-4. ">Sobel 1989</a>; <a href="./references#CD009151-bbs2-0020" title="SobelJD , WiesenfeldHC , MartensM , DannaP , HootonTM , RompaloA , et al.Maintenance fluconazole therapy for recurrent vulvovaginal candidiasis. New England Journal of Medicine2004;351:876-83. ">Sobel 2004</a>; <a href="./references#CD009151-bbs2-0022" title="SpinilloA , ColonnaL , PiazziG , BaltaroF , MonacoA , FerrariA .Managing recurrent vulvovaginal candidiasis. Intermittent prevention with itraconazole. Journal of Reproductive Medicine1997;42:83-7. ">Spinillo 1997</a>). </p> </section> </section> </section> <section id="CD009151-sec-0094"> <h4 class="title">Comparison 2: Oral drug treatment versus topical drug treatment</h4> <p>See <a href="./full#CD009151-tbl-0002">summary of findings Table 2</a>. </p> <p>Four studies examined oral drug treatment versus topical drug treatment (<a href="./references#CD009151-bbs2-0006" title="FanS , LiuX , WuC , XuL , LiJ .Vaginal nystatin versus oral fluconazole for the treatment for recurrent vulvovaginal candidiasis. Mycopathologia2015;179:95-101. [DOI: https://doi.org/10.1007/s11046-014-9827-4]">Fan 2015</a>; <a href="./references#CD009151-bbs2-0007" title="FardyazarZ , HabibzadehS , Abdollahi-FardS , TelloM .Vaginal azoles versus oral fluconazole in treatment of recurrent vulvovaginal candidiasis. Iranian Journal of Clinical Infectious Diseases2007;2:17-22. FardyazarZ , HabibzadehS .Long term vaginal azoles versus prophylactic oral fluconazole in treatment of recurrent vulvovaginal candidiasis. Research Journal of Biological Sciences2007;2(6):663-6. ">Fardyazar 2007</a>; <a href="./references#CD009151-bbs2-0008" title="FongIW .The value of chronic suppressive therapy with itraconazole versus clotrimazole in women with recurrent vaginal candidiasis. Genitourinary Medicine1992;68:374-7. ">Fong 1992a</a>; <a href="./references#CD009151-bbs2-0013" title="Lopez-OlmosJ , LermaE .Treatment of recurring vulvo-vaginal candidiasis: a comparative prospective study during six months of three anti-mycotic preparations of a single dosis. Clinica e Investigacion en Ginecologia y Obstetricia2000;27:366-75. ">Lopez‐Olmos 2000</a>). <a href="./references#CD009151-bbs2-0006" title="FanS , LiuX , WuC , XuL , LiJ .Vaginal nystatin versus oral fluconazole for the treatment for recurrent vulvovaginal candidiasis. Mycopathologia2015;179:95-101. [DOI: https://doi.org/10.1007/s11046-014-9827-4]">Fan 2015</a> compared oral fluconazole to nystatin. <a href="./references#CD009151-bbs2-0007" title="FardyazarZ , HabibzadehS , Abdollahi-FardS , TelloM .Vaginal azoles versus oral fluconazole in treatment of recurrent vulvovaginal candidiasis. Iranian Journal of Clinical Infectious Diseases2007;2:17-22. FardyazarZ , HabibzadehS .Long term vaginal azoles versus prophylactic oral fluconazole in treatment of recurrent vulvovaginal candidiasis. Research Journal of Biological Sciences2007;2(6):663-6. ">Fardyazar 2007</a> compared oral fluconazole to clotrimazole. <a href="./references#CD009151-bbs2-0008" title="FongIW .The value of chronic suppressive therapy with itraconazole versus clotrimazole in women with recurrent vaginal candidiasis. Genitourinary Medicine1992;68:374-7. ">Fong 1992a</a> compared oral itraconazole to topical clotrimazole, and <a href="./references#CD009151-bbs2-0013" title="Lopez-OlmosJ , LermaE .Treatment of recurring vulvo-vaginal candidiasis: a comparative prospective study during six months of three anti-mycotic preparations of a single dosis. Clinica e Investigacion en Ginecologia y Obstetricia2000;27:366-75. ">Lopez‐Olmos 2000</a> compared oral fluconazole (19 participants) to both oral itraconazole (14 participants) and topical clotrimazole (12 participants). Each of these studies had a six‐month active‐treatment phase followed by a further six months of surveillance. The characteristics of studies against this comparison are summarised in a supplementary table (<a href="#CD009151-tbl-0004">Table 2</a>). </p> <div class="table" id="CD009151-tbl-0004"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Summary of characteristics of studies included in Comparison 2: Oral drug treatment versus topical drug treatment</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Study ID</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><a href="./references#CD009151-bbs2-0006" title="FanS , LiuX , WuC , XuL , LiJ .Vaginal nystatin versus oral fluconazole for the treatment for recurrent vulvovaginal candidiasis. Mycopathologia2015;179:95-101. [DOI: https://doi.org/10.1007/s11046-014-9827-4]"><b>Fan 2015</b> </a> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><a href="./references#CD009151-bbs2-0007" title="FardyazarZ , HabibzadehS , Abdollahi-FardS , TelloM .Vaginal azoles versus oral fluconazole in treatment of recurrent vulvovaginal candidiasis. Iranian Journal of Clinical Infectious Diseases2007;2:17-22. FardyazarZ , HabibzadehS .Long term vaginal azoles versus prophylactic oral fluconazole in treatment of recurrent vulvovaginal candidiasis. Research Journal of Biological Sciences2007;2(6):663-6. "><b>Fardyazar 2007</b> </a> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><a href="./references#CD009151-bbs2-0008" title="FongIW .The value of chronic suppressive therapy with itraconazole versus clotrimazole in women with recurrent vaginal candidiasis. Genitourinary Medicine1992;68:374-7. "><b>Fong 1992a</b> </a> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><a href="./references#CD009151-bbs2-0013" title="Lopez-OlmosJ , LermaE .Treatment of recurring vulvo-vaginal candidiasis: a comparative prospective study during six months of three anti-mycotic preparations of a single dosis. Clinica e Investigacion en Ginecologia y Obstetricia2000;27:366-75. "><b>Lopez‐Olmos 2000</b> </a> </p> </th> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Participants (n)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>330</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>124</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>44</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i><b>Candida albicans</b> </i><b>at enrolment (%)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>77.5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>98</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>27<sup>a</sup> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mean episodes in previous 12 months</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NS<sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NS<sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8.8 (itraconazole), 9.7 (clotrimazole)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NS<sup>b</sup> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Withdrawals/loss to follow‐up (%)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Setting</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Outpatient clinic</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Outpatient clinic</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hospital outpatient clinic</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Multicentre ‐ a gynaecology outpatient clinic and a family planning clinic</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Country</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>China</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Iran</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Canada</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Spain</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Intervention 1</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fluconazole (weekly)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fluconazole (weekly)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Itraconazole (twice weekly)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fluconazole (with menses)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Intervention 2</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Nystatin (with menses)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clotrimazole (twice weekly)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clotrimazole (twice weekly)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Itraconazole (with menses)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Intervention 3</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clotrimazole (with menses)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Duration of intervention</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 months</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Duration of observation after intervention</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 months</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Planned assessments</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Monthly for 6 months and at 9 months and 12 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Monthly for 12 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Monthly for 12 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>At 6 months and 12 months</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Assessment between planned visits if symptoms developed</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><sup>a</sup>Not all participants had positive cultures at enrolment; 12 (27%) participants had <i>C albicans</i> and 5 (11%) had <i>C glabrata.</i><br/><sup>b</sup>Not reported or unclear. </p> </div> </div> <section id="CD009151-sec-0095"> <h5 class="title">Primary outcomes</h5> <section id="CD009151-sec-0096"> <h6 class="title">1. Number of clinical recurrences per participant per year</h6> <p>None of the four studies in this comparison reported this outcome (<a href="./references#CD009151-bbs2-0006" title="FanS , LiuX , WuC , XuL , LiJ .Vaginal nystatin versus oral fluconazole for the treatment for recurrent vulvovaginal candidiasis. Mycopathologia2015;179:95-101. [DOI: https://doi.org/10.1007/s11046-014-9827-4]">Fan 2015</a>; <a href="./references#CD009151-bbs2-0007" title="FardyazarZ , HabibzadehS , Abdollahi-FardS , TelloM .Vaginal azoles versus oral fluconazole in treatment of recurrent vulvovaginal candidiasis. Iranian Journal of Clinical Infectious Diseases2007;2:17-22. FardyazarZ , HabibzadehS .Long term vaginal azoles versus prophylactic oral fluconazole in treatment of recurrent vulvovaginal candidiasis. Research Journal of Biological Sciences2007;2(6):663-6. ">Fardyazar 2007</a>; <a href="./references#CD009151-bbs2-0008" title="FongIW .The value of chronic suppressive therapy with itraconazole versus clotrimazole in women with recurrent vaginal candidiasis. Genitourinary Medicine1992;68:374-7. ">Fong 1992a</a>; <a href="./references#CD009151-bbs2-0013" title="Lopez-OlmosJ , LermaE .Treatment of recurring vulvo-vaginal candidiasis: a comparative prospective study during six months of three anti-mycotic preparations of a single dosis. Clinica e Investigacion en Ginecologia y Obstetricia2000;27:366-75. ">Lopez‐Olmos 2000</a>). </p> </section> <section id="CD009151-sec-0097"> <h6 class="title">Clinical recurrence at 6 months</h6> <p>At six months when all oral drug treatments versus topical treatment were considered, oral treatments may have little to no effect on clinical recurrence compared with topical treatments, but the evidence is very uncertain(RR 1.66, 95% CI 0.83 to 3.31; participants = 206; studies = 3; I<sup>2</sup> = 0%; fixed‐effect; very low certainty evidence; <a href="./references#CD009151-fig-0012" title="">Analysis 2.1</a>, <a href="#CD009151-fig-0006">Figure 6</a>). There was an incidence of 21% (24/113) in the oral treatments group compared to 12% (11/93) in the topical treatment group. However, our confidence in these findings is very low. </p> <div class="figure" id="CD009151-fig-0006"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 6</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 2 Oral drug treatment versus topical drug treatment (Comparison 2), outcome: 2.1 Clinical recurrence at 6 months." data-id="CD009151-fig-0006" src="/cdsr/doi/10.1002/14651858.CD009151.pub2/media/CDSR/CD009151/image_n/nCD009151-FIG-06.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 2 Oral drug treatment versus topical drug treatment (Comparison 2), outcome: 2.1 Clinical recurrence at 6 months. </p> </div> </div> </div> <p><a href="./references#CD009151-bbs2-0013" title="Lopez-OlmosJ , LermaE .Treatment of recurring vulvo-vaginal candidiasis: a comparative prospective study during six months of three anti-mycotic preparations of a single dosis. Clinica e Investigacion en Ginecologia y Obstetricia2000;27:366-75. ">Lopez‐Olmos 2000</a> had a high risk of selection bias as it appeared to have not used a random allocation method, therefore we conducted a sensitivity analysis of this effect estimate by removing <a href="./references#CD009151-bbs2-0013" title="Lopez-OlmosJ , LermaE .Treatment of recurring vulvo-vaginal candidiasis: a comparative prospective study during six months of three anti-mycotic preparations of a single dosis. Clinica e Investigacion en Ginecologia y Obstetricia2000;27:366-75. ">Lopez‐Olmos 2000</a> from the analysis. This did not alter the direction of effect or the conclusion (RR 1.31, 95% CI 0.63 to 2.75; participants = 161; studies 2; I<sup>2</sup> = 0%; fixed‐effect). </p> <p>We downgraded the certainty of the evidence by three levels to very low due to very serious risk of bias (allocation concealment (<a href="./references#CD009151-bbs2-0013" title="Lopez-OlmosJ , LermaE .Treatment of recurring vulvo-vaginal candidiasis: a comparative prospective study during six months of three anti-mycotic preparations of a single dosis. Clinica e Investigacion en Ginecologia y Obstetricia2000;27:366-75. ">Lopez‐Olmos 2000</a>), blinding of participants (<a href="./references#CD009151-bbs2-0007" title="FardyazarZ , HabibzadehS , Abdollahi-FardS , TelloM .Vaginal azoles versus oral fluconazole in treatment of recurrent vulvovaginal candidiasis. Iranian Journal of Clinical Infectious Diseases2007;2:17-22. FardyazarZ , HabibzadehS .Long term vaginal azoles versus prophylactic oral fluconazole in treatment of recurrent vulvovaginal candidiasis. Research Journal of Biological Sciences2007;2(6):663-6. ">Fardyazar 2007</a>; <a href="./references#CD009151-bbs2-0008" title="FongIW .The value of chronic suppressive therapy with itraconazole versus clotrimazole in women with recurrent vaginal candidiasis. Genitourinary Medicine1992;68:374-7. ">Fong 1992a</a>; <a href="./references#CD009151-bbs2-0013" title="Lopez-OlmosJ , LermaE .Treatment of recurring vulvo-vaginal candidiasis: a comparative prospective study during six months of three anti-mycotic preparations of a single dosis. Clinica e Investigacion en Ginecologia y Obstetricia2000;27:366-75. ">Lopez‐Olmos 2000</a>), blinding of assessment (<a href="./references#CD009151-bbs2-0008" title="FongIW .The value of chronic suppressive therapy with itraconazole versus clotrimazole in women with recurrent vaginal candidiasis. Genitourinary Medicine1992;68:374-7. ">Fong 1992a</a>), and pharmaceutical funding (<a href="./references#CD009151-bbs2-0007" title="FardyazarZ , HabibzadehS , Abdollahi-FardS , TelloM .Vaginal azoles versus oral fluconazole in treatment of recurrent vulvovaginal candidiasis. Iranian Journal of Clinical Infectious Diseases2007;2:17-22. FardyazarZ , HabibzadehS .Long term vaginal azoles versus prophylactic oral fluconazole in treatment of recurrent vulvovaginal candidiasis. Research Journal of Biological Sciences2007;2(6):663-6. ">Fardyazar 2007</a>) and imprecision. </p> </section> <section id="CD009151-sec-0098"> <h6 class="title">Clinical recurrence at 12 months</h6> <p>At 12 months, when all oral drug treatments versus topical treatment were considered, oral treatments may have little to no effect on clinical recurrence compared with topical treatments, but the evidence is very uncertain (RR 0.95, 95% CI 0.71 to 1.27; participants = 206; studies = 3; I<sup>2</sup> = 10%; fixed‐effect; very low certainty evidence; <a href="./references#CD009151-fig-0013" title="">Analysis 2.2</a>, <a href="#CD009151-fig-0007">Figure 7</a>). There was an incidence of 47% (53/113) in the oral treatment group compared to 49% (46/93) in the topical treatment group. However, our confidence in these findings is very low. </p> <div class="figure" id="CD009151-fig-0007"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 7</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 2 Oral drug treatment versus topical drug treatment (Comparison 2), outcome: 2.2 Clinical recurrence at 12 months (6 months active, 6 months observation)." data-id="CD009151-fig-0007" src="/cdsr/doi/10.1002/14651858.CD009151.pub2/media/CDSR/CD009151/image_n/nCD009151-FIG-07.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 2 Oral drug treatment versus topical drug treatment (Comparison 2), outcome: 2.2 Clinical recurrence at 12 months (6 months active, 6 months observation). </p> </div> </div> </div> <p><a href="./references#CD009151-bbs2-0013" title="Lopez-OlmosJ , LermaE .Treatment of recurring vulvo-vaginal candidiasis: a comparative prospective study during six months of three anti-mycotic preparations of a single dosis. Clinica e Investigacion en Ginecologia y Obstetricia2000;27:366-75. ">Lopez‐Olmos 2000</a> had a high risk of selection bias as it appeared to have not used a random allocation method, therefore we conducted a sensitivity analysis of this effect estimate by removing <a href="./references#CD009151-bbs2-0013" title="Lopez-OlmosJ , LermaE .Treatment of recurring vulvo-vaginal candidiasis: a comparative prospective study during six months of three anti-mycotic preparations of a single dosis. Clinica e Investigacion en Ginecologia y Obstetricia2000;27:366-75. ">Lopez‐Olmos 2000</a> from the analysis. This did not alter the direction of effect or the conclusion (RR 0.91, 95% CI 0.66 to 1.25; participants = 161; I<sup>2</sup> = 44%; fixed‐effect). </p> <p>Two studies compared fluconazole to clotrimazole (<a href="./references#CD009151-bbs2-0007" title="FardyazarZ , HabibzadehS , Abdollahi-FardS , TelloM .Vaginal azoles versus oral fluconazole in treatment of recurrent vulvovaginal candidiasis. Iranian Journal of Clinical Infectious Diseases2007;2:17-22. FardyazarZ , HabibzadehS .Long term vaginal azoles versus prophylactic oral fluconazole in treatment of recurrent vulvovaginal candidiasis. Research Journal of Biological Sciences2007;2(6):663-6. ">Fardyazar 2007</a>; <a href="./references#CD009151-bbs2-0013" title="Lopez-OlmosJ , LermaE .Treatment of recurring vulvo-vaginal candidiasis: a comparative prospective study during six months of three anti-mycotic preparations of a single dosis. Clinica e Investigacion en Ginecologia y Obstetricia2000;27:366-75. ">Lopez‐Olmos 2000</a>). When pooled, oral fluconazole compared to topical clotrimazole may slightly reduce clinical recurrence, but the evidence is very uncertain at six months (clinical recurrence of 18% in fluconazole group and 8% in clotrimazole group; RR 1.94, 95% CI 0.75 to 5.03; participants = 148; I<sup>2</sup> = 57%; fixed‐effect; very low certainty evidence) or at 12 months (clinical recurrence of 48% in fluconazole group and 42% in clotrimazole group; RR 1.12, 95% CI 0.78 to 1.62; participants = 148; I<sup>2</sup> = 0%; fixed‐effect; very low certainty evidence). </p> <p>We downgraded the certainty of the evidence for this outcome by three levels to very low due to very serious risk of bias (allocation concealment (<a href="./references#CD009151-bbs2-0013" title="Lopez-OlmosJ , LermaE .Treatment of recurring vulvo-vaginal candidiasis: a comparative prospective study during six months of three anti-mycotic preparations of a single dosis. Clinica e Investigacion en Ginecologia y Obstetricia2000;27:366-75. ">Lopez‐Olmos 2000</a>), blinding of participants (<a href="./references#CD009151-bbs2-0007" title="FardyazarZ , HabibzadehS , Abdollahi-FardS , TelloM .Vaginal azoles versus oral fluconazole in treatment of recurrent vulvovaginal candidiasis. Iranian Journal of Clinical Infectious Diseases2007;2:17-22. FardyazarZ , HabibzadehS .Long term vaginal azoles versus prophylactic oral fluconazole in treatment of recurrent vulvovaginal candidiasis. Research Journal of Biological Sciences2007;2(6):663-6. ">Fardyazar 2007</a>; <a href="./references#CD009151-bbs2-0008" title="FongIW .The value of chronic suppressive therapy with itraconazole versus clotrimazole in women with recurrent vaginal candidiasis. Genitourinary Medicine1992;68:374-7. ">Fong 1992a</a>; <a href="./references#CD009151-bbs2-0013" title="Lopez-OlmosJ , LermaE .Treatment of recurring vulvo-vaginal candidiasis: a comparative prospective study during six months of three anti-mycotic preparations of a single dosis. Clinica e Investigacion en Ginecologia y Obstetricia2000;27:366-75. ">Lopez‐Olmos 2000</a>), blinding of assessment (<a href="./references#CD009151-bbs2-0008" title="FongIW .The value of chronic suppressive therapy with itraconazole versus clotrimazole in women with recurrent vaginal candidiasis. Genitourinary Medicine1992;68:374-7. ">Fong 1992a</a>), and pharmaceutical funding (<a href="./references#CD009151-bbs2-0007" title="FardyazarZ , HabibzadehS , Abdollahi-FardS , TelloM .Vaginal azoles versus oral fluconazole in treatment of recurrent vulvovaginal candidiasis. Iranian Journal of Clinical Infectious Diseases2007;2:17-22. FardyazarZ , HabibzadehS .Long term vaginal azoles versus prophylactic oral fluconazole in treatment of recurrent vulvovaginal candidiasis. Research Journal of Biological Sciences2007;2(6):663-6. ">Fardyazar 2007</a>), inconsistent results, and imprecision. </p> </section> <section id="CD009151-sec-0099"> <h6 class="title">3. Adverse events</h6> <p>Three studies reported findings for this outcome. In <a href="./references#CD009151-bbs2-0006" title="FanS , LiuX , WuC , XuL , LiJ .Vaginal nystatin versus oral fluconazole for the treatment for recurrent vulvovaginal candidiasis. Mycopathologia2015;179:95-101. [DOI: https://doi.org/10.1007/s11046-014-9827-4]">Fan 2015</a>, one woman from the nystatin group switched to the fluconazole group due to aggravated vaginal burning pain, vulvar or edema, and vulvar itching. In the fluconazole group, three women (2%) experienced oligomenorrhoea, and one woman (0.7%) experienced gastrointestinal symptoms (including nausea). </p> <p><a href="./references#CD009151-bbs2-0007" title="FardyazarZ , HabibzadehS , Abdollahi-FardS , TelloM .Vaginal azoles versus oral fluconazole in treatment of recurrent vulvovaginal candidiasis. Iranian Journal of Clinical Infectious Diseases2007;2:17-22. FardyazarZ , HabibzadehS .Long term vaginal azoles versus prophylactic oral fluconazole in treatment of recurrent vulvovaginal candidiasis. Research Journal of Biological Sciences2007;2(6):663-6. ">Fardyazar 2007</a> had no withdrawals due to adverse effects in the fluconazole group (0/58), but 5% of participants (3/59) withdrew due to adverse effects in the clotrimazole group. Fluconazole users reported nausea (20 women) and vomiting (four women) and some mild gastrointestinal effects that were not specified or quantified. In the clotrimazole group, five women experienced local sensitivity (three of whom withdrew from the study). The authors also reported that systemic complications were significantly less in the cream users than in the capsule users, but did not provide any participant numbers to support this claim (<a href="./references#CD009151-bbs2-0007" title="FardyazarZ , HabibzadehS , Abdollahi-FardS , TelloM .Vaginal azoles versus oral fluconazole in treatment of recurrent vulvovaginal candidiasis. Iranian Journal of Clinical Infectious Diseases2007;2:17-22. FardyazarZ , HabibzadehS .Long term vaginal azoles versus prophylactic oral fluconazole in treatment of recurrent vulvovaginal candidiasis. Research Journal of Biological Sciences2007;2(6):663-6. ">Fardyazar 2007</a>). </p> <p>In <a href="./references#CD009151-bbs2-0008" title="FongIW .The value of chronic suppressive therapy with itraconazole versus clotrimazole in women with recurrent vaginal candidiasis. Genitourinary Medicine1992;68:374-7. ">Fong 1992a</a>, no withdrawals occurred due to adverse effects in either arm, but adverse effects occurred in 33% (7/21) of the itraconazole group compared to no adverse effects (0/22) in the clotrimazole group at six months. Reported adverse events in the itraconazole group included mild nausea (four women), mild diarrhoea (one woman), headaches (one woman), and transient faintness with dizziness (one woman). </p> <p>We downgraded the certainty of the evidence by three levels to very low due to very serious risk of bias (selection bias (<a href="./references#CD009151-bbs2-0006" title="FanS , LiuX , WuC , XuL , LiJ .Vaginal nystatin versus oral fluconazole for the treatment for recurrent vulvovaginal candidiasis. Mycopathologia2015;179:95-101. [DOI: https://doi.org/10.1007/s11046-014-9827-4]">Fan 2015</a>), blinding of participants (<a href="./references#CD009151-bbs2-0006" title="FanS , LiuX , WuC , XuL , LiJ .Vaginal nystatin versus oral fluconazole for the treatment for recurrent vulvovaginal candidiasis. Mycopathologia2015;179:95-101. [DOI: https://doi.org/10.1007/s11046-014-9827-4]">Fan 2015</a>; <a href="./references#CD009151-bbs2-0007" title="FardyazarZ , HabibzadehS , Abdollahi-FardS , TelloM .Vaginal azoles versus oral fluconazole in treatment of recurrent vulvovaginal candidiasis. Iranian Journal of Clinical Infectious Diseases2007;2:17-22. FardyazarZ , HabibzadehS .Long term vaginal azoles versus prophylactic oral fluconazole in treatment of recurrent vulvovaginal candidiasis. Research Journal of Biological Sciences2007;2(6):663-6. ">Fardyazar 2007</a>; <a href="./references#CD009151-bbs2-0008" title="FongIW .The value of chronic suppressive therapy with itraconazole versus clotrimazole in women with recurrent vaginal candidiasis. Genitourinary Medicine1992;68:374-7. ">Fong 1992a</a>), blinding of assessment (<a href="./references#CD009151-bbs2-0008" title="FongIW .The value of chronic suppressive therapy with itraconazole versus clotrimazole in women with recurrent vaginal candidiasis. Genitourinary Medicine1992;68:374-7. ">Fong 1992a</a>), incomplete outcome data (<a href="./references#CD009151-bbs2-0006" title="FanS , LiuX , WuC , XuL , LiJ .Vaginal nystatin versus oral fluconazole for the treatment for recurrent vulvovaginal candidiasis. Mycopathologia2015;179:95-101. [DOI: https://doi.org/10.1007/s11046-014-9827-4]">Fan 2015</a>), and pharmaceutical funding (<a href="./references#CD009151-bbs2-0007" title="FardyazarZ , HabibzadehS , Abdollahi-FardS , TelloM .Vaginal azoles versus oral fluconazole in treatment of recurrent vulvovaginal candidiasis. Iranian Journal of Clinical Infectious Diseases2007;2:17-22. FardyazarZ , HabibzadehS .Long term vaginal azoles versus prophylactic oral fluconazole in treatment of recurrent vulvovaginal candidiasis. Research Journal of Biological Sciences2007;2(6):663-6. ">Fardyazar 2007</a>)) and imprecision (we were not able to pool results). </p> </section> </section> <section id="CD009151-sec-0100"> <h5 class="title">Secondary outcomes</h5> <section id="CD009151-sec-0101"> <h6 class="title">1. Time to first recurrence</h6> <p>None of the four studies in this comparison reported this outcome (<a href="./references#CD009151-bbs2-0006" title="FanS , LiuX , WuC , XuL , LiJ .Vaginal nystatin versus oral fluconazole for the treatment for recurrent vulvovaginal candidiasis. Mycopathologia2015;179:95-101. [DOI: https://doi.org/10.1007/s11046-014-9827-4]">Fan 2015</a>; <a href="./references#CD009151-bbs2-0007" title="FardyazarZ , HabibzadehS , Abdollahi-FardS , TelloM .Vaginal azoles versus oral fluconazole in treatment of recurrent vulvovaginal candidiasis. Iranian Journal of Clinical Infectious Diseases2007;2:17-22. FardyazarZ , HabibzadehS .Long term vaginal azoles versus prophylactic oral fluconazole in treatment of recurrent vulvovaginal candidiasis. Research Journal of Biological Sciences2007;2(6):663-6. ">Fardyazar 2007</a>; <a href="./references#CD009151-bbs2-0008" title="FongIW .The value of chronic suppressive therapy with itraconazole versus clotrimazole in women with recurrent vaginal candidiasis. Genitourinary Medicine1992;68:374-7. ">Fong 1992a</a>; <a href="./references#CD009151-bbs2-0013" title="Lopez-OlmosJ , LermaE .Treatment of recurring vulvo-vaginal candidiasis: a comparative prospective study during six months of three anti-mycotic preparations of a single dosis. Clinica e Investigacion en Ginecologia y Obstetricia2000;27:366-75. ">Lopez‐Olmos 2000</a>). </p> </section> <section id="CD009151-sec-0102"> <h6 class="title">2. Number of symptomatic days per year</h6> <p>None of the four studies in this comparison reported this outcome (<a href="./references#CD009151-bbs2-0006" title="FanS , LiuX , WuC , XuL , LiJ .Vaginal nystatin versus oral fluconazole for the treatment for recurrent vulvovaginal candidiasis. Mycopathologia2015;179:95-101. [DOI: https://doi.org/10.1007/s11046-014-9827-4]">Fan 2015</a>; <a href="./references#CD009151-bbs2-0007" title="FardyazarZ , HabibzadehS , Abdollahi-FardS , TelloM .Vaginal azoles versus oral fluconazole in treatment of recurrent vulvovaginal candidiasis. Iranian Journal of Clinical Infectious Diseases2007;2:17-22. FardyazarZ , HabibzadehS .Long term vaginal azoles versus prophylactic oral fluconazole in treatment of recurrent vulvovaginal candidiasis. Research Journal of Biological Sciences2007;2(6):663-6. ">Fardyazar 2007</a>; <a href="./references#CD009151-bbs2-0008" title="FongIW .The value of chronic suppressive therapy with itraconazole versus clotrimazole in women with recurrent vaginal candidiasis. Genitourinary Medicine1992;68:374-7. ">Fong 1992a</a>; <a href="./references#CD009151-bbs2-0013" title="Lopez-OlmosJ , LermaE .Treatment of recurring vulvo-vaginal candidiasis: a comparative prospective study during six months of three anti-mycotic preparations of a single dosis. Clinica e Investigacion en Ginecologia y Obstetricia2000;27:366-75. ">Lopez‐Olmos 2000</a>). </p> </section> <section id="CD009151-sec-0103"> <h6 class="title">3. Number of mycological recurrences per participant per year</h6> <p>None of the four studies in this comparison reported this outcome (<a href="./references#CD009151-bbs2-0006" title="FanS , LiuX , WuC , XuL , LiJ .Vaginal nystatin versus oral fluconazole for the treatment for recurrent vulvovaginal candidiasis. Mycopathologia2015;179:95-101. [DOI: https://doi.org/10.1007/s11046-014-9827-4]">Fan 2015</a>; <a href="./references#CD009151-bbs2-0007" title="FardyazarZ , HabibzadehS , Abdollahi-FardS , TelloM .Vaginal azoles versus oral fluconazole in treatment of recurrent vulvovaginal candidiasis. Iranian Journal of Clinical Infectious Diseases2007;2:17-22. FardyazarZ , HabibzadehS .Long term vaginal azoles versus prophylactic oral fluconazole in treatment of recurrent vulvovaginal candidiasis. Research Journal of Biological Sciences2007;2(6):663-6. ">Fardyazar 2007</a>; <a href="./references#CD009151-bbs2-0008" title="FongIW .The value of chronic suppressive therapy with itraconazole versus clotrimazole in women with recurrent vaginal candidiasis. Genitourinary Medicine1992;68:374-7. ">Fong 1992a</a>; <a href="./references#CD009151-bbs2-0013" title="Lopez-OlmosJ , LermaE .Treatment of recurring vulvo-vaginal candidiasis: a comparative prospective study during six months of three anti-mycotic preparations of a single dosis. Clinica e Investigacion en Ginecologia y Obstetricia2000;27:366-75. ">Lopez‐Olmos 2000</a>). </p> </section> <section id="CD009151-sec-0104"> <h6 class="title">4. Proportion of participants with at least one mycological recurrence during the treatment and follow‐up period </h6> <p>Only <a href="./references#CD009151-bbs2-0008" title="FongIW .The value of chronic suppressive therapy with itraconazole versus clotrimazole in women with recurrent vaginal candidiasis. Genitourinary Medicine1992;68:374-7. ">Fong 1992a</a> reported findings for this outcome, with mycological recurrence 50% (11/22) in the itraconazole group compared to 41% (9/22) in the clotrimazole group at six months (RR 1.22, 95% CI 0.64 to 2.35; participants = 44; very low certainty evidence; <a href="./references#CD009151-fig-0014" title="">Analysis 2.3</a>). </p> <p>We downgraded the certainty of the evidence for this outcome by three levels to very low due to very serious risk of bias and imprecision (based on only one study). </p> </section> <section id="CD009151-sec-0105"> <h6 class="title">5. Duration of symptoms after treatment initiation</h6> <p>None of the four studies in this comparison reported this outcome (<a href="./references#CD009151-bbs2-0006" title="FanS , LiuX , WuC , XuL , LiJ .Vaginal nystatin versus oral fluconazole for the treatment for recurrent vulvovaginal candidiasis. Mycopathologia2015;179:95-101. [DOI: https://doi.org/10.1007/s11046-014-9827-4]">Fan 2015</a>; <a href="./references#CD009151-bbs2-0007" title="FardyazarZ , HabibzadehS , Abdollahi-FardS , TelloM .Vaginal azoles versus oral fluconazole in treatment of recurrent vulvovaginal candidiasis. Iranian Journal of Clinical Infectious Diseases2007;2:17-22. FardyazarZ , HabibzadehS .Long term vaginal azoles versus prophylactic oral fluconazole in treatment of recurrent vulvovaginal candidiasis. Research Journal of Biological Sciences2007;2(6):663-6. ">Fardyazar 2007</a>; <a href="./references#CD009151-bbs2-0008" title="FongIW .The value of chronic suppressive therapy with itraconazole versus clotrimazole in women with recurrent vaginal candidiasis. Genitourinary Medicine1992;68:374-7. ">Fong 1992a</a>; <a href="./references#CD009151-bbs2-0013" title="Lopez-OlmosJ , LermaE .Treatment of recurring vulvo-vaginal candidiasis: a comparative prospective study during six months of three anti-mycotic preparations of a single dosis. Clinica e Investigacion en Ginecologia y Obstetricia2000;27:366-75. ">Lopez‐Olmos 2000</a>). </p> </section> <section id="CD009151-sec-0106"> <h6 class="title">6. Patient preference</h6> <p>Only <a href="./references#CD009151-bbs2-0007" title="FardyazarZ , HabibzadehS , Abdollahi-FardS , TelloM .Vaginal azoles versus oral fluconazole in treatment of recurrent vulvovaginal candidiasis. Iranian Journal of Clinical Infectious Diseases2007;2:17-22. FardyazarZ , HabibzadehS .Long term vaginal azoles versus prophylactic oral fluconazole in treatment of recurrent vulvovaginal candidiasis. Research Journal of Biological Sciences2007;2(6):663-6. ">Fardyazar 2007</a> reported data for this outcome, finding that participants in the clotrimazole group more commonly missed two or more consecutive doses of the drug (15% (9/59)) than participants in the fluconazole group (7 % (4/58)). </p> <p>We downgraded the certainty of the evidence for this outcome by four levels to very low due to very serious risk of bias in <a href="./references#CD009151-bbs2-0007" title="FardyazarZ , HabibzadehS , Abdollahi-FardS , TelloM .Vaginal azoles versus oral fluconazole in treatment of recurrent vulvovaginal candidiasis. Iranian Journal of Clinical Infectious Diseases2007;2:17-22. FardyazarZ , HabibzadehS .Long term vaginal azoles versus prophylactic oral fluconazole in treatment of recurrent vulvovaginal candidiasis. Research Journal of Biological Sciences2007;2(6):663-6. ">Fardyazar 2007</a>, indirectness (<a href="./references#CD009151-bbs2-0007" title="FardyazarZ , HabibzadehS , Abdollahi-FardS , TelloM .Vaginal azoles versus oral fluconazole in treatment of recurrent vulvovaginal candidiasis. Iranian Journal of Clinical Infectious Diseases2007;2:17-22. FardyazarZ , HabibzadehS .Long term vaginal azoles versus prophylactic oral fluconazole in treatment of recurrent vulvovaginal candidiasis. Research Journal of Biological Sciences2007;2(6):663-6. ">Fardyazar 2007</a> used a proxy to measure patient preference), and imprecision (based on only one study). </p> </section> </section> </section> <section id="CD009151-sec-0107"> <h4 class="title">Comparison 3: Oral drug treatment versus oral drug treatment</h4> <p>One study presented findings relevant to the comparison of oral treatment versus a different oral treatment (<a href="./references#CD009151-bbs2-0013" title="Lopez-OlmosJ , LermaE .Treatment of recurring vulvo-vaginal candidiasis: a comparative prospective study during six months of three anti-mycotic preparations of a single dosis. Clinica e Investigacion en Ginecologia y Obstetricia2000;27:366-75. ">Lopez‐Olmos 2000</a>). In this study, fluconazole was administered as a single tablet of 150 mg (19 participants) compared to itraconazole (100 mg, 2 capsules a day; 14 participants). Each regimen was administered on the sixth day of the menstrual cycle over a period of six months. </p> <section id="CD009151-sec-0108"> <h5 class="title">Primary outcomes</h5> <section id="CD009151-sec-0109"> <h6 class="title">1. Number of clinical recurrences per participant per year</h6> <p>The one study in this comparison did not report this outcome (<a href="./references#CD009151-bbs2-0013" title="Lopez-OlmosJ , LermaE .Treatment of recurring vulvo-vaginal candidiasis: a comparative prospective study during six months of three anti-mycotic preparations of a single dosis. Clinica e Investigacion en Ginecologia y Obstetricia2000;27:366-75. ">Lopez‐Olmos 2000</a>). </p> </section> <section id="CD009151-sec-0110"> <h6 class="title">2. Proportion of participants with at least one clinical recurrence during the treatment and follow‐up period </h6> <p><a href="./references#CD009151-bbs2-0013" title="Lopez-OlmosJ , LermaE .Treatment of recurring vulvo-vaginal candidiasis: a comparative prospective study during six months of three anti-mycotic preparations of a single dosis. Clinica e Investigacion en Ginecologia y Obstetricia2000;27:366-75. ">Lopez‐Olmos 2000</a> found 47% recurrences in the fluconazole group compared with 14% in the itraconazole group at 6 months (RR 3.32, 95% CI 0.84 to 13.02; participants = 33; studies = 1; very low certainty evidence; <a href="./references#CD009151-fig-0015" title="">Analysis 3.1</a>) and 58% (11/19) in the fluconazole group versus 36% (5/14) in the itraconazole group at 12 months (6 months active treatment, 6 months observation) (RR 1.62, 95% CI 0.73 to 3.61; participants = 33; studies = 1; very low certainty evidence; <a href="./references#CD009151-fig-0016" title="">Analysis 3.2</a>). Our confidence in these findings is very low. </p> <p>We downgraded the certainty of the evidence by three levels to very low due to very serious risk of bias and imprecision. </p> </section> <section id="CD009151-sec-0111"> <h6 class="title">3. Adverse events</h6> <p>The one study in this comparison did not report this outcome (<a href="./references#CD009151-bbs2-0013" title="Lopez-OlmosJ , LermaE .Treatment of recurring vulvo-vaginal candidiasis: a comparative prospective study during six months of three anti-mycotic preparations of a single dosis. Clinica e Investigacion en Ginecologia y Obstetricia2000;27:366-75. ">Lopez‐Olmos 2000</a>). </p> </section> </section> <section id="CD009151-sec-0112"> <h5 class="title">Secondary outcomes</h5> <p>None of the secondary outcomes could be extracted.</p> </section> </section> <section id="CD009151-sec-0113"> <h4 class="title">Comparison 4: Topical drug treatment versus topical drug treatment</h4> <p>None of the included studies compared an active topical treatment with another active tropical treatment. </p> </section> <section id="CD009151-sec-0114"> <h4 class="title">Comparison 5: Comparison of different doses of the same agent</h4> <p>Three studies presented findings relevant to this comparison (<a href="./references#CD009151-bbs2-0010" title="FongIW .The value of prophylactic (monthly) clotrimazole versus empiric self-treatment in recurrent vaginal candidiasis. Genitourinary Medicine1994;70:124-6. ">Fong 1994</a>; <a href="./references#CD009151-bbs2-0018" title="SobelJD .Recurrent vulvovaginal candidiasis. A prospective study of the efficacy of maintenance ketoconazole therapy. New England Journal of Medicine1986;315:1455-8. ">Sobel 1986</a>; <a href="./references#CD009151-bbs2-0021" title="SpacekJ , BuchtaV .Itraconazole in the treatment of acute and recurrent vulvovaginal candidosis: comparison of a 1-day and a 3-day regimen. Mycoses2005;48:165-71. ">Spacek 2005</a>). <a href="./references#CD009151-bbs2-0010" title="FongIW .The value of prophylactic (monthly) clotrimazole versus empiric self-treatment in recurrent vaginal candidiasis. Genitourinary Medicine1994;70:124-6. ">Fong 1994</a> compared empiric self‐treatment with cyclical monthly prophylactic use of 500 mg clotrimazole vaginal ovules. <a href="./references#CD009151-bbs2-0018" title="SobelJD .Recurrent vulvovaginal candidiasis. A prospective study of the efficacy of maintenance ketoconazole therapy. New England Journal of Medicine1986;315:1455-8. ">Sobel 1986</a> compared 400 mg of daily perimenstrual ketoconazole for six cycles with 100 mg of ketoconazole daily for five months. <a href="./references#CD009151-bbs2-0021" title="SpacekJ , BuchtaV .Itraconazole in the treatment of acute and recurrent vulvovaginal candidosis: comparison of a 1-day and a 3-day regimen. Mycoses2005;48:165-71. ">Spacek 2005</a> compared a one‐day regimen of 400 mg itraconazole with a three‐day regimen of 600 mg itraconazole. The characteristics of studies against this comparison are summarised in a supplementary table (<a href="#CD009151-tbl-0005">Table 3</a>). </p> <div class="table" id="CD009151-tbl-0005"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Summary of characteristics of studies included in Comparison 5: Comparison of different doses of the same agent</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Study ID</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009151-bbs2-0010" title="FongIW .The value of prophylactic (monthly) clotrimazole versus empiric self-treatment in recurrent vaginal candidiasis. Genitourinary Medicine1994;70:124-6. ">Fong 1994</a> </p> </td> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><a href="./references#CD009151-bbs2-0018" title="SobelJD .Recurrent vulvovaginal candidiasis. A prospective study of the efficacy of maintenance ketoconazole therapy. New England Journal of Medicine1986;315:1455-8. "><b>Sobel 1986</b> </a> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><a href="./references#CD009151-bbs2-0021" title="SpacekJ , BuchtaV .Itraconazole in the treatment of acute and recurrent vulvovaginal candidosis: comparison of a 1-day and a 3-day regimen. Mycoses2005;48:165-71. "><b>Spacek 2005</b> </a> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Participants (n)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>74</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b><i>Candida albicans</i> at enrolment (%)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>87</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>96</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mean episodes in previous 12 months</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NS<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NS<sup>a</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Withdrawals/loss to follow‐up (%)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Setting</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NS<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Outpatient clinic</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Country</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Canada</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>USA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Czech Republic</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Intervention 1</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Clotrimazole (perimenstrually)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ketoconazole (with menses)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Itraconazole, 400 mg</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Intervention 2</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Clotrimazole (empirically, with symptoms)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ketoconazole (daily)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Itraconazole, 600 mg</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Intervention 3</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo (daily)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Duration of intervention</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 to 3 days</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Duration of observation after intervention</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A Cross over trial</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 months</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Planned assessments</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Bimonthly for 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Monthly for 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14 days, 1 month, 3 months, 6 months</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Assessment between planned visits if symptoms developed</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><sup>a</sup>Not reported or unclear. </p> </div> </div> <section id="CD009151-sec-0115"> <h5 class="title">Primary outcomes</h5> <section id="CD009151-sec-0116"> <h6 class="title">1. Number of clinical recurrences per participant per year</h6> <p>None of the three studies in this comparison reported this outcome (<a href="./references#CD009151-bbs2-0010" title="FongIW .The value of prophylactic (monthly) clotrimazole versus empiric self-treatment in recurrent vaginal candidiasis. Genitourinary Medicine1994;70:124-6. ">Fong 1994</a>; <a href="./references#CD009151-bbs2-0018" title="SobelJD .Recurrent vulvovaginal candidiasis. A prospective study of the efficacy of maintenance ketoconazole therapy. New England Journal of Medicine1986;315:1455-8. ">Sobel 1986</a>; <a href="./references#CD009151-bbs2-0021" title="SpacekJ , BuchtaV .Itraconazole in the treatment of acute and recurrent vulvovaginal candidosis: comparison of a 1-day and a 3-day regimen. Mycoses2005;48:165-71. ">Spacek 2005</a>). </p> </section> <section id="CD009151-sec-0117"> <h6 class="title">2. Proportion of participants with at least one clinical recurrence during the treatment and follow‐up period </h6> <p>Due to considerable clinical heterogeneity between the two studies, we decided not to pool the results. After six months 29% of participants in the perimenstrual ketoconazole group compared to 5% in the daily ketoconazole group developed at least one clinical recurrence in the <a href="./references#CD009151-bbs2-0018" title="SobelJD .Recurrent vulvovaginal candidiasis. A prospective study of the efficacy of maintenance ketoconazole therapy. New England Journal of Medicine1986;315:1455-8. ">Sobel 1986</a> study. In the <a href="./references#CD009151-bbs2-0021" title="SpacekJ , BuchtaV .Itraconazole in the treatment of acute and recurrent vulvovaginal candidosis: comparison of a 1-day and a 3-day regimen. Mycoses2005;48:165-71. ">Spacek 2005</a> study, 62% of participants in the one‐day group and 77% in the three‐day treatment group developed at least one clinical recurrence (see <a href="./references#CD009151-fig-0017" title="">Analysis 4.1</a>). <a href="./references#CD009151-bbs2-0010" title="FongIW .The value of prophylactic (monthly) clotrimazole versus empiric self-treatment in recurrent vaginal candidiasis. Genitourinary Medicine1994;70:124-6. ">Fong 1994</a> did not report this outcome. </p> <p>We downgraded the certainty of the evidence by three levels to very low due to very serious risk of bias (high risk of bias for incomplete outcome data in <a href="./references#CD009151-bbs2-0018" title="SobelJD .Recurrent vulvovaginal candidiasis. A prospective study of the efficacy of maintenance ketoconazole therapy. New England Journal of Medicine1986;315:1455-8. ">Sobel 1986</a> and blinding of participants in <a href="./references#CD009151-bbs2-0021" title="SpacekJ , BuchtaV .Itraconazole in the treatment of acute and recurrent vulvovaginal candidosis: comparison of a 1-day and a 3-day regimen. Mycoses2005;48:165-71. ">Spacek 2005</a>) and imprecision. </p> <p>Only <a href="./references#CD009151-bbs2-0018" title="SobelJD .Recurrent vulvovaginal candidiasis. A prospective study of the efficacy of maintenance ketoconazole therapy. New England Journal of Medicine1986;315:1455-8. ">Sobel 1986</a> reported results at 12 months, finding low‐dose ketoconazole compared to high‐dose may not reduce clinical recurrence (RR 0.83, 95% CI 0.47 to 1.49; participants = 42; studies = 1; I<sup>2</sup> = 0%; fixed‐effect; very low certainty evidence; <a href="./references#CD009151-fig-0018" title="">Analysis 4.2</a>). Our confidence in these findings is very low. </p> <p>We downgraded the certainty of the evidence by three levels to very low due to very serious risk of bias and imprecision. </p> </section> <section id="CD009151-sec-0118"> <h6 class="title">3. Adverse events</h6> <p>Only <a href="./references#CD009151-bbs2-0021" title="SpacekJ , BuchtaV .Itraconazole in the treatment of acute and recurrent vulvovaginal candidosis: comparison of a 1-day and a 3-day regimen. Mycoses2005;48:165-71. ">Spacek 2005</a> reported adverse events. In this study of 26 participants with RVVC and 34 participants with acute VVC, one participant developed reversible alopecia areata and one reported mild nausea with diarrhoea. However, it was not clear if these women had RVVC or acute VCC nor to which treatment group they had been allocated. Our confidence in these findings is very low. </p> <p>We downgraded the certainty of the evidence by three levels to very low due to very serious risk of bias and imprecision. </p> </section> </section> <section id="CD009151-sec-0119"> <h5 class="title">Secondary outcomes</h5> <section id="CD009151-sec-0120"> <h6 class="title">1. Time to first recurrence</h6> <p>In <a href="./references#CD009151-bbs2-0018" title="SobelJD .Recurrent vulvovaginal candidiasis. A prospective study of the efficacy of maintenance ketoconazole therapy. New England Journal of Medicine1986;315:1455-8. ">Sobel 1986</a>, the mean time to first recurrence after cessation of therapy was the same (2.6 months) in both the perimenstrual ketoconazole and the daily ketoconazole groups. </p> </section> <section id="CD009151-sec-0121"> <h6 class="title">2. Number of symptomatic days per year</h6> <p>None of the three studies in this comparison reported this outcome (<a href="./references#CD009151-bbs2-0010" title="FongIW .The value of prophylactic (monthly) clotrimazole versus empiric self-treatment in recurrent vaginal candidiasis. Genitourinary Medicine1994;70:124-6. ">Fong 1994</a>; <a href="./references#CD009151-bbs2-0018" title="SobelJD .Recurrent vulvovaginal candidiasis. A prospective study of the efficacy of maintenance ketoconazole therapy. New England Journal of Medicine1986;315:1455-8. ">Sobel 1986</a>; <a href="./references#CD009151-bbs2-0021" title="SpacekJ , BuchtaV .Itraconazole in the treatment of acute and recurrent vulvovaginal candidosis: comparison of a 1-day and a 3-day regimen. Mycoses2005;48:165-71. ">Spacek 2005</a>). </p> </section> <section id="CD009151-sec-0122"> <h6 class="title">3. Number of mycological recurrences per participant per year</h6> <p>None of the three studies in this comparison reported this outcome (<a href="./references#CD009151-bbs2-0010" title="FongIW .The value of prophylactic (monthly) clotrimazole versus empiric self-treatment in recurrent vaginal candidiasis. Genitourinary Medicine1994;70:124-6. ">Fong 1994</a>; <a href="./references#CD009151-bbs2-0018" title="SobelJD .Recurrent vulvovaginal candidiasis. A prospective study of the efficacy of maintenance ketoconazole therapy. New England Journal of Medicine1986;315:1455-8. ">Sobel 1986</a>; <a href="./references#CD009151-bbs2-0021" title="SpacekJ , BuchtaV .Itraconazole in the treatment of acute and recurrent vulvovaginal candidosis: comparison of a 1-day and a 3-day regimen. Mycoses2005;48:165-71. ">Spacek 2005</a>). </p> </section> <section id="CD009151-sec-0123"> <h6 class="title">4. Proportion of participants with at least one mycological recurrence during the treatment and follow‐up period </h6> <p>Only <a href="./references#CD009151-bbs2-0018" title="SobelJD .Recurrent vulvovaginal candidiasis. A prospective study of the efficacy of maintenance ketoconazole therapy. New England Journal of Medicine1986;315:1455-8. ">Sobel 1986</a> reported this outcome, finding daily administration of ketoconazole may not reduce mycological recurrence compared to perimenstrual administration at six months (RR 0.50, 95% CI 0.14 to 1.74; participants = 42; very low certainty evidence; <a href="./references#CD009151-fig-0019" title="">Analysis 4.3</a>) and at 12 months (RR 0.86, 95% CI 0.53 to 1.38; participants = 42; very low certainty evidence; <a href="./references#CD009151-fig-0020" title="">Analysis 4.4</a>). The rate of mycological recurrence was 29% (6/21) in the perimenstrual ketoconazole group and 14% (3/21) in the daily ketoconazole group at six months and 67% (14/21) and 57% (12/21) respectively at 12 months. Our confidence in these findings is very low. </p> <p>We downgraded the certainty of the evidence by three levels to very low due to very serious risk of bias and imprecision. </p> </section> <section id="CD009151-sec-0124"> <h6 class="title">5. Duration of symptoms after treatment initiation</h6> <p>None of the three studies in this comparison reported this outcome (<a href="./references#CD009151-bbs2-0010" title="FongIW .The value of prophylactic (monthly) clotrimazole versus empiric self-treatment in recurrent vaginal candidiasis. Genitourinary Medicine1994;70:124-6. ">Fong 1994</a>; <a href="./references#CD009151-bbs2-0018" title="SobelJD .Recurrent vulvovaginal candidiasis. A prospective study of the efficacy of maintenance ketoconazole therapy. New England Journal of Medicine1986;315:1455-8. ">Sobel 1986</a>; <a href="./references#CD009151-bbs2-0021" title="SpacekJ , BuchtaV .Itraconazole in the treatment of acute and recurrent vulvovaginal candidosis: comparison of a 1-day and a 3-day regimen. Mycoses2005;48:165-71. ">Spacek 2005</a>). </p> </section> <section id="CD009151-sec-0125"> <h6 class="title">6. Patient preference</h6> <p>In <a href="./references#CD009151-bbs2-0010" title="FongIW .The value of prophylactic (monthly) clotrimazole versus empiric self-treatment in recurrent vaginal candidiasis. Genitourinary Medicine1994;70:124-6. ">Fong 1994</a>, participants preferred empiric self‐treatment with clotrimazole (73.9%) with perimenstrual clotrimazole (17.4%), with some participants not expressing a preference (8.7%) (P&lt;0.05). </p> </section> </section> </section> <section id="CD009151-sec-0126"> <h4 class="title">Comparison 6: Short duration of treatment versus longer duration of treatment</h4> <p>One study compared a one‐day regimen of itraconazole with a three‐day regimen of itraconazole (<a href="./references#CD009151-bbs2-0021" title="SpacekJ , BuchtaV .Itraconazole in the treatment of acute and recurrent vulvovaginal candidosis: comparison of a 1-day and a 3-day regimen. Mycoses2005;48:165-71. ">Spacek 2005</a>). </p> <section id="CD009151-sec-0127"> <h5 class="title">Primary outcomes</h5> <section id="CD009151-sec-0128"> <h6 class="title">1. Number of clinical recurrences per participant per year</h6> <p>The one study in this comparison did not report this outcome (<a href="./references#CD009151-bbs2-0021" title="SpacekJ , BuchtaV .Itraconazole in the treatment of acute and recurrent vulvovaginal candidosis: comparison of a 1-day and a 3-day regimen. Mycoses2005;48:165-71. ">Spacek 2005</a>). </p> </section> <section id="CD009151-sec-0129"> <h6 class="title">2. Proportion of participants with at least one clinical recurrence during the treatment and follow‐up period </h6> <p><a href="./references#CD009151-bbs2-0021" title="SpacekJ , BuchtaV .Itraconazole in the treatment of acute and recurrent vulvovaginal candidosis: comparison of a 1-day and a 3-day regimen. Mycoses2005;48:165-71. ">Spacek 2005</a> only reported the proportion of participants with at least one clinical recurrence after six months. In this single study, short‐term treatment may reduce to no reduce clinical recurrence compared to and long‐term treatment (RR 0.80, 95% CI 0.47 to 1.35; participants = 26; studies = 1; I<sup>2</sup> = 0%; fixed‐effect; very low certainty evidence; <a href="./references#CD009151-fig-0021" title="">Analysis 5.1</a>). Our confidence in these findings is very low. </p> <p>We downgraded the certainty of the evidence by three levels to very low due to very serious risk of bias and imprecision. </p> </section> <section id="CD009151-sec-0130"> <h6 class="title">3. Adverse events</h6> <p>In this study of 26 participants with RVVC and 34 participants with acute VVC, one participant developed reversible alopecia areata and one reported mild nausea with diarrhoea (<a href="./references#CD009151-bbs2-0021" title="SpacekJ , BuchtaV .Itraconazole in the treatment of acute and recurrent vulvovaginal candidosis: comparison of a 1-day and a 3-day regimen. Mycoses2005;48:165-71. ">Spacek 2005</a>). However, it was not clear if these women had RVVC or acute VCC nor to which treatment group they had been allocated. </p> <p>We downgraded the certainty of the evidence by three levels to very low due to very serious risk of bias and imprecision. </p> </section> </section> <section id="CD009151-sec-0131"> <h5 class="title">Secondary outcomes</h5> <p>None of the secondary outcomes could be extracted.</p> </section> </section> <section id="CD009151-sec-0132"> <h4 class="title">Comparison 7: Partner treatment versus placebo/no treatment</h4> <p>Two studies examined this comparison: <a href="./references#CD009151-bbs2-0009" title="FongIW .The value of treating the sexual partners of women with recurrent vaginal candidiasis with ketoconazole. Genitourinary Medicine1992;68:174-6. ">Fong 1992b</a>, where male partners were treated with a short course of ketoconazole, and <a href="./references#CD009151-bbs2-0017" title="SobelJD .Management of recurrent vulvovaginal candidiasis (VVC) with ketoconazole (K) prophylaxis [abstract]. Archives of Gynecology1985;237 Suppl:281. SobelJD .Management of recurrent vulvovaginal candidiasis with intermittent ketoconazole prophylaxis. Obstetrics &amp; Gynecology1985;65:435-40. ">Sobel 1985a</a>, where male partners were treated with a short course of miconazole cream. In both studies, the control group received no treatment. The characteristics of studies against this comparison are summarised in a supplementary table (<a href="#CD009151-tbl-0006">Table 4</a>). </p> <div class="table" id="CD009151-tbl-0006"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Summary of characteristics of studies included in Comparison 7: Partner treatment versus placebo/no treatment</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Study ID (*)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><a href="./references#CD009151-bbs2-0009" title="FongIW .The value of treating the sexual partners of women with recurrent vaginal candidiasis with ketoconazole. Genitourinary Medicine1992;68:174-6. "><b>Fong 1992b</b> </a> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><a href="./references#CD009151-bbs2-0017" title="SobelJD .Management of recurrent vulvovaginal candidiasis (VVC) with ketoconazole (K) prophylaxis [abstract]. Archives of Gynecology1985;237 Suppl:281. SobelJD .Management of recurrent vulvovaginal candidiasis with intermittent ketoconazole prophylaxis. Obstetrics &amp; Gynecology1985;65:435-40. "><b>Sobel 1985a</b> </a> </p> </th> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Participants (n)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>58</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i><b>Candida albicans</b> </i><b>at enrolment (%)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mean episodes in previous 12 months</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8.4 (ketoconazole), 9.5 (no treatment)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5.1 (miconazole), 5.3 (no treatment)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Withdrawals/loss to follow‐up (%)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Setting</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hospital outpatient clinic</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NS<sup>a</sup> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Country</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Canada</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>USA</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Intervention 1</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Partner treatment with ketoconazole daily for 5 days</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1% miconazole cream daily for 1 week</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Intervention 2</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No treatment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No treatment</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Intervention 3</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Duration of intervention</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single treatment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 week</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Duration of observation after intervention</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 months</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Planned assessments</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Monthly for 12 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Monthly for 6 months, then 9 months, 12 months</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Assessment between planned visits if symptoms developed</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><sup>a</sup>Not reported or unclear. </p> </div> </div> <section id="CD009151-sec-0133"> <h5 class="title">Primary outcomes</h5> <section id="CD009151-sec-0134"> <h6 class="title">1. Number of clinical recurrences per participant per year</h6> <p>Neither of the two studies in this comparison reported this outcome (<a href="./references#CD009151-bbs2-0009" title="FongIW .The value of treating the sexual partners of women with recurrent vaginal candidiasis with ketoconazole. Genitourinary Medicine1992;68:174-6. ">Fong 1992b</a>; <a href="./references#CD009151-bbs2-0017" title="SobelJD .Management of recurrent vulvovaginal candidiasis (VVC) with ketoconazole (K) prophylaxis [abstract]. Archives of Gynecology1985;237 Suppl:281. SobelJD .Management of recurrent vulvovaginal candidiasis with intermittent ketoconazole prophylaxis. Obstetrics &amp; Gynecology1985;65:435-40. ">Sobel 1985a</a>). </p> </section> <section id="CD009151-sec-0135"> <h6 class="title">2. Proportion of participants with at least one clinical recurrence during the treatment and follow‐up period </h6> <p>Only <a href="./references#CD009151-bbs2-0009" title="FongIW .The value of treating the sexual partners of women with recurrent vaginal candidiasis with ketoconazole. Genitourinary Medicine1992;68:174-6. ">Fong 1992b</a> reported one of our primary outcomes, finding that may reduce to no reduce clinical recurrence at six or 12 months. The incidence of clinical recurrence at six months was 65% (17/26) in the ketoconazole group compared to 71% (20/28) in the no‐treatment group (RR 0.92, 95% CI 0.64 to 1.32; participants = 54; very low certainty evidence; <a href="./references#CD009151-fig-0022" title="">Analysis 6.1</a>). At 12 months, it was 85% (22/26) and 82% (23/28), respectively (RR 1.03, 95% CI 0.81 to 1.31; participants = 54; very low certainty evidence; <a href="./references#CD009151-fig-0023" title="">Analysis 6.2</a>). Our confidence in these findings is very low. </p> <p>We downgraded the certainty of the evidence by three levels to very low due to very serious risk of bias and imprecision. </p> </section> <section id="CD009151-sec-0136"> <h6 class="title">3. Adverse events</h6> <p>In <a href="./references#CD009151-bbs2-0009" title="FongIW .The value of treating the sexual partners of women with recurrent vaginal candidiasis with ketoconazole. Genitourinary Medicine1992;68:174-6. ">Fong 1992b</a>, the adverse event rate was minimal. One participant in the untreated group was removed from the study due to an adverse reaction. No removals occurred for this reason in the treated group. </p> <p>We downgraded the certainty of the evidence by three levels to very low due to very serious risk of bias and imprecision. </p> </section> </section> <section id="CD009151-sec-0137"> <h5 class="title">Secondary outcomes</h5> <section id="CD009151-sec-0138"> <h6 class="title">1. Time to first recurrence</h6> <p>Neither of the two studies in this comparison reported this outcome (<a href="./references#CD009151-bbs2-0009" title="FongIW .The value of treating the sexual partners of women with recurrent vaginal candidiasis with ketoconazole. Genitourinary Medicine1992;68:174-6. ">Fong 1992b</a>; <a href="./references#CD009151-bbs2-0017" title="SobelJD .Management of recurrent vulvovaginal candidiasis (VVC) with ketoconazole (K) prophylaxis [abstract]. Archives of Gynecology1985;237 Suppl:281. SobelJD .Management of recurrent vulvovaginal candidiasis with intermittent ketoconazole prophylaxis. Obstetrics &amp; Gynecology1985;65:435-40. ">Sobel 1985a</a>). </p> </section> <section id="CD009151-sec-0139"> <h6 class="title">2. Number of symptomatic days per year</h6> <p>Neither of the two studies in this comparison reported this outcome (<a href="./references#CD009151-bbs2-0009" title="FongIW .The value of treating the sexual partners of women with recurrent vaginal candidiasis with ketoconazole. Genitourinary Medicine1992;68:174-6. ">Fong 1992b</a>; <a href="./references#CD009151-bbs2-0017" title="SobelJD .Management of recurrent vulvovaginal candidiasis (VVC) with ketoconazole (K) prophylaxis [abstract]. Archives of Gynecology1985;237 Suppl:281. SobelJD .Management of recurrent vulvovaginal candidiasis with intermittent ketoconazole prophylaxis. Obstetrics &amp; Gynecology1985;65:435-40. ">Sobel 1985a</a>). </p> </section> <section id="CD009151-sec-0140"> <h6 class="title">3. Number of mycological recurrences per participant per year</h6> <p>Neither of the two studies in this comparison reported this outcome (<a href="./references#CD009151-bbs2-0009" title="FongIW .The value of treating the sexual partners of women with recurrent vaginal candidiasis with ketoconazole. Genitourinary Medicine1992;68:174-6. ">Fong 1992b</a>; <a href="./references#CD009151-bbs2-0017" title="SobelJD .Management of recurrent vulvovaginal candidiasis (VVC) with ketoconazole (K) prophylaxis [abstract]. Archives of Gynecology1985;237 Suppl:281. SobelJD .Management of recurrent vulvovaginal candidiasis with intermittent ketoconazole prophylaxis. Obstetrics &amp; Gynecology1985;65:435-40. ">Sobel 1985a</a>). </p> </section> <section id="CD009151-sec-0141"> <h6 class="title">4. Proportion of participants with at least one mycological recurrence during the treatment and follow‐up period </h6> <section id="CD009151-sec-0142"> <p><b>Clinical recurrence at 6 months</b></p> <p><a href="./references#CD009151-bbs2-0017" title="SobelJD .Management of recurrent vulvovaginal candidiasis (VVC) with ketoconazole (K) prophylaxis [abstract]. Archives of Gynecology1985;237 Suppl:281. SobelJD .Management of recurrent vulvovaginal candidiasis with intermittent ketoconazole prophylaxis. Obstetrics &amp; Gynecology1985;65:435-40. ">Sobel 1985a</a> reported this outcome, finding a mycological recurrence rate of 55% (11/20) in the treated‐partners group compared to 75% (15/20) in the untreated‐partners group at six months (RR 0.73, 95% CI 0.46 to 1.17; participants = 40; very low certainty evidence; <a href="./references#CD009151-fig-0024" title="">Analysis 6.3</a>). Our confidence in these findings is very low. </p> <p>We downgraded the certainty of the evidence by three levels to very low due to very serious risk of bias (high risk of bias for allocation concealment in <a href="./references#CD009151-bbs2-0017" title="SobelJD .Management of recurrent vulvovaginal candidiasis (VVC) with ketoconazole (K) prophylaxis [abstract]. Archives of Gynecology1985;237 Suppl:281. SobelJD .Management of recurrent vulvovaginal candidiasis with intermittent ketoconazole prophylaxis. Obstetrics &amp; Gynecology1985;65:435-40. ">Sobel 1985a</a> and blinding of participants and assessment in <a href="./references#CD009151-bbs2-0017" title="SobelJD .Management of recurrent vulvovaginal candidiasis (VVC) with ketoconazole (K) prophylaxis [abstract]. Archives of Gynecology1985;237 Suppl:281. SobelJD .Management of recurrent vulvovaginal candidiasis with intermittent ketoconazole prophylaxis. Obstetrics &amp; Gynecology1985;65:435-40. ">Sobel 1985a</a>) and imprecision. </p> </section> <section id="CD009151-sec-0143"> <p><b>Clinical recurrence at 12 months</b></p> <p>At 12 months the mycological recurrence rates were 70% (14/20) in the treated group and 80% (16/20) in the untreated group (RR 0.88, 95% CI 0.61 to 1.26; participants = 40; very low certainty evidence; <a href="./references#CD009151-fig-0025" title="">Analysis 6.4</a>). Our confidence in these findings is very low. </p> <p>We downgraded the certainty of the evidence by three levels to very low due to very serious risk of bias (high risk of bias for allocation concealment in <a href="./references#CD009151-bbs2-0017" title="SobelJD .Management of recurrent vulvovaginal candidiasis (VVC) with ketoconazole (K) prophylaxis [abstract]. Archives of Gynecology1985;237 Suppl:281. SobelJD .Management of recurrent vulvovaginal candidiasis with intermittent ketoconazole prophylaxis. Obstetrics &amp; Gynecology1985;65:435-40. ">Sobel 1985a</a> and blinding of participants and assessment in <a href="./references#CD009151-bbs2-0017" title="SobelJD .Management of recurrent vulvovaginal candidiasis (VVC) with ketoconazole (K) prophylaxis [abstract]. Archives of Gynecology1985;237 Suppl:281. SobelJD .Management of recurrent vulvovaginal candidiasis with intermittent ketoconazole prophylaxis. Obstetrics &amp; Gynecology1985;65:435-40. ">Sobel 1985a</a>) and imprecision. </p> </section> </section> <section id="CD009151-sec-0144"> <h6 class="title">5. Duration of symptoms after treatment initiation</h6> <p>Neither of the two studies in this comparison reported this outcome (<a href="./references#CD009151-bbs2-0009" title="FongIW .The value of treating the sexual partners of women with recurrent vaginal candidiasis with ketoconazole. Genitourinary Medicine1992;68:174-6. ">Fong 1992b</a>; <a href="./references#CD009151-bbs2-0017" title="SobelJD .Management of recurrent vulvovaginal candidiasis (VVC) with ketoconazole (K) prophylaxis [abstract]. Archives of Gynecology1985;237 Suppl:281. SobelJD .Management of recurrent vulvovaginal candidiasis with intermittent ketoconazole prophylaxis. Obstetrics &amp; Gynecology1985;65:435-40. ">Sobel 1985a</a>). </p> </section> <section id="CD009151-sec-0145"> <h6 class="title">6. Patient preference</h6> <p><a href="./references#CD009151-bbs2-0017" title="SobelJD .Management of recurrent vulvovaginal candidiasis (VVC) with ketoconazole (K) prophylaxis [abstract]. Archives of Gynecology1985;237 Suppl:281. SobelJD .Management of recurrent vulvovaginal candidiasis with intermittent ketoconazole prophylaxis. Obstetrics &amp; Gynecology1985;65:435-40. ">Sobel 1985a</a> reported that an "overwhelming majority" felt like they had benefited from the treatment, but did not provide additional detail on patient preference. </p> </section> </section> </section> <section id="CD009151-sec-0146"> <h4 class="title">Comparison 8: Complementary and alternative medicine versus placebo/no treatment</h4> <p><a href="./references#CD009151-bbs2-0015" title="MettsJ , FamulaTR , TrenevN , ClemensRA .Lactobacillus acidophilus, strain NAS (H2O2 positive), in reduction of recurrent candidal vulvovaginitis. Journal of Applied Research2003;3:340-8. ">Metts 2003</a> evaluated <i>Lactobacillus</i> vaginal tablets and probiotic oral tablets in a three‐way comparison against placebo tablets over a six‐month period. This study enrolled 34 women, but only nine women completed the study. No data could be extracted. </p> <section id="CD009151-sec-0147"> <h5 class="title">Primary outcomes</h5> <section id="CD009151-sec-0148"> <h6 class="title">1. Number of clinical recurrences per participant per year</h6> <p>The one study in this comparison did not report this outcome (<a href="./references#CD009151-bbs2-0015" title="MettsJ , FamulaTR , TrenevN , ClemensRA .Lactobacillus acidophilus, strain NAS (H2O2 positive), in reduction of recurrent candidal vulvovaginitis. Journal of Applied Research2003;3:340-8. ">Metts 2003</a>). </p> </section> <section id="CD009151-sec-0149"> <h6 class="title">2. Proportion of participants with at least one clinical recurrence during the treatment and follow‐up period </h6> <p>Data to calculate clinical recurrence rate were collected but were not presented in a format that permitted extraction from the article. We contacted the authors but received no additional information. </p> </section> <section id="CD009151-sec-0150"> <h6 class="title">3. Adverse events</h6> <p><a href="./references#CD009151-bbs2-0015" title="MettsJ , FamulaTR , TrenevN , ClemensRA .Lactobacillus acidophilus, strain NAS (H2O2 positive), in reduction of recurrent candidal vulvovaginitis. Journal of Applied Research2003;3:340-8. ">Metts 2003</a> reported that one participant in the group receiving vaginal <i>Lactobacillus</i> tablets and an oral probiotic tablet dropped out due to brown vaginal discharge. We downgraded the certainty of the evidence by two levels to low due to high risk of bias for incomplete outcome data and imprecision. </p> </section> </section> <section id="CD009151-sec-0151"> <h5 class="title">Secondary outcomes</h5> <p>Secondary outcomes were not reported for this comparison.</p> </section> </section> <section id="CD009151-sec-0152"> <h4 class="title">Comparison 9: Complementary and alternative medicine versus drug treatments</h4> <p>Three studies examined this comparison (<a href="./references#CD009151-bbs2-0002" title="ChopraV , MarottaF , KumariA , BishierMP , HeF , ZerbinatiN , et al.Prophylactic strategies in recurrent vulvovaginal candidiasis: a 2-year study testing a phytonutrient vs itraconazole. Journal of Biological Regulators and Homeostatic Agents2013;27(3):875-82. [PMID: 24152852]">Chopra 2013</a>; <a href="./references#CD009151-bbs2-0011" title="KumariA , BishierMP , NaitoY , SharmaA , SolimeneU , JainS , et al.Protective effect of an oral natural phytonutrient in recurrent vulvovaginal candidiasis: a 12-month study. Journal of Biological Regulators &amp; Homeostatic Agents2011;25(4):543-51. ">Kumari 2011</a>; <a href="./references#CD009151-bbs2-0023" title="WittA , KaufmannU , BitschnauM , TempferC , OzbalA , HaytougluE , et al.Monthly itraconazole versus classic homeopathy for the treatment of recurrent vulvovaginal candidiasis: a randomized trial. Obstetrical and Gynecological Survey2010;65(1):26-7. WittA , KaufmannU , BitschnauM , TempferC , OzbalA , HaytougluE , GregorH , KissH .Monthly itraconazole versus classic homeopathy for the treatment of recurrent vulvovaginal candidiasis: a randomised trial. British Journal of Obstetrics &amp; Gynaecology2009;116(11):1499-505. ">Witt 2009</a>). <a href="./references#CD009151-bbs2-0002" title="ChopraV , MarottaF , KumariA , BishierMP , HeF , ZerbinatiN , et al.Prophylactic strategies in recurrent vulvovaginal candidiasis: a 2-year study testing a phytonutrient vs itraconazole. Journal of Biological Regulators and Homeostatic Agents2013;27(3):875-82. [PMID: 24152852]">Chopra 2013</a> and <a href="./references#CD009151-bbs2-0011" title="KumariA , BishierMP , NaitoY , SharmaA , SolimeneU , JainS , et al.Protective effect of an oral natural phytonutrient in recurrent vulvovaginal candidiasis: a 12-month study. Journal of Biological Regulators &amp; Homeostatic Agents2011;25(4):543-51. ">Kumari 2011</a> evaluated the effect of a polygodyal/anethole phytocompound (K‐712) compared to oral itraconazole. <a href="./references#CD009151-bbs2-0023" title="WittA , KaufmannU , BitschnauM , TempferC , OzbalA , HaytougluE , et al.Monthly itraconazole versus classic homeopathy for the treatment of recurrent vulvovaginal candidiasis: a randomized trial. Obstetrical and Gynecological Survey2010;65(1):26-7. WittA , KaufmannU , BitschnauM , TempferC , OzbalA , HaytougluE , GregorH , KissH .Monthly itraconazole versus classic homeopathy for the treatment of recurrent vulvovaginal candidiasis: a randomised trial. British Journal of Obstetrics &amp; Gynaecology2009;116(11):1499-505. ">Witt 2009</a> randomised participants into three groups to compare monthly 1) itraconazole to 2) vaginal lactobacilli and to 3) classical homeopathy. The characteristics of studies against this comparison are summarised in a supplementary table (<a href="#CD009151-tbl-0007">Table 5</a>). </p> <div class="table" id="CD009151-tbl-0007"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Summary of characteristics of studies included in Comparison 9: Complementary and alternative medicine versus placebo/no treatment</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Study ID</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><a href="./references#CD009151-bbs2-0002" title="ChopraV , MarottaF , KumariA , BishierMP , HeF , ZerbinatiN , et al.Prophylactic strategies in recurrent vulvovaginal candidiasis: a 2-year study testing a phytonutrient vs itraconazole. Journal of Biological Regulators and Homeostatic Agents2013;27(3):875-82. [PMID: 24152852]"><b>Chopra 2013</b> </a> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><a href="./references#CD009151-bbs2-0011" title="KumariA , BishierMP , NaitoY , SharmaA , SolimeneU , JainS , et al.Protective effect of an oral natural phytonutrient in recurrent vulvovaginal candidiasis: a 12-month study. Journal of Biological Regulators &amp; Homeostatic Agents2011;25(4):543-51. "><b>Kumari 2011</b> </a> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><a href="./references#CD009151-bbs2-0023" title="WittA , KaufmannU , BitschnauM , TempferC , OzbalA , HaytougluE , et al.Monthly itraconazole versus classic homeopathy for the treatment of recurrent vulvovaginal candidiasis: a randomized trial. Obstetrical and Gynecological Survey2010;65(1):26-7. WittA , KaufmannU , BitschnauM , TempferC , OzbalA , HaytougluE , GregorH , KissH .Monthly itraconazole versus classic homeopathy for the treatment of recurrent vulvovaginal candidiasis: a randomised trial. British Journal of Obstetrics &amp; Gynaecology2009;116(11):1499-505. "><b>Witt 2009</b> </a> </p> </th> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Participants (n)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>122</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>82</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>150</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i><b>Candida albicans</b> </i><b>at enrolment (%)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>54</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100<sup>a</sup> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mean episodes in previous 12 months</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NS<sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NS<sup>b</sup> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Withdrawals/loss to follow‐up (%)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>53</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Setting</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Gynaecology outpatients clinic</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hospital outpatient clinic</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NS<sup>b</sup> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Country</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Italy</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Italy</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Austria</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Intervention 1</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Itraconazole (weekly)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Itraconazole (weekly)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Itraconazole (weekly)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Intervention 2</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Polygodyal/anethole phytocompound (twice daily for 1 week a month)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Polygodyal/anethole phytocompound (twice weekly)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Itraconazole (monthly) and lactobacilli (monthly for 6 days)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Intervention 3</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Classic homeopathy</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Duration of intervention</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 months</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Duration of observation after intervention</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 months</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Planned assessments</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Monthly for 24 months, then 6 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Monthly for 6 months, then 9 months, 12 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Monthly for 12 months</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Assessment between planned visits if symptoms developed</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><sup>a</sup><i>C albicans</i> was a selection criterion.<br/><sup>b</sup>Not reported or unclear. </p> </div> </div> <section id="CD009151-sec-0153"> <h5 class="title">Primary outcomes</h5> <section id="CD009151-sec-0154"> <h6 class="title">1. Number of clinical recurrences per participant per year</h6> <p>None of the three studies in this comparison reported this outcome (<a href="./references#CD009151-bbs2-0002" title="ChopraV , MarottaF , KumariA , BishierMP , HeF , ZerbinatiN , et al.Prophylactic strategies in recurrent vulvovaginal candidiasis: a 2-year study testing a phytonutrient vs itraconazole. Journal of Biological Regulators and Homeostatic Agents2013;27(3):875-82. [PMID: 24152852]">Chopra 2013</a>; <a href="./references#CD009151-bbs2-0011" title="KumariA , BishierMP , NaitoY , SharmaA , SolimeneU , JainS , et al.Protective effect of an oral natural phytonutrient in recurrent vulvovaginal candidiasis: a 12-month study. Journal of Biological Regulators &amp; Homeostatic Agents2011;25(4):543-51. ">Kumari 2011</a>; <a href="./references#CD009151-bbs2-0023" title="WittA , KaufmannU , BitschnauM , TempferC , OzbalA , HaytougluE , et al.Monthly itraconazole versus classic homeopathy for the treatment of recurrent vulvovaginal candidiasis: a randomized trial. Obstetrical and Gynecological Survey2010;65(1):26-7. WittA , KaufmannU , BitschnauM , TempferC , OzbalA , HaytougluE , GregorH , KissH .Monthly itraconazole versus classic homeopathy for the treatment of recurrent vulvovaginal candidiasis: a randomised trial. British Journal of Obstetrics &amp; Gynaecology2009;116(11):1499-505. ">Witt 2009</a>). </p> </section> <section id="CD009151-sec-0155"> <h6 class="title">2. Proportion of participants with at least one clinical recurrence during the treatment and follow‐up period </h6> <p><a href="./references#CD009151-bbs2-0002" title="ChopraV , MarottaF , KumariA , BishierMP , HeF , ZerbinatiN , et al.Prophylactic strategies in recurrent vulvovaginal candidiasis: a 2-year study testing a phytonutrient vs itraconazole. Journal of Biological Regulators and Homeostatic Agents2013;27(3):875-82. [PMID: 24152852]">Chopra 2013</a> and <a href="./references#CD009151-bbs2-0011" title="KumariA , BishierMP , NaitoY , SharmaA , SolimeneU , JainS , et al.Protective effect of an oral natural phytonutrient in recurrent vulvovaginal candidiasis: a 12-month study. Journal of Biological Regulators &amp; Homeostatic Agents2011;25(4):543-51. ">Kumari 2011</a> reported this outcome. </p> <section id="CD009151-sec-0156"> <p><b>Clinical recurrence at 6 months</b></p> <p>Only <a href="./references#CD009151-bbs2-0011" title="KumariA , BishierMP , NaitoY , SharmaA , SolimeneU , JainS , et al.Protective effect of an oral natural phytonutrient in recurrent vulvovaginal candidiasis: a 12-month study. Journal of Biological Regulators &amp; Homeostatic Agents2011;25(4):543-51. ">Kumari 2011</a> reported results for this outcome after six months. Recurrence rate was similar in the six‐month treatment phase, with 5% (2/41) recurrence in the K‐712 group and 10% (4/41) recurrence in itraconazole group (RR 0.50, 95% CI 0.10 to 2.58; participants = 82; studies = 1; very low certainty evidence; <a href="./references#CD009151-fig-0026" title="">Analysis 7.1</a>). Our confidence in these findings is very low. </p> <p>We downgraded the certainty of the evidence by three levels to very low due to very serious risk of bias (blinding of participants, incomplete outcome data, and selective reporting) and imprecision. </p> </section> <section id="CD009151-sec-0157"> <p><b>Clinical recurrence at 12 months</b></p> <p>However, at 12 months, pooling of <a href="./references#CD009151-bbs2-0002" title="ChopraV , MarottaF , KumariA , BishierMP , HeF , ZerbinatiN , et al.Prophylactic strategies in recurrent vulvovaginal candidiasis: a 2-year study testing a phytonutrient vs itraconazole. Journal of Biological Regulators and Homeostatic Agents2013;27(3):875-82. [PMID: 24152852]">Chopra 2013</a> and <a href="./references#CD009151-bbs2-0011" title="KumariA , BishierMP , NaitoY , SharmaA , SolimeneU , JainS , et al.Protective effect of an oral natural phytonutrient in recurrent vulvovaginal candidiasis: a 12-month study. Journal of Biological Regulators &amp; Homeostatic Agents2011;25(4):543-51. ">Kumari 2011</a> showed that complementary medicine may reduce clinical recurrence (RR 0.54, 95% CI 0.36 to 0.80; participants = 189; studies = 2; I<sup>2</sup> = 0%; fixed‐effect; NNTB = 5; very low certainty evidence; <a href="./references#CD009151-fig-0027" title="">Analysis 7.2</a>). We downgraded the certainty of the evidence by three levels to very low due to imprecision and very serious risk of bias in <a href="./references#CD009151-bbs2-0011" title="KumariA , BishierMP , NaitoY , SharmaA , SolimeneU , JainS , et al.Protective effect of an oral natural phytonutrient in recurrent vulvovaginal candidiasis: a 12-month study. Journal of Biological Regulators &amp; Homeostatic Agents2011;25(4):543-51. ">Kumari 2011</a>. </p> </section> <section id="CD009151-sec-0158"> <p><b>Clinical recurrence at 24 months</b></p> <p>Only <a href="./references#CD009151-bbs2-0002" title="ChopraV , MarottaF , KumariA , BishierMP , HeF , ZerbinatiN , et al.Prophylactic strategies in recurrent vulvovaginal candidiasis: a 2-year study testing a phytonutrient vs itraconazole. Journal of Biological Regulators and Homeostatic Agents2013;27(3):875-82. [PMID: 24152852]">Chopra 2013</a> reported results after 24 months, finding a lower recurrence rate in the group receiving complementary medicine: 36% (22/56) recurrence in the K‐712 group and 64% (39/51) recurrence in itraconazole group (RR 0.51, 95% CI 0.36 to 0.74; participants = 107; studies = 1; low certainty evidence; <a href="./references#CD009151-fig-0028" title="">Analysis 7.3</a>). Our confidence in these findings is low. </p> <p>We downgraded the certainty of the evidence by two levels to low due to serious risk of bias for blinding of participants and imprecision. </p> </section> </section> <section id="CD009151-sec-0159"> <h6 class="title">3. Adverse events</h6> <p>All three studies reported adverse events. <a href="./references#CD009151-bbs2-0002" title="ChopraV , MarottaF , KumariA , BishierMP , HeF , ZerbinatiN , et al.Prophylactic strategies in recurrent vulvovaginal candidiasis: a 2-year study testing a phytonutrient vs itraconazole. Journal of Biological Regulators and Homeostatic Agents2013;27(3):875-82. [PMID: 24152852]">Chopra 2013</a> reported transient/mild symptoms in 5% of participants in the K‐712 group compared to 31% in the itraconazole group. <a href="./references#CD009151-bbs2-0011" title="KumariA , BishierMP , NaitoY , SharmaA , SolimeneU , JainS , et al.Protective effect of an oral natural phytonutrient in recurrent vulvovaginal candidiasis: a 12-month study. Journal of Biological Regulators &amp; Homeostatic Agents2011;25(4):543-51. ">Kumari 2011</a> reported no adverse events in the K‐712 group compared to a rate of 10% in (4/41) in the itraconazole group, where participants suffered from nausea, abdominal discomfort, and an unpleasant taste. In <a href="./references#CD009151-bbs2-0023" title="WittA , KaufmannU , BitschnauM , TempferC , OzbalA , HaytougluE , et al.Monthly itraconazole versus classic homeopathy for the treatment of recurrent vulvovaginal candidiasis: a randomized trial. Obstetrical and Gynecological Survey2010;65(1):26-7. WittA , KaufmannU , BitschnauM , TempferC , OzbalA , HaytougluE , GregorH , KissH .Monthly itraconazole versus classic homeopathy for the treatment of recurrent vulvovaginal candidiasis: a randomised trial. British Journal of Obstetrics &amp; Gynaecology2009;116(11):1499-505. ">Witt 2009</a>, an adverse event thought to be attributable to itraconazole occurred in two participants (local allergic reaction and diarrhoea), resulting in discontinuation of the treatment. However, no adverse events were recorded in the classical homeopathy group. Our confidence in these findings is very low. </p> <p>We downgraded the certainty of the evidence by three levels to very low due to very serious risk of bias in the included studies and imprecision. </p> </section> </section> <section id="CD009151-sec-0160"> <h5 class="title">Secondary outcomes</h5> <section id="CD009151-sec-0161"> <h6 class="title">1. Time to first recurrence</h6> <p>None of the three studies in this comparison reported this outcome (<a href="./references#CD009151-bbs2-0002" title="ChopraV , MarottaF , KumariA , BishierMP , HeF , ZerbinatiN , et al.Prophylactic strategies in recurrent vulvovaginal candidiasis: a 2-year study testing a phytonutrient vs itraconazole. Journal of Biological Regulators and Homeostatic Agents2013;27(3):875-82. [PMID: 24152852]">Chopra 2013</a>; <a href="./references#CD009151-bbs2-0011" title="KumariA , BishierMP , NaitoY , SharmaA , SolimeneU , JainS , et al.Protective effect of an oral natural phytonutrient in recurrent vulvovaginal candidiasis: a 12-month study. Journal of Biological Regulators &amp; Homeostatic Agents2011;25(4):543-51. ">Kumari 2011</a>; <a href="./references#CD009151-bbs2-0023" title="WittA , KaufmannU , BitschnauM , TempferC , OzbalA , HaytougluE , et al.Monthly itraconazole versus classic homeopathy for the treatment of recurrent vulvovaginal candidiasis: a randomized trial. Obstetrical and Gynecological Survey2010;65(1):26-7. WittA , KaufmannU , BitschnauM , TempferC , OzbalA , HaytougluE , GregorH , KissH .Monthly itraconazole versus classic homeopathy for the treatment of recurrent vulvovaginal candidiasis: a randomised trial. British Journal of Obstetrics &amp; Gynaecology2009;116(11):1499-505. ">Witt 2009</a>). </p> </section> <section id="CD009151-sec-0162"> <h6 class="title">2. Number of symptomatic days per year</h6> <p>None of the three studies in this comparison reported this outcome (<a href="./references#CD009151-bbs2-0002" title="ChopraV , MarottaF , KumariA , BishierMP , HeF , ZerbinatiN , et al.Prophylactic strategies in recurrent vulvovaginal candidiasis: a 2-year study testing a phytonutrient vs itraconazole. Journal of Biological Regulators and Homeostatic Agents2013;27(3):875-82. [PMID: 24152852]">Chopra 2013</a>; <a href="./references#CD009151-bbs2-0011" title="KumariA , BishierMP , NaitoY , SharmaA , SolimeneU , JainS , et al.Protective effect of an oral natural phytonutrient in recurrent vulvovaginal candidiasis: a 12-month study. Journal of Biological Regulators &amp; Homeostatic Agents2011;25(4):543-51. ">Kumari 2011</a>; <a href="./references#CD009151-bbs2-0023" title="WittA , KaufmannU , BitschnauM , TempferC , OzbalA , HaytougluE , et al.Monthly itraconazole versus classic homeopathy for the treatment of recurrent vulvovaginal candidiasis: a randomized trial. Obstetrical and Gynecological Survey2010;65(1):26-7. WittA , KaufmannU , BitschnauM , TempferC , OzbalA , HaytougluE , GregorH , KissH .Monthly itraconazole versus classic homeopathy for the treatment of recurrent vulvovaginal candidiasis: a randomised trial. British Journal of Obstetrics &amp; Gynaecology2009;116(11):1499-505. ">Witt 2009</a>). </p> </section> <section id="CD009151-sec-0163"> <h6 class="title">3. Number of mycological recurrences per participant per year</h6> <p>None of the three studies in this comparison reported this outcome (<a href="./references#CD009151-bbs2-0002" title="ChopraV , MarottaF , KumariA , BishierMP , HeF , ZerbinatiN , et al.Prophylactic strategies in recurrent vulvovaginal candidiasis: a 2-year study testing a phytonutrient vs itraconazole. Journal of Biological Regulators and Homeostatic Agents2013;27(3):875-82. [PMID: 24152852]">Chopra 2013</a>; <a href="./references#CD009151-bbs2-0011" title="KumariA , BishierMP , NaitoY , SharmaA , SolimeneU , JainS , et al.Protective effect of an oral natural phytonutrient in recurrent vulvovaginal candidiasis: a 12-month study. Journal of Biological Regulators &amp; Homeostatic Agents2011;25(4):543-51. ">Kumari 2011</a>; <a href="./references#CD009151-bbs2-0023" title="WittA , KaufmannU , BitschnauM , TempferC , OzbalA , HaytougluE , et al.Monthly itraconazole versus classic homeopathy for the treatment of recurrent vulvovaginal candidiasis: a randomized trial. Obstetrical and Gynecological Survey2010;65(1):26-7. WittA , KaufmannU , BitschnauM , TempferC , OzbalA , HaytougluE , GregorH , KissH .Monthly itraconazole versus classic homeopathy for the treatment of recurrent vulvovaginal candidiasis: a randomised trial. British Journal of Obstetrics &amp; Gynaecology2009;116(11):1499-505. ">Witt 2009</a>). </p> </section> <section id="CD009151-sec-0164"> <h6 class="title">4. Proportion of participants with at least one mycological recurrence during the treatment and follow‐up period </h6> <p>One study examined this outcome. <a href="./references#CD009151-bbs2-0011" title="KumariA , BishierMP , NaitoY , SharmaA , SolimeneU , JainS , et al.Protective effect of an oral natural phytonutrient in recurrent vulvovaginal candidiasis: a 12-month study. Journal of Biological Regulators &amp; Homeostatic Agents2011;25(4):543-51. ">Kumari 2011</a> found a 22% (9/41) mycological recurrence rate in the K‐712 group compared to 17% (7/41) in itraconazole group at six months. This rose to 34% (14/41) and 66% respectively at 12 months. Our confidence in these findings is very low. </p> <p>We downgraded the certainty of the evidence by three levels to very low due to imprecision and very serious risk of bias in <a href="./references#CD009151-bbs2-0011" title="KumariA , BishierMP , NaitoY , SharmaA , SolimeneU , JainS , et al.Protective effect of an oral natural phytonutrient in recurrent vulvovaginal candidiasis: a 12-month study. Journal of Biological Regulators &amp; Homeostatic Agents2011;25(4):543-51. ">Kumari 2011</a>. </p> </section> <section id="CD009151-sec-0165"> <h6 class="title">5. Duration of symptoms after treatment initiation</h6> <p>None of the three studies in this comparison reported this outcome (<a href="./references#CD009151-bbs2-0002" title="ChopraV , MarottaF , KumariA , BishierMP , HeF , ZerbinatiN , et al.Prophylactic strategies in recurrent vulvovaginal candidiasis: a 2-year study testing a phytonutrient vs itraconazole. Journal of Biological Regulators and Homeostatic Agents2013;27(3):875-82. [PMID: 24152852]">Chopra 2013</a>; <a href="./references#CD009151-bbs2-0011" title="KumariA , BishierMP , NaitoY , SharmaA , SolimeneU , JainS , et al.Protective effect of an oral natural phytonutrient in recurrent vulvovaginal candidiasis: a 12-month study. Journal of Biological Regulators &amp; Homeostatic Agents2011;25(4):543-51. ">Kumari 2011</a>; <a href="./references#CD009151-bbs2-0023" title="WittA , KaufmannU , BitschnauM , TempferC , OzbalA , HaytougluE , et al.Monthly itraconazole versus classic homeopathy for the treatment of recurrent vulvovaginal candidiasis: a randomized trial. Obstetrical and Gynecological Survey2010;65(1):26-7. WittA , KaufmannU , BitschnauM , TempferC , OzbalA , HaytougluE , GregorH , KissH .Monthly itraconazole versus classic homeopathy for the treatment of recurrent vulvovaginal candidiasis: a randomised trial. British Journal of Obstetrics &amp; Gynaecology2009;116(11):1499-505. ">Witt 2009</a>). </p> </section> <section id="CD009151-sec-0166"> <h6 class="title">6. Patient preference</h6> <p>None of the three studies in this comparison reported this outcome (<a href="./references#CD009151-bbs2-0002" title="ChopraV , MarottaF , KumariA , BishierMP , HeF , ZerbinatiN , et al.Prophylactic strategies in recurrent vulvovaginal candidiasis: a 2-year study testing a phytonutrient vs itraconazole. Journal of Biological Regulators and Homeostatic Agents2013;27(3):875-82. [PMID: 24152852]">Chopra 2013</a>; <a href="./references#CD009151-bbs2-0011" title="KumariA , BishierMP , NaitoY , SharmaA , SolimeneU , JainS , et al.Protective effect of an oral natural phytonutrient in recurrent vulvovaginal candidiasis: a 12-month study. Journal of Biological Regulators &amp; Homeostatic Agents2011;25(4):543-51. ">Kumari 2011</a>; <a href="./references#CD009151-bbs2-0023" title="WittA , KaufmannU , BitschnauM , TempferC , OzbalA , HaytougluE , et al.Monthly itraconazole versus classic homeopathy for the treatment of recurrent vulvovaginal candidiasis: a randomized trial. Obstetrical and Gynecological Survey2010;65(1):26-7. WittA , KaufmannU , BitschnauM , TempferC , OzbalA , HaytougluE , GregorH , KissH .Monthly itraconazole versus classic homeopathy for the treatment of recurrent vulvovaginal candidiasis: a randomised trial. British Journal of Obstetrics &amp; Gynaecology2009;116(11):1499-505. ">Witt 2009</a>). </p> </section> </section> </section> <section id="CD009151-sec-0167"> <h4 class="title">Comparison 10: Complementary and alternative medicine versus non‐drug treatments</h4> <p>Two studies examined this comparison (<a href="./references#CD009151-bbs2-0004" title="D'AntuonoA , BaldiE , BellavistaS , BanzolaN , ZauliS , PatriziA .Use of Dermasilk briefs in recurrent vulvovaginal candidosis: safety and effectiveness. Mycoses2012;55(3):e85-9. ">D'Antuono 2012</a>; <a href="./references#CD009151-bbs2-0005" title="D'AntuonoA , BellavistaS , GaspariV , FilippiniA , PatriziA .Dermasilk® briefs in recurrent vulvovaginal candidosis. An alternative option in long-lasting disease. Minerva Ginecologica2013;65(6):697-705. ">D'Antuono 2013</a>). <a href="./references#CD009151-bbs2-0004" title="D'AntuonoA , BaldiE , BellavistaS , BanzolaN , ZauliS , PatriziA .Use of Dermasilk briefs in recurrent vulvovaginal candidosis: safety and effectiveness. Mycoses2012;55(3):e85-9. ">D'Antuono 2012</a> and <a href="./references#CD009151-bbs2-0005" title="D'AntuonoA , BellavistaS , GaspariV , FilippiniA , PatriziA .Dermasilk® briefs in recurrent vulvovaginal candidosis. An alternative option in long-lasting disease. Minerva Ginecologica2013;65(6):697-705. ">D'Antuono 2013</a> both evaluated the effect of DermaSilk briefs compared to cotton underwear for a six‐month period. The only difference between the two studies was that in the 2012 study, participants were also treated with fluconazole (150 mg weekly) for six months, whereas in the 2013 study, the only intervention was wearing DermaSilk versus cotton briefs. The characteristics of studies against this comparison are summarised in a supplementary table (<a href="#CD009151-tbl-0008">Table 6</a>). </p> <div class="table" id="CD009151-tbl-0008"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 6.</span> <span class="table-title">Summary of characteristics of studies included in Comparison 10: Non‐drug treatment versus other treatment</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Study ID (*)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><a href="./references#CD009151-bbs2-0004" title="D'AntuonoA , BaldiE , BellavistaS , BanzolaN , ZauliS , PatriziA .Use of Dermasilk briefs in recurrent vulvovaginal candidosis: safety and effectiveness. Mycoses2012;55(3):e85-9. "><b>D'Antuono 2012</b> </a> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><a href="./references#CD009151-bbs2-0005" title="D'AntuonoA , BellavistaS , GaspariV , FilippiniA , PatriziA .Dermasilk® briefs in recurrent vulvovaginal candidosis. An alternative option in long-lasting disease. Minerva Ginecologica2013;65(6):697-705. "><b>D'Antuono 2013</b> </a> </p> </th> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Participants (n)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i><b>Candida albicans</b> </i><b>at enrolment (%)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>85</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mean episodes in previous 12 months</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NS<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NS<sup>a</sup> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Withdrawals/loss to follow‐up (%)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Setting</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hospital outpatient clinic</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hospital outpatient clinic</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Country</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Italy</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Italy</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Intervention 1</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>DermaSilk briefs</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>DermaSilk briefs</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Intervention 2</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cotton briefs</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cotton briefs</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Intervention 3</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Duration of intervention</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 months</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Duration of observation after intervention</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Planned assessments</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 months, 3 months, and 6 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 months and 6 months</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Assessment between planned visits if symptoms developed</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><sup>a</sup>Not reported or unclear. </p> </div> </div> <section id="CD009151-sec-0168"> <h5 class="title">Primary outcomes</h5> <section id="CD009151-sec-0169"> <h6 class="title">1. Number of clinical recurrences per participant per year</h6> <p>Neither of the two studies in this comparison reported this outcome (<a href="./references#CD009151-bbs2-0004" title="D'AntuonoA , BaldiE , BellavistaS , BanzolaN , ZauliS , PatriziA .Use of Dermasilk briefs in recurrent vulvovaginal candidosis: safety and effectiveness. Mycoses2012;55(3):e85-9. ">D'Antuono 2012</a>; <a href="./references#CD009151-bbs2-0005" title="D'AntuonoA , BellavistaS , GaspariV , FilippiniA , PatriziA .Dermasilk® briefs in recurrent vulvovaginal candidosis. An alternative option in long-lasting disease. Minerva Ginecologica2013;65(6):697-705. ">D'Antuono 2013</a>). </p> </section> <section id="CD009151-sec-0170"> <h6 class="title">2. Proportion of participants with at least one clinical recurrence during the treatment and follow‐up period </h6> <p>Both studies reported on the proportion of participants with clinical recurrence (<a href="./references#CD009151-bbs2-0004" title="D'AntuonoA , BaldiE , BellavistaS , BanzolaN , ZauliS , PatriziA .Use of Dermasilk briefs in recurrent vulvovaginal candidosis: safety and effectiveness. Mycoses2012;55(3):e85-9. ">D'Antuono 2012</a>; <a href="./references#CD009151-bbs2-0005" title="D'AntuonoA , BellavistaS , GaspariV , FilippiniA , PatriziA .Dermasilk® briefs in recurrent vulvovaginal candidosis. An alternative option in long-lasting disease. Minerva Ginecologica2013;65(6):697-705. ">D'Antuono 2013</a>). However, only the results of <a href="./references#CD009151-bbs2-0004" title="D'AntuonoA , BaldiE , BellavistaS , BanzolaN , ZauliS , PatriziA .Use of Dermasilk briefs in recurrent vulvovaginal candidosis: safety and effectiveness. Mycoses2012;55(3):e85-9. ">D'Antuono 2012</a> were presented in a way that permitted data extraction. At six months, clinical recurrence was lower in the DermaSilk brief group (77% (37/48)) than in the cotton brief group (92% (44/48)) (RR 0.84, 95% CI 0.71 to 1.00; participants = 96; studies = 1; low certainty evidence; <a href="./references#CD009151-fig-0029" title="">Analysis 8.1</a>). Our confidence in these findings is low. </p> <p>We downgraded the certainty of the evidence by two levels to low due to imprecision and serious risk of bias (unclear randomisation). </p> </section> <section id="CD009151-sec-0171"> <h6 class="title">3. Adverse events</h6> <p>No side effects were reported in either arm of <a href="./references#CD009151-bbs2-0004" title="D'AntuonoA , BaldiE , BellavistaS , BanzolaN , ZauliS , PatriziA .Use of Dermasilk briefs in recurrent vulvovaginal candidosis: safety and effectiveness. Mycoses2012;55(3):e85-9. ">D'Antuono 2012</a> or <a href="./references#CD009151-bbs2-0005" title="D'AntuonoA , BellavistaS , GaspariV , FilippiniA , PatriziA .Dermasilk® briefs in recurrent vulvovaginal candidosis. An alternative option in long-lasting disease. Minerva Ginecologica2013;65(6):697-705. ">D'Antuono 2013</a>. </p> </section> </section> <section id="CD009151-sec-0172"> <h5 class="title">Secondary outcomes</h5> <p>Not reported.</p> </section> </section> <section id="CD009151-sec-0173"> <h4 class="title">Comparison 11: Vaccination versus other treatment</h4> <p>One study examined the impact of 1) <i>Lactobacillus</i> vaccination (three vaccinations over six weeks), 2) heliotherapy (six‐week course), and 3) ciclopyroxolamine (six‐day course) (<a href="./references#CD009151-bbs2-0014" title="MendlingW , BirknerV .Vaccination with inactivated lactobacilli or heliotherapy can improve the quality-of-life of women with chronic recurrent vulvovaginal candidosis a prospective randomized study [Die Vakzination mit inaktivierten Laktobazillen oder mit Heliotherapie kann die Lebensqualitat von Frauen mit rezidivierender vulvovaginaler Kandidose verbessern - Eine prospektive 3-armige randomisierte Studie]. Geburtshilfe und Frauenheilkunde2011;71(9):767-72. ">Mendling 2011</a>). Ninety participants were randomised over the three treatment groups. </p> <section id="CD009151-sec-0174"> <h5 class="title">Primary outcomes</h5> <section id="CD009151-sec-0175"> <h6 class="title">1. Number of clinical recurrences per participant per year</h6> <p><a href="./references#CD009151-bbs2-0014" title="MendlingW , BirknerV .Vaccination with inactivated lactobacilli or heliotherapy can improve the quality-of-life of women with chronic recurrent vulvovaginal candidosis a prospective randomized study [Die Vakzination mit inaktivierten Laktobazillen oder mit Heliotherapie kann die Lebensqualitat von Frauen mit rezidivierender vulvovaginaler Kandidose verbessern - Eine prospektive 3-armige randomisierte Studie]. Geburtshilfe und Frauenheilkunde2011;71(9):767-72. ">Mendling 2011</a> reported results for this outcome. Participants randomised to <i>Lactobacillus</i> vaccination had a mean number of clinical recurrences per participant per year of 1.4 (standard deviation 1.6), compared to 2.0 (1.9) in the heliotherapy group and 1.8 (1.6) in the ciclopyroxolamine group (see <a href="./references#CD009151-fig-0030" title="">Analysis 9.1</a>). All three groups had significantly fewer recurrences compared to the year prior to study enrolment, but there was no difference in recurrence rate across the 12‐month study period between groups. Our confidence in these findings is very low. </p> <p>We downgraded the certainty of the evidence by two levels to very low due to imprecision and very serious risk of bias in the included study. </p> </section> <section id="CD009151-sec-0176"> <h6 class="title">2. Proportion of participants with at least one clinical recurrence during the treatment and follow‐up period </h6> <p>The one study in this comparison did not report this outcome (<a href="./references#CD009151-bbs2-0014" title="MendlingW , BirknerV .Vaccination with inactivated lactobacilli or heliotherapy can improve the quality-of-life of women with chronic recurrent vulvovaginal candidosis a prospective randomized study [Die Vakzination mit inaktivierten Laktobazillen oder mit Heliotherapie kann die Lebensqualitat von Frauen mit rezidivierender vulvovaginaler Kandidose verbessern - Eine prospektive 3-armige randomisierte Studie]. Geburtshilfe und Frauenheilkunde2011;71(9):767-72. ">Mendling 2011</a>). </p> </section> <section id="CD009151-sec-0177"> <h6 class="title">3. Adverse events</h6> <p>In <a href="./references#CD009151-bbs2-0014" title="MendlingW , BirknerV .Vaccination with inactivated lactobacilli or heliotherapy can improve the quality-of-life of women with chronic recurrent vulvovaginal candidosis a prospective randomized study [Die Vakzination mit inaktivierten Laktobazillen oder mit Heliotherapie kann die Lebensqualitat von Frauen mit rezidivierender vulvovaginaler Kandidose verbessern - Eine prospektive 3-armige randomisierte Studie]. Geburtshilfe und Frauenheilkunde2011;71(9):767-72. ">Mendling 2011</a>, two participants in the vaccine group reported flu‐like symptoms, one of whom withdrew from the study. Our confidence in these findings is very low. </p> <p>We downgraded the certainty of the evidence by two levels to very low due to imprecision and very serious risk of bias in the included study. </p> </section> </section> <section id="CD009151-sec-0178"> <h5 class="title">Secondary outcomes</h5> <section id="CD009151-sec-0179"> <h6 class="title">1. Time to first recurrence</h6> <p>The one study in this comparison did not report this outcome (<a href="./references#CD009151-bbs2-0014" title="MendlingW , BirknerV .Vaccination with inactivated lactobacilli or heliotherapy can improve the quality-of-life of women with chronic recurrent vulvovaginal candidosis a prospective randomized study [Die Vakzination mit inaktivierten Laktobazillen oder mit Heliotherapie kann die Lebensqualitat von Frauen mit rezidivierender vulvovaginaler Kandidose verbessern - Eine prospektive 3-armige randomisierte Studie]. Geburtshilfe und Frauenheilkunde2011;71(9):767-72. ">Mendling 2011</a>). </p> </section> <section id="CD009151-sec-0180"> <h6 class="title">2. Number of symptomatic days per year</h6> <p>The one study in this comparison did not report this outcome (<a href="./references#CD009151-bbs2-0014" title="MendlingW , BirknerV .Vaccination with inactivated lactobacilli or heliotherapy can improve the quality-of-life of women with chronic recurrent vulvovaginal candidosis a prospective randomized study [Die Vakzination mit inaktivierten Laktobazillen oder mit Heliotherapie kann die Lebensqualitat von Frauen mit rezidivierender vulvovaginaler Kandidose verbessern - Eine prospektive 3-armige randomisierte Studie]. Geburtshilfe und Frauenheilkunde2011;71(9):767-72. ">Mendling 2011</a>). </p> </section> <section id="CD009151-sec-0181"> <h6 class="title">3. Number of mycological recurrences per participant per year</h6> <p>The one study in this comparison did not report this outcome (<a href="./references#CD009151-bbs2-0014" title="MendlingW , BirknerV .Vaccination with inactivated lactobacilli or heliotherapy can improve the quality-of-life of women with chronic recurrent vulvovaginal candidosis a prospective randomized study [Die Vakzination mit inaktivierten Laktobazillen oder mit Heliotherapie kann die Lebensqualitat von Frauen mit rezidivierender vulvovaginaler Kandidose verbessern - Eine prospektive 3-armige randomisierte Studie]. Geburtshilfe und Frauenheilkunde2011;71(9):767-72. ">Mendling 2011</a>). </p> </section> <section id="CD009151-sec-0182"> <h6 class="title">4. Proportion of participants with at least one mycological recurrence during the treatment and follow‐up period </h6> <p>The one study in this comparison did not report this outcome (<a href="./references#CD009151-bbs2-0014" title="MendlingW , BirknerV .Vaccination with inactivated lactobacilli or heliotherapy can improve the quality-of-life of women with chronic recurrent vulvovaginal candidosis a prospective randomized study [Die Vakzination mit inaktivierten Laktobazillen oder mit Heliotherapie kann die Lebensqualitat von Frauen mit rezidivierender vulvovaginaler Kandidose verbessern - Eine prospektive 3-armige randomisierte Studie]. Geburtshilfe und Frauenheilkunde2011;71(9):767-72. ">Mendling 2011</a>). </p> </section> <section id="CD009151-sec-0183"> <h6 class="title">5. Duration of symptoms after treatment initiation</h6> <p>The one study in this comparison did not report this outcome (<a href="./references#CD009151-bbs2-0014" title="MendlingW , BirknerV .Vaccination with inactivated lactobacilli or heliotherapy can improve the quality-of-life of women with chronic recurrent vulvovaginal candidosis a prospective randomized study [Die Vakzination mit inaktivierten Laktobazillen oder mit Heliotherapie kann die Lebensqualitat von Frauen mit rezidivierender vulvovaginaler Kandidose verbessern - Eine prospektive 3-armige randomisierte Studie]. Geburtshilfe und Frauenheilkunde2011;71(9):767-72. ">Mendling 2011</a>). </p> </section> <section id="CD009151-sec-0184"> <h6 class="title">6. Patient preference</h6> <p><a href="./references#CD009151-bbs2-0014" title="MendlingW , BirknerV .Vaccination with inactivated lactobacilli or heliotherapy can improve the quality-of-life of women with chronic recurrent vulvovaginal candidosis a prospective randomized study [Die Vakzination mit inaktivierten Laktobazillen oder mit Heliotherapie kann die Lebensqualitat von Frauen mit rezidivierender vulvovaginaler Kandidose verbessern - Eine prospektive 3-armige randomisierte Studie]. Geburtshilfe und Frauenheilkunde2011;71(9):767-72. ">Mendling 2011</a> assessed patient preference by measuring the percentage of participants satisfied with the treatment. Overall, this was low across the study, with 48%, 27%, and 20% being satisfied in the vaccine, heliotherapy, and ciclopyroxolamine groups, respectively. Our confidence in these findings is very low. </p> <p>We downgraded the certainty of the evidence by three levels to very low due to imprecision and very serious risk of bias in the included study. </p> <section id="CD009151-sec-0185"> <p><b>Subgroup analyses</b></p> <p>We were unable to undertake the subgroup analyses planned in our protocol due to insufficient data. </p> </section> </section> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD009151-sec-0186" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD009151-sec-0186"></div> <section id="CD009151-sec-0187"> <h3 class="title" id="CD009151-sec-0187">Summary of main results</h3> <p>Only one study reported results for our first primary outcome (number of clinical recurrences per participant per year) (<a href="./references#CD009151-bbs2-0014" title="MendlingW , BirknerV .Vaccination with inactivated lactobacilli or heliotherapy can improve the quality-of-life of women with chronic recurrent vulvovaginal candidosis a prospective randomized study [Die Vakzination mit inaktivierten Laktobazillen oder mit Heliotherapie kann die Lebensqualitat von Frauen mit rezidivierender vulvovaginaler Kandidose verbessern - Eine prospektive 3-armige randomisierte Studie]. Geburtshilfe und Frauenheilkunde2011;71(9):767-72. ">Mendling 2011</a>). Eighteen studies presented data for our second primary outcome (proportion of participants with at least one clinical recurrence during the treatment and follow‐up period) (<a href="./references#CD009151-bbs2-0001" title="BolouriF , TabriziNM , TanhaFD , NiroomandN , AzmoodehA , EmamiS , et al.Effectiveness of fluconazole for suppressive maintenance therapy in patients with RVVC: a randomized placebo-controlled study. Iranian Journal of Pharmaceutical Research2009;8:307-13. ">Bolouri 2009</a>; <a href="./references#CD009151-bbs2-0002" title="ChopraV , MarottaF , KumariA , BishierMP , HeF , ZerbinatiN , et al.Prophylactic strategies in recurrent vulvovaginal candidiasis: a 2-year study testing a phytonutrient vs itraconazole. Journal of Biological Regulators and Homeostatic Agents2013;27(3):875-82. [PMID: 24152852]">Chopra 2013</a>; <a href="./references#CD009151-bbs2-0004" title="D'AntuonoA , BaldiE , BellavistaS , BanzolaN , ZauliS , PatriziA .Use of Dermasilk briefs in recurrent vulvovaginal candidosis: safety and effectiveness. Mycoses2012;55(3):e85-9. ">D'Antuono 2012</a>; <a href="./references#CD009151-bbs2-0005" title="D'AntuonoA , BellavistaS , GaspariV , FilippiniA , PatriziA .Dermasilk® briefs in recurrent vulvovaginal candidosis. An alternative option in long-lasting disease. Minerva Ginecologica2013;65(6):697-705. ">D'Antuono 2013</a>; <a href="./references#CD009151-bbs2-0007" title="FardyazarZ , HabibzadehS , Abdollahi-FardS , TelloM .Vaginal azoles versus oral fluconazole in treatment of recurrent vulvovaginal candidiasis. Iranian Journal of Clinical Infectious Diseases2007;2:17-22. FardyazarZ , HabibzadehS .Long term vaginal azoles versus prophylactic oral fluconazole in treatment of recurrent vulvovaginal candidiasis. Research Journal of Biological Sciences2007;2(6):663-6. ">Fardyazar 2007</a>; <a href="./references#CD009151-bbs2-0008" title="FongIW .The value of chronic suppressive therapy with itraconazole versus clotrimazole in women with recurrent vaginal candidiasis. Genitourinary Medicine1992;68:374-7. ">Fong 1992a</a>; <a href="./references#CD009151-bbs2-0009" title="FongIW .The value of treating the sexual partners of women with recurrent vaginal candidiasis with ketoconazole. Genitourinary Medicine1992;68:174-6. ">Fong 1992b</a>; <a href="./references#CD009151-bbs2-0011" title="KumariA , BishierMP , NaitoY , SharmaA , SolimeneU , JainS , et al.Protective effect of an oral natural phytonutrient in recurrent vulvovaginal candidiasis: a 12-month study. Journal of Biological Regulators &amp; Homeostatic Agents2011;25(4):543-51. ">Kumari 2011</a>; <a href="./references#CD009151-bbs2-0013" title="Lopez-OlmosJ , LermaE .Treatment of recurring vulvo-vaginal candidiasis: a comparative prospective study during six months of three anti-mycotic preparations of a single dosis. Clinica e Investigacion en Ginecologia y Obstetricia2000;27:366-75. ">Lopez‐Olmos 2000</a>; <a href="./references#CD009151-bbs2-0016" title="RothAC , MilsomI , ForssmanL , WahlenP .Intermittent prophylactic treatment of recurrent vaginal candidiasis by postmenstrual application of a 500 mg clotrimazole vaginal tablet. Genitourinary Medicine1990;66:357-60. ">Roth 1990</a>; <a href="./references#CD009151-bbs2-0017" title="SobelJD .Management of recurrent vulvovaginal candidiasis (VVC) with ketoconazole (K) prophylaxis [abstract]. Archives of Gynecology1985;237 Suppl:281. SobelJD .Management of recurrent vulvovaginal candidiasis with intermittent ketoconazole prophylaxis. Obstetrics &amp; Gynecology1985;65:435-40. ">Sobel 1985a</a>; <a href="./references#CD009151-bbs2-0018" title="SobelJD .Recurrent vulvovaginal candidiasis. A prospective study of the efficacy of maintenance ketoconazole therapy. New England Journal of Medicine1986;315:1455-8. ">Sobel 1986</a>; <a href="./references#CD009151-bbs2-0019" title="SobelJD , SchmittC , MeriwetherC .Clotrimazole treatment of recurrent and chronic candida vulvovaginitis. Obstetrics &amp; Gynecology1989;73:330-4. ">Sobel 1989</a>; <a href="./references#CD009151-bbs2-0020" title="SobelJD , WiesenfeldHC , MartensM , DannaP , HootonTM , RompaloA , et al.Maintenance fluconazole therapy for recurrent vulvovaginal candidiasis. New England Journal of Medicine2004;351:876-83. ">Sobel 2004</a>; <a href="./references#CD009151-bbs2-0021" title="SpacekJ , BuchtaV .Itraconazole in the treatment of acute and recurrent vulvovaginal candidosis: comparison of a 1-day and a 3-day regimen. Mycoses2005;48:165-71. ">Spacek 2005</a>; <a href="./references#CD009151-bbs2-0022" title="SpinilloA , ColonnaL , PiazziG , BaltaroF , MonacoA , FerrariA .Managing recurrent vulvovaginal candidiasis. Intermittent prevention with itraconazole. Journal of Reproductive Medicine1997;42:83-7. ">Spinillo 1997</a>). Sixteen studies reported on adverse events (<a href="./references#CD009151-bbs2-0001" title="BolouriF , TabriziNM , TanhaFD , NiroomandN , AzmoodehA , EmamiS , et al.Effectiveness of fluconazole for suppressive maintenance therapy in patients with RVVC: a randomized placebo-controlled study. Iranian Journal of Pharmaceutical Research2009;8:307-13. ">Bolouri 2009</a>; <a href="./references#CD009151-bbs2-0002" title="ChopraV , MarottaF , KumariA , BishierMP , HeF , ZerbinatiN , et al.Prophylactic strategies in recurrent vulvovaginal candidiasis: a 2-year study testing a phytonutrient vs itraconazole. Journal of Biological Regulators and Homeostatic Agents2013;27(3):875-82. [PMID: 24152852]">Chopra 2013</a>; <a href="./references#CD009151-bbs2-0004" title="D'AntuonoA , BaldiE , BellavistaS , BanzolaN , ZauliS , PatriziA .Use of Dermasilk briefs in recurrent vulvovaginal candidosis: safety and effectiveness. Mycoses2012;55(3):e85-9. ">D'Antuono 2012</a>; <a href="./references#CD009151-bbs2-0006" title="FanS , LiuX , WuC , XuL , LiJ .Vaginal nystatin versus oral fluconazole for the treatment for recurrent vulvovaginal candidiasis. Mycopathologia2015;179:95-101. [DOI: https://doi.org/10.1007/s11046-014-9827-4]">Fan 2015</a>; <a href="./references#CD009151-bbs2-0007" title="FardyazarZ , HabibzadehS , Abdollahi-FardS , TelloM .Vaginal azoles versus oral fluconazole in treatment of recurrent vulvovaginal candidiasis. Iranian Journal of Clinical Infectious Diseases2007;2:17-22. FardyazarZ , HabibzadehS .Long term vaginal azoles versus prophylactic oral fluconazole in treatment of recurrent vulvovaginal candidiasis. Research Journal of Biological Sciences2007;2(6):663-6. ">Fardyazar 2007</a>; <a href="./references#CD009151-bbs2-0008" title="FongIW .The value of chronic suppressive therapy with itraconazole versus clotrimazole in women with recurrent vaginal candidiasis. Genitourinary Medicine1992;68:374-7. ">Fong 1992a</a>; <a href="./references#CD009151-bbs2-0009" title="FongIW .The value of treating the sexual partners of women with recurrent vaginal candidiasis with ketoconazole. Genitourinary Medicine1992;68:174-6. ">Fong 1992b</a>; <a href="./references#CD009151-bbs2-0011" title="KumariA , BishierMP , NaitoY , SharmaA , SolimeneU , JainS , et al.Protective effect of an oral natural phytonutrient in recurrent vulvovaginal candidiasis: a 12-month study. Journal of Biological Regulators &amp; Homeostatic Agents2011;25(4):543-51. ">Kumari 2011</a>; <a href="./references#CD009151-bbs2-0014" title="MendlingW , BirknerV .Vaccination with inactivated lactobacilli or heliotherapy can improve the quality-of-life of women with chronic recurrent vulvovaginal candidosis a prospective randomized study [Die Vakzination mit inaktivierten Laktobazillen oder mit Heliotherapie kann die Lebensqualitat von Frauen mit rezidivierender vulvovaginaler Kandidose verbessern - Eine prospektive 3-armige randomisierte Studie]. Geburtshilfe und Frauenheilkunde2011;71(9):767-72. ">Mendling 2011</a>; <a href="./references#CD009151-bbs2-0015" title="MettsJ , FamulaTR , TrenevN , ClemensRA .Lactobacillus acidophilus, strain NAS (H2O2 positive), in reduction of recurrent candidal vulvovaginitis. Journal of Applied Research2003;3:340-8. ">Metts 2003</a>; <a href="./references#CD009151-bbs2-0016" title="RothAC , MilsomI , ForssmanL , WahlenP .Intermittent prophylactic treatment of recurrent vaginal candidiasis by postmenstrual application of a 500 mg clotrimazole vaginal tablet. Genitourinary Medicine1990;66:357-60. ">Roth 1990</a>; <a href="./references#CD009151-bbs2-0018" title="SobelJD .Recurrent vulvovaginal candidiasis. A prospective study of the efficacy of maintenance ketoconazole therapy. New England Journal of Medicine1986;315:1455-8. ">Sobel 1986</a>; <a href="./references#CD009151-bbs2-0019" title="SobelJD , SchmittC , MeriwetherC .Clotrimazole treatment of recurrent and chronic candida vulvovaginitis. Obstetrics &amp; Gynecology1989;73:330-4. ">Sobel 1989</a>; <a href="./references#CD009151-bbs2-0020" title="SobelJD , WiesenfeldHC , MartensM , DannaP , HootonTM , RompaloA , et al.Maintenance fluconazole therapy for recurrent vulvovaginal candidiasis. New England Journal of Medicine2004;351:876-83. ">Sobel 2004</a>; <a href="./references#CD009151-bbs2-0021" title="SpacekJ , BuchtaV .Itraconazole in the treatment of acute and recurrent vulvovaginal candidosis: comparison of a 1-day and a 3-day regimen. Mycoses2005;48:165-71. ">Spacek 2005</a>; <a href="./references#CD009151-bbs2-0023" title="WittA , KaufmannU , BitschnauM , TempferC , OzbalA , HaytougluE , et al.Monthly itraconazole versus classic homeopathy for the treatment of recurrent vulvovaginal candidiasis: a randomized trial. Obstetrical and Gynecological Survey2010;65(1):26-7. WittA , KaufmannU , BitschnauM , TempferC , OzbalA , HaytougluE , GregorH , KissH .Monthly itraconazole versus classic homeopathy for the treatment of recurrent vulvovaginal candidiasis: a randomised trial. British Journal of Obstetrics &amp; Gynaecology2009;116(11):1499-505. ">Witt 2009</a>). However, we were unable to pool any of the adverse events due to heterogeneity in reporting. </p> <p>At six months, the proportion of women with clinical and mycological recurrences of VVC may be lower in those receiving antifungal drug treatment compared with those receiving placebo or no treatment. At 12 months (following six months active treatment/placebo or no treatment followed by six months observation), the proportion of women with clinical recurrence may be lower in the treatment group compared with the placebo/no treatment group; however, no differences were found in mycological recurrences between the two groups. The evidence at six and twelve months is uncertain. </p> <p>Four studies compared oral versus topical antifungal treatment (<a href="./references#CD009151-bbs2-0006" title="FanS , LiuX , WuC , XuL , LiJ .Vaginal nystatin versus oral fluconazole for the treatment for recurrent vulvovaginal candidiasis. Mycopathologia2015;179:95-101. [DOI: https://doi.org/10.1007/s11046-014-9827-4]">Fan 2015</a>; <a href="./references#CD009151-bbs2-0007" title="FardyazarZ , HabibzadehS , Abdollahi-FardS , TelloM .Vaginal azoles versus oral fluconazole in treatment of recurrent vulvovaginal candidiasis. Iranian Journal of Clinical Infectious Diseases2007;2:17-22. FardyazarZ , HabibzadehS .Long term vaginal azoles versus prophylactic oral fluconazole in treatment of recurrent vulvovaginal candidiasis. Research Journal of Biological Sciences2007;2(6):663-6. ">Fardyazar 2007</a>; <a href="./references#CD009151-bbs2-0008" title="FongIW .The value of chronic suppressive therapy with itraconazole versus clotrimazole in women with recurrent vaginal candidiasis. Genitourinary Medicine1992;68:374-7. ">Fong 1992a</a>; <a href="./references#CD009151-bbs2-0013" title="Lopez-OlmosJ , LermaE .Treatment of recurring vulvo-vaginal candidiasis: a comparative prospective study during six months of three anti-mycotic preparations of a single dosis. Clinica e Investigacion en Ginecologia y Obstetricia2000;27:366-75. ">Lopez‐Olmos 2000</a>). The evidence is very uncertain if there is a difference in clinical recurrence between oral and topical treatments. This concurs with a previous Cochrane Review (<a href="./references#CD009151-bbs2-0083" title="NurbhaiM , GrimshawJ , WatsonM , BondCM , MollisonJA , LudbrookA .Oral versus intra-vaginal imidazole and triazole anti-fungal treatment of uncomplicated vulvovaginal candidiasis (thrush). Cochrane Database of Systematic Reviews2007, Issue 4. Art. No: CD002845. [DOI: 10.1002/14651858.CD002845.pub2]">Nurbhai 2007</a>), which found no difference in efficacy between oral and topical antifungal treatments. It is possible that non‐compliance may have contributed to therapeutic failure in some participants. However, participant compliance was not adequately reported in most studies. </p> </section> <section id="CD009151-sec-0188"> <h3 class="title" id="CD009151-sec-0188">Overall completeness and applicability of evidence</h3> <p>This review has some key strengths. Whilst other authors have summarised part of this body of literature (<a href="./references#CD009151-bbs2-0092" title="PontesAC , AmaralRLG , GiraldoPC , BeghiniJ , GiraldoHPD , CordeiroES .A systematic review of the effect of daily panty liner use on the vulvovaginal environment. International Journal of Gynecology and Obstetrics2014;127:1-5.">Pontes 2014</a>; <a href="./references#CD009151-bbs2-0096" title="RosaMI , SilvaBR , PiresPS , SilvaFR , SilvaNC , SilvaFR , et al.Weekly fluconazole therapy for recurrent vulvovaginal candidiasis: a systematic review and meta-analysis. European Journal of Obstetrics &amp; Gynecology and Reproductive Biology2013;167:132-136.">Rosa 2013</a>; <a href="./references#CD009151-bbs2-0106" title="Van KesselK , AssefiN , MarrazzoJ , EckertL .Common complementary and alternative therapies for yeast vaginitis and bacterial vaginosis: A systematic review. Obstetrical &amp; Gynecological Survey2003;58(5):351-58.">Van Kessel 2003</a>; <a href="./references#CD009151-bbs2-0108" title="WatsonC , CalabrettoH .Comprehensive review of conventional and non-conventional methods of management of recurrent vulvovaginal candidiasis. Australian and New Zealand Journal of Obstetrics and Gynaecology2007;47:262-272.">Watson 2007</a>), this is the first systematic review to comprehensively address treatments for recurrent vulvovaginal candidiasis. The search strategy for this review was comprehensive and included contacting manufacturers of antifungal medications and content experts, which resulted in one trial being included despite the abstract not referring to the study as a randomised controlled trial (<a href="./references#CD009151-bbs2-0017" title="SobelJD .Management of recurrent vulvovaginal candidiasis (VVC) with ketoconazole (K) prophylaxis [abstract]. Archives of Gynecology1985;237 Suppl:281. SobelJD .Management of recurrent vulvovaginal candidiasis with intermittent ketoconazole prophylaxis. Obstetrics &amp; Gynecology1985;65:435-40. ">Sobel 1985a</a>). </p> <p>We were unable to perform analysis for many of the intended outcomes due to heterogeneity between included studies and the lack of studies reporting similar outcomes. Many studies compared different intervention regimens, with timing of treatments weekly, twice weekly, monthly, or for several days at a particular phase of the menstrual cycle. There are limited data on the efficacy of non‐pharmaceutical management of RVVC. </p> <p>The vast majority of women included in the studies were colonised with <i>Candida albicans</i> (when reported usually &gt;80%) and only a small proportion with <i>C. krusei or C. glabrata,</i> the latter requiring culture for diagnosis and often more difficult to treat with standard first line treatments (<a href="./references#CD009151-bbs2-0068" title="Vulvovaginal candidiasis. Sexually Transmitted Diseases Treatment Guidelines2015. [https://www.cdc.gov/std/tg2015/candidiasis.htm]">CDC 2015</a>). Assessing the significance of mycological <i>Candida</i> spp. as a stand‐alone outcome was uncertain due to the high prevalence of asymptomatic colonisation in the community (<a href="./references#CD009151-bbs2-0067" title="BeigiRH , MeynLA , MooreDM , KrohnMA , HillierSL .Vaginal yeast colonization in nonpregnant women: a longitudinal study. Obstetrics &amp; Gynecology2004;104(5 Pt 1):926-930.">Beigi 2004</a>). However, colonisation is necessary for subsequent symptomatic episodes. It is uncertain what causes a commensal organism like <i>Candida</i> spp. to become pathogenic. </p> <p>Comparison of some studies was complicated by the induction regimen. Several studies required women to achieve culture‐negative status prior to commencing the treatment phase (<a href="./references#CD009151-bbs2-0001" title="BolouriF , TabriziNM , TanhaFD , NiroomandN , AzmoodehA , EmamiS , et al.Effectiveness of fluconazole for suppressive maintenance therapy in patients with RVVC: a randomized placebo-controlled study. Iranian Journal of Pharmaceutical Research2009;8:307-13. ">Bolouri 2009</a>; <a href="./references#CD009151-bbs2-0016" title="RothAC , MilsomI , ForssmanL , WahlenP .Intermittent prophylactic treatment of recurrent vaginal candidiasis by postmenstrual application of a 500 mg clotrimazole vaginal tablet. Genitourinary Medicine1990;66:357-60. ">Roth 1990</a>; <a href="./references#CD009151-bbs2-0019" title="SobelJD , SchmittC , MeriwetherC .Clotrimazole treatment of recurrent and chronic candida vulvovaginitis. Obstetrics &amp; Gynecology1989;73:330-4. ">Sobel 1989</a>; <a href="./references#CD009151-bbs2-0020" title="SobelJD , WiesenfeldHC , MartensM , DannaP , HootonTM , RompaloA , et al.Maintenance fluconazole therapy for recurrent vulvovaginal candidiasis. New England Journal of Medicine2004;351:876-83. ">Sobel 2004</a>); one study gave additional induction treatment to achieve negative cultures (<a href="./references#CD009151-bbs2-0022" title="SpinilloA , ColonnaL , PiazziG , BaltaroF , MonacoA , FerrariA .Managing recurrent vulvovaginal candidiasis. Intermittent prevention with itraconazole. Journal of Reproductive Medicine1997;42:83-7. ">Spinillo 1997</a>); and some studies did not require participants to achieve culture‐negative status for <i>Candida spp</i>. (<a href="./references#CD009151-bbs2-0007" title="FardyazarZ , HabibzadehS , Abdollahi-FardS , TelloM .Vaginal azoles versus oral fluconazole in treatment of recurrent vulvovaginal candidiasis. Iranian Journal of Clinical Infectious Diseases2007;2:17-22. FardyazarZ , HabibzadehS .Long term vaginal azoles versus prophylactic oral fluconazole in treatment of recurrent vulvovaginal candidiasis. Research Journal of Biological Sciences2007;2(6):663-6. ">Fardyazar 2007</a>; <a href="./references#CD009151-bbs2-0008" title="FongIW .The value of chronic suppressive therapy with itraconazole versus clotrimazole in women with recurrent vaginal candidiasis. Genitourinary Medicine1992;68:374-7. ">Fong 1992a</a>; <a href="./references#CD009151-bbs2-0018" title="SobelJD .Recurrent vulvovaginal candidiasis. A prospective study of the efficacy of maintenance ketoconazole therapy. New England Journal of Medicine1986;315:1455-8. ">Sobel 1986</a>). </p> <p>Although we did not exclude pregnant women from our eligibility criteria, all but three studies identified studies (<a href="./references#CD009151-bbs2-0007" title="FardyazarZ , HabibzadehS , Abdollahi-FardS , TelloM .Vaginal azoles versus oral fluconazole in treatment of recurrent vulvovaginal candidiasis. Iranian Journal of Clinical Infectious Diseases2007;2:17-22. FardyazarZ , HabibzadehS .Long term vaginal azoles versus prophylactic oral fluconazole in treatment of recurrent vulvovaginal candidiasis. Research Journal of Biological Sciences2007;2(6):663-6. ">Fardyazar 2007</a>; <a href="./references#CD009151-bbs2-0009" title="FongIW .The value of treating the sexual partners of women with recurrent vaginal candidiasis with ketoconazole. Genitourinary Medicine1992;68:174-6. ">Fong 1992b</a>; <a href="./references#CD009151-bbs2-0013" title="Lopez-OlmosJ , LermaE .Treatment of recurring vulvo-vaginal candidiasis: a comparative prospective study during six months of three anti-mycotic preparations of a single dosis. Clinica e Investigacion en Ginecologia y Obstetricia2000;27:366-75. ">Lopez‐Olmos 2000</a>) explicitly excluded pregnant women. It is unlikely that these studies will have included pregnant women and therefore, the conclusions of our review cannot be considered generalisable to women who are pregnant. Diabetes mellitus was an exclusion criterion in ten of the included studies, limiting our ability to draw conclusions about treatment of RVVC in this group. </p> <p>Adverse events were variably reported. Systemic adverse events were reported more frequently with oral antifungal agents (nausea, vomiting, and diarrhoea) in two studies, whilst local sensitivity was reported with topical antifungal agents in two studies. Some studies reported this outcome comprehensively; others mentioned adverse events that resulted in withdrawal from the study; and still others did not mention adverse events. Due in part to this and the small number of included trials, a significant limitation is that rare adverse events were unlikely to have been detected in this review. Patient preference and cost‐effectiveness of the interventions were poorly reported in the included studies. </p> <p>We were unable to draw conclusions regarding partner treatment. Comparing studies for some outcomes was problematic due to methodological issues and the small sample sizes of studies. For example, it was unclear in <a href="./references#CD009151-bbs2-0009" title="FongIW .The value of treating the sexual partners of women with recurrent vaginal candidiasis with ketoconazole. Genitourinary Medicine1992;68:174-6. ">Fong 1992b</a> why a dose of 200 mg of ketoconazole was used for five days to treat male partners of women with RVVC, when a previous study demonstrated that 400 mg of ketoconazole for five days resulted in significantly fewer clinical recurrences (<a href="./references#CD009151-bbs2-0018" title="SobelJD .Recurrent vulvovaginal candidiasis. A prospective study of the efficacy of maintenance ketoconazole therapy. New England Journal of Medicine1986;315:1455-8. ">Sobel 1986</a>). </p> </section> <section id="CD009151-sec-0189"> <h3 class="title" id="CD009151-sec-0189">Quality of the evidence</h3> <p>The majority of the 21 included studies were small, with most having fewer than 100 participants. Most studies did not report sample size calculations, resulting in studies that were not powered to detect stated outcomes. There was generally a lack of homogeneity amongst included studies, with different comparators, length of intervention, and follow‐up periods. This resulted in small numbers of studies that could be pooled for each outcome. </p> <p>The assessment of risk of bias across the included studies was challenged by poor reporting of the methods used in the studies. In particular, older studies often reported insufficient information to assess the risk of selection, performance, or detection bias. Many of the 'Risk of bias' items were therefore ranked as unclear or high risk of bias. </p> <p>Only one of the included studies reported adequate blinding of participants, personnel, and assessors (<a href="./references#CD009151-bbs2-0016" title="RothAC , MilsomI , ForssmanL , WahlenP .Intermittent prophylactic treatment of recurrent vaginal candidiasis by postmenstrual application of a 500 mg clotrimazole vaginal tablet. Genitourinary Medicine1990;66:357-60. ">Roth 1990</a>). Only five included studies had placebo controls. We regarded the lack of placebo blinding with the use of vaginal cream or pessaries as a major issue, especially where studies compared the effect of non‐vaginal medications such as oral tablets (<a href="./references#CD009151-bbs2-0007" title="FardyazarZ , HabibzadehS , Abdollahi-FardS , TelloM .Vaginal azoles versus oral fluconazole in treatment of recurrent vulvovaginal candidiasis. Iranian Journal of Clinical Infectious Diseases2007;2:17-22. FardyazarZ , HabibzadehS .Long term vaginal azoles versus prophylactic oral fluconazole in treatment of recurrent vulvovaginal candidiasis. Research Journal of Biological Sciences2007;2(6):663-6. ">Fardyazar 2007</a>; <a href="./references#CD009151-bbs2-0008" title="FongIW .The value of chronic suppressive therapy with itraconazole versus clotrimazole in women with recurrent vaginal candidiasis. Genitourinary Medicine1992;68:374-7. ">Fong 1992a</a>; <a href="./references#CD009151-bbs2-0013" title="Lopez-OlmosJ , LermaE .Treatment of recurring vulvo-vaginal candidiasis: a comparative prospective study during six months of three anti-mycotic preparations of a single dosis. Clinica e Investigacion en Ginecologia y Obstetricia2000;27:366-75. ">Lopez‐Olmos 2000</a>; <a href="./references#CD009151-bbs2-0016" title="RothAC , MilsomI , ForssmanL , WahlenP .Intermittent prophylactic treatment of recurrent vaginal candidiasis by postmenstrual application of a 500 mg clotrimazole vaginal tablet. Genitourinary Medicine1990;66:357-60. ">Roth 1990</a>; <a href="./references#CD009151-bbs2-0019" title="SobelJD , SchmittC , MeriwetherC .Clotrimazole treatment of recurrent and chronic candida vulvovaginitis. Obstetrics &amp; Gynecology1989;73:330-4. ">Sobel 1989</a>) and intramuscular injections (<a href="./references#CD009151-bbs2-0014" title="MendlingW , BirknerV .Vaccination with inactivated lactobacilli or heliotherapy can improve the quality-of-life of women with chronic recurrent vulvovaginal candidosis a prospective randomized study [Die Vakzination mit inaktivierten Laktobazillen oder mit Heliotherapie kann die Lebensqualitat von Frauen mit rezidivierender vulvovaginaler Kandidose verbessern - Eine prospektive 3-armige randomisierte Studie]. Geburtshilfe und Frauenheilkunde2011;71(9):767-72. ">Mendling 2011</a>). This generally resulted in a high risk of bias due to lack of blinding of participants and assessors. We considered only five studies as at low risk of bias regarding documentation and explanation of attrition. Additionally, most studies were funded by companies with a vested interest. </p> <p>We downgraded the certainty of the evidence for the majority of outcomes to low, mainly due to serious risk of bias in the included studies and imprecision (low number of studies and inability to pool data). This means that additional studies are likely to have an important impact on our confidence in the estimates of effect and are likely to change the estimate. However, they may not alter the conclusions of this review. </p> </section> <section id="CD009151-sec-0190"> <h3 class="title" id="CD009151-sec-0190">Potential biases in the review process</h3> <p>We conducted a comprehensive search in multiple databases for this review. Several review authors independently assessed the eligibility of the studies identified by the search. Nevertheless, we may have missed studies in our search. By monitoring clinical trials registers, we attempt to keep this review up‐to‐date. Due to insufficient studies per comparison, we were unable to construct a funnel plot to assess for publication bias in this way. </p> <p>Data extraction and 'Risk of bias' assessment were also conducted by up to four review authors independently. Any discrepancies were discussed by the team to ensure consistency. </p> </section> <section id="CD009151-sec-0191"> <h3 class="title" id="CD009151-sec-0191">Agreements and disagreements with other studies or reviews</h3> <p>A systematic review has examined the effect of weekly fluconazole therapy for recurrent vulvovaginal candidiasis (<a href="./references#CD009151-bbs2-0096" title="RosaMI , SilvaBR , PiresPS , SilvaFR , SilvaNC , SilvaFR , et al.Weekly fluconazole therapy for recurrent vulvovaginal candidiasis: a systematic review and meta-analysis. European Journal of Obstetrics &amp; Gynecology and Reproductive Biology2013;167:132-136.">Rosa 2013</a>). This study identified the same two trials we found in our systematic search of the literature (<a href="./references#CD009151-bbs2-0001" title="BolouriF , TabriziNM , TanhaFD , NiroomandN , AzmoodehA , EmamiS , et al.Effectiveness of fluconazole for suppressive maintenance therapy in patients with RVVC: a randomized placebo-controlled study. Iranian Journal of Pharmaceutical Research2009;8:307-13. ">Bolouri 2009</a>; <a href="./references#CD009151-bbs2-0020" title="SobelJD , WiesenfeldHC , MartensM , DannaP , HootonTM , RompaloA , et al.Maintenance fluconazole therapy for recurrent vulvovaginal candidiasis. New England Journal of Medicine2004;351:876-83. ">Sobel 2004</a>), and also concluded that fluconazole reduced the frequency of clinical recurrence for the six months of active treatment as well as in the subsequent six months. However, unlike our review, <a href="./references#CD009151-bbs2-0096" title="RosaMI , SilvaBR , PiresPS , SilvaFR , SilvaNC , SilvaFR , et al.Weekly fluconazole therapy for recurrent vulvovaginal candidiasis: a systematic review and meta-analysis. European Journal of Obstetrics &amp; Gynecology and Reproductive Biology2013;167:132-136.">Rosa 2013</a> rated the risk of bias of the included studies as satisfactory overall. Of note, <a href="./references#CD009151-bbs2-0096" title="RosaMI , SilvaBR , PiresPS , SilvaFR , SilvaNC , SilvaFR , et al.Weekly fluconazole therapy for recurrent vulvovaginal candidiasis: a systematic review and meta-analysis. European Journal of Obstetrics &amp; Gynecology and Reproductive Biology2013;167:132-136.">Rosa 2013</a> did not assess selective outcome reporting or other sources of bias in their assessment. </p> <p>A second systematic review examined the impact of panty liners on vulvovaginal candidiasis (<a href="./references#CD009151-bbs2-0092" title="PontesAC , AmaralRLG , GiraldoPC , BeghiniJ , GiraldoHPD , CordeiroES .A systematic review of the effect of daily panty liner use on the vulvovaginal environment. International Journal of Gynecology and Obstetrics2014;127:1-5.">Pontes 2014</a>). As in our review, <a href="./references#CD009151-bbs2-0092" title="PontesAC , AmaralRLG , GiraldoPC , BeghiniJ , GiraldoHPD , CordeiroES .A systematic review of the effect of daily panty liner use on the vulvovaginal environment. International Journal of Gynecology and Obstetrics2014;127:1-5.">Pontes 2014</a> did not identify any RCTs in RVVC. <a href="./references#CD009151-bbs2-0106" title="Van KesselK , AssefiN , MarrazzoJ , EckertL .Common complementary and alternative therapies for yeast vaginitis and bacterial vaginosis: A systematic review. Obstetrical &amp; Gynecological Survey2003;58(5):351-58.">Van Kessel 2003</a> examined the evidence for complementary and alternative therapies for yeast vaginitis and bacterial vaginosis and arrived at a similar conclusion to this review regarding the paucity and low certainty of evidence in this area. </p> <p>Four Cochrane Reviews evaluate treatments for vulvovaginal candidiasis (<a href="./references#CD009151-bbs2-0083" title="NurbhaiM , GrimshawJ , WatsonM , BondCM , MollisonJA , LudbrookA .Oral versus intra-vaginal imidazole and triazole anti-fungal treatment of uncomplicated vulvovaginal candidiasis (thrush). Cochrane Database of Systematic Reviews2007, Issue 4. Art. No: CD002845. [DOI: 10.1002/14651858.CD002845.pub2]">Nurbhai 2007</a>; <a href="./references#CD009151-bbs2-0094" title="RayA , RayS , GeorgeAT , SwaminathanN .Interventions for prevention and treatment of vulvovaginal candidiasis in women with HIV infection. Cochrane Database of Systematic Reviews2011, Issue 8. Art. No: CD008739. [DOI: 10.1002/14651858.CD008739.pub2]">Ray 2011</a>; <a href="./references#CD009151-bbs2-0111" title="XieHY , FengD , WeiDM , MeiL , ChenH , WangX , FangF .Probiotics for vulvovaginal candidiasis in non-pregnant women. Cochrane Database of Systematic Reviews2017, Issue 11. Art. No: CD010496. [DOI: 10.1002/14651858.CD010496.pub2]">Xie 2017</a>; <a href="./references#CD009151-bbs2-0112" title="YoungG , JewellD .Topical treatment for vaginal candidiasis (thrush) in pregnancy. Cochrane Database of Systematic Reviews2001, Issue 4. Art. No: CD000225. [DOI: 10.1002/14651858.CD000225]">Young 2001</a>), although only in the acute setting. As in our review of RVVC, the authors of <a href="./references#CD009151-bbs2-0083" title="NurbhaiM , GrimshawJ , WatsonM , BondCM , MollisonJA , LudbrookA .Oral versus intra-vaginal imidazole and triazole anti-fungal treatment of uncomplicated vulvovaginal candidiasis (thrush). Cochrane Database of Systematic Reviews2007, Issue 4. Art. No: CD002845. [DOI: 10.1002/14651858.CD002845.pub2]">Nurbhai 2007</a> found no difference in cure rates between oral or topical antifungals in acute uncomplicated vulvovaginal candidiasis. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD009151-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009151.pub2/media/CDSR/CD009151/urn:x-wiley:14651858:media:CD009151:CD009151-FIG-01" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram." data-id="CD009151-fig-0001" src="/cdsr/doi/10.1002/14651858.CD009151.pub2/media/CDSR/CD009151/image_n/nCD009151-FIG-01.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009151.pub2/media/CDSR/CD009151/image_t/tCD009151-FIG-01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009151.pub2/full#CD009151-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009151.pub2/media/CDSR/CD009151/image_n/nCD009151-FIG-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009151-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009151.pub2/media/CDSR/CD009151/urn:x-wiley:14651858:media:CD009151:CD009151-FIG-02" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD009151-fig-0002" src="/cdsr/doi/10.1002/14651858.CD009151.pub2/media/CDSR/CD009151/image_n/nCD009151-FIG-02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009151.pub2/media/CDSR/CD009151/image_t/tCD009151-FIG-02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009151.pub2/full#CD009151-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009151.pub2/media/CDSR/CD009151/image_n/nCD009151-FIG-02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009151-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009151.pub2/media/CDSR/CD009151/urn:x-wiley:14651858:media:CD009151:CD009151-FIG-03" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD009151-fig-0003" src="/cdsr/doi/10.1002/14651858.CD009151.pub2/media/CDSR/CD009151/image_n/nCD009151-FIG-03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009151.pub2/media/CDSR/CD009151/image_t/tCD009151-FIG-03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009151.pub2/full#CD009151-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009151.pub2/media/CDSR/CD009151/image_n/nCD009151-FIG-03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009151-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009151.pub2/media/CDSR/CD009151/urn:x-wiley:14651858:media:CD009151:CD009151-FIG-04" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 Drug treatment versus placebo/no treatment (excluding partner treatment) (Comparison 1), outcome: 1.1 Clinical recurrence at 6 months." data-id="CD009151-fig-0004" src="/cdsr/doi/10.1002/14651858.CD009151.pub2/media/CDSR/CD009151/image_n/nCD009151-FIG-04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009151.pub2/media/CDSR/CD009151/image_t/tCD009151-FIG-04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 Drug treatment versus placebo/no treatment (excluding partner treatment) (Comparison 1), outcome: 1.1 Clinical recurrence at 6 months. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009151.pub2/full#CD009151-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009151.pub2/media/CDSR/CD009151/image_n/nCD009151-FIG-04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009151-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009151.pub2/media/CDSR/CD009151/urn:x-wiley:14651858:media:CD009151:CD009151-FIG-05" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 Drug treatment versus placebo/no treatment (excluding partner treatment) (Comparison 1), outcome: 1.2 Clinical recurrence at 12 months (6 months active, 6 months observation)." data-id="CD009151-fig-0005" src="/cdsr/doi/10.1002/14651858.CD009151.pub2/media/CDSR/CD009151/image_n/nCD009151-FIG-05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009151.pub2/media/CDSR/CD009151/image_t/tCD009151-FIG-05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 5</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 Drug treatment versus placebo/no treatment (excluding partner treatment) (Comparison 1), outcome: 1.2 Clinical recurrence at 12 months (6 months active, 6 months observation). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009151.pub2/full#CD009151-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009151.pub2/media/CDSR/CD009151/image_n/nCD009151-FIG-05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009151-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009151.pub2/media/CDSR/CD009151/urn:x-wiley:14651858:media:CD009151:CD009151-FIG-06" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 2 Oral drug treatment versus topical drug treatment (Comparison 2), outcome: 2.1 Clinical recurrence at 6 months." data-id="CD009151-fig-0006" src="/cdsr/doi/10.1002/14651858.CD009151.pub2/media/CDSR/CD009151/image_n/nCD009151-FIG-06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009151.pub2/media/CDSR/CD009151/image_t/tCD009151-FIG-06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 6</div> <div class="figure-caption"> <p>Forest plot of comparison: 2 Oral drug treatment versus topical drug treatment (Comparison 2), outcome: 2.1 Clinical recurrence at 6 months. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009151.pub2/full#CD009151-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009151.pub2/media/CDSR/CD009151/image_n/nCD009151-FIG-06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009151-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009151.pub2/media/CDSR/CD009151/urn:x-wiley:14651858:media:CD009151:CD009151-FIG-07" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 2 Oral drug treatment versus topical drug treatment (Comparison 2), outcome: 2.2 Clinical recurrence at 12 months (6 months active, 6 months observation)." data-id="CD009151-fig-0007" src="/cdsr/doi/10.1002/14651858.CD009151.pub2/media/CDSR/CD009151/image_n/nCD009151-FIG-07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009151.pub2/media/CDSR/CD009151/image_t/tCD009151-FIG-07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 7</div> <div class="figure-caption"> <p>Forest plot of comparison: 2 Oral drug treatment versus topical drug treatment (Comparison 2), outcome: 2.2 Clinical recurrence at 12 months (6 months active, 6 months observation). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009151.pub2/full#CD009151-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009151.pub2/media/CDSR/CD009151/image_n/nCD009151-FIG-07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009151-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009151.pub2/media/CDSR/CD009151/urn:x-wiley:14651858:media:CD009151:CD009151-CMP-001.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Drug treatment versus placebo/no treatment (excluding partner treatment) (Comparison 1), Outcome 1: Clinical recurrence at 6 months" data-id="CD009151-fig-0008" src="/cdsr/doi/10.1002/14651858.CD009151.pub2/media/CDSR/CD009151/image_n/nCD009151-CMP-001.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009151.pub2/media/CDSR/CD009151/image_t/tCD009151-CMP-001.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1: Drug treatment versus placebo/no treatment (excluding partner treatment) (Comparison 1), Outcome 1: Clinical recurrence at 6 months </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009151.pub2/references#CD009151-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009151.pub2/media/CDSR/CD009151/image_n/nCD009151-CMP-001.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009151-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009151.pub2/media/CDSR/CD009151/urn:x-wiley:14651858:media:CD009151:CD009151-CMP-001.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Drug treatment versus placebo/no treatment (excluding partner treatment) (Comparison 1), Outcome 2: Clinical recurrence at 12 months (6 months active, 6 months observation)" data-id="CD009151-fig-0009" src="/cdsr/doi/10.1002/14651858.CD009151.pub2/media/CDSR/CD009151/image_n/nCD009151-CMP-001.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009151.pub2/media/CDSR/CD009151/image_t/tCD009151-CMP-001.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1: Drug treatment versus placebo/no treatment (excluding partner treatment) (Comparison 1), Outcome 2: Clinical recurrence at 12 months (6 months active, 6 months observation) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009151.pub2/references#CD009151-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009151.pub2/media/CDSR/CD009151/image_n/nCD009151-CMP-001.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009151-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009151.pub2/media/CDSR/CD009151/urn:x-wiley:14651858:media:CD009151:CD009151-CMP-001.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Drug treatment versus placebo/no treatment (excluding partner treatment) (Comparison 1), Outcome 3: Mycological recurrence at 6 months" data-id="CD009151-fig-0010" src="/cdsr/doi/10.1002/14651858.CD009151.pub2/media/CDSR/CD009151/image_n/nCD009151-CMP-001.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009151.pub2/media/CDSR/CD009151/image_t/tCD009151-CMP-001.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1: Drug treatment versus placebo/no treatment (excluding partner treatment) (Comparison 1), Outcome 3: Mycological recurrence at 6 months </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009151.pub2/references#CD009151-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009151.pub2/media/CDSR/CD009151/image_n/nCD009151-CMP-001.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009151-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009151.pub2/media/CDSR/CD009151/urn:x-wiley:14651858:media:CD009151:CD009151-CMP-001.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Drug treatment versus placebo/no treatment (excluding partner treatment) (Comparison 1), Outcome 4: Mycological recurrence at 12 months" data-id="CD009151-fig-0011" src="/cdsr/doi/10.1002/14651858.CD009151.pub2/media/CDSR/CD009151/image_n/nCD009151-CMP-001.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009151.pub2/media/CDSR/CD009151/image_t/tCD009151-CMP-001.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1: Drug treatment versus placebo/no treatment (excluding partner treatment) (Comparison 1), Outcome 4: Mycological recurrence at 12 months </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009151.pub2/references#CD009151-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009151.pub2/media/CDSR/CD009151/image_n/nCD009151-CMP-001.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009151-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009151.pub2/media/CDSR/CD009151/urn:x-wiley:14651858:media:CD009151:CD009151-CMP-002.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Oral drug treatment versus topical drug treatment (Comparison 2), Outcome 1: Clinical recurrence at 6 months" data-id="CD009151-fig-0012" src="/cdsr/doi/10.1002/14651858.CD009151.pub2/media/CDSR/CD009151/image_n/nCD009151-CMP-002.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009151.pub2/media/CDSR/CD009151/image_t/tCD009151-CMP-002.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2: Oral drug treatment versus topical drug treatment (Comparison 2), Outcome 1: Clinical recurrence at 6 months </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009151.pub2/references#CD009151-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009151.pub2/media/CDSR/CD009151/image_n/nCD009151-CMP-002.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009151-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009151.pub2/media/CDSR/CD009151/urn:x-wiley:14651858:media:CD009151:CD009151-CMP-002.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Oral drug treatment versus topical drug treatment (Comparison 2), Outcome 2: Clinical recurrence at 12 months (6 months active, 6 months observation)" data-id="CD009151-fig-0013" src="/cdsr/doi/10.1002/14651858.CD009151.pub2/media/CDSR/CD009151/image_n/nCD009151-CMP-002.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009151.pub2/media/CDSR/CD009151/image_t/tCD009151-CMP-002.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2: Oral drug treatment versus topical drug treatment (Comparison 2), Outcome 2: Clinical recurrence at 12 months (6 months active, 6 months observation) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009151.pub2/references#CD009151-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009151.pub2/media/CDSR/CD009151/image_n/nCD009151-CMP-002.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009151-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009151.pub2/media/CDSR/CD009151/urn:x-wiley:14651858:media:CD009151:CD009151-CMP-002.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Oral drug treatment versus topical drug treatment (Comparison 2), Outcome 3: Mycological recurrence at 6 months" data-id="CD009151-fig-0014" src="/cdsr/doi/10.1002/14651858.CD009151.pub2/media/CDSR/CD009151/image_n/nCD009151-CMP-002.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009151.pub2/media/CDSR/CD009151/image_t/tCD009151-CMP-002.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2: Oral drug treatment versus topical drug treatment (Comparison 2), Outcome 3: Mycological recurrence at 6 months </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009151.pub2/references#CD009151-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009151.pub2/media/CDSR/CD009151/image_n/nCD009151-CMP-002.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009151-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009151.pub2/media/CDSR/CD009151/urn:x-wiley:14651858:media:CD009151:CD009151-CMP-003.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Oral drug treatment versus oral drug treatment (Comparison 3), Outcome 1: Clinical recurrence at 6 months" data-id="CD009151-fig-0015" src="/cdsr/doi/10.1002/14651858.CD009151.pub2/media/CDSR/CD009151/image_n/nCD009151-CMP-003.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009151.pub2/media/CDSR/CD009151/image_t/tCD009151-CMP-003.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3: Oral drug treatment versus oral drug treatment (Comparison 3), Outcome 1: Clinical recurrence at 6 months </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009151.pub2/references#CD009151-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009151.pub2/media/CDSR/CD009151/image_n/nCD009151-CMP-003.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009151-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009151.pub2/media/CDSR/CD009151/urn:x-wiley:14651858:media:CD009151:CD009151-CMP-003.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Oral drug treatment versus oral drug treatment (Comparison 3), Outcome 2: Clinical recurrence at 12 months" data-id="CD009151-fig-0016" src="/cdsr/doi/10.1002/14651858.CD009151.pub2/media/CDSR/CD009151/image_n/nCD009151-CMP-003.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009151.pub2/media/CDSR/CD009151/image_t/tCD009151-CMP-003.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3: Oral drug treatment versus oral drug treatment (Comparison 3), Outcome 2: Clinical recurrence at 12 months </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009151.pub2/references#CD009151-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009151.pub2/media/CDSR/CD009151/image_n/nCD009151-CMP-003.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009151-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009151.pub2/media/CDSR/CD009151/urn:x-wiley:14651858:media:CD009151:CD009151-CMP-004.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Comparison of different doses of the same agent (Comparison 4), Outcome 1: Clinical recurrence at 6 months" data-id="CD009151-fig-0017" src="/cdsr/doi/10.1002/14651858.CD009151.pub2/media/CDSR/CD009151/image_n/nCD009151-CMP-004.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009151.pub2/media/CDSR/CD009151/image_t/tCD009151-CMP-004.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.1</div> <div class="figure-caption"> <p>Comparison 4: Comparison of different doses of the same agent (Comparison 4), Outcome 1: Clinical recurrence at 6 months </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009151.pub2/references#CD009151-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009151.pub2/media/CDSR/CD009151/image_n/nCD009151-CMP-004.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009151-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009151.pub2/media/CDSR/CD009151/urn:x-wiley:14651858:media:CD009151:CD009151-CMP-004.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Comparison of different doses of the same agent (Comparison 4), Outcome 2: Clinical recurrence at 12 months" data-id="CD009151-fig-0018" src="/cdsr/doi/10.1002/14651858.CD009151.pub2/media/CDSR/CD009151/image_n/nCD009151-CMP-004.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009151.pub2/media/CDSR/CD009151/image_t/tCD009151-CMP-004.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.2</div> <div class="figure-caption"> <p>Comparison 4: Comparison of different doses of the same agent (Comparison 4), Outcome 2: Clinical recurrence at 12 months </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009151.pub2/references#CD009151-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009151.pub2/media/CDSR/CD009151/image_n/nCD009151-CMP-004.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009151-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009151.pub2/media/CDSR/CD009151/urn:x-wiley:14651858:media:CD009151:CD009151-CMP-004.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Comparison of different doses of the same agent (Comparison 4), Outcome 3: Mycological recurrence at 6 months" data-id="CD009151-fig-0019" src="/cdsr/doi/10.1002/14651858.CD009151.pub2/media/CDSR/CD009151/image_n/nCD009151-CMP-004.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009151.pub2/media/CDSR/CD009151/image_t/tCD009151-CMP-004.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.3</div> <div class="figure-caption"> <p>Comparison 4: Comparison of different doses of the same agent (Comparison 4), Outcome 3: Mycological recurrence at 6 months </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009151.pub2/references#CD009151-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009151.pub2/media/CDSR/CD009151/image_n/nCD009151-CMP-004.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009151-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009151.pub2/media/CDSR/CD009151/urn:x-wiley:14651858:media:CD009151:CD009151-CMP-004.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Comparison of different doses of the same agent (Comparison 4), Outcome 4: Mycological recurrence at 12 months" data-id="CD009151-fig-0020" src="/cdsr/doi/10.1002/14651858.CD009151.pub2/media/CDSR/CD009151/image_n/nCD009151-CMP-004.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009151.pub2/media/CDSR/CD009151/image_t/tCD009151-CMP-004.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.4</div> <div class="figure-caption"> <p>Comparison 4: Comparison of different doses of the same agent (Comparison 4), Outcome 4: Mycological recurrence at 12 months </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009151.pub2/references#CD009151-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009151.pub2/media/CDSR/CD009151/image_n/nCD009151-CMP-004.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009151-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009151.pub2/media/CDSR/CD009151/urn:x-wiley:14651858:media:CD009151:CD009151-CMP-005.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Short duration versus long duration of the same treatment (Comparison 5), Outcome 1: Clinical recurrence at 6 months" data-id="CD009151-fig-0021" src="/cdsr/doi/10.1002/14651858.CD009151.pub2/media/CDSR/CD009151/image_n/nCD009151-CMP-005.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009151.pub2/media/CDSR/CD009151/image_t/tCD009151-CMP-005.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.1</div> <div class="figure-caption"> <p>Comparison 5: Short duration versus long duration of the same treatment (Comparison 5), Outcome 1: Clinical recurrence at 6 months </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009151.pub2/references#CD009151-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009151.pub2/media/CDSR/CD009151/image_n/nCD009151-CMP-005.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009151-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009151.pub2/media/CDSR/CD009151/urn:x-wiley:14651858:media:CD009151:CD009151-CMP-006.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Partner treatment versus placebo/no treatment (Comparison 6), Outcome 1: Clinical recurrence at 6 months" data-id="CD009151-fig-0022" src="/cdsr/doi/10.1002/14651858.CD009151.pub2/media/CDSR/CD009151/image_n/nCD009151-CMP-006.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009151.pub2/media/CDSR/CD009151/image_t/tCD009151-CMP-006.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.1</div> <div class="figure-caption"> <p>Comparison 6: Partner treatment versus placebo/no treatment (Comparison 6), Outcome 1: Clinical recurrence at 6 months </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009151.pub2/references#CD009151-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009151.pub2/media/CDSR/CD009151/image_n/nCD009151-CMP-006.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009151-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009151.pub2/media/CDSR/CD009151/urn:x-wiley:14651858:media:CD009151:CD009151-CMP-006.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Partner treatment versus placebo/no treatment (Comparison 6), Outcome 2: Clinical recurrence at 12 months (6 months active, 6 months observation)" data-id="CD009151-fig-0023" src="/cdsr/doi/10.1002/14651858.CD009151.pub2/media/CDSR/CD009151/image_n/nCD009151-CMP-006.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009151.pub2/media/CDSR/CD009151/image_t/tCD009151-CMP-006.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.2</div> <div class="figure-caption"> <p>Comparison 6: Partner treatment versus placebo/no treatment (Comparison 6), Outcome 2: Clinical recurrence at 12 months (6 months active, 6 months observation) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009151.pub2/references#CD009151-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009151.pub2/media/CDSR/CD009151/image_n/nCD009151-CMP-006.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009151-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009151.pub2/media/CDSR/CD009151/urn:x-wiley:14651858:media:CD009151:CD009151-CMP-006.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Partner treatment versus placebo/no treatment (Comparison 6), Outcome 3: Mycological recurrence at 6 months" data-id="CD009151-fig-0024" src="/cdsr/doi/10.1002/14651858.CD009151.pub2/media/CDSR/CD009151/image_n/nCD009151-CMP-006.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009151.pub2/media/CDSR/CD009151/image_t/tCD009151-CMP-006.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.3</div> <div class="figure-caption"> <p>Comparison 6: Partner treatment versus placebo/no treatment (Comparison 6), Outcome 3: Mycological recurrence at 6 months </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009151.pub2/references#CD009151-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009151.pub2/media/CDSR/CD009151/image_n/nCD009151-CMP-006.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009151-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009151.pub2/media/CDSR/CD009151/urn:x-wiley:14651858:media:CD009151:CD009151-CMP-006.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Partner treatment versus placebo/no treatment (Comparison 6), Outcome 4: Mycological recurrence at 12 months" data-id="CD009151-fig-0025" src="/cdsr/doi/10.1002/14651858.CD009151.pub2/media/CDSR/CD009151/image_n/nCD009151-CMP-006.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009151.pub2/media/CDSR/CD009151/image_t/tCD009151-CMP-006.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.4</div> <div class="figure-caption"> <p>Comparison 6: Partner treatment versus placebo/no treatment (Comparison 6), Outcome 4: Mycological recurrence at 12 months </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009151.pub2/references#CD009151-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009151.pub2/media/CDSR/CD009151/image_n/nCD009151-CMP-006.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009151-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009151.pub2/media/CDSR/CD009151/urn:x-wiley:14651858:media:CD009151:CD009151-CMP-007.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: Complementary and alternative medicine versus drug treatments (Comparison 7), Outcome 1: Clinical recurrence at 6 months" data-id="CD009151-fig-0026" src="/cdsr/doi/10.1002/14651858.CD009151.pub2/media/CDSR/CD009151/image_n/nCD009151-CMP-007.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009151.pub2/media/CDSR/CD009151/image_t/tCD009151-CMP-007.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.1</div> <div class="figure-caption"> <p>Comparison 7: Complementary and alternative medicine versus drug treatments (Comparison 7), Outcome 1: Clinical recurrence at 6 months </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009151.pub2/references#CD009151-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009151.pub2/media/CDSR/CD009151/image_n/nCD009151-CMP-007.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009151-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009151.pub2/media/CDSR/CD009151/urn:x-wiley:14651858:media:CD009151:CD009151-CMP-007.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: Complementary and alternative medicine versus drug treatments (Comparison 7), Outcome 2: Clinical recurrence at 12 months" data-id="CD009151-fig-0027" src="/cdsr/doi/10.1002/14651858.CD009151.pub2/media/CDSR/CD009151/image_n/nCD009151-CMP-007.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009151.pub2/media/CDSR/CD009151/image_t/tCD009151-CMP-007.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.2</div> <div class="figure-caption"> <p>Comparison 7: Complementary and alternative medicine versus drug treatments (Comparison 7), Outcome 2: Clinical recurrence at 12 months </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009151.pub2/references#CD009151-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009151.pub2/media/CDSR/CD009151/image_n/nCD009151-CMP-007.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009151-fig-0028"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009151.pub2/media/CDSR/CD009151/urn:x-wiley:14651858:media:CD009151:CD009151-CMP-007.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: Complementary and alternative medicine versus drug treatments (Comparison 7), Outcome 3: Clinical recurrence at 24 months" data-id="CD009151-fig-0028" src="/cdsr/doi/10.1002/14651858.CD009151.pub2/media/CDSR/CD009151/image_n/nCD009151-CMP-007.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009151.pub2/media/CDSR/CD009151/image_t/tCD009151-CMP-007.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.3</div> <div class="figure-caption"> <p>Comparison 7: Complementary and alternative medicine versus drug treatments (Comparison 7), Outcome 3: Clinical recurrence at 24 months </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009151.pub2/references#CD009151-fig-0028">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009151.pub2/media/CDSR/CD009151/image_n/nCD009151-CMP-007.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009151-fig-0029"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009151.pub2/media/CDSR/CD009151/urn:x-wiley:14651858:media:CD009151:CD009151-CMP-008.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 8: Non‐drug treatment versus other treatment (Comparison 8), Outcome 1: Clinical recurrence at 6 months" data-id="CD009151-fig-0029" src="/cdsr/doi/10.1002/14651858.CD009151.pub2/media/CDSR/CD009151/image_n/nCD009151-CMP-008.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009151.pub2/media/CDSR/CD009151/image_t/tCD009151-CMP-008.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.1</div> <div class="figure-caption"> <p>Comparison 8: Non‐drug treatment versus other treatment (Comparison 8), Outcome 1: Clinical recurrence at 6 months </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009151.pub2/references#CD009151-fig-0029">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009151.pub2/media/CDSR/CD009151/image_n/nCD009151-CMP-008.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009151-fig-0030"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009151.pub2/media/CDSR/CD009151/urn:x-wiley:14651858:media:CD009151:CD009151-CMP-009.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 9: Vaccination versus other treatment (Comparison 9), Outcome 1: Mean number of clinical recurrences per participant per year" data-id="CD009151-fig-0030" src="/cdsr/doi/10.1002/14651858.CD009151.pub2/media/CDSR/CD009151/image_n/nCD009151-CMP-009.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009151.pub2/media/CDSR/CD009151/image_t/tCD009151-CMP-009.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.1</div> <div class="figure-caption"> <p>Comparison 9: Vaccination versus other treatment (Comparison 9), Outcome 1: Mean number of clinical recurrences per participant per year </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009151.pub2/references#CD009151-fig-0030">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009151.pub2/media/CDSR/CD009151/image_n/nCD009151-CMP-009.01.svg" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD009151-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Drug treatment compared to placebo or no treatment for recurrent vulvovaginal candidiasis</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Drug treatment compared to placebo/no treatment (excluding partner treatment) for recurrent vulvovaginal candidiasis (thrush)</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> non‐pregnant women with a diagnosis of recurrent vulvovaginal candidiasis<br/><b>Setting:</b> outpatients<br/><b>Intervention:</b> antifungals (fluconazole, clotrimazole, ketoconazole, itraconazole)<br/><b>Comparison:</b> placebo or no treatment (excluding partner treatment) </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with placebo/no treatment (excluding partner treatment)</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with drug treatment</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Primary outcome 1: Number of clinical recurrences per participant per year</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(0 studies)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Primary outcome 2: Clinical recurrence at 6 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.36<br/>(0.21 to 0.63) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>607<br/>(6 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>647 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>233 per 1000<br/>(136 to 408) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Primary outcome 2: Clinical recurrence at 12 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.80<br/>(0.72 to 0.89) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>585<br/>(6 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>781 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>625 per 1000<br/>(562 to 695) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Primary outcome 3: Adverse events</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(5 RCTs)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW <sup>2 3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pooling of the incidence of adverse events was not possible as the outcome was reported differently across the included trials. Overall the adverse event rate was low for both placebo and treatment arms. <a href="./references#CD009151-bbs2-0020" title="SobelJD , WiesenfeldHC , MartensM , DannaP , HootonTM , RompaloA , et al.Maintenance fluconazole therapy for recurrent vulvovaginal candidiasis. New England Journal of Medicine2004;351:876-83. ">Sobel 2004</a> reported that 2.9% of participants dropped out due to adverse events in the fluconazole group and 1.2% in the placebo group. 2 participants dropped out in <a href="./references#CD009151-bbs2-0018" title="SobelJD .Recurrent vulvovaginal candidiasis. A prospective study of the efficacy of maintenance ketoconazole therapy. New England Journal of Medicine1986;315:1455-8. ">Sobel 1986</a>. No participants dropped out in <a href="./references#CD009151-bbs2-0001" title="BolouriF , TabriziNM , TanhaFD , NiroomandN , AzmoodehA , EmamiS , et al.Effectiveness of fluconazole for suppressive maintenance therapy in patients with RVVC: a randomized placebo-controlled study. Iranian Journal of Pharmaceutical Research2009;8:307-13. ">Bolouri 2009</a>. Less than 5% reported adverse effects in <a href="./references#CD009151-bbs2-0019" title="SobelJD , SchmittC , MeriwetherC .Clotrimazole treatment of recurrent and chronic candida vulvovaginitis. Obstetrics &amp; Gynecology1989;73:330-4. ">Sobel 1989</a>, and no side effects or complications occurred in <a href="./references#CD009151-bbs2-0016" title="RothAC , MilsomI , ForssmanL , WahlenP .Intermittent prophylactic treatment of recurrent vaginal candidiasis by postmenstrual application of a 500 mg clotrimazole vaginal tablet. Genitourinary Medicine1990;66:357-60. ">Roth 1990</a>. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> confidence interval; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Downgraded two levels due to very serious risk of bias for blinding or participants and assessors (<a href="./references#CD009151-bbs2-0022" title="SpinilloA , ColonnaL , PiazziG , BaltaroF , MonacoA , FerrariA .Managing recurrent vulvovaginal candidiasis. Intermittent prevention with itraconazole. Journal of Reproductive Medicine1997;42:83-7. ">Spinillo 1997</a>), incomplete outcome data (<a href="./references#CD009151-bbs2-0001" title="BolouriF , TabriziNM , TanhaFD , NiroomandN , AzmoodehA , EmamiS , et al.Effectiveness of fluconazole for suppressive maintenance therapy in patients with RVVC: a randomized placebo-controlled study. Iranian Journal of Pharmaceutical Research2009;8:307-13. ">Bolouri 2009</a>; <a href="./references#CD009151-bbs2-0018" title="SobelJD .Recurrent vulvovaginal candidiasis. A prospective study of the efficacy of maintenance ketoconazole therapy. New England Journal of Medicine1986;315:1455-8. ">Sobel 1986</a>; <a href="./references#CD009151-bbs2-0019" title="SobelJD , SchmittC , MeriwetherC .Clotrimazole treatment of recurrent and chronic candida vulvovaginitis. Obstetrics &amp; Gynecology1989;73:330-4. ">Sobel 1989</a>), and pharmaceutical funding (<a href="./references#CD009151-bbs2-0020" title="SobelJD , WiesenfeldHC , MartensM , DannaP , HootonTM , RompaloA , et al.Maintenance fluconazole therapy for recurrent vulvovaginal candidiasis. New England Journal of Medicine2004;351:876-83. ">Sobel 2004</a>).<br/><sup>2</sup>Downgraded two levels due to very serious risk of bias for incomplete outcome data, <a href="./references#CD009151-bbs2-0001" title="BolouriF , TabriziNM , TanhaFD , NiroomandN , AzmoodehA , EmamiS , et al.Effectiveness of fluconazole for suppressive maintenance therapy in patients with RVVC: a randomized placebo-controlled study. Iranian Journal of Pharmaceutical Research2009;8:307-13. ">Bolouri 2009</a>; <a href="./references#CD009151-bbs2-0018" title="SobelJD .Recurrent vulvovaginal candidiasis. A prospective study of the efficacy of maintenance ketoconazole therapy. New England Journal of Medicine1986;315:1455-8. ">Sobel 1986</a>; <a href="./references#CD009151-bbs2-0019" title="SobelJD , SchmittC , MeriwetherC .Clotrimazole treatment of recurrent and chronic candida vulvovaginitis. Obstetrics &amp; Gynecology1989;73:330-4. ">Sobel 1989</a>, and pharmaceutical funding, <a href="./references#CD009151-bbs2-0020" title="SobelJD , WiesenfeldHC , MartensM , DannaP , HootonTM , RompaloA , et al.Maintenance fluconazole therapy for recurrent vulvovaginal candidiasis. New England Journal of Medicine2004;351:876-83. ">Sobel 2004</a>.<br/><sup>3</sup>Downgraded one level due to imprecision (we were not able to pool the data). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Drug treatment compared to placebo or no treatment for recurrent vulvovaginal candidiasis</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009151.pub2/full#CD009151-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD009151-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Oral drug treatment compared to topical drug treatment for recurrent vulvovaginal candidiasis</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Oral drug treatment compared to topical drug treatment for recurrent vulvovaginal candidiasis</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> non‐pregnant women with a diagnosis of recurrent vulvovaginal candidiasis<br/><b>Setting:</b> outpatients<br/><b>Intervention:</b> oral drug treatment (fluconazole, itraconazole)<br/><b>Comparison:</b> topical drug treatment (nystatin, clotrimazole) </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with topical drug treatment</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with oral drug treatment</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Primary outcome 1: Number of clinical recurrences per participant per year</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(0 studies)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Primary outcome 2: Clinical recurrence at 6 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.66<br/>(0.83 to 3.31) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>206<br/>(3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW <sup>1 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>118 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>196 per 1000<br/>(98 to 392) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Primary outcome 2: Clinical recurrence at 12 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.95<br/>(0.71 to 1.27) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>206<br/>(3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW <sup>1 2 3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>495 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>470 per 1000<br/>(351 to 628) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Primary outcome 3: Adverse events</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(3 RCTs)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW <sup>4 5</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Due to heterogeneity in reporting we were not able to pool the data.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> confidence interval; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Downgraded two levels due to very serious risk of bias (allocation concealment (<a href="./references#CD009151-bbs2-0013" title="Lopez-OlmosJ , LermaE .Treatment of recurring vulvo-vaginal candidiasis: a comparative prospective study during six months of three anti-mycotic preparations of a single dosis. Clinica e Investigacion en Ginecologia y Obstetricia2000;27:366-75. ">Lopez‐Olmos 2000</a>), blinding of participants (<a href="./references#CD009151-bbs2-0007" title="FardyazarZ , HabibzadehS , Abdollahi-FardS , TelloM .Vaginal azoles versus oral fluconazole in treatment of recurrent vulvovaginal candidiasis. Iranian Journal of Clinical Infectious Diseases2007;2:17-22. FardyazarZ , HabibzadehS .Long term vaginal azoles versus prophylactic oral fluconazole in treatment of recurrent vulvovaginal candidiasis. Research Journal of Biological Sciences2007;2(6):663-6. ">Fardyazar 2007</a>; <a href="./references#CD009151-bbs2-0008" title="FongIW .The value of chronic suppressive therapy with itraconazole versus clotrimazole in women with recurrent vaginal candidiasis. Genitourinary Medicine1992;68:374-7. ">Fong 1992a</a>; <a href="./references#CD009151-bbs2-0013" title="Lopez-OlmosJ , LermaE .Treatment of recurring vulvo-vaginal candidiasis: a comparative prospective study during six months of three anti-mycotic preparations of a single dosis. Clinica e Investigacion en Ginecologia y Obstetricia2000;27:366-75. ">Lopez‐Olmos 2000</a>), blinding of assessment (<a href="./references#CD009151-bbs2-0008" title="FongIW .The value of chronic suppressive therapy with itraconazole versus clotrimazole in women with recurrent vaginal candidiasis. Genitourinary Medicine1992;68:374-7. ">Fong 1992a</a>), and pharmaceutical funding (<a href="./references#CD009151-bbs2-0007" title="FardyazarZ , HabibzadehS , Abdollahi-FardS , TelloM .Vaginal azoles versus oral fluconazole in treatment of recurrent vulvovaginal candidiasis. Iranian Journal of Clinical Infectious Diseases2007;2:17-22. FardyazarZ , HabibzadehS .Long term vaginal azoles versus prophylactic oral fluconazole in treatment of recurrent vulvovaginal candidiasis. Research Journal of Biological Sciences2007;2(6):663-6. ">Fardyazar 2007</a>)).<br/><sup>2</sup>Downgraded one level due to imprecision (wide confidence interval).<br/><sup>3</sup>Downgraded one level due to inconsistency (some studies showed superior effects for oral treatment, whereas others showed superior effects for topical treatment).<br/><sup>4</sup>Downgraded two levels due to very serious risk of bias (selection bias (<a href="./references#CD009151-bbs2-0006" title="FanS , LiuX , WuC , XuL , LiJ .Vaginal nystatin versus oral fluconazole for the treatment for recurrent vulvovaginal candidiasis. Mycopathologia2015;179:95-101. [DOI: https://doi.org/10.1007/s11046-014-9827-4]">Fan 2015</a>), blinding of participants (<a href="./references#CD009151-bbs2-0006" title="FanS , LiuX , WuC , XuL , LiJ .Vaginal nystatin versus oral fluconazole for the treatment for recurrent vulvovaginal candidiasis. Mycopathologia2015;179:95-101. [DOI: https://doi.org/10.1007/s11046-014-9827-4]">Fan 2015</a>; <a href="./references#CD009151-bbs2-0007" title="FardyazarZ , HabibzadehS , Abdollahi-FardS , TelloM .Vaginal azoles versus oral fluconazole in treatment of recurrent vulvovaginal candidiasis. Iranian Journal of Clinical Infectious Diseases2007;2:17-22. FardyazarZ , HabibzadehS .Long term vaginal azoles versus prophylactic oral fluconazole in treatment of recurrent vulvovaginal candidiasis. Research Journal of Biological Sciences2007;2(6):663-6. ">Fardyazar 2007</a>; <a href="./references#CD009151-bbs2-0008" title="FongIW .The value of chronic suppressive therapy with itraconazole versus clotrimazole in women with recurrent vaginal candidiasis. Genitourinary Medicine1992;68:374-7. ">Fong 1992a</a>), blinding of assessment (<a href="./references#CD009151-bbs2-0008" title="FongIW .The value of chronic suppressive therapy with itraconazole versus clotrimazole in women with recurrent vaginal candidiasis. Genitourinary Medicine1992;68:374-7. ">Fong 1992a</a>), incomplete outcome data (<a href="./references#CD009151-bbs2-0006" title="FanS , LiuX , WuC , XuL , LiJ .Vaginal nystatin versus oral fluconazole for the treatment for recurrent vulvovaginal candidiasis. Mycopathologia2015;179:95-101. [DOI: https://doi.org/10.1007/s11046-014-9827-4]">Fan 2015</a>), and pharmaceutical funding (<a href="./references#CD009151-bbs2-0007" title="FardyazarZ , HabibzadehS , Abdollahi-FardS , TelloM .Vaginal azoles versus oral fluconazole in treatment of recurrent vulvovaginal candidiasis. Iranian Journal of Clinical Infectious Diseases2007;2:17-22. FardyazarZ , HabibzadehS .Long term vaginal azoles versus prophylactic oral fluconazole in treatment of recurrent vulvovaginal candidiasis. Research Journal of Biological Sciences2007;2(6):663-6. ">Fardyazar 2007</a>)).<br/><sup>5</sup>Downgraded one level due to imprecision (we were not able to pool data). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Oral drug treatment compared to topical drug treatment for recurrent vulvovaginal candidiasis</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009151.pub2/full#CD009151-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD009151-tbl-0003"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Summary of characteristics of studies included in Comparison 1: Drug treatment versus placebo/no treatment (excluding partner treatment)</span></div> <tbody> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study ID</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><a href="./references#CD009151-bbs2-0001" title="BolouriF , TabriziNM , TanhaFD , NiroomandN , AzmoodehA , EmamiS , et al.Effectiveness of fluconazole for suppressive maintenance therapy in patients with RVVC: a randomized placebo-controlled study. Iranian Journal of Pharmaceutical Research2009;8:307-13. "><b>Bolouri 2009</b> </a> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><a href="./references#CD009151-bbs2-0016" title="RothAC , MilsomI , ForssmanL , WahlenP .Intermittent prophylactic treatment of recurrent vaginal candidiasis by postmenstrual application of a 500 mg clotrimazole vaginal tablet. Genitourinary Medicine1990;66:357-60. "><b>Roth 1990</b> </a> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><a href="./references#CD009151-bbs2-0018" title="SobelJD .Recurrent vulvovaginal candidiasis. A prospective study of the efficacy of maintenance ketoconazole therapy. New England Journal of Medicine1986;315:1455-8. "><b>Sobel 1986</b> </a> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><a href="./references#CD009151-bbs2-0019" title="SobelJD , SchmittC , MeriwetherC .Clotrimazole treatment of recurrent and chronic candida vulvovaginitis. Obstetrics &amp; Gynecology1989;73:330-4. "><b>Sobel 1989</b> </a> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><a href="./references#CD009151-bbs2-0020" title="SobelJD , WiesenfeldHC , MartensM , DannaP , HootonTM , RompaloA , et al.Maintenance fluconazole therapy for recurrent vulvovaginal candidiasis. New England Journal of Medicine2004;351:876-83. "><b>Sobel 2004</b> </a> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><a href="./references#CD009151-bbs2-0022" title="SpinilloA , ColonnaL , PiazziG , BaltaroF , MonacoA , FerrariA .Managing recurrent vulvovaginal candidiasis. Intermittent prevention with itraconazole. Journal of Reproductive Medicine1997;42:83-7. "><b>Spinillo 1997</b> </a> </p> </th> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Participants (n)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>97</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>64</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>74</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>42</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>387</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>114</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i><b>Candida albicans</b> </i><b>at enrolment (%)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>78</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>87</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>86</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>94</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100<sup>a</sup> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mean episodes in previous 12 months</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NS<sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6.2 (clotrimazole), 6.5 (placebo)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NS<sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9.2 (clotrimazole), 8.3 (placebo)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NS<sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NS<sup>b</sup> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Withdrawals/loss to follow‐up (%)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Setting</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hospital outpatient clinic</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NS<sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NS<sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NS<sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Multicentre</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Outpatient clinic</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Country</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Iran</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sweden</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>USA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>USA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>USA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Italy</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Intervention 1</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fluconazole (weekly)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clotrimazole (postmenstrual)*</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ketoconazole (with menses)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clotrimazole (postmenstrual)*</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fluconazole (weekly)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Itraconazole (with menses)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Intervention 2</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo (weekly)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo (postmenstrual)*</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ketoconazole (daily)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo (postmenstrual)*</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo (weekly)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No treatment (with menses)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Intervention 3</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo (daily)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Duration of intervention</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 months</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Duration of observation after intervention</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 months</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Planned assessments</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Monthly for 6 months, then 9 months, 12 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Monthly for 6 months, then 9 months, 12 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Monthly for 12 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Monthly for 6 months, then 9 months, 12 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Monthly for 6 months, then 9 months, 12 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3, 6, and 12 months</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Assessment between planned visits if symptoms developed</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup><i>C albicans</i> was a selection criterion.<br/><sup>b</sup>Not reported or unclear. </p> <p>*Topical treatment</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Summary of characteristics of studies included in Comparison 1: Drug treatment versus placebo/no treatment (excluding partner treatment)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009151.pub2/full#CD009151-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD009151-tbl-0004"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Summary of characteristics of studies included in Comparison 2: Oral drug treatment versus topical drug treatment</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Study ID</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><a href="./references#CD009151-bbs2-0006" title="FanS , LiuX , WuC , XuL , LiJ .Vaginal nystatin versus oral fluconazole for the treatment for recurrent vulvovaginal candidiasis. Mycopathologia2015;179:95-101. [DOI: https://doi.org/10.1007/s11046-014-9827-4]"><b>Fan 2015</b> </a> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><a href="./references#CD009151-bbs2-0007" title="FardyazarZ , HabibzadehS , Abdollahi-FardS , TelloM .Vaginal azoles versus oral fluconazole in treatment of recurrent vulvovaginal candidiasis. Iranian Journal of Clinical Infectious Diseases2007;2:17-22. FardyazarZ , HabibzadehS .Long term vaginal azoles versus prophylactic oral fluconazole in treatment of recurrent vulvovaginal candidiasis. Research Journal of Biological Sciences2007;2(6):663-6. "><b>Fardyazar 2007</b> </a> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><a href="./references#CD009151-bbs2-0008" title="FongIW .The value of chronic suppressive therapy with itraconazole versus clotrimazole in women with recurrent vaginal candidiasis. Genitourinary Medicine1992;68:374-7. "><b>Fong 1992a</b> </a> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><a href="./references#CD009151-bbs2-0013" title="Lopez-OlmosJ , LermaE .Treatment of recurring vulvo-vaginal candidiasis: a comparative prospective study during six months of three anti-mycotic preparations of a single dosis. Clinica e Investigacion en Ginecologia y Obstetricia2000;27:366-75. "><b>Lopez‐Olmos 2000</b> </a> </p> </th> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Participants (n)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>330</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>124</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>44</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i><b>Candida albicans</b> </i><b>at enrolment (%)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>77.5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>98</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>27<sup>a</sup> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mean episodes in previous 12 months</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NS<sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NS<sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8.8 (itraconazole), 9.7 (clotrimazole)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NS<sup>b</sup> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Withdrawals/loss to follow‐up (%)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Setting</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Outpatient clinic</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Outpatient clinic</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hospital outpatient clinic</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Multicentre ‐ a gynaecology outpatient clinic and a family planning clinic</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Country</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>China</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Iran</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Canada</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Spain</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Intervention 1</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fluconazole (weekly)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fluconazole (weekly)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Itraconazole (twice weekly)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fluconazole (with menses)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Intervention 2</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Nystatin (with menses)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clotrimazole (twice weekly)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clotrimazole (twice weekly)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Itraconazole (with menses)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Intervention 3</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clotrimazole (with menses)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Duration of intervention</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 months</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Duration of observation after intervention</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 months</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Planned assessments</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Monthly for 6 months and at 9 months and 12 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Monthly for 12 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Monthly for 12 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>At 6 months and 12 months</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Assessment between planned visits if symptoms developed</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="5"> <div class="table-footnote"> <p><sup>a</sup>Not all participants had positive cultures at enrolment; 12 (27%) participants had <i>C albicans</i> and 5 (11%) had <i>C glabrata.</i><br/><sup>b</sup>Not reported or unclear. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Summary of characteristics of studies included in Comparison 2: Oral drug treatment versus topical drug treatment</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009151.pub2/full#CD009151-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD009151-tbl-0005"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Summary of characteristics of studies included in Comparison 5: Comparison of different doses of the same agent</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Study ID</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009151-bbs2-0010" title="FongIW .The value of prophylactic (monthly) clotrimazole versus empiric self-treatment in recurrent vaginal candidiasis. Genitourinary Medicine1994;70:124-6. ">Fong 1994</a> </p> </td> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><a href="./references#CD009151-bbs2-0018" title="SobelJD .Recurrent vulvovaginal candidiasis. A prospective study of the efficacy of maintenance ketoconazole therapy. New England Journal of Medicine1986;315:1455-8. "><b>Sobel 1986</b> </a> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><a href="./references#CD009151-bbs2-0021" title="SpacekJ , BuchtaV .Itraconazole in the treatment of acute and recurrent vulvovaginal candidosis: comparison of a 1-day and a 3-day regimen. Mycoses2005;48:165-71. "><b>Spacek 2005</b> </a> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Participants (n)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>74</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b><i>Candida albicans</i> at enrolment (%)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>87</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>96</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mean episodes in previous 12 months</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NS<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NS<sup>a</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Withdrawals/loss to follow‐up (%)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Setting</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NS<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Outpatient clinic</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Country</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Canada</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>USA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Czech Republic</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Intervention 1</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Clotrimazole (perimenstrually)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ketoconazole (with menses)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Itraconazole, 400 mg</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Intervention 2</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Clotrimazole (empirically, with symptoms)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ketoconazole (daily)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Itraconazole, 600 mg</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Intervention 3</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo (daily)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Duration of intervention</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 to 3 days</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Duration of observation after intervention</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A Cross over trial</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 months</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Planned assessments</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Bimonthly for 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Monthly for 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14 days, 1 month, 3 months, 6 months</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Assessment between planned visits if symptoms developed</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="4"> <div class="table-footnote"> <p><sup>a</sup>Not reported or unclear. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Summary of characteristics of studies included in Comparison 5: Comparison of different doses of the same agent</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009151.pub2/full#CD009151-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD009151-tbl-0006"> <div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Summary of characteristics of studies included in Comparison 7: Partner treatment versus placebo/no treatment</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Study ID (*)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><a href="./references#CD009151-bbs2-0009" title="FongIW .The value of treating the sexual partners of women with recurrent vaginal candidiasis with ketoconazole. Genitourinary Medicine1992;68:174-6. "><b>Fong 1992b</b> </a> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><a href="./references#CD009151-bbs2-0017" title="SobelJD .Management of recurrent vulvovaginal candidiasis (VVC) with ketoconazole (K) prophylaxis [abstract]. Archives of Gynecology1985;237 Suppl:281. SobelJD .Management of recurrent vulvovaginal candidiasis with intermittent ketoconazole prophylaxis. Obstetrics &amp; Gynecology1985;65:435-40. "><b>Sobel 1985a</b> </a> </p> </th> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Participants (n)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>58</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i><b>Candida albicans</b> </i><b>at enrolment (%)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mean episodes in previous 12 months</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8.4 (ketoconazole), 9.5 (no treatment)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5.1 (miconazole), 5.3 (no treatment)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Withdrawals/loss to follow‐up (%)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Setting</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hospital outpatient clinic</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NS<sup>a</sup> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Country</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Canada</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>USA</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Intervention 1</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Partner treatment with ketoconazole daily for 5 days</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1% miconazole cream daily for 1 week</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Intervention 2</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No treatment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No treatment</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Intervention 3</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Duration of intervention</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single treatment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 week</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Duration of observation after intervention</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 months</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Planned assessments</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Monthly for 12 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Monthly for 6 months, then 9 months, 12 months</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Assessment between planned visits if symptoms developed</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="3"> <div class="table-footnote"> <p><sup>a</sup>Not reported or unclear. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Summary of characteristics of studies included in Comparison 7: Partner treatment versus placebo/no treatment</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009151.pub2/full#CD009151-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD009151-tbl-0007"> <div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Summary of characteristics of studies included in Comparison 9: Complementary and alternative medicine versus placebo/no treatment</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Study ID</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><a href="./references#CD009151-bbs2-0002" title="ChopraV , MarottaF , KumariA , BishierMP , HeF , ZerbinatiN , et al.Prophylactic strategies in recurrent vulvovaginal candidiasis: a 2-year study testing a phytonutrient vs itraconazole. Journal of Biological Regulators and Homeostatic Agents2013;27(3):875-82. [PMID: 24152852]"><b>Chopra 2013</b> </a> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><a href="./references#CD009151-bbs2-0011" title="KumariA , BishierMP , NaitoY , SharmaA , SolimeneU , JainS , et al.Protective effect of an oral natural phytonutrient in recurrent vulvovaginal candidiasis: a 12-month study. Journal of Biological Regulators &amp; Homeostatic Agents2011;25(4):543-51. "><b>Kumari 2011</b> </a> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><a href="./references#CD009151-bbs2-0023" title="WittA , KaufmannU , BitschnauM , TempferC , OzbalA , HaytougluE , et al.Monthly itraconazole versus classic homeopathy for the treatment of recurrent vulvovaginal candidiasis: a randomized trial. Obstetrical and Gynecological Survey2010;65(1):26-7. WittA , KaufmannU , BitschnauM , TempferC , OzbalA , HaytougluE , GregorH , KissH .Monthly itraconazole versus classic homeopathy for the treatment of recurrent vulvovaginal candidiasis: a randomised trial. British Journal of Obstetrics &amp; Gynaecology2009;116(11):1499-505. "><b>Witt 2009</b> </a> </p> </th> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Participants (n)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>122</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>82</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>150</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i><b>Candida albicans</b> </i><b>at enrolment (%)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>54</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100<sup>a</sup> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mean episodes in previous 12 months</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NS<sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NS<sup>b</sup> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Withdrawals/loss to follow‐up (%)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>53</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Setting</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Gynaecology outpatients clinic</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hospital outpatient clinic</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NS<sup>b</sup> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Country</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Italy</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Italy</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Austria</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Intervention 1</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Itraconazole (weekly)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Itraconazole (weekly)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Itraconazole (weekly)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Intervention 2</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Polygodyal/anethole phytocompound (twice daily for 1 week a month)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Polygodyal/anethole phytocompound (twice weekly)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Itraconazole (monthly) and lactobacilli (monthly for 6 days)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Intervention 3</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Classic homeopathy</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Duration of intervention</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 months</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Duration of observation after intervention</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 months</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Planned assessments</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Monthly for 24 months, then 6 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Monthly for 6 months, then 9 months, 12 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Monthly for 12 months</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Assessment between planned visits if symptoms developed</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="4"> <div class="table-footnote"> <p><sup>a</sup><i>C albicans</i> was a selection criterion.<br/><sup>b</sup>Not reported or unclear. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Summary of characteristics of studies included in Comparison 9: Complementary and alternative medicine versus placebo/no treatment</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009151.pub2/full#CD009151-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD009151-tbl-0008"> <div class="table-heading"><span class="table-label">Table 6.</span> <span class="table-title">Summary of characteristics of studies included in Comparison 10: Non‐drug treatment versus other treatment</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Study ID (*)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><a href="./references#CD009151-bbs2-0004" title="D'AntuonoA , BaldiE , BellavistaS , BanzolaN , ZauliS , PatriziA .Use of Dermasilk briefs in recurrent vulvovaginal candidosis: safety and effectiveness. Mycoses2012;55(3):e85-9. "><b>D'Antuono 2012</b> </a> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><a href="./references#CD009151-bbs2-0005" title="D'AntuonoA , BellavistaS , GaspariV , FilippiniA , PatriziA .Dermasilk® briefs in recurrent vulvovaginal candidosis. An alternative option in long-lasting disease. Minerva Ginecologica2013;65(6):697-705. "><b>D'Antuono 2013</b> </a> </p> </th> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Participants (n)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i><b>Candida albicans</b> </i><b>at enrolment (%)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>85</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mean episodes in previous 12 months</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NS<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NS<sup>a</sup> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Withdrawals/loss to follow‐up (%)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Setting</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hospital outpatient clinic</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hospital outpatient clinic</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Country</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Italy</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Italy</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Intervention 1</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>DermaSilk briefs</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>DermaSilk briefs</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Intervention 2</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cotton briefs</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cotton briefs</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Intervention 3</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Duration of intervention</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 months</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Duration of observation after intervention</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Planned assessments</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 months, 3 months, and 6 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 months and 6 months</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Assessment between planned visits if symptoms developed</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="3"> <div class="table-footnote"> <p><sup>a</sup>Not reported or unclear. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 6.</span> <span class="table-title">Summary of characteristics of studies included in Comparison 10: Non‐drug treatment versus other treatment</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009151.pub2/full#CD009151-tbl-0008">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD009151-tbl-0009"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Drug treatment versus placebo/no treatment (excluding partner treatment) (Comparison 1)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.1 Clinical recurrence at 6 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>607</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.36 [0.21, 0.63]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.1 Oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>518</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.29 [0.14, 0.62]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.2 Topical</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>89</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.55 [0.26, 1.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.2 Clinical recurrence at 12 months (6 months active, 6 months observation) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>585</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.80 [0.72, 0.89]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.1 Oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>496</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.77 [0.68, 0.88]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.2 Topical</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>89</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.77, 1.13]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.3 Mycological recurrence at 6 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>568</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.44 [0.25, 0.78]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3.1 Oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>506</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.37 [0.22, 0.63]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3.2 Topical</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>62</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.81 [0.62, 1.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.4 Mycological recurrence at 12 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>189</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.79, 1.03]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4.1 Oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>127</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.86 [0.71, 1.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4.2 Topical</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>62</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.82, 1.17]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Drug treatment versus placebo/no treatment (excluding partner treatment) (Comparison 1)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009151.pub2/references#CD009151-tbl-0009">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD009151-tbl-0010"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Oral drug treatment versus topical drug treatment (Comparison 2)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.1 Clinical recurrence at 6 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>206</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.66 [0.83, 3.31]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.2 Clinical recurrence at 12 months (6 months active, 6 months observation) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>206</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.71, 1.27]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.3 Mycological recurrence at 6 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>44</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.22 [0.64, 2.35]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Oral drug treatment versus topical drug treatment (Comparison 2)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009151.pub2/references#CD009151-tbl-0010">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD009151-tbl-0011"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Oral drug treatment versus oral drug treatment (Comparison 3)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.1 Clinical recurrence at 6 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.32 [0.84, 13.02]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.2 Clinical recurrence at 12 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.62 [0.73, 3.61]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Oral drug treatment versus oral drug treatment (Comparison 3)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009151.pub2/references#CD009151-tbl-0011">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD009151-tbl-0012"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Comparison of different doses of the same agent (Comparison 4)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.1 Clinical recurrence at 6 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>68</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.45 [0.08, 2.69]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.2 Clinical recurrence at 12 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.83 [0.47, 1.49]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.3 Mycological recurrence at 6 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.50 [0.14, 1.74]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.4 Mycological recurrence at 12 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.86 [0.53, 1.38]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Comparison of different doses of the same agent (Comparison 4)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009151.pub2/references#CD009151-tbl-0012">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD009151-tbl-0013"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Short duration versus long duration of the same treatment (Comparison 5)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.1 Clinical recurrence at 6 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.80 [0.47, 1.35]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Short duration versus long duration of the same treatment (Comparison 5)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009151.pub2/references#CD009151-tbl-0013">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD009151-tbl-0014"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">Partner treatment versus placebo/no treatment (Comparison 6)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.1 Clinical recurrence at 6 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>54</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.64, 1.32]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.2 Clinical recurrence at 12 months (6 months active, 6 months observation) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>54</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.03 [0.81, 1.31]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.3 Mycological recurrence at 6 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.73 [0.46, 1.17]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.4 Mycological recurrence at 12 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.88 [0.61, 1.26]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">Partner treatment versus placebo/no treatment (Comparison 6)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009151.pub2/references#CD009151-tbl-0014">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD009151-tbl-0015"> <div class="table-heading"><span class="table-label">Comparison 7.</span> <span class="table-title">Complementary and alternative medicine versus drug treatments (Comparison 7)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.1 Clinical recurrence at 6 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>82</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.50 [0.10, 2.58]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.2 Clinical recurrence at 12 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>189</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.54 [0.36, 0.80]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.3 Clinical recurrence at 24 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>107</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.51 [0.36, 0.74]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 7.</span> <span class="table-title">Complementary and alternative medicine versus drug treatments (Comparison 7)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009151.pub2/references#CD009151-tbl-0015">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD009151-tbl-0016"> <div class="table-heading"><span class="table-label">Comparison 8.</span> <span class="table-title">Non‐drug treatment versus other treatment (Comparison 8)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8.1 Clinical recurrence at 6 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>96</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.84 [0.71, 1.00]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 8.</span> <span class="table-title">Non‐drug treatment versus other treatment (Comparison 8)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009151.pub2/references#CD009151-tbl-0016">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD009151-tbl-0017"> <div class="table-heading"><span class="table-label">Comparison 9.</span> <span class="table-title">Vaccination versus other treatment (Comparison 9)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9.1 Mean number of clinical recurrences per participant per year <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.1.1 Vaccination versus heliotherapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>47</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.60 [‐1.61, 0.41]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.1.2 Vaccination versus ciclopirox olamine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>46</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.40 [‐1.33, 0.53]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 9.</span> <span class="table-title">Vaccination versus other treatment (Comparison 9)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009151.pub2/references#CD009151-tbl-0017">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD009151.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD009151-note-0019">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD009151-note-0017">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD009151-note-0018">Français</a> </li> <li class="section-language"> <a class="" href="ja#CD009151-note-0016">日本語</a> </li> <li class="section-language"> <a class="" href="ko#CD009151-note-0012">한국어</a> </li> <li class="section-language"> <a class="" href="ms#CD009151-note-0015">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="pt#CD009151-note-0014">Português</a> </li> <li class="section-language"> <a class="" href="ru#CD009151-note-0011">Русский</a> </li> <li class="section-language"> <a class="" href="th#CD009151-note-0013">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD009151-note-0009">简体中文</a> </li> <li class="section-language"> <a class="" href="zh_HANT#CD009151-note-0010">繁體中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734739000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734739000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773542000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773471000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009151\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD009151\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009151\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD009151\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009151\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD009151\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009151\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD009151\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009151\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD009151\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009151\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD009151\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009151\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD009151\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009151\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD009151\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009151\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD009151\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=dLyXbLct&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD009151.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD009151.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD009151.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD009151.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD009151.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740718725791"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD009151.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740718725795"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD009151.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918dd75b3b62f47a',t:'MTc0MDcxODcyNi4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 